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ENTRY  
 
 
  There is an urgent need for detection of viral respiratory pathogens to identify the 
causal agent(s) involved and to prevent the spread of related diseases. The first part of 
this dissertation focuses on development, optimization and validation of Real-time 
reverse transcription polymerase chain reaction (rRT-PCR) assays for the detection of 
several common equine viral pathogens: equine arteritis virus (EAV), equine influenza 
virus and equine rhinitis viruses A and B.  Emphasis of the second part of this 
dissertation is on studying the role of EAV envelope proteins in virus attachment and 
entry. Using an infectious cDNA clone of EAV and reverse genetics, a panel of chimeric 
viruses was generated by swapping the N-terminal ectodomains and full-lengths of the 
two major envelope proteins (GP5 and M) from porcine reproductive and respiratory 
syndrome virus (PRRSV). The recombinant viruses expressing the N-terminal 
ectodomain of PRRSV GP5 or M or both (GP5ecto, Mecto, and GP5&Mecto, 
respectively) in an EAV backbone were viable and genetically stable. Compared to the 
parental virus, these three chimeric viruses produced lower titers and smaller plaque sizes 
indicating that they have a crippled phenotype. Interestingly, the three chimeric viruses 
could only infect EAV susceptible cell lines but not the PRRSV susceptible cell line. 
Therefore, the exchange of GP5 and/or M protein N-terminal ectodomains from PRRSV 
did not alter the cellular tropism of the chimeric viruses.? ?We also investigated the role of 
one of the minor envelope proteins (E) of EAV in virus attachment and entry. The results 
showed that EAV infection of equine endothelial cells is heparin-dependent and the C-
terminus of the E protein contains a putative heparin-binding domain. We generated a 
panel of arginine to glycine mutations in the conserved region of both the full-length 
EAV infectious cDNA clone and individual E protein expression vectors.  The triple 
mutation R52,60,65G construct grew significantly slower and produced much smaller 
plaques. The double mutant R52,60G completely blocked the interaction between E 
protein and heparin. Taken together, these data indicated that E protein interacts with 
heparin to facilitate virus attachment and plays a major role in EAV infection.
KEYWORDS: Molecular Diagnostics, Real-time RT-PCR, Equine Viral Respiratory 
Disease, Equine Arteritis Virus, Viral Envelope Protein 
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CHAPTER ONE 
 
Literature Review 
 
 
1.1  Application of molecular diagnostic assays for the detection of equine 
respiratory viruses 
 Respiratory diseases can be costly for the horse owner and equine industry in 
many ways. Infectious diseases involving the respiratory tract of horses have been 
identified as one of the most common clinical conditions encountered by equine 
veterinarians in the USA and worldwide.1  Clinical diagnosis of respiratory disease is 
difficult because most of the infectious agents and non-infectious disease conditions give 
rise to similar clinical presentations.  Some of the viral respiratory pathogens also cause 
abortion and this can result in severe economic loss for the equine industry. Rapid 
detection and identification of viral pathogens causing respiratory tract infections are 
critical in selecting appropriate treatment strategies and very important to minimize days 
lost in training, racing, showing or poor performance, which is often the greatest cost to 
the owner.2  The major challenge encountered by equine veterinarians when confronted 
with a case of respiratory tract infection is to determine the contagious nature of the 
disease in order to properly manage the affected animal and to reduce the risk of 
exposure of other horses.  This requires the availability of fast and reliable diagnostic 
tests.  
 The invention of the polymerase chain reaction (PCR) by Kary Mullis and 
colleagues in 1983 set the stage for a scientific revolution.3 The PCR assay established a 
base technology from which many specific and diverse applications have been developed; 
these have dramatically impacted the advancement of medicine and the basic science.  
After the invention of PCR, the detection of amplification products has undergone, and 
continues to undergo, pronounced changes that have taken the technology into new 
contexts and uses. The most dramatic innovation has been the invention of real-time 
?? 
quantitative PCR, which has addressed many of the practical limitations associated with 
gel-based PCR.4 This adaptation allows detection of the accumulation of amplified DNA 
in real time after each amplification cycle.  There are several real-time PCR protocols 
available to investigate a respiratory tract infection. The short turnaround time and 
accuracy of real-time PCR make it an ideal method for the detection of infectious 
respiratory viruses.5   
 A good understanding of these diseases and diagnostic options will help us to 
choose the most appropriate diagnostic method and to facilitate disease prevention and 
control. In this section, a general introduction is provided to provide to the most common 
equine respiratory viruses; that is followed by a description of the diagnostic methods 
used to detect these pathogens.   
1.1.1 Common equine viral respiratory pathogens 
 The most important viral respiratory diseases affecting horses are equine 
influenza virus (EIV), equine arteritis virus (EAV), equine herpesvirus type 1 and 4 
(EHV-1,-4), equine rhinitis virus A and B (ERAV and ERBV), and equine adenovirus 1 
(EAdV1). 6-7  A recent surveillance study investigated the prevalence and epidemiology 
of the presence of EIV, EHV-1, and EHV-4 in horses with upper respiratory tract signs 
and/or acute febrile infection with neurological signs.8 In this study, a total of 761 horses, 
mules and donkeys were enrolled in the surveillance program over a 24-month study 
period in the USA. In total, 201 (26.4%) cases tested PCR-positive for one or more of the 
four viral pathogens. The highest detection rate was for EHV-4 (82 cases, 10.8%), 
followed by EIV (60 cases, 7.9%), and EHV-1 (23 cases, 3.0%). There were 15 horses 
with double infections (six EHV-4/EIV, five EHV-4/Streptococcus equi subspecies equi, 
two EHV-1/EHV-4, one EHV-1/ Streptococcus equi subspecies equi, one EIV/ 
Streptococcus equi subspecies equi), and one horse with a triple infection (EHV-1/EHV-
4/Streptococcus equi subspecies equi). The detection rate for the different pathogens 
varied by season and with the age, breed, sex, and use of the animal.8  A similar 
epidmiological study of equine respiratory disease was conducted in Ontario from 
October 2003 to October 2005.9  Nasopharyngeal swabs and acute and convalescent 
?? 
serum samples were collected from 115 client-owned horses in 23 outbreaks of 
respiratory disease in Ontario and sera were tested for EIV, EHV-1, EHV-4, ERAV, and 
ERBV.  EIV H3N8 subtype was isolated from 15 horses in 5 outbreaks and contributed to 
56.5% of the case-specific morbidity rate. A 4-fold increase in antibody levels or the 
presence of a high titer against ERAV or ERBV was observed in 10 out of 13 outbreaks.9  
These data indicate that EHV and EIV probably cause the majority of the viral respiratory 
disease, but other viruses may also be a problem for the equine industry.    
 
RNA Viruses  
Equine influenza virus 
Equine influenza (EI; family Orthomyxoviridae, genus Influenzavirus) is an acute, 
highly contagious viral respiratory disease of equids (horses, donkeys, mules, and zebras) 
caused by infection with type A influenza virus.10  Equine influenza virus (EIV) is highly 
pleomorphic, spherical, or filamentous with a diameter of 80-120 nm and a segmented (8 
segments), single-stranded RNA genome of negative sense. The eight gene segments 
encode for eleven polypeptides: two envelope glycoproteins (hemagglutinin [HA] and 
neuraminidase [NA]), two matrix proteins (M1 and M2), two nonstructural proteins (NS1 
and NS2/NEP), three proteins that make up the viral RNA polymerase (PB1, PB2 and 
PA), and the nucleocapsid protein (NP), as well as a recently discovered PB1-F2 
mitochondrial protein 11-12 Equine influenza virus was first isolated in Hungary in 1956 
following a widespread epidemic of respiratory disease in horses in Eastern Europe and 
the virus was subsequently isolated in the United States. The initial strain of EIV, was 
characterized as subtype H7N7 and designated influenza virus A/equine/Praque/56 
[equine influenza subtype-1 or A/equine-1;13-14].  Minor antigenic drift was identified 
within the H7N7 subtype. The last confirmed outbreak caused by this virus was recorded 
in 1979. A second EIV subtype, H3N8 prototype (influenza A/equine/Miami/63 [equine 
influenza subtype-2 or A/equine-2]) was first isolated in Miami, Florida, USA in 196315-
16  Subtype H3N8 viruses have been identified with all recorded outbreaks of equine 
influenza in the past 25-30 years. Extensive antigenic drift has been detected in this virus 
over the years.17-20  Phylogenetic analysis based on the nucleotide sequencing of the 
hemagglutinin gene has led to categorization of EIV isolates from around the world into 
?? 
two lineages: American and Eurasian lineages.21 Currently, equine H3N8 influenza virus 
continues to be the single most important equine respiratory pathogen of the horse in 
many countries around the world.  Equine influenza is considered endemic in the USA, 
UK, and many European countries.   Australia, a country previously free of EI, suffered 
an outbreak in 2007.  The virus was apparently brought into Australia with horses 
imported from Japan22, despite the fact that Japan itself had not experienced an outbreak 
of EI for 35 years prior to 2007.23  In 2005, inter-species transmission of EIV H3N8 
subtype from horse to dog was reported for the first time.24   
 Cases of influenza occur most commonly in the spring and fall.  EI has a short 
incubation period of only one to three days. Therefore, the disease can spread rapidly 
through a group of susceptible horses and cause very high morbidity by 24-48 hours after 
exposure to the virus.  The virus attacks and damages the respiratory tract lining and 
normally, it takes three weeks for the lining to regenerate, which predisposes the 
respiratory tract to secondary bacterial infection or to recurrent airway obstructive 
disease.25  The clinical signs of influenza usually include a high fever, depression, and 
anorexia. In uncomplicated influenza cases, most clinical signs last from 2 to 10 days, but 
affected horses often develop a dry, nonproductive cough that can last for weeks.  
Intermandibular lymph nodes may become enlarged and some horses may experience 
muscle soreness.  Horses can develop a generalized vasculitis, which is manifested as 
dependent swelling of the limbs, inflammation of the heart resulting in a high heart rate, 
and inflammation of the eye resulting in tearing and squinting of the eye.16    
 
Equine rhinitis virus 
 Equine rhinitis A virus (ERAV; family Picornaviridae, genus Aphthovirus) and 
equine rhinitis B viruses 1 and 2 (ERBV 1 and ERBV 2; family Picornaviridae, genus 
Erbovius) are recognized as the causes of an acute respiratory disease with systemic 
clinical signs in horses.26-27 Seroprevalence data reported in different studies indicated 
that neutralizing antibodies to ERAV and ERBV can be found in from 50% to 80% of 
horses worldwide and the presence of antibodies seems to be correlated with the age of 
the animals.28-31 Most of ERAV, ERBV1, and ERBV2 isolates have been recovered from 
horses with acute febrile respiratory disease with clinical signs of fever, nasal discharge, 
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anorexia, leg edema, and enlarged lymph nodes.  However, horses may carry and shed 
virus in their urine for a long time. Subclinical infection and subsequent seroconversion 
were also reported.32-33 Due to difficulty in isolation of these viruses in cell culture, 
ERAV is relatively infrequently isolated, and hence was rarely diagnosed prior to the 
validation of molecular diagnostic methods. Epidemiologic studies have shown that 
ERAV is a primary cause of respiratory disease in horses, although it might have been 
underestimated when evaluating equine respiratory outbreaks.9,27  
Equine arteritis virus 
 Equine arteritis virus (EAV; family Arteriviridae, genus Arterivirus) is the 
causative agent of equine viral arteritis (EVA), which can cause respiratory disease and 
abortions.34 Stallions infected with EAV may shed the virus in their semen for months to 
years and are capable of transmitting the infection to mares during artificial insemination 
or natual breeding.  Equine arteritis virus is spread by respiratory and venereal routes, and 
the persistently infected carrier stallion is the essential natural reservoir of the virus.34-35  
The clinical signs associated with EAV infection are similar to other viral respiratory 
diseases and can vary from severe to subclinical infections. This disease should be 
suspected if the following clinical signs are present: 1) pronounced discharges from the 
eyes, 2) dependent limb edema, 3) edema of the periorbital or supraorbital areas, 
midventral regions, scrotum, prepucec and mammary gland, and 4) abortion in the later 
acute or early convalescent phase of the infection.36  A detailed introduction to EAV and 
EVA will be provided in the second part of this chapter.  
 
DNA viruses 
Alphaherpesvirus 
 Equine herpesvirus-1 and equine herpesvirus-4 (family Herpesviridae, subfamily 
Alphaherpesvirinae, genus Varicellovirus	 ? are the major viral causes of reproductive and 
respiratory disease in equine populations worldwide.37 Both viruses cause upper 
respiratory tract infection in horses, and EHV-1 is also the single most significant cause 
of viral abortion in pregnant mares. Acute, naturally occurring respiratory disease due to 
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EHV-1 or EHV-4 is characterized by fever, anorexia, nasal discharge of varying severity, 
and sometimes as ocular discharge. Clinical signs of the respiratory form of EHV-1 and 
EHV-4 are typically seen in young horses and frequently weanlings less than two years of 
age.  Certain neuropathogenic strains of EHV-1 can cause myeloencephalopathy in horses 
of any age.38 EHV-1 and EHV-4 establish life-long latent infections in lymphoid as well 
as in neural tissues in a high percentage of infected animals. The CD5+/CD8+ T 
lymphocytes are believed to be a significant site of EHV-1 latency, which is 
independently and indirectly activated by both IL-2 and equine chorionic 
gonadotrophin.39  Reactivated EHV-4 is predominantly shed in nasal secretions from 
natually-infected horses following corticosteroid treatment.40 The reactivation of latent 
virus results in virus shedding and the risk of transmission to susceptible horses.37,41  
Gammaherpesvirus 
 Gammaherpesvirus includes EHV-2 and EHV-5.42  Equine herpesvirus-2 (family 
Herpesviridae, subfamily Gammaherpesvirinae, genus Rhadinovirus	  is ubiquitous in 
equine populations worldwide and has been associated with a variety of clinical disorders 
including respiratory tract disease, generalized malaise, fever, pharyngeal lymphoid 
hyperplasia, enlarged lymph nodes, keratoconjunctivitis, granulomatous dermatitis, and 
abortion.43-50 EHV-2 shares many similarities with Epstein-Barr virus, the causative agent 
of human infectious mononucleosis, which is characterized by fever, persistant sore 
throat, and generalized lymphadenopathy.51   
 Equine herpesvirus-5 (family Herpesviridae, subfamily Gammaherpesvirinae, 
genus Percavirus) has been linked to multinodular pulmonary fibrosis (EMPF), a fibrotic 
interstitial lung disease of horses older than four years.52-53 The virus has been detected in 
nasal swabs and peripheral blood leukocytes in young and adult horses with or without 
clinical signs of respiratory disease.53-55  
 
Equine adenovirus 
 The earliest reports of equine adenovirus (EAdV; family Adenoviridae, Genus 
Mastadenovirus) isolation were obtained from pneumonic lungs of Arab foals in the 
United States in 1969 and in Germany in 1971. 56-58 Two serotypes of EAdV designated 
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EAdV-1 and EAdV-2 have been isolated to date. Studies have shown that EAdV-1 is 
predominantly associated with upper respiratory tract infections, conjunctivitis, and 
bronchopneumonia, while EAdV-2 has mainly been isolated from horses with 
gastrointestinal tract infections.59? ? Clinical signs exhibited by adult horses with 
serological evidence of infection included mild respiratory signs and soft feces. Signs 
persisted in individual horses for four to eight weeks over a period of three to four 
months, although not all infections were associated with clinical disease. The possible 
association of soft feces with adenovirus infection may be important in the differential 
diagnosis of infectious respiratory disease.6  Equine adenovirus-1 is primarily associated 
with the uniformly fatal, inherited disease syndrome, primary severe combined 
immunodeficiency disease (PSCID). When PSCID was first recognized in the early 
1970s, it was estimated that it caused the death of about 3% of all purebred Arabian foals. 
Foals are born with a total absence of T and B lymphocytes. The disease is inherited as an 
autosomal recessive gene.60-61    
1.1.2 Diagnosis of equine respiratory viruses  
1.1.2.1 Conventional diagnostic methods for equine respiratory viruses  
 There are essentially four approaches which can be utilized in attempting a 
diagnosis by conventional laboratory methods: 
1. Isolation and identification of the infectious agent. 
2. Demonstration of the presence of or a significant rise in specific antibodies during 
the course of disease (serologic diagnosis).  
3. Histopathological examination of infected tissues for characterization and 
determination of specific viral pathogens.  
4. Electron microscopy to visualize and characterize a viral pathogen.  
It is not always possible or necessary to follow all these suggested diagnostic 
approaches in each case.  The decision on which approach to follow is largely determined 
by the nature of the infection encountered, the stage of the illness in which the horse is 
first seen, and the amount of information the method will yield in relation to the time and 
effort involved.   
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Virus isolation 
 It was the discovery that poliovirus could replicate in nonneural tissue culture that 
revolutionized diagnostic virology.62  Generally, three main types of cell cultures are used: 
primary cell cultures, diploid cell lines, and continuous cell lines.  Primary cell cultures 
are made directly from animal or human tissues and can be passaged for only a few times. 
Diploid cell strains are generally derived from embryonic tissues, particularly embryonic 
lung, and in some cases can be passaged up to 50 times. Continuous cell lines are usually 
derived from human or animal tumors and can divide indefinitely.63  After inoculation 
into cell culture, viruses can induce changes, such as rounded refractile cells or grape-like 
clusters called cytopathic effect (CPE).  Some viruses such as respiratory syncytial virus 
and parainfluenza virus, can induce characteristic syncytial formation while others, such 
as some strains of ERAV or ERBV and bovine viral diarrhea virus (BVDV), may 
produce no visible changes. These require other tests to identify their presence.27,64  
Preliminary identification of a virus isolate can be made based on the type of cell culture 
where the virus growing and the characteristic of CPE. For instance, cytomegalovirus 
induces CPE only in human fibroblast cells, while herpes simplex virus induces CPE in 
both human fibroblast and rabbit kidney cells.63  However, the final confirmation usually 
requires a neutralization test using virus-specific antiserum.  Ability to isolate virus in 
cell culture greatly facilitates the study and characterization of viruses, allows antigen 
production, and development of vaccines.   
 The three primary benefits of virus isolation in tissue culture include:  
 (1). It has the ability to propagate a number of animal and human viruses, the 
generation of infectious virus particles for biological characterization, and potential 
production of killed and modified live vaccine.65 By inoculating several cell lines, it is 
possible to isolate known and unknown viruses. Because there are no virus-specific 
reagents required, cell culture allows clinicians to amplify any virus that has the ability to 
replicate in a particular cell line. This is a big difference compared to molecular 
diagnostic methods which requires the pathogen’s genome sequence be known prior to 
diagnosis.  
 (2). Live virus particles can be used to characterize certain viral biological 
features such as cytopathic effect and size of the viral particles which cannot be obtained 
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through use of a nucleic acid assay. Oseltamivir (Tamiflu), an influenza virus 
neuraminidase (NA) inhibitor, is characterized by a NA enzyme inhibition assay.66-67 
Recently, some genetic markers indicative of antiviral resistance to this drug have been 
identified.68 Without actually testing the biological response of each virus to each 
antiviral drug/gene, the resistance pattern is only a deduction.  
 (3). The cost of cell culture is relatively inexpensive because it does not require 
expensive modern diagnostic equipment.  
 While the advantages are beneficial, these are often outweighed by distinct 
disadvantages. It can take 5-14 days to get results from virus isolation. Often, the sick 
horse has already recovered by that time, rendering the diagnosis of little value in guiding 
treatment. Virus isolation also requires expertise to interpret results, particularly the 
capability of differentiating CPE caused by one virus from that of another. Finally, 
because tissue culture relies on inoculation of a virus from a specimen, sample selection, 
collection, handling, and storage are critical to insure that infectious virus is not 
inactivated before the specimen can be inoculated into cell culture.  
 
Immunologic diagnostic methods 
 Immunologic diagnostic methods are a group of rapid techniques based on a 
specific reaction between antigen and antibody.  The reaction must be labeled with a 
marker which can be a fluorescent dye, a radioisotype, or an enzyme such as peroxidase.  
Immunofluorescence (IF) techniques have long been used for the diagnosis of viral 
infections. The method was introduced by Albert Coons and colleagues in 1941,69 and 
was first applied to the direct detection of influenza A virus in nasal smears in 1956.70 In 
the 1980s, IF was applied to the diagnosis of RSV,71 parainfluenza,72-73 and adenovirus,74 
and recently to human metapneumovirus (HMPV).75 Immunofluorescence is labor 
intensive; yet when done well, it is the most sensitive and specific immunoassay and able 
to detect just one infected cell. Immunofluorescence is also the only current immunologic 
method that can screen for 7 to 8 viruses in a single assay.76  
 The enzyme-linked immunosorbent assay (ELISA) is another commonly used 
immunologic method for viral diagnosis.  Whereas IF detects only viral proteins in 
infected cells, ELISA can also detect cell-free viral proteins.  In the 1980s, a microwell 
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ELISA was first applied to the detection of respiratory viruses, RSV77-78 and influenza A 
virus.79  In veterinary diagnostic laboratories, ELISA has been developed for the 
detection of EHV-1, EHV-480, ERAV,81 and ERBV.82 Membrane ELISA is a type of 
ELISA using individual cassettes and requiring no equipment.  It only takes 20-30 
minutes to complete and is considered a first generation rapid test for RSV and influenza. 
Current examples include Directigen RSV and Directigen Flu A+B kits. The latter can 
also be used in detection of equine influenza viruses.  A successful ELISA test requires 
high titers of virus shed because no amplification step is involved in the process.  
Therefore, in clinical practice, it may not be sensitive.  Careful and thorough washing is 
critical to avoid false positive results. For membrane assays, viscous samples such as 
nasopharyngeal aspirates can trap reagents and give rise to false positive results. 
 The virus neutralization (VN) assay is one of the most trusted and widely used 
methods employed for the detection of virus-specific neutralizing antibodies.83 The 
power of the neutralization assay lies in its ability to detect biologically active antibodies.  
It is the most sensitive and accurate method for identifying a virus isolate. VN is 
considered the “gold standard” for detection and determination of antibodies to EAV.84 
Currently, the VN is the only validated test accepted for international trade.  Although the 
VN is highly sensitive and accurate, it has several disadvantages: it is expensive, labor-
intensive, and time-consuming to perform.  In addition, results can vary among 
laboratories when adequate attention is not paid to standardization of both test reagents 
and procedure.  Moreover, serum cytotoxicity caused by anti-cellular antibodies directed 
against cells can be mistaken for viral CPE and give rise to difficulties in test 
interpretation at lower serum dilutions.  Also, the VN cannot differentiate an antibody 
response of vaccinated from naturally infected horses.   
 
Electron microscope 
 The electron microscope (EM) has been used in the diagnosis of viral diseases for 
decades.  This is the only method that allows a virus to be directly visualized.  Virus size 
and shape can be easily identified.  Although it may take there or more days to prepare a 
specimen, it is still a reliable diagnostic method since the fine structure of the virus 
particles and cells are very likely to be preserved.  The recognition of a human 
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papovavirus in the brain cells of a patient with progressive multifocal 
leukoencephalopathy and the identification of Epstein-Barr virus in cultured 
lymphoblastic cells derived from a Burkitt’s lymphoma patient would have been missed 
had not EM been used.85-86 In the 1970s, the application of EM and immune EM (IEM) 
contributed to the identification of a number of new viruses which could not be isolated 
in cultures, e.g.hepatitis A and B viruses, enteric adenoviruses, rotavirus, and the 
Norwalk agent.87-91 However, despite the many contributions of EM and IEM to virus 
diagnosis, it is still too expensive and cumbersome for routine viral diagnosis.  
 Currently there is tremendous interest in the development of rapid diagnostic 
techniques. However, conventional diagnostic methods remain the most widely used and 
are critical in confirming the usefulness of newer techniques.63  
 
1.1.2.2 Molecular diagnostic methods 
 Nucleic acid amplification technology has opened new avenues of microbial 
detection and characterization, such that growth in cell culture is no longer required for 
microbial identification.  Over the past decades, the focus of rapid diagnosis of infectious 
disease has shifted towards the nucleic acid amplification-based techniques, primarily 
PCR at the expense of traditional methods of clinical microbiology.92  
 
1.1.2.2.1 Standard PCR technology 
 The application of PCR as a diagnosic method was first developed in 1985 for the 
prenatal diagnosis of sickle cell anemia.93  It was based on the remarkable insight of Kary 
Mullis, who realized that repetition of a DNA extension reaction bounded by two 
synthetic oligonucleotide primers would generate a large quantity of any specified DNA 
sequence.94  The basic technique of PCR includes repeated cycles of amplifying selected 
nucleic acid sequences.  Each cycle consists of three steps: 1) a DNA denaturation step, 
in which the double strands of the target DNA are separated; 2) a primer annealing step, 
performed at a lower temperature, in which primers anneal to their complementary target 
sequences; and 3) an extension step, in which DNA polymerase extends the sequence 
between the primers.  At the end of each cycle, the amount of PCR product is doubled.  
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Therefore, performance of 30 to 50 thermal cycles results in an exponetial increase in the 
total number of DNA copies amplified.95-96 
 Initially, PCR required the addition of thermolabile Escherchia coli DNA 
polymerase at each cycle, limiting its applications, although one of the earliest papers 
describing the detection of human papilloma virus (HPV) DNA by PCR used an 
automated pipetting device for the addition of the polymerase.97 Two unique innovation 
that made PCR available to scientists were the purification of a thermostable polymerase 
from Thermus aquaticus (Taq) which is heat stable and the invention of thermal cycling 
heating blocks, both of which came from Mullis and other scientists at the Cetus and 
PerkinElmer corporations. Although Taq polymerase is the most widely used polymerase; 
it lacks a 3'-5' exonuclease activity.  There are other enzymes available, some of which 
have properties that make them better suited than Taq for certain purposes. For example, 
Pfu from Pyrococcus furiosus has a higher copying fidelity than Taq and is a better 
choice for sequencing or protein expression studies where nucleotide misincorporation is 
not acceptable.98  
 
Reverse transcriptase -PCR 
 Numerous modifications of the standard PCR procedure have been developed.99-
101 Some of these modifications greatly expand the diagnostic capabilities of PCR. 
Reverse transcriptase-PCR (RT-PCR) was developed to target RNA molecules.  The 
RNA is first reverse transcribed into complementary DNA (cDNA) using the reverse 
transcriptase (RTase).  The cDNA is further amplified using DNA polymerase. MMLV 
reverse transcriptase from the Moloney murine leukemia virus and AMV reverse 
transcriptase from the avian myeloblastosis virus are the commonly used reverse 
transcriptases.  However, with the technolgy development, more RTases were generated 
using recombinant technology. For instance, the SuperScript II and SuperScript III 
RTases are engineered version of MMLV RTase with reduced RNase H activity and 
increased thermal stability. The PowerScript RTase is a point mutant of MMLV RTase 
which lacks the RNase H enzyme and retains wild-type polymerase activity, thus being 
able to synthesize longer cDNA fragments.102  The conventional RT reactions are 
fastidious because the enzyme can not tolerate higher temperatures. Accordingly, the RT 
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and PCR steps are normally separate which limits wide application of this method in 
clinical diagnosis.  Nowadays, many companies provide commercial RTase and DNA 
polymerase mixtures which make the single-tube one-step RT-PCR possible.  After the 
reverse transcription step, reactions are heated to a high temperature (normally 95 ºC) to 
activate heat-stable DNA polymerase and to simultaneously inactivate the reverse 
transcriptase.  The single-step RT-PCR dramatically enhances the diagnostic capability of 
detect RNA viral pathogens. 103-104 
 
Nested PCR 
 Nested PCR was developed mainly to increase the sensitivity of the assay using 
two sets of primers.105-106  One set of primers is used for first round of amplification and 
the amplification product of the first reaction is then subjected to a second round of 
amplification with another set of primers that are specific for an internal sequence that 
was amplified by the first primer pair.  The sensitivity of the nested PCR is extremetly 
high due to the dual amplification process.  The DNA product from the first round 
contains the hybridization sites for the second primer pair.  Therefore, the second primer 
set further verifies the specificity of the first-round product.  However, the major 
disadvantage of the nested PCR is the high risk of cross-contamination during transfer of 
the first-round amplification products to a second reaction tube. This can be overcome if 
the inner and outer primers are all present in the initial reaction mix and the primer sets 
use substantially different annealing temperatures.99 
 Semi-nested PCR is a modification of nested PCR.  Instead of using two primer 
pairs (a total of four primers) in nested PCR, semi-nested PCR uses the same one primer 
for both rounds (a total of three primers).107-110 Semi-nested PCR is also highly sensitive 
as compared to nested PCR, but the potential chance of cross-contamination is still a big 
disadvantage.   
 
Multiplex PCR 
 Multiplex PCR is an amplification process in which two or more sets of primer 
pairs specific for different targets are introduced into the same tube.111  Therefore, more 
than one DNA target in a specimen can be detected simultaneously.112  It is critical to 
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design primers that have similar annealing temperatures, which often requires extensive 
optimization.  Multiplex PCR can be used to detect multiple pathogens in a single 
specimen for diagnostic purposes.113-116  The amount of target DNA or RNA in a 
specimen can also be quantified using a quantitative competitive PCR, which is a 
variation of the multiplex PCR.117-118 
 
Broad-range PCR   
 Another important technical modification is the development of the broad-range 
PCR, in which a conserved sequence within phylogenetically informative genetic targets 
is used to diagnosis microbial infection.  A universal primer set designed to target 
herpesvirus DNA polymerase might be useful to detect different types of herpesvirus 
infection in one reaction.119   Broad-range ribosomal RNA (rRNA) PCR techniques offer 
the possibility of rapid bacterial identification through use of a single pair of primers 
targeting bacterial small-subunit 16S rRNA or DNA.120-122  
 Overall PCR technology has distinct advantages as a diagnostic tool over 
conventional microbology, especially in the detection of slow-growing, difficult-to-
cultivate, or noncultivatable microorganisms. It can be used successfully in situations 
where inhibitory substances, such as antimicrobials, are present. Due to the stability of 
DNA, pathogens can be detected in a variety of specimen types, even in formalin-fixed 
tissue. The PCR also has inherent disadvantages. The risk of amplicon contamination is 
very high. Specifically, as the PCR amplifies the target, any contamination will also be 
amplified. Plus it is difficult to set up a quantitative assay.  In addition, PCR requires 
laborious post-PCR handling steps to visualize the amplified end products. These 
problems are being addressed by the development of commercial automated systems such 
as the Roch Cobas Amplicor which requires minimum handling.  The use of synthetic 
internal competitive targets in these commercial assays has facilitated the accurate 
quantification of the results.  However, these assays are very expensive which is a hurdle 
to their application for routine diagnostic purposes. 
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1.1.2.2.2 Real-time PCR technology 
 Technological advances in PCR thermocycler performance and fluorescent signal 
detection in the early 1990s allowed introduction of a second-generation real-time PCR 
method in 1996 employing TaqMan® chemistry.123  This method uses a fluorescent dual-
labeled probe added to the PCR reaction mix.  The 5 prime exonuclease activity of the 
DNA polymerase displaces and digests the probe upon primer extension.  This causes the 
release of the quenched fluorescent signal, which is measured during each PCR cycle in a 
closed-tube detection system, hence the term real-time. A digital camera collects 
fluorescence signal in real-time and the data are stored on a computer.  All post-PCR 
analysis is computer-based and does not require any agarose-gel analysis.  The 
development of rPCR has revolutionized the way clinical microbiology laboratories 
diagnose human and animal pathogens.124-127 This approach is a highly sensitive 
technique enabling simultaneous amplification and quantification of specific nucleic acid 
sequences. In addition to enhanced sensitivity, the benefits of real-time PCR assays over 
conventional detection methods include their large dynamic range, a low risk of cross-
contamination due to its close-tube format, high-throughput applications, and the 
potential for accurate target quantifications.128-130 Real-time PCR is suitable for a wide 
range of applications such as gene expression analysis, determination of viral load, 
detection of genetically modified organisms, single nucleotide polymorphism genotyping, 
and allelic discrimination.  Detection of target sequences occurs by monitoring the 
fluorescence generated by intercalating dyes, fluorophore-labelled primers, or sequence-
specific probes.  There are many probe chemistries other than TaqMan® and those will be 
dicussed in detail in the following section.      
 
1.1.2.2.2.1  Detection formats 
1.1.2.2.2.1.1  Detection formats without sequence confirmation of the PCR product 
 Fluorescent dyes such as ethidium bromide (EtBr) that are specific for double-
stranded DNA (dsDNA) were the first systems applied in real-time PCR assays in the 
early 1990s.131 They used a video camera to detect the accumulation of dsDNA in each 
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PCR using the increase in fluorescence of EtBr that results from its binding to duplex 
DNA. Other intercalating dyes such as YO-PRO-1 have also been used.132-133 Nowadays, 
SYBR Green I is the most commonly used intercalating dye in real-time PCR (Fig 1.1).  
 
Fig 1.1. Principle of SYBR Green I technique. SYBR Green I fluorescence increases 
enormously upon binding to double-stranded DNA. During the extension phase, more 
and more SYBR Green I will bind to the PCR product, resulting in increased 
fluorescence. Consequently, during each subsequent PCR cycle more fluorescent signal 
will be detected. Modified from Van der Velden et al (2003)134 with permission. 
  
 It has a 100 times higher binding affinity than ethidium bromide, and the 
fluorescence of bound dye is more than 1000-fold higher than that of free dye. These 
features make SYBR Green I highly suitable for monitoring product accumulation during 
PCR.135-136 The biggest disadvantage using intercalating dyes is that non-specific dsDNA 
products, such as primer dimers can interfere with the assay signal and yield false 
positive results. Therefore, it is important to optimize the assay prior to use in clinical 
diagnosis to avoid non-specific amplification products. To solve this problem, specific 
PCR products can be discriminated from these potential artifacts by using melting curve 
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analysis, in which the melting temperature (Tm) of the product is determined.137 Different 
melting curves can be easily distinguished from each other, indicating that the PCR 
products were not all identical in sequence.  Another detection technology known as 
“LUX (Light Upon eXtention)” utilizes self-quenched fluorogenic primers which are 
labeled with a single fluorophore on a base close to the 3?-end with no quencher required. 
A tail of 5-7 nucleotides is added to the 5'-end of the primer to form a blunt-end hairpin 
when the primer is not incorporated into a PCR product. This design provides a low 
initial fluorescence of the primers that increases upon formation of the PCR product.138-
139 A similar approach called Amplifluor Quantitative PCR detection system uses both 
labeled and unlabeled primers. The PCR primers contain hairpin structures on their 5?-
ends with donor and acceptor moieties located in close proximity on the hairpin stem. 
The primers are designed in such a way that a fluorescent signal is generated only when 
the primers are incorporated into an amplification product.128,140-141 Both of these systems 
are highly flexible but have not been used frequently for diagnostic tests.  
  
1.1.2.2.2.1.2 Detection formats with increased target specificity 
 Sensitive and specific detection is possible with real-time PCR by using novel 
fluorescent probe technology. The incorporation of a probe confirms the specificity of the 
amplicon. Fluorophore-labelled oligonucleotide probes are most commonly used for the 
specific detection of target sequences.142-144 Three types of nucleic acid detection 
chemistries have been used most frequently with real-time PCR formats in clinical 
microbiology: 5' nuclease (TaqMan® probes), molecular beacons, and fluorescence 
resonance energy transfer (FRET) hybridization probes.125 Collectively, these 3 types of 
probes are frequently referred to as FRET probes. However, when specifically referring 
to each of these three probes in the following section, only FRET appears in the name of 
FRET hybridization probes. In these assays, an increase in fluorescent signal proportional 
to the accumulation of PCR product arises as a consequence of FRET between two 
separate fluorogenic labels (reporter and quencher) conjugated to the probe. FRET is a 
spectroscopic process by which energy is passed over a maximum distance of 70Å 
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between reporter and acceptor molecules possessing overlapping emission and absorption 
spectra.145  
 For all types of FRET probes, FRET decreases as the distance between adjacent 
dye molecules increases. For TaqMan® probes or molecular beacons, the reporter and 
quencher dyes are attached to a single probe. In contrast, for FRET hybridization probes, 
dyes are attached separately to two probes that align in a head-to-tail configuration on 
target nucleic acids. The first dye is a fluorescent dye and the second is either a quencher 
dye or another fluorescent dye which can absorb fluorescent light transferred from the 
first dye and reemit light at a different wavelength. The most widely used detection 
chemistries are briefly reviewed below.   
FRET hybridization probes 
 Hybridization probes use a pair of adjacent, fluorogenic hybridization oligos and 
are the only detection format that directly measures FRET.142 FRET probes are labeled 
with different fluorescent dyes and are designed to anneal in a head-to-tail orientation to 
the target DNA between the PCR primers (Fig 1.2).  
 
Fig 1.2. Principle of hybridization probes technique. In this technique one probe is 
labeled with a donor fluorochrome at the 3' end and a second probe is labeled with an 
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acceptor fluorochrome. When the two fluorochromes are in close vicinity (i.e. within 1–5 
nucleotides), the emitted light of the donor fluorochrome will excite the acceptor 
fluorochrome. This results in the emission of fluorescence, which subsequently can be 
detected during the annealing phase and first part of the extension phase of the PCR 
reaction. After each subsequent PCR cycle more hybridization probes can anneal, 
resulting in higher fluorescence signals.  Modified from Cardullo et al (1988)142 with 
permission. 
 
 The upstream probe contains a donor fluorophore at the 3?-end; the downstream 
probe contains an acceptor fluorophore at the 5?-end. When the probes hybridize next to 
each other, fluorescence energy is transferred from the donor to the acceptor fluorophor, 
causing it to emit a unique fluorescent signal that can then be measured. If the two probes 
do not anneal adjacent to each other, a signal is not generated; therefore, nonspecific 
events do not contribute to the fluorescent signal. The requirement that a second probe 
bind before a signal is generated increases the number of specific events required for 
signal generation. Theoretically, this additional requirement enhances specificity beyond 
single fluorescent probe formats, like those that use TaqMan® probes.    
 
TaqMan
®
 probes 
 The first real-time fluorescent probes developed were 5’ nuclease probes, which 
are commonly referred to by their proprietary name, TaqMan® probes (Fig 1.3).  
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Fig 1.3. Principle of TaqMan
®
 hydrolysis probe technique. The hydrolysis probe is 
conjugated with a quencher fluorochrome, which absorbs the fluorescence of the reporter 
fluorochrome as long as the probe is intact. However, upon amplification of the target 
sequence, the hydrolysis probe is displaced and subsequently hydrolyzed by the Taq 
polymerase. This results in the separation of the reporter and quencher fluorochrome and 
consequently the fluorescence of the reporter fluorochrome becomes detectable. During 
each consecutive PCR cycle this fluorescence will further increase because of the 
progressive and exponential accumulation of free reporter fluorochromes. Modified from 
Livak et al (1995)146 with permission.  
 
 A TaqMan® probe is a short dual-fluorophore-labelled oligonucleotide (DNA) 
that contains a 5'-terminal reporter dye (e.g. FAM) and a 3'-terminal quencher dye (e.g. 
TAMRA). To generate a light signal, two events must occur. First, the probe must bind to 
a complementary strand of DNA at 60 ºC. Second, at this temperature, Taq polymerase, 
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the same enzyme used for the PCR, must cleave the 5' end of the TaqMan probe, 
separating the fluorescent dye from the quenching dye. Once the dyes are separated by 
destroying the TaqMan probe based on the 5' exonuclease activity of the DNA 
polymerase, the increase in reporter fluorescence caused by the removal of the adjacent 
quencher dye is monitored by a real-time PCR instrument.146-148  
 One important point is that the Tm of the probes should be higher (usually 5-10 ºC) 
than that of the primers to ensure strong binding of the probes during annealing. 
Therefore, the probes are normally between 20 and 30 nucleotides long. The design of 
this relatively long nucleotide may sometimes be difficult to optimize because of a 
particular AT-rich region in the sequence or becaue of sequence variability.149  
 A modification of this strategy exploits the so-called minor groove binding (MGB) 
probes. MGB probes form extremely stable duplexes with single-stranded DNA targets 
mediated mainly by van der Waals forces, and as a result, shorter-length probes are 
required for hybridization. A/T rich duplexes are stabilized more than G/C rich duplexes, 
therefore increasing Tm and simplifying design.150 The shorter MGB probes are ideal for 
allele discrimination studies or for detection of single-nucleotide polymorphisms (SNPs) 
because they are more significantly destabilized by nucleotide changes within the 
hybridization site compared with probes of long of length.151-153 
 In the TaqMan® assay, the requirement that 5'-3' hydrolysis be performed between 
the fluorophore and quencher dye can be met only when these two moieties are not too 
close to each other.154 This is a serious drawback of the assay since the efficiency of the 
energy transfer decreases with the inverse sixth power of the distance between the 
reporter and quencher dye.155  
   
Molecular beacons 
Molecular beacons are similar to Taqman probes but are not designed to be 
cleaved by the 5' nuclease activity of Taq polymerase. These beacons are hairpin-shaped 
oligonucleotides with a fluorescent dye on the 5'-end and a quencher dye on the 3'-end 
(Fig 1.4).156-158  
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Fig 1.4. Principle of molecular beacons. The beacons are hairpin-shaped 
oligonucleotides with a fluorescent dye on the 5' end and a quencher dye on the 3' end. 
The central part of the probe is designed to be complementary to the PCR amplification 
target sequence. At high temperatures, both the PCR amplification product and probe are 
single stranded. When the temperature decreases, the central part of the molecular beacon 
probe binds to the target sequence and forces the separation of the fluorescent reporter 
dye from the quenching dye. Therefore the effects of the quencher dye are obviated and 
the light signal from the reporter dye can be detected. Modified from Tyagi et al 
(1998)157 with permission.  
 
A region at each end of the molecular beacon probe is designed to be 
complementary to itself, so at low temperature, the ends anneal forming the hairpin 
structure. This integral annealing property puts the two dyes in close proximity, 
quenching the fluorescence from the reporter dye. The central part of the probe is 
designed to be complementary to the PCR amplification target sequence. At high 
temperatures, both the PCR amplification product and probe are single stranded. When 
the temperature decreases, the central part of the molecular beacon probe binds to the 
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target sequence and forces the separation of the fluorescent reporter dye from the 
quenching dye. Therefore the effects of the quencher dye are obviated and the light signal 
from the reporter dye can be detected. If no PCR amplification product is available for 
binding, the probe reanneals to itself, forcing the reporter dye and quencher dye to move 
together, preventing a fluorescent signal.125  
Typically, a single molecular beacon is used for detection of a PCR amplification 
product and multiple beacon probes with different reporter dyes are used for single 
nucleotide polymorphism detection. By choosing appropriate PCR temperatures and/or 
extension of the probe length, molecular beacons will bind to the target product when an 
unknown nucleotide polymorphism is present but at a slight cost of reduced specificity.  
The advantage of molecular beacons is that no specific temperature thermocycling 
machine is required so that the temperature optimization of the PCR is simplified. 
Molecular beacons have been used to detect viral pathogens such as SARS virus and 
hepatitis B virus.159-160  
 
Scorpion primer 
 Scorpions are bi-functional molecules that carry both primer and probes together 
on the same oligonucleotide construct (Fig 1.5).161   
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Fig 1.5. Principle of scorpion primers. Scorpion contains primer, probe sections, and a 
blocker. After annealing, the primer section is extended by the DNA polymerase. After 
strand separation, the probe section of the Scorpion oligodeoxynucleotide hybridizes to a 
region downstream from the primer sequence during the annealing step of the PCR 
reaction. The hairpin structure of the Scorpion primer is blocked from extension to ensure 
that the reporter dye and quencher are only separated by specific hybridization of the 
probe section to the target sequence.  Modified from Whitcombe et al (1999)161 with 
permission.  
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 The probe is attached as a tail to the primer element through a PCR blocker that 
ensures the probe element does not get incorporated into the double-stranded product.162   
The Scorpion construct is arranged such that the probe element is complementary to the 
anticipated extension product of the primer element. The probe carries a reporter 
fluorphore that is quenched with a non-fluorescent quencher through a collisional 
mechanism. The quencher is held in close proximity to the fluorophore by base pairing 
which can be achieved by introduction of a stem-loop in the probe or through a second 
molecule, substantially complementary to the probe element.161   
 There are several advantages of a Scorpion probe. The appearance of signal is 
rapid and reliable, because probe-target binding is kinetically favored over duplex 
reannealing and thermodynamically favored over intrastrand secondary structures.161 
Scorpion probe’s unimolecular binding events makes this technology faster and more 
efficient than the bimolecular mechanism because it does not depend on enzymatic 
cleavage of the probe.163 This method works very well for the detection of amplicon and 
the detection is highly specific, down to the level of single base changes. The use of 
stems in the probe element offers two advantages: first, background signals are minimal 
because signals from unincorporated Scorpion primers are switched off; second, the stem 
can be designed to be thermodynamically favored over the binding of probe to mismatch 
target.161 Therefore, a Scorpion probe is commonly used in allelic discrimination.161,163 
Development of a cystic fibrosis mutation detection assay shows that Scorpion primers 
are selective enough to detect single base mutations and give good sensitivity in all cases. 
Simultaneous detection of both normal and mutant alleles in a single reaction is possible 
by combining two Scorpions in a multiplex reaction.163 Single nucleotide polymorphism 
(SNP) genotyping is another important application for Scorpion primers.164  
 
Locked nucleic acid (LNA) probes 
 Locked nucleic acids (LNA) are a novel class of bicyclic DNA analogs in which 
the 2? and 4? positions in the furanose ring are joined via an O-methylene (oxy-LNA), S-
methylene (thio-LNA), or amino-methylene (amino-LNA) moiety (Fig 1.6).165-166  
??  

 
Fig 1.6. Chemical structures of DNA, RNA and LNA. LNA forms stable hybrid 
duplexes with DNA and RNA. Duplexes formed between two LNA oligonucleotides 
exhibit unparalleled affinity and specificity. LNA units can be incorporated into normal 
DNA or RNA oligonucleotides to increase the stability of probe-target hybrids. This is 
manifested as an increased melting temperature (Tm) of the hybrid duplex.  Modified 
from Kumar et al (1998)166 with permission.  
  
 The characteristics of LNA include: unprecedented thermal stabilities of duplexes 
towards complementary DNA and RNA; stability towards 3?-exonucleolytic degradation; 
efficient automated oligomerization, and good aqueous solubility.166 The affinity between 
LNA toward complementary nucleic acids is by far the highest reported for a DNA 
analog.166 The very high affinity allows the design of small probes because the specificity 
of a probe is inversely related to its size. These markedly shorter probes are used as 
allele-specific tools in genotyping assays.149,167-169 
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1.1.2.2.2.2 Multiplexing 
 Multiplex PCR is the simultaneous amplification of more than one target 
sequence in a single reaction.170 The ability to multiplex PCR by probe color and Tm 
greatly expands the power of real-time PCR application. Each PCR probe has a unique 
Tm which can distinguish between different PCR products. This allows PCR multiplexing 
by Tm, a powerful tool with a multiplexing potential similar to that of fluorescence 
emission spectra. Simple hybridization probes with only a single fluorescent dye can be 
used for quantification and allele typing. Different probes are labeled with dyes that have 
unique emission spectra. Spectral data are collected with discrete optics or dispersed onto 
an array for detection.171  
 Many different fluorescence techniques are available for real-time PCR. Dyes like 
SYBR Green I can be used in any amplification, but they are not sequence-specific and 
not feasible for multiplexing by color.  
 Color multiplexing is possible with oligonucleotide probes that are labeled with 
different fluorescent groups. Real-time PCR instruments can discriminate between the 
different dyes. The signal from each dye is used to separately quantitate the amount of 
each target (Fig. 1.7). The multiplex PCR assays must be validated and often require 
optimization, which can be a challenge. It is necessary to keep in mind that since both 
assays are amplified in the same tube, they compete for the same reagents. This 
competition needs to be minimized. The two assays can also inhibit each other through 
interactions among the primers and probes, amplicons, or any combination of these. The 
goal is to accurately quantitate the amount of individual target without interference from 
competition or inhibition between assays. It is common to have duplex dyes depending 
on the application. More than three dyes can be used at the same time. TaqMan probe, 
MGB probe, or Scorpion probe are commonly used probes for multiplex real-time 
PCR.172-176  
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Fig 1.7. Common reporter fluors and quenchers used in multiplex real-time PCR. 
Modified from www.operon.com  with permission. 
 
 For duplex real-time PCR testing, there are three possible scenarios for the 
relative expression level of the two targets:  
1. One target (typically the endogenous control) is always abundant. In such cases, 
the greater starting quantity of the more abundant target causes the assay for that target to 
perform better than the other from the start, using up the reagents, and leaving little for 
the other assay. This problem can be solved by limiting the amount of primer for the 
more abundantly expressed target. As a result, the primers for that assay are used up 
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quickly, leading the reaction to plateau early and leaving sufficient reagents for the 
amplification of the less abundant target. 
2. The two targets are expressed at similar levels. In this situation, neither assay 
needs to be primer-limited. The assays can simply be run as single or duplex reactions. If 
validations fail, it might require a primer-limit in one or both assays to ensure the 
duplexing performs better. 
3. Either target may be more abundant. If either target could be more abundant than 
the other, depending on the samples being investigated, then both assays need to be 
primer-limited.171  
 Multiplexing PCR can be used in detection of common respiratory viruses such as 
influenza A and B viruses and respiratory syncytial virus from nasophayngeal 
specimens.177-180 They can also be used to detect and determine different genotypes or 
serotypes of the target virus.181-182  
 
1.1.2.2.2.3 Quality control in real-time PCR technology  
 Quality control allows the laboratory to minimize the reporting of inaccurate 
results, to report results with a high degree of confidence, and to decrease costs by 
detecting errors prior to reporting results. The ultimate goal of quality control is to reduce 
the number of controls needed for reporting reliable results.  
 
Lab settings 
 The appropriate arrangement or design of a PCR laboratory is of great importance 
in maintaining a high standard of performance. As a minimum requirement, three 
dedicated areas are necessary: the reagent preparation area which is mainly to prepare the 
PCR master mix, the specimen preparation area which refers to the DNA/RNA extraction 
area, and the PCR detection area.  If more space is available, it may be used to good 
advantage.  This one-way workflow will significantly reduce the chance of cross-
contamination. 
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Positive and negative controls 
 The ideal positive control is a specimen containing the target nucleic acid, but this 
is often not practical or feasible. An acceptable positive control is pooled negative 
specimens spiked with the infectious organism, or a representative sample of the nucleic 
acid to be detected. The positive control should be at the concentration near the lower 
limit of detection of the assay to challenge the detection system but still high enough to 
provide consistent positive results.125  
 Water or buffer is commonly used as a negative control. However, an ideal 
negative control is a sample containing non-target nucleic acid to determine that the 
nonspecific PCR amplification and detection of amplified product is not happening. 
Additionally, the negative control is used to demonstrate that the reagents are not 
contaminated and can be used to compensate for background signal generated by the 
reagents.183 A carryover contamination due to PCR products from previous PCR runs is a 
major source of PCR contamination. This problem can be reduced by adding enzyme 
uracil-N-glycosylase to remove uracil from dUMP incorporated into any contamination 
molecules, leaving apyrimidinic sites which will be destroyed by cleavage at the abasic 
sites at a later PCR amplification step.184 
 
Internal and inhibition controls 
 The use of an internal control is an important aspect of quality control. The 
internal control is necessary for ensuring adequate efficiency of RNA extraction and 
confirming the absence of PCR-inhibitors in each sample, therefore reducing false 
negative results.183 It is a valuable tool when testing nucleic acid extracted from difficult 
biological matrices such as degraded samples where the presence of PCR-inhibitors could 
cause big problems. In such cases, co-amplification of an internal control increases the 
reliability of the results and is used to validate negative results.  
 There are different formats of internal controls. One approach is to detect an 
endogenous gene that is present naturally in the test specimen. The selected gene should 
be present as a constant, basal cell cycle-independent level of transcription that is not 
influenced by the cellular pathology associated with the disease tested by the real-time 
PCR. Genes fulfilling these criteria are commonly known as housekeeping genes such as 
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glyceraldehydes-3-phosphate, ?-actin, 18S ribosomal RNA, glutamate decarboxylase 
(GAD), and ?2-microglobulin.185-192 In contrast to an endogenous internal control, an 
exogenous internal control does not occur naturally within the nucleic acid preparation. 
This type of internal control can be designed to contain an all-purpose heterologous target 
sequence or a complete heterologous viral genome which is unrelated to the sequence to 
be tested.193-197 The exogenous internal control can be added to each test sample before 
either the template extraction step or prior to real-time PCR amplification testing. 
Depending on the particular design of the internal controls, amplification of the control 
sequences may require an extra set of primer pairs in the reaction. Alternatively, in vitro 
transcripts, plasmids, or chimeric viruses can be generated containing homologous target 
sequences for the same primer pair as the diagnostic test. These “mimic” internal controls 
can contain internal sequences not present in the target amplicon to yield an 
amplification198 product with a different length, which can be differentiated a from wild-
type amplicon by a second, internal control-specific probe.183,198-200  The advantage of 
this type of control is that it directly monitors the performance of diagnostic primer sets 
ensuring that the appropriate PCR components have been added.  
 
1.1.2.2.2.4 Application of real-time PCR in detecting equine respiratory viruses  
 Many techniques discussed in this section have been used in veterinary diagnostic 
laboratories to detect common equine respiratory viruses.  Our lab has taken leadership in 
developing several TaqMan® real-time PCR assays for the detection of EIV, EAV, equine 
rhinitis viruses A and B, and EHV-1.201-203  The development and evaluation of the real-
time PCR assays for the detection of EIV, EAV, and equine rhinitis viruses will be 
discussed in the following chapters in detail.  Several real-time assays developed by other 
groups are also available for the detection of these common viral pathogens. For instance, 
Quinlivan et al (2005) developed a real-time PCR targeting equine influenza virus using 
SYBR Green I and evaluated the assay with conventional virus isolation and Directigen 
Flu A test.204  There was a significant positive correlation (P< 0.05) between the 
quantitative RT-PCR and both of these assays.  Mori et al (2009) developed a duplex 
real-time PCR for the detection of equine rhinitis A and B viruses.205  Quinlivan et al 
(2010) developed two single real-time PCR for the detection of equine rhinitis A and 
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B.206  All of these molecular assays have tremendously increased the detection capability 
of equine viral pathogens which has been beneficial to the equine industry.  
------------------------------------------------------------------------------------------------------------ 
1.2 Introduction to equine arteritis virus attachment and entry 
1.2.1 Equine viral arteritis 
 Equine viral arteritis (EVA) is a contagious disease caused by equine arteritis 
virus (EAV) infection. EVA was first described perhaps 450 years ago with clinical 
descriptions of “pinkeye”, “infectious or epizootic cellulitis”, “influenza erysipelatosa”, 
“Pferdestaupe”, “Rotlaufseuche”, and “equine influenza” in the European veterinary 
literature.207-211 However, the virus was first isolated during an outbreak of respiratory 
disease and abortion on a Standardbred breeding farm in Bucyrus, Ohio, in 1953.212 
Serologic surveys have confirmed EAV is present in many horse populations throughout 
the world; Japan and Iceland are notable exceptions.34,213-219 The consequences of EAV 
infection range from subclinical infection to a flu-like illness in adult horses, abortion in 
pregnant mares, and interstitial pneumonia in neonatal foals.34,215,220-222 A variable 
percentage (from 10-70%) of acutely infected stallions can become persistently infected 
carriers after natural infection and continue to shed virus in their semen for periods that 
range from several weeks to the lifespan of individual stallions.34,223-225 Carrier stallions 
are the natural reservoir of EAV; they ensure the virus is maintained in equine 
populations between breeding seasons.34 Furthermore, EAV behaves as a quasispecies in 
the reproductive tract of the carrier stallion and novel genotypic and phenotypic variants 
arise during persistent infection.35,226-227 
 Transmission of EAV can occur either by respiratory or venereal routes. Aerosol 
transmission of EAV occurs after aerosolization of infected respiratory tract secretions 
from acutely infected horses. Venereal transmission of EAV occurs during natural or 
artificial breeding of a carrier stallion to susceptible mares.228-231 Mares that become 
infected can then acutely transmit the virus by the respiratory route to susceptible cohorts 
in close proximity.  EAV persists only in the reproductive tract of carrier stallions, mainly 
in the ampulla of the vas deferens. It has been demonstrated that testosterone plays a 
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critical role in the establishment and maintenance of the EAV carrier state in the stallion. 
Persistently infected stallions eliminate the virus following castration, whereas those that 
receive sufficient testosterone after castration continue to shed virus in their semen.223,231 
Persistent EAV infection does not occur in geldings, mares, fetuses, or in colts infected 
by the virus prior to their puberty. 34,223-224,232-233 The shedding of virus in carrier stallions 
is not related to the titer of neutralizing antibody in the serum, indicating that the humoral 
immunity alone does not prevent the virus persistence in the male reproductive system.231  
 Following respiratory infection, the virus initially replicates in endothelial cells 
and pulmonary macrophages, from which it rapidly spreads into the regional lymph 
nodes, especially in the lung and the bronchial lymph nodes, and from where it is 
disseminated throughout the body. In addition to the primarily infected macrophages and 
endothelial cells, EAV can also replicate in other cell types such as epithelial cells, 
mesothelium, and smooth muscle cells of small blood vessels and myometrium.36,234-235 
The immune response to EAV infection can be divided into two categories: innate 
immunity and adaptive immunity.  The innate immune response of the mucosal lining of 
the respiratory and genital tracts is the first line of defense after natural exposure to EAV. 
Equine arteritis virus infection of equine macrophages results in increased transcription 
of genes encoding proinflammatory mediators, including IL-1?, IL-6, IL-8, and TNF-?, 
with the release of substantial quantities of TNF-? into the culture medium.236   
Furthermore, virulent and avirulent strains of EAV induced different quantities of TNF-? 
and other proinflammatory cytokines (IL-1?, IL-6, IL-8), and the magnitude of the 
cytokine response of macrophage to EAV infection reflected the virulence of the 
infecting virus strain.236  These studies clearly show that cytokine mediators are produced 
by EAV infected equine cells and, presumably, play an important role in determining the 
nature and severity of the outcome of infection.  The humoral immune response to EAV 
includes the development of both complement-fixing (CF) and virus-specific neutralizing 
(VN) antibodies. 237-238 The CF antibodies appear between 1-2 weeks and peak 2-3 weeks 
after EAV infection in adult horses and ponies.238 Neutralization of EAV is complement 
dependent and is associated with the IgG fraction of the late antiserum, but not the early 
antisera or their IgG and IgM fractions.239-242  The requirement of complement for 
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efficient virus neutralization is also virus strain dependent.243-244 The humoral immune 
response to EAV is mainly directed to the major envelope proteins, GP5, M, and N 
proteins 245-251.  The neutralization determinants of EAV are located in the GP5 protein 
and at least four potential neutralization sites on the N-terminal hydrophilic ectodomain 
of the GP5 protein, including aa 49 (site A), 61 (site B), 67-90 (site C), and 99-106 (site 
D) have been characterized.252 It is speculated that the aa changes in the GP5 n-terminal 
ectodomain, especially if they occur during persistent infection in carrier stallions, 
contribute to the emergence of EAV strains with different neutralization phenotypes.253 
Besides neutralizing antibodies recognizing GP5 protein, horses also produce non-
neutralizing anti-GP5 antibodies in response to EAV infection or immunization with an 
inactivated whole-virus vaccine.247,254  Non-neutralizing antibodies against N and M 
proteins 249,251,254 were detected as early as 14 days post-infection and lasted at least 145 
days in sequential sera from horses experimentally infected with EAV.250  
 
1.2.2 Equine arteritis virus 
 1.2.2.1  Genome properties and organization 
 Because of the similarities in genome organization and protein expression 
strategies, the Arteriviridae (genus Arterivirus), Coronaviridae (genera Coronavirus and 
Torovirus) and Roniviridae (genus Okavirus) were grouped together in the order 
Nidovirales.255 The name Nidovirales, derived from the Latin nidus for nest, reflects the 
nested-set arrangement of the subgenomic mRNAs (sg mRNAs) produced by this order 
of viruses during their replication cycle. The Nidovirales are grouped based on their 
phylogenetic relationships and genome organization. There are four members in the 
arterivirus genus: equine arteritis virus (EAV), porcine respiratory and reproductive 
syndrome virus (PRRSV), lactate dehydrogenase-elevating virus (LDV), and simian 
hemorrhagic fever virus (SHFV).256  
 Equine arteritis virus (EAV) is a single-stranded, positive sense RNA virus.  It is 
the causative agent of equine viral arteritis (EVA) in horses and other equids.212,255,257 
The virion of EAV is spherical with a diameter of 40 to 60 nm. The isometric core 
particle (25 to 35 nm in diameter) is surrounded by a relatively smooth envelope that 
lacks large projections.  EAV genome length varies between 12,704 to 12,731 bp among 
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different strains.255,258-259  The EAV genome includes a 5? leader sequence and at least 
nine ORFs (Fig 1.8). 260-261   
 
 
Fig 1.8.  The EAV particle and genome organization.  A. Overview of the 
polycistronic nature of EAV genome.  The leader sequence and leader TRS (transcription 
regulating sequence) located at the 5?-end of genome are indicated as a red circle and a 
yellow box, respectively.  Translation of E and GP2 genes occurs by leaky scanning of 
the 5’-proximal end of sg mRNA2.262  The green square indicates the newly identified 
open reading frame, ORF5a, and the protein is likely to be expressed from the same sg 
mRNA.263 B. Schematic representation of the EAV particle. The viral RNA is 
encapsidated by the nucleocapsid protein (N; encoded by ORF7) into an isometric core 
which is surrounded by an envelope containing eight structural proteins.  
 
 The two most 5?-proximal ORFs (1a and 1b) occupy approximately three-quarters 
of the genome and encode two replicase polyproteins (pp1a and pp1ab).  The two 
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precursor proteins are extensively processed after translation into at least 13 nsps (nsp1-
12, including nsp7 ?/?) by three viral proteases (nsp1, nsp2 and nsp4).258,264-265  The 
structural proteins of EAV are expressed from a 3?-coterminal nested set of sg mRNAs 
and not from the genomic RNA.  Three of the minor envelope proteins (GP2, GP3, and 
GP4) form a heterotrimer in the EAV particle, which may also interact with another 
minor envelope protein E.256,262  The two major envelope proteins (M and GP5) form a 
disulfide-linked heterodimer in the EAV virion.266-268  The GP5 protein expresses the 
known major neutralization determinants of EAV.252-253,269-273  Although there is 
considerable variation in the sequence of the GP5 protein of field strains of the virus, 
there is only one known major serotype of EAV and all strains evaluated thus far are 
neutralized by polyclonal equine antiserum raised against the Bucyrus strain of EAV.34,229  
However, field strains differ both in their neutralization and virulence phenotypes and not 
all strains are neutralized to the same degree.227-228,252,259,274 
EAV is stable at -70 °C for years without significant loss of infectivity.  Virus 
infectivity is lost within six months at room temperature, and after a month at 37 °C.275  It 
has been reported that tissue culture fluid containing the experimentally derived virulent 
Bucyrus strain of EAV survived more than 75 days at 4 °C, 2~3 days at 37 °C, and 20~30 
min at 56 °C.276 Lyophilized virus is highly stable at -20 °C and moderately stable at 
4 °C.277 
 
1.2.2.2  Equine arteritis virus life cycle 
 Equine arteritis virus can be propagated in a variety of primary cell cultures such 
as equine macrophages, equine endothelial cells, equine kidney cells, and hamster kidney 
cells.236,276,278-279 Many other continuous cell lines such as rabbit kidney (RK-13), baby 
hamster kidney (BHK-21), African green monkey kidney (Vero), human cervix cells 
(Hela), and mouse connective tissue (L-M) are also susceptible to EAV infection.280-282 
Equine arteritis virus infection of primary cells and continuous cell lines is highly 
cytocidal. The appearance of cytopathic effect (CPE) in EAV-infected cells is 
characterized by rounding of cells and cell dissociation from the culture plate 
surface.276,281 The appearance of CPE varies among different cell lines.  
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(I) Virus attachment and entry    
The initial events in a viral infection consist of attachment of the virus to the 
surface of the host cell, followed by penetration of the virus particle into the cytoplasm of 
the cell. The success of these events depends on the recognition of specific molecules 
(receptors) on the cell surface by the virus. The replication cycle of EAV has been 
studied extensively. However, there is very limited information on EAV receptor binding 
and virus entry.  Previous studies have shown that heparin treatment of EAV can reduce 
plaque formation by 14% as compared to untreated control virus.289 The 
hemagglutination caused by EAV was also inhibited by heparin.290 Mouse erythrocytes 
treated with heparinase can dramatically reduce the agglutination activity of EAV.290 
Therefore, all the data suggest that a heparin-like molecule plays an important role in 
EAV infection, probably in the attachment and entry step. But the precise mechanism of 
this aspect of EAV infection is not yet known. 
 The viral protein involved in receptor attachment and binding is still a mystery. 
By analogy with many other animal RNA viruses and in view of its recognition by 
neutralizing antibodies, it has been speculated for many years that the ectodomain of the 
arterivirus major glycoprotein GP5 is involved in receptor recognition. However, direct 
experimental studies by exchanging the ectodomain of the EAV GP5 protein with that of 
PRRSV or LDV in the context of an infectious EAV cDNA clone did not alter the cell 
tropism of the virus.291  Similarly, PRRSV mutants in which the ectodomain of the M 
protein was replaced by that of EAV or LDV retained the ability to infect porcine 
alveolar macrophages and did not aquire tropism to cells susceptible to the respective 
viruses from which the foreign ectodomains were derived.292 These results indicate that 
neither GP5 nor M proteins are responsible for receptor binding of EAV although they 
are the main neutralization antibody recognition sites. It is anticipated that the EAV 
minor envelope glycoproteins GP2, GP3, and GP4 together with minor structural protein 
E are likely to mediate the initial virus attachment to the host cell surface based on the 
fact that the E, GP2, GP3, and GP4 proteins are not required for the formation of EAV 
particles, although these proteins are believed essential for ensuring that the virus 
particles are infectious, however detailed experiments have not been performed.262,268,293  
A very recent publication by Tian et al used a PRRSV infectious cDNA clone to replace 
??  
its own minor structural protein genes encoding E, GP2, GP3, and GP4 with those of 
EAV. The chimeric virus expressing EAV ORF2ab34 gained the broad in vitro cell 
tropism of EAV, indicating that the minor envelope proteins (GP2, GP3, GP4, and E) 
play a critical role as viral attachment proteins.294  This is direct evidence that minor 
envelope structural proteins are involved in cellular tropism determination.  
 The entry of EAV into BHK cells is mediated via clathrin-dependent endocytosis 
and delivery to acidic endosomal compartments.283 The plaque formation is strongly 
inhibited by substances which interfere with clathrin-dependent endocytosis and by 
lysosomotropic compounds. The infection of BHK cells is suppressed when antisense 
RNA against clathrin-heavy chain is used. Other members of the family Arteriviridae, 
such as PRRSV use a similar receptor-mediated, low pH-dependent pathway to enter host 
cells.295-296 
  The process of EAV attachment and entry still needs further investigation. The 
virus attachment molecules and/or receptors need to be identified.  It is not clear whether 
EAV uses the same receptors in different cell lines or whether different EAV strains use 
the same or different receptors.  
(II) Biosynthesis: genome translation and replication, mRNA 
transcription, and viral protein synthesis 
A. Genome translation and post-translational processing of replicase 
polyproteins  
  The EAV replication cycle starts with the expression of the replicase gene from 
the genome. Replicase ORF1a and ORF1b, generated from -1 ribosomal reading 
frameshift, are both expressed from the genomic mRNA. The ORF1b ribosomal 
frameshift is located just before ORF1a.260  There are two signals assumed to promote 
this event: a “slippery signal” 5’ GUUAAAC 3’ and a downstream RNA pseudoknot 
structure.256  
 Translation of the EAV replicase gene yields two large polyproteins: the 
polyprotein (pp) 1a and pp1ab. The EAV pp1a and pp1ab are cleaved by three ORF 1a-
encoded proteases: nsp 1, nsp 2, and nsp4.264,288,297-299 The nsp1 protease is a papain-like 
cysteine protease (PCP) which directs an autoproteolytic cleavage at C terminus (Gly-260 
| Gly-261) of pp1a resulting in the rapid release of nsp1.298 The EAV PCP mediates 
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probably exclusively in cis cleavage, and attempts to achieve cleavage in trans were 
unsuccessful.298,300 The nsp2 protease is a cysteine protease which cleaves nsp2 at 
position Gly-831 | Gly-832.298 The nsp2|3 cleavage can be performed in cis or in trans, 
although trans-cleavage activity is relatively low.265,299 The nsp4 protease is the major 
viral protease which contains several unique characteristics. It utilizes the His-Asp-Ser 
(His-1103, Asp 1129, and Ser-1184) catalytic triad, a typical characteristic of classical 
chymotrypsin-like protease.301 The putative substrate-binding region of nsp4 protease 
also contains Thr and His residues (Thr-1179 and His-1198) which are conserved in viral 
3C-like cysteine proteases and determine the specificity of cleavage sites containing a 
(Glu/Gln) | (Gly-Ser) dipeptide.301 Therefore, the nsp4 protease was defined as the 
prototype of a novel group of chymotrypsin-like enzymes, the 3C-like serine proteases 
(3CLSP). It mediates five cleavages in pp1a and three in ORF1b-encoded polypeptides. 
But these sites are not equally sensitive to the nsp4 protease. The C-terminal half of the 
EAV pp1a can be cleaved via two alternative pathways.302(Fig 1.10)  
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Fig 1.10. Overview of the proteolytic processing of the EAV replicase ORF1a and 
ORF1ab polyproteins. The three EAV proteinases (located in nsp1, nsp2, and nsp4), 
their cleavage sites, and the EAV nsp nomenclature are displayed. Abbreviations: PCP, 
papain-like cysteine proteinase; SP, serine proteinase; RdRP, RNA-dependent RNA 
polymerase; Z, zinc finger; Hel, helicase; N, Nidovirus-specific conserved domain. The 
association of cleaved nsp2 with nsp3-8 (and probably also nsp3-12) was shown to direct 
the cleavage of the nsp4|5 site by the nsp4 proteinase (major pathway). Alternatively, in 
the absence of nsp2, the nsp5|6 and 6|7 sites are processed, and the nsp4|5 junction 
remains uncleaved. Figure modified from Wassenar et al (1997)302 with permission.   
 
 In the major pathway, the nsp4 first cleaves the nsp 4|5 site, followed by cleavage 
of the nsp 3|4 and nsp 7|8 junctions, and the nsp 5-7 remained uncleaved. In the minor 
pathway, the nsp 4|5 is not cleaved. Instead, the nsp 5|6 and nsp 6|7 sites are cleaved, 
followed by cleavage of the nsp 3|4 and nsp 7|8 sites. These two pathways are mutually 
exclusive and multiple processing intermediates are generated.302 The presence of 
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liberated nsp2 is believed to determine whether the nsp4 serine protease will cleave the 
nsp 4|5 site of the nsp 3-8 precursor and thus the major pathway takes place.  
B. Genome replication 
The RNA synthesis (including genome replication and mRNA transcription) 
depends on the viral-encoded RNA-dependent polymerase. As discussed before, the nsp1, 
nsp2, and nsp4 are viral proteases. The nsp9 to 11 contain highly conserved domains 
which are crucial for EAV genome replication and subgenomic transcription. Based on 
comparative sequence analysis, a putative RNA-dependent RNA polymerase and a NTP-
binding RNA/helicase motif were identified in nsp9 and nsp10, respectively.303-304  
A typical feature of arterivirus replication is the formation of paired 
membranes and double membrane vesicles (DMV) at 3-6 h post infection.285 DMV are 
approximately 80 nm in diameter. The inner and outer membranes of DMV are tightly 
apposed but clearly separated.285 These profiles sometimes contain a neck between the 
paired EM-membrane and a forming DMV which is not pinched off. Biochemical and 
immunofluorescence assays have revealed that most EAV replicase subunits and viral 
RNA synthesis co-localize to the perinuclear region of the infected cells.287 Those 
replicase subunits are associated with intriguing DMVs which appear to be derived from 
the endoplasmic reticulum (ER) since the outer membrane of DMV is sometimes 
continuous with the ER.285 Very similar membrane alternations can be induced, in the 
absence of EAV infection, upon expression of the ORF1a-encoded replicase subunits 
nsp2 and nsp3. However, when nsp2 or nsp3 are individually expressed, DMV are not 
visible.286 These data strongly suggest the ORF1a-encoded replicase subunits play 
important roles in the formation of a membrane-bound scaffold for the EAV replication 
complex. With the development of a robust in vitro RNA synthesis assay, the active EAV 
replication complex from infected cells was successfully isolated which allowed the 
initial biochemical characterization of its composition and RNA-synthesizing activity.305 
In that experiment, van Hemert et al isolated replication complex from cytoplasmic 
extracts by differential centrifugation and identified a 59-70 kDa cytosolic host protein 
factor which is required for the activity of DMV.305 Replicase subunits directly involved 
in viral RNA synthesis (nsp9 and nsp10) or DMV formation (nsp2 and nsp3) exclusively 
co-sedimented with the active replication/transcription complex. Subgenomic mRNAs 
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appeared to be released from the complex, whereas newly made genomic RNA remained 
more tightly associated. Taken together, these data strongly support a link between 
DMVs and the RNA-synthesizing machinery of EAV.305 
C. Subgenomic RNA synthesis 
  One of the hallmarks of the nidovirus replication cycle is the generation of a 
nested set of subgenomic mRNAs from which the the 3?-proximal region of the 
polycistronic genome is expressed.256 These sg mRNAs are 3? coterminal and contain a 
common 5? leader sequence which is derived from the 5? end of the viral genome. The 
leader sequence is fused to the sg mRNA “bodies” by a discontinuous transcription 
mechanism. There are two widely considered but conflicting models of arterivirus 
transcription: leader-primed transcription and discontinuous extension of minus-strand 
RNA synthesis (Fig 1.11).  
 
Fig 1.11.  Two transcription models in nidoviruses: “leader-primed transcription” 
306-308
 and “discontinuous extension of minus-strand RNA”
309
 models.  (A) The 
“leader-primed transcription” proposes that the discontinuous step of viral sg mRNA 
synthesis occurs during the plus-strand synthesis.  In this model, the production of new 
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genome RNA is continuous and the discontinuous step occurs during the plus-strand 
synthesis and the body TRS complementary to the minus-strand genome acts as promoter 
for transcription.  After transcription of a leader primer (+L) from the 3?- end of minus-
strand full-length genome, the leader TRS in this primer joins to the anti-body TRS in the 
minus-strand genome and is extended to generate sg mRNA.  (B) The alternative model, 
“discontinuous extension of minus-strand RNA model” proposes that sg-length negative 
strand is produced and functions as a template for generation of sg mRNA.  The anti-
body TRS may serve as a “jump” signal of the nascent minus-strand to leader TRS 
located at the 5?-end of the plus-strand full-length genome.  After the anti-leader (-L) is 
added to the nascent minus-strand, the sg-length minus-strand functions as template for 
transcription.  The latter model is more widely accepted based on data from biochemical 
and genetic studies.  Modified from Pasternak et al. (2006) 310 with permission.   
 
 Both models require transcription-regulating sequences (TRS; 5’-UCAAC-3’) 
that determine a base-pairing interaction between positive and nascent minus-strand RNA 
and are essential for leader-to-body joining. 311-313 In the “leader-primed transcription 
model”, transcription is initiated from the 3?-end of the minus-strand genome to produce a 
leader primer form with the 3?-terminal leader TRS base paired with the anti-TRS in the 
minus-strand genome. In this model, the production of new genome RNA is continuous 
and the discontinuous step occurs during the plus-strand synthesis and the body TRS 
complementary to the minus-strand genome acts as promoter for transcription.306-308 
Another “discontinuous extension of minus-strand RNA model” was proposed by Sawiki 
and Sawiki which is also the widely accepted model. 309 In this model, the anti-genome is 
produced in a continuous fashion while the sg mRNAs are produced by a discontinuous 
transcription mechanism controlled by the TRS. The EAV sg mRNAs contain a common 
5? sequence of 208 nt “leader”, which is identical to the 5? end of the viral genomic RNA. 
258 The leader TRS is located in a hairpin structure at the 3?-end of the leader and the 
body; the TRS is located upstream of each structural protein gene.314-316 The EAV 
genome contains 17 other 5?UCAAC3? motifs besides the leader TRS, only six of which 
function as body TRSs participating in a leader-body junction to generate major sg 
mRNAs 2-7.260  For instance, the RNA3 uses three alternative leader-body junction sites, 
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TRSs 3.1, 3.2, and 3.3 among which only TRS 3.2 is functional. There are two UCAAC 
boxes upstream of ORF4, -5 and -7 whereas three UCAAC sequences are found upstream 
of ORF2 and -2b.317 But only a single TRS has been identified as an active site for each 
sg mRNA. Taken together, the same sequence motif UCAAC can be actively, less 
actively, or not used for leader-body junction to generate mRNAs. The TRSs are thought 
to regulate transcription of the genome template and to serve as singles for either 
attenuation or termination of minus-strand RNA synthesis in all nidoviruses to produce 
subgenome-sized minus strands that are used for sg mRNA synthesis. 318 Minus-strand 
RNA synthesis, initiated at the 3?-end of the viral genome, is attenuated at one of the 
body TRS regions.310,319 Subsequently, the nascent minus strand carrying the body TRS 
complement at its 3’ end is translocated to the 5?-end of the genomic template. The 
genomic leader TRS functions as a base-pairing target for the 3? end of the nascent minus 
strand. When minus-strand synthesis resumes, nascent strands are extended with the 
complementation of the genomic leader sequence, producing a nested set of subgenome-
length minus-strand templates that are used for the subsequent synthesis of the various sg 
mRNAs. If attenuation does not occur, minus-strand RNA synthesis proceeds to yield a 
full-length complement of genome, which then is used as template for genome replication. 
In this model, the TRS at the 3?-end of the leader transcript base pairs with the 
complement of body TRS in the negative-stranded template allowing extension of the 
complement of genomic leader sequence in the nascent negative strand. 309  The resulting 
sg negative-stranded RNA serves as template for the synthesis of the corresponding sg 
mRNA. With some exceptions, only the 5?-proximal ORF is translated from each sg 
mRNA and therefore, the number of sg mRNA produced is proportional to the number of 
ORFs located downstream of ORF1b.  
(III) Virus assembly, budding and release 
 EAV gains its envelope from the internal membrane of the infected cells rather 
than from the plasma membrane. The assembly of EAV takes place at the cytoplasmic 
site of the endoplasmic reticulum (ER), and/or the Golgi complex. The newly synthesized 
genome is encapsidated into the N proteins forming the nucleocapsid, which becomes 
enveloped by budding through the ER-Golgi intermediate compartment that contains 
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membranes with viral envelope proteins.  Newly formed virions mature in the Golgi 
complex via exocytosis and are ultimately released from infected cells.320 
 It has been shown that seven EAV structural proteins (E, GP2b, GP3, GP4, GP5, 
M, and N proteins) are indispensable for the production of infectious progeny virus.262,267 
However, only the structural proteins GP5, M, and N but not the E, GP2, GP3, or GP4 
are essential for the formation of virus-like particles.268 Interestingly, all attempts to 
produce virus-like particles by the cotransfection of cells with expression plasmids 
encoding the EAV GP5, M, and N proteins were not successful indicating there must be 
additional factors involved in formation of the virus-like particles.268    
  
1.2.3 Virus receptors 
 The life cycle of viruses includes the following stages: attachment, entry, 
uncoating, replication, virion assembly, and progeny virus release. Virus can only infect 
cells to which they can bind. Therefore, a successful viral infection starts with the step 
where viral surface proteins have direct interactions with attachment factors and virus 
receptors on the surface of the cell. There are several key differences between receptors 
and attachment factors. The interactions between the virus particles and the attachment 
factors can be relatively non-specific. These interactions mainly contribute to concentrate 
virus particles on the cell surface rather than promote entry.321 In contrast, virus receptors 
actively promote virus entry into the cell by initiating conformational changes in the virus 
particle which lead to association with other co-receptors, membrane fusion, and 
penetration. Furthermore, receptors can activate signaling pathways through the plasma 
membrane to promote virus endocytic internalization. Therefore, it is the receptors, not 
the attachment factors, that determine the virus tropism to target cells. Following virus-
receptor interaction, viruses are able to enter the host cell to further replicate their 
genome and produce progeny virus.  
 Viruses use receptors and attachment factors in very diverse ways. Sometimes, 
one receptor is not sufficient for productive entry, and a co-receptor is required for virus 
entry.322-323 Many viruses use multiple and different attachment factors and receptors to 
enter into different cell types. Overall, the binding of attachment factors, receptors or co-
receptors to viral protein is a well-organized process. For example, human 
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immunodeficiency virus type 1 (HIV-1) can infect a variety of immune cells such as T 
lymphocytes and macrophages. The viral envelope glycoprotein gp120 of HIV-1 first 
attaches to the attachment factor, heparan sulfate, and then binds to its receptor, CD4 
molecule, which is mainly expressed on T lymphocytes and to a lesser extent in 
macrophages.324-325 After binding to the CD4 receptors, the macrophage tropic and the T 
lymphocyte tropic HIV strains (M-tropic and T-tropic respectively), require different co-
receptors to enter into cells. The ?-chemokine receptor CCR5 is the primary co-receptor 
for the M-tropic strain during the early and chronic phases of infection in macrophage 
cells. In contrast, the T-tropic isolates use the CXCR4 as the key cofactor in late-stage 
infection of primary CD4+ T cells.326 The use of attachment factors and multiple 
receptors allows conformational changes of gp120 to facilitate successful virus entry into 
different cell types. 322 
 
 1.2.3.1  Role of carbohydrates as cellular receptors and co-receptors 
 Carbohydrates covalently linked with other nonsugar moieties are generally 
classified as glycoconjugates. The glycoconjugates can be divided into different 
categories such as glycoproteins, glycopeptides, and glycolipids. Glycoconjugates on the 
cell surface are involved in cell-cell interactions and have an important role during virus 
attachment and entry into cells.  
 Sialic acids are a family of acid sugars that are usually found on the terminal 
capping positions of glycans which are linked to cell-surface glycoproteins and 
glycolipids. Sialic acids are commonly used as receptors or attachment factors by a 
number of viruses (e.g. orthomyxo-, paramyxo-, and papovaviruses).327-329 In the case of 
influenza A virus, sialic acid which is associated with galactose functions as the 
receptor.328 The sialic acid ?(2,3)-Gal linkage is recognized by avian and equine 
influenza viruses and the sialic acid ?(2,6)-Gal linkage is recognized by human viruses, 
whereas porcine viruses are able to recognize both.328  
 This specificity reflects the glycan structure that is expressed in the different 
species and is critical in preventing cross-species transmission. Since pigs have both 
types of receptors on respiratory epithelial cells, they were proposed to be the 
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hypothetical “mixing vessel” for assortment of avian and human influenza viruses. The 
emergence of influenza pandemics is related to reassortment of different strains of 
influenza virus resulting in a change of carbohydrate specificity. 
 In addition to sialic acids, another family of polysaccharides, glycosaminoglycan 
(GAG), is also a commonly used attachment factor to concentrate viruses on the cell 
surface and facilitate further entry.330 GAG is a long branched polysaccharide consisting 
of a repeating disaccharide unit. It covalently attaches to a core protein to form 
proteoglycan which is a subclass of glycoprotein. The GAG family includes chondroitin 
sulfate, dermatan sulfate, heparin, heparan sulfate, keratan sulfate, and hyaluronan. 
Among all the GAG members, heparan sulfate and heparin are the most commonly used 
receptors for viruses.  
 1.2.3.2  Receptors used by Nidoviruses 
 The order Nidovirales consists of three families: the Coronaviridae, the 
Arteriviridae, and the Roniviridae.331 Many receptors have been identified for the 
members of the genus Coronaviruses in the family Coronaviridae.  
 Murine hepatitis virus (MHV) strain A59, a member of the Coronaviridae family, 
uses the glycoproteins in the carcinoembryonic antigen-related cell adhesion molecule 
(CEACAM) family as its receptor.332-334 It has an extracellular domain with four Ig-like 
loops which can bind to the viral spike glycoprotein for attachment. Although most 
strains of coronavirus are species specific, it has also been demonstrated that these 
viruses can readily mutate during passage in vitro or in vivo to adapt to environmental 
changes. Under selective pressure, in vitro MHV variants with mutations in the spike 
glycoprotein can use human CEA as receptors to infect humans to cross the species 
barrier.335 Other coronaviruses such as human coronavirus strain 229E (HCoV-229E), 
transmissible gastroenteritis virus (TGEV), feline infectious peritonitis virus (FIPV), and 
canine coronavirus all use the cell membrane-bound metalloprotease, aminopeptidase N 
(APN) of their respective host species as their receptor.336-337  
 Angiotensin-converting enzyme 2 (ACE2) is the receptor for SARS-CoV.338 It 
has been shown that liver and lymph node sinusoidal endothelial cells C-type lectin 
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(LSECtin) functions as the attachment factor for SARS-CoV to concentrate viral particles 
in liver and lymph nodes.339 Other lectins such as CD209L can also augment virus entry; 
however, this molecule is not sufficient to confer susceptibility to a cell without the 
expression of ACE2.340 The precise relationship between lectin binding and subsequent 
specific binding to ACE2 is not clear yet. 
 Among the four members of the family Arteriviridae, only the cellular receptor 
for PRRSV has been studied extensively. PRRSV has a very restricted host tropism and 
prefers to infect the cells of porcine monocyte-macrophage lineage. Two putative 
receptors have been identified on porcine macrophages: heparan sulfate and 
sialoadhesin.341-343 It has been shown that both heparan sulfate and sialoadhesin are able 
to mediate the virus attachment to porcine alveolar macrophages (PAM). Attachment 
kinetic analysis reveals that the early attachment is mediated mainly via an interaction 
with heparan sulfate, followed by a gradual increase in interaction with sialoadhesin. By 
using the CHO cells and CHO mutant cells which are deficient in heparan sulfate 
expression, it has been shown that heparan sulfate alone is sufficient to mediate PRRSV 
attachment, but not entry, and sialoadhesin functions as a PRRSV internalization 
receptor.344 Recently, Calvet et al used a cDNA library derived from PAM cells to 
identify CD163 as the PRRSV receptor.345  Transfection of CD163 cDNAs to PRRSV 
nonsuceptible cells successfully confers susceptibility to the virus and yields a high titer 
of progeny viruses.345 Further studies suggest that CD163, rather than being a receptor, 
functions as entry mediator involved in PRRSV uncoating, based on the observations that 
cells expressing recombinant sialoadhesin internalize PRRSV without uncoating the virus; 
whereas cells expressing both recombinant sialoadhesin and CD163 show virus uncoating 
upon internalization.346 In the current model for PRRSV infection of porcine 
macrophages, PRRSV first binds to its attachment factor, heparan sulfate, followed by a 
more stable interaction involving sialic acids present on the virion and the N-terminal 
sialic acid-binding domain of sialoadhesin.347-350 The sialoadhesin mediates the virus 
internalization process and CD163 is involved in virus uncoating.346   
 It has been reported that the receptor for LDV, another member of the family 
Arteriviridae, on macrophages correlated with the trypsin-sensitive molecule.351 Inada 
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and Mims et al (1984 and 1985) suggested that the I region-coded antigens (Ia) might be 
involved in LDV entry because most Ia-positive cells were LDV infected and treatment 
with trypsin subsequently removed the Ia antigens and simultaneously abolished 
susceptibility to LDV.352-353 In contrast, Buxton et al (1988) reported that Ia is not the 
receptor by showing trypsin treatment of macrophages destroyed the LDV receptor with 
minimal loss of the Ia antigen.354 Therefore, the receptor for LDV in the mouse 
macrophage is clearly not yet identified. 
1.2.4 Viral proteins responsible for receptor binding 
 1.2.4.1  Enveloped viruses 
 Among the enveloped viruses, the spike glycoprotein or projected viral protein is 
normally responsible for binding to the host cells. Typically, they are oligomeric, type I 
integral membrane proteins that have the bulk of their mass outside the membrane with 
the receptor-binding domain exposed.321  
 The hemagglutinin (HA) in the envelope spikes of influenza A virus is the 
receptor-binding protein of the virus.328 The HA has two peptide subunits called HA1 and 
HA2 and the entire HA spike is a trimer formed by three HA1/HA2 molecules.  HA1 has 
a large globule located at the membrane-distal tip. Each of the three large globules from 
the trimer form a small pocket as the receptor binding domain. As previously discussed, 
distinct sialic acid linkage expression on host cells decide receptor specificity and 
generally prevent cross-species transmission; however, there are several other factors that 
also contribute to the capability of influenza virus to cross the species barrier. Studies 
have shown that HA can shift binding specificity between sialic acid-?-2,6-galactose and  
sialic acid-?-2,3-galactose with as few as two amino acid changes (position 182 and 192) 
and avian H5N1 influenza A viruses with dual specificity have been isolated.355  
 The envelope glycoprotein gp120 of HIV-1 is responsible for binding to the CD4 
molecule on T cells. The gp120 binds to the most amino-terminal of the four 
immunoglobulin-like domains of CD4. The binding induces further conformational 
changes in gp120 to expose and form the binding sites for subsequent binding of specific 
chemokine co-receptors, CCR5 and CXCR4.356 Mutagenesis in conserved gp120 residues 
reveals several important amino acids for CD4 binding.357 Amino acid changes in two 
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hydrophobic regions (Thr-257 and Trp-427) and two hydrophilic regions (Asp-368, Glu-
370 and Asp-457) result in significant reductions in CD4 binding.358 A single amino acid 
(Trp-432) can abrogate CD4 binding and that mutant virus becomes non-infectious.359 A 
recent study has shown that the gp120 contains four heparan sulfate binding regions and 
three of them are also involved in co-receptor binding.360 
1.2.4.2  Non-enveloped viruses 
 In the case of nonenveloped viruses, the attachment depends on whether the virus 
has spikes or not. Adenoviruses have a triple helix spike which is formed from three 
identical fiber proteins. The C-terminal amino acids of each fiber form globular shapes 
that together create a knob with a deep indentation on its exterior surface. The different 
subgroups of the virus that recognize a given cell surface receptor have a distinctive set 
of amino acids in the knob indentation, suggesting that is the site for attachment.361  
 All the other nonenveloped viruses that lack spikes use their capsids to directly 
interact with the host cell receptors. The family Picornaviridae is the best studied 
example to demonstrate this interaction. Poliovirus is a member of the family 
Picornaviridae and the causative agent of poliomyelitis. The icosahedral symmetrical 
capsid of poliovirus is composed of 60 copies of 4 viral proteins (VP1, VP2, VP3, and 
VP4).362 The capsid surface is corrugated. It has a prominent star-shaped peak at the 5-
fold axis of symmetry, surrounded by a deep “canyon”. The canyon is considered the 
receptor binding position. 363 
 1.2.4.3 Arteriviruses 
 Among the four members in the family Arteriviridae, PRRSV has been studied 
extensively to identify viral proteins associated with the receptors. The structural M 
protein and the M-GP5 complex were reported to contribute to PRRSV attachment to a 
heparin-like receptor on porcine alveolar macrophages.341 Sialoadhesin was previously 
shown to be a sialic acid-binding lectin.364 When sialic acid was removed from the 
PRRSV virion surface, virus infection was almost completely blocked and virus 
attachment was reduced up to 50%. These data indicate that sialic acid on viral 
glycoprotein rather than viral protein itself may mediate virus attachment to 
sialoadhesin.347 
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 In the case of LDV, the cysteine residue in the short N-terminal ectodomain of the 
envelope protein M forms an intermolecular disulfide bridge with the cysteine residue in 
the ectodomain of the major envelope protein VP-3 (equivalent to GP5 of PRRSV and 
EAV). Treatment of LDV virions with 5 to 10 mM dithiothreitol, which is known to 
reduce disulfide bonds, can reduce the LDV infectivity quickly and irreversibly.365 These 
data suggest that the heterodimers of the M protein and the VP-3 glycoprotein are 
important for receptor binding.  
 Although it has been speculated that the major glycoprotein in arteriviruses is 
involved in receptor binding, direct experimental evidence using chimeric viruses 
containing envelope protein sequences from other arteriviruses have led to the opposite 
conclusion. In one experimental study, ectodomains of EAV GP5 and M were replaced 
with sequences from envelope proteins of other arteriviruses and unrelated RNA viruses. 
The only viable chimeras were those containing the GP5 ectodomains from porcine 
(PRRSV) or mouse (LDV) arteriviruses. These chimeric viruses can infect RK-13 and 
BHK-21 cells which are susceptible to EAV but nonsusceptible to PRRSV or LDV.291 
This implies that the ectodomain of GP5 of EAV is not the receptor binding domain in 
cell culture as expected. Similarly, PRRSV mutants in which the ectodomain of the M 
protein was replaced by that of other arteriviruses maintained the original cell tropism.292 
The available data of the EAV minor envelope glycoproteins GP2b, GP3, and GP4 
suggest that this complex is likely to mediate the initial virus attachment to host cell 
surface since noninfectious viral particles are produced in the absence of the GP2b, GP3, 
or GP4 protein, although detailed experiments have not been performed.262,268,293 A recent 
study using immunoprecipitation has shown that PRRSV scavenger receptor CD163 
interacts with GP2 and GP4.366 
 It has been shown that interaction among all minor (GP2, GP3, and GP4) and 
major (GP5 and M) enveloped proteins of EAV plays a major role in determining the 
CD14+ monocyte tropism while the tropism for CD3+ T lymphocytes was determined by 
GP2, GP4, GP5, and M envelope proteins but not the GP3 protein.367  Most recently, 
reverse genetic studies have shown that the minor envelope proteins (GP2, GP3, GP4,  
and E) play a critical role as viral attachment proteins for EAV.294  
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1.3.   Scope and outline of dissertation 
 Viral respiratory diseases can present a significant threat to both animal and 
human health.  The overlapping clinical presentation of various respiratory infections 
makes it difficult to predict the pathogens solely based on clinical signs or symptoms.  
The real-time reverse transcription polymerase chain reaction (rRT-PCR) has become one 
of the most commonly used methods in molecular diagnostics and research. This 
molecular technique provides fast, sensitive, and specific detection of viral nucleic acid in 
clinical specimens and thus becomes an indispensable tool for diagnosing important 
animal viral pathogens. A number of equine bacterial and viral pathogens cause 
respiratory infections in horses. Therefore, there is an urgent need for the detection and 
accurate identification of the viral respiratory pathogens involved in determinating the 
most appropriate quarantine and control measures to prevent the spread of different viral 
respiratory diseases.  
 As an obligatory intracellular infectious agent, viruses can only replicate inside of 
living cells or organisms. Therefore, successful infection depends on complex interaction 
between host and virus. At the molecular level, interactions that occur between cellular 
and viral gene products are the first step of virus infection and determine the host tropism 
of the infection.  Thus, elucidating the functional roles that viral proteins play during 
productive viral infection as well as identifying the cellular molecules involved in virus 
interaction is critical in preventing and treating viral diseases. 
 The objective of this project was to develop highly sensitive and specific real-time 
PCR assays for the detection of different equine respiratory viruses, and to study the role 
of major envelope viral protein GP5 and M, as well as minor envelope protein E using 
infectious cDNA clones, and study the importance of heparin in EAV attachment and 
entry.  Assays using rRT-PCR for the detection of the common equine viral pathogens 
equine arteritis virus (EAV), equine influenza virus, and equine rhinitis viruses A and B 
were developed, optimized, and validated. This provides the clinician and diaganostician 
with their capability to detect these common equine pathogens within a very short period 
of time. Furthermore, we investigated the functional analysis of viral proteins in relation 
to cellular tropism using a full-length infectious cDNA clone and reverse genetic systems. 
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The interactions of viral major and minor structural proteins that determine the host cell 
tropism are discussed and the role of heparin as an attachment molecule is then addressed. 
Development of diagnostic methods as well as understanding how cellular proteins 
interact with viral proteins will allow for a better understanding of viral pathogenesis and 
disease prevention and control.  
 Chapter one, literature review, provides a broad prespective on the molecular 
diagnostic methods and molecular biology of EAV.  
 Chapter two compares the two published real-time reverse transcription 
polymerase chain reaction assays for the detection of equine arteritis virus nucleic acid in 
equine semen and tissue culture fluid. The specificity and sensitivity of these two 
molecular-based assays were compared to traditional virus isolation (VI) in cell culture. 
The results revealed that the T1 assay developed by Balasuriya et al (2002) has a better 
sensitivity compared to the T2 assay developed by Westcott et al (2003), but was still less 
sensitive than the gold standard virus isolation test. The results of this study underscore 
the importance of comparative evaluation and validation of real-time RT-PCR assays 
prior to their recommended use in a diagnostic setting for the detection and identification 
of specific infectious agents.  
 Chapter three describes the development and evaluation of one-step TaqMan® 
real-time reverse transcription-PCR assays targeting NP, M, and HA genes of equine 
influenza virus. A total of eight rRT-PCR assays were developed and none of the eight 
assays cross-reacted with any of the other known equine respiratory viruses. All three 
rRT-PCR assays targeting the current circulating equine influenza virus H3N8 subtype 
have greater specificity and sensitivity than virus isolation by egg inoculation (93%, 89%, 
and 87% sensitivity for EqFlu NP, EqFlu M, and EqFlu HA3 assays, respectively). 
Comparison of the sensitivities of rRT-PCR assays targeting the NP and M genes of both 
subtypes with egg inoculation and the Directigen Flu A test clearly shows that molecular 
assays provide the highest sensitivity. 
 Chapter four describes the application of three H3N8 specific equine influenza 
real-time RT-PCR assays targeting the nucleoprotein (NP), matrix (M), and 
hemagglutinin (HA) genes of equine influenza virus (EIV NP, EIV M, and EIV HA3 
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assays) for the detection of canine influenza virus (CIV) in clinical specimens. The 
findings demonstrate that previously described real-time RT-PCR assays targeting NP, M, 
and H3 HA gene segments of H3N8 EIV are also valuable for the diagnosis of CIV 
infection in dogs. The assays should expedite the detection and identification of CIV. 
 Chapter five describes the development of one-step TaqMan® real-time reverse 
transcription-PCR and conventional reverse transcription PCR assays for the detection of 
equine rhinitis A and B viruses.  The assays targeting the 5?UTR or polymerase regions of 
rhinitis A and B regions are able to differentiate these two viruses and detect archived 
viruses. They provide fast and reliable detection methods for equine rhinitis A and B 
viruses.  
 Chapter six describes the generation of a panel of chimeric viruses by swapping 
the N-terminal ectodomains and full-lengths of the two major envelope proteins (GP5 and 
M) from porcine reproductive and respiratory syndrome virus (PRRSV). The 
recombinant viruses expressing the N-terminal ectodomain of PRRSV GP5 or M or 
together (GP5ecto, Mecto, and GP5&Mecto, respectively) in the EAV backbone were 
viable and genetically stable for more than 10 serial passages in BHK-21 cells. Compared 
to the parental virus, these three chimeric viruses produced lower titers and smaller 
plaque sizes indicating that although the viruses are genetically stable, they have a 
crippled phenotype and are unable to replicate and spread as efficiently as the parental 
virus. These chimeric viruses were further tested in different EAV or PRRSV susceptible 
cell lines to evaluate the progeny virus cellular tropism and infectivity.  Interestingly, the 
three chimeric viruses containing the GP5 and/or M ectodomains could only infect EAV 
susceptible cell lines but not pig alveolar macrophage cells in which PRRSV infects and 
replicates efficiently. Therefore, the exchange of GP5 and/or M protein N-terminal 
ectodomains from PRRSV (individual or double) could not alter the cellular tropism of 
the chimeric viruses.???
 Chapter seven investigates the role of one of the minor envelope proteins (E) in 
virus attachment and entry. The data from this study showed that EAV infection of 
equine endothelial cells is heparin-dependent. Sequence analysis revealed that the C-
terminus of E protein contains a putative heparin-binding domain. By using site-directed 
mutagenesis, we generated a panel of arginine to glycine mutations at the conserved 
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region in both the full-length EAV cDNA clone and individual E protein expression 
constructs.  The mutant cDNA clones R52G; R57G; R52;60G; R57;63G; and R63,65G 
have a similar growth pattern and plaque morphology compared to the wild type control. 
In contrast, the triple mutation R52,60,65G construct grew significantly slower and 
produced much smaller plaques. When these mutations were introduced in the individual 
E protein expression construct, double mutant R52,60G completely blocked the 
interaction between E protein and heparin. Taken together, these data showed that E 
protein interacts with heparin to facilitate virus attachment and play a major role in EAV 
infection.
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CHAPTER TWO 
 
Comparison of two real-time reverse transcription polymerase chain reaction assays 
for the detection of equine arteritis virus nucleic acid in equine semen and tissue 
culture fluid  
J Vet Diagn Invest 20:147–155 (2008) 
Reprinted with permission 
 
2.1.  SUMMARY 
Two previously developed TaqMan? fluorogenic probe-based one-tube real-time 
reverse transcription polymerase chain reaction (real-time RT-PCR) assays (T1 and T2) 
were compared and validated for the detection of equine arteritis virus (EAV) nucleic 
acid in equine semen and tissue culture fluid (TCF). The specificity and sensitivity of 
these two molecular-based assays were compared to traditional virus isolation (VI) in cell 
culture. The T1 real-time RT-PCR had a higher sensitivity (93.4%) than the T2 real-time 
RT-PCR (42.6%) for detection of EAV RNA in semen. However, the T1 real-time RT-
PCR was less sensitive (93.4%) than the World Organization for Animal Health (OIE)-
prescribed VI test (gold standard). The sensitivity of both PCR assays was high (100.0% 
[T1] and 95.2% [T2]) for detecting EAV RNA in TCF. In light of the discrepancy in 
sensitivity between either real-time RT-PCR assay and VI, semen that is negative for 
EAV nucleic acid by real-time RT-PCR should be confirmed free of virus by VI. 
Similarly, the presence of EAV in TCF samples that are VI-positive but real-time RT-
PCR–negative should be confirmed in a one-way neutralization test using anti-EAV 
equine serum or by immunofluorescence assay using monoclonal antibodies to EAV. If 
the viral isolate is not identified as EAV, such samples should be tested for other equine 
viral pathogens. The results of this study underscore the importance of comparative 
evaluation and validation of real-time RT-PCR assays prior to their recommended use in 
a diagnostic setting for the detection and identification of specific infectious agents. 
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2.2.  INTRODUCTION 
Equine arteritis virus (EAV) is an enveloped, positive-stranded RNA virus in the 
family Arteriviridae, order Nidovirales.255 It is the causative agent of equine viral arteritis 
(EVA), a contagious disease of horses and other equid species.212,257 Serologic surveys 
have confirmed EAV infection in equine populations in North and South America, 
Europe, Australia, Africa, and Asia.34,213-216,218,368 However, the seroprevalence of EAV 
infection of horses varies between countries and different breeds within countries.34,213 
The majority cases of primary EAV infection are asymptomatic.230 Occasionally infected 
animals will develop clinical signs of disease. The most common clinical manifestations 
of EVA include anorexia, depression, fever, and dependent limb edema, and less 
frequently, ocular and nasal discharge and conjunctivitis. EAV infection may also result 
in abortion in pregnant mares and interstitial pneumonia or pneumoenteritis in very 
young foals.34,369 A variable percentage (up to 10-70%) of acutely infected stallions can 
become persistently infected and continue to shed virus in their semen.34,223 Carrier 
stallions are the natural reservoir of EAV; they ensure the virus is maintained in equine 
populations between breeding seasons.34 Furthermore, the long term carrier state in the 
stallion enables the generation of genetic heterogeneity within the virus that helps to 
distinguish field strains of EAV.35,226-227 The two principal modes of transmission of 
EAV are horizontal, by direct contact with infectious respiratory tract secretions from 
acutely infected horses, and venereal through natural breeding or artificial insemination 
with infective semen from persistently infected stallions.228-231 The continued growth in 
international trade in horses and semen has served as a significant means of 
dissemination of EAV strains around the world.34,216,223,228,231 Identification of the carrier 
stallion is therefore of critical epidemiological influence in the prevention and control of 
EAV infection.34,229-230 
The EAV genome consists of two large replicase genes (open reading frame 
[ORFs] 1a and 1b) and partially overlapping structural genes (ORFs 2a, 2b, 3-7).256,320 
The EAV RNA is encapsidated by the nucleocapsid protein (N; encoded by ORF7) into 
an icosahedral core that is surrounded by an envelope containing six structural proteins. 
Two major envelope proteins of EAV, large glycosylated protein (GP5; ORF5) and 
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nonglycosylated membrane protein (M; ORF6), form a covalently linked heterodimer in 
the virion.266 In addition to these, small envelope protein E (ORF2a) and three minor 
glycoproteins named GP2, GP3, and GP4 (ORFs 2b, 3, and 4, respectively) also contribute 
to the viral particle formation.256,262 The latter three proteins form a covalently linked 
heterotrimer in the virion.320,370 
A definitive diagnosis of EVA is based on isolation of EAV in cell culture, 
detection of viral nucleic acid by RT-PCR assay, or by serologic means based on testing 
paired (acute and convalescent) serum samples.34,229-230,371 Detection of EAV in the 
semen of carrier stallions is frequently determined by virus isolation (VI) in cell culture 
or much less frequently, by breeding a stallion to two seronegative mares and testing for 
development of an antibody response after 28 days.34,371 Virus isolation is currently the 
World Organization for Animal Health (OIE)-approved gold standard for the detection of 
EAV in semen and is the prescribed test for international trade. Isolates of EAV from 
clinical specimens, including semen, are often confirmed in a one-way neutralization 
assay using polyclonal equine sera raised against the prototype Bucyrus strain of EAV or 
by immunofluorescent assay using monoclonal antibodies to EAV.371-372 These methods, 
although of proven reliability, are time-consuming, expensive, and cumbersome. The 
availability of modern nucleic acid-based assays has revolutionized diagnostic testing of 
clinical specimens for many infectious disease agents.5,183,188,373-379 Compared to 
traditional virus isolation, these assays are frequently more sensitive, less expensive, and 
less time-consuming.5,183,374-375 Sensitive standard RT-PCR, RT-nested PCR (RT-nPCR), 
and real-time RT-PCR assays have been developed for the detection of EAV nucleic acid 
in tissue culture fluid (TCF), nasal secretions, and semen, and these assays are being 
increasingly used for routine diagnostic purposes.219,373,376,379-383 However, further 
validation of most of these assays is needed before they can be fully accepted as 
providing equivalent reliability to VI in cell culture for the detection of EAV. 
The development of two TaqMan? fluorogenic probe-based one-tube real-time 
PCR assays for the detection of EAV nucleic acid has been previously described.373,379 
The purpose of the present study was to compare the specificity and sensitivity of these 
specific real-time PCR assays to each other as well as to VI for the detection of EAV in 
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semen and in TCF. The analytical sensitivity of these 2 assays was also established by 
using in vitro transcribed (IVT) EAV RNA containing the complete region of ORF7 and 
flanking portion of ORF6 and 3' nontranslated region (3' NTR) of the virus. 
 
2.3.  MATERIALS AND METHODS 
Equine semen samples, viruses, and cells 
Three hundred raw equine semen samples received between April 2006 and May 
2007 by the OIE EAV Reference Laboratory at the Maxwell H. Gluck Equine Research 
Center, University of Kentucky, were tested for the presence of EAV by VI and EAV 
nucleic acid by 2 previously referenced real-time TaqMan® RT-PCR assays.373,379 A total 
of 155 tissue culture fluid (TCF) samples were included in the study. These comprised 
one sample containing the modified live virus (MLV) vaccine strain of EAV 
(ARVAC®),a 61 samples containing North American and European strains of EAV, 77 
EAV negative samples, and 16 TCF samples containing a variety of other equine viral 
pathogens. All EAV-positive TCF samples used in the present study were previously 
confirmed to contain EAV in a one-way serum neutralization assay using polyclonal anti-
EAV equine serum or by immunofluorescent assay using monoclonal antibodies to GP5 
of EAV.371-372 These included TCF samples containing 25 archived EAV field isolates 
from the OIE Reference Laboratory at the Gluck Center, and TCF samples containing 36 
strains of EAV collected at the Animal Health Diagnostic Center, New York College of 
Veterinary Medicine, Cornell University. The TCF samples included representation of 
North American and European strains of EAV.35,226-228,384-385 To determine the specificity 
of these 2 real-time PCR assays, TCF containing the following equine viral pathogens 
were included in the study: equine herpesviruses 1-5 (EHV-1 [ATCC VR-700],b EHV-2 
[ATCC VR-702], EHV-3 [ATCC VR-352],b EHV-4 [ATCC VR-2230],b and EHV-5386); 
equine rhinitis virus A (NVSL-0600EDV8501)c and B (NVSL-0610EDV85010)c; equine 
adenovirus 1 (NVSL-001EDV8401)c and 2; equine influenza virus type A1 (equine-
1/Prague/1/56 [H7N7]; ATCC VR-297)b and A2 (equine/Miami1/63/ [H3N8; NVSL-
060IDV0501],c equine/Kentucky/81 [H3N8; NVSL-040IDV0001],c equine/Alaska/ 
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29759/91 [H3N8; NVSL-020IDV9101])c; and Salem virus, a novel paramyxovirus of 
horses.387 
The low passage RK-13 cell line (ATCC CCL37; passage level 194-204)b and 
high passage RK-13 cell line (RK-13 KY; passage level 399-409) were maintained in 
Eagle’s minimum essential medium (EMEM)d supplemented with 10% ferritin-
supplemented bovine calf serum (FSCS),e 1% penicillin and streptomycin,d and 0.1% 
amphotericin B (1,000 ?g/ml).d The overlay medium used for inoculated cultures was of 
0.75% carboxymethyl cellulose (CMC)f in supplemented EMEM. 
Virus isolation 
Isolation of EAV from equine semen samples was attempted in both high and low 
passage RK-13 cell lines according to the standard laboratory protocol used by the OIE 
Reference Laboratory.371 Briefly, semen samples were sonicated for 45 sec (3 ? 15 sec), 
and sperm and cellular debris were sedimented by centrifugation (2800 ? g, 10 min) at 
4 °C. Serial decimal dilutions (10-1-10-3) of the supernatant of each sample were made in 
supplemented EMEM and 1 ml of each dilution was inoculated into each of 2 × 25-cm2 
flasks containing confluent monolayers of RK-13 cells. Flasks were incubated at 37 °C 
for 1 hr before being overlaid with supplemented EMEM containing 0.75% CMC. Flasks 
were incubated at 37 °C and checked for the appearance of cytopathic effect (CPE) on 
postinoculation days 3 and 4. If there was no detectable CPE, a second blind passage was 
performed on day 4. The RK-13 cell monolayers were fixed and stained with a 1% crystal 
violet solution containing 1% formaldehyde on postinoculation day 5 for the first passage 
and postinoculation day 4 for the second passage in cell culture. 
RNA isolation 
Viral nucleic acid was directly isolated from semen and TCF samples using a 
commercial kit.g,384 Briefly, semen or TCF samples were microcentrifuged at 13,800 ? g 
for 2 min, and 140 ?l of supernatant was removed and used for nucleic acid extraction 
according to the manufacturer’s instructions. The viral nucleic acid was eluted in 60 ?l of 
nuclease free water and stored at -80 °C. 
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Generation of in vitro transcribed RNA 
The analytical sensitivity of the 2 real-time TaqMan RT-PCR assays was 
determined using a decimal dilution series (101-1010 molecules/reaction) of in vitro 
transcribed (IVT) EAV RNA containing complete ORF7 and the flanking regions of 
ORF6 and 3' NTR of EAV genome. Briefly, a 636-bp fragment of EAV (nucleotide [nt] 
12069-12704; numbered according to GenBank accession number Y07862261) was PCR 
amplified from the plasmid containing the complete genomic sequence of the virulent 
Bucyrus strain of EAV (pEAVrVBS)388 using primers 12069P ([12069-12088] 
5’TTTGTTATAGTTGGAAGAGC3’) and 12704N ([12681-12704] 
5’GGTTCCTGGGTGGCTAATAACTAC3’), and cloned into the pDrive cloning vector 
according to the manufacturer’s instructions.h The plasmids were purified using a 
commercial kit,i and the authenticity and orientation of the insert was determined by 
sequencing both strands of DNA with T7 and SP6 reverse and forward primers. 
Following sequencing, the recombinant plasmid with ORF7 and flanking ORF6 and 3’ 
NTR sequence downstream of the SP6 promoter was named pORF7.SP6 and used to 
generate IVT ORF7 RNA. Runoff pORF7.SP6 RNA transcripts were generated from 
Bam HI-linearized pORF7.SP6 plasmid according to a previously described protocol.384 
Briefly, a 50 ?l reaction volume containing 2 ?g of Bam HI-linearized pORF7.SP6 
plasmid DNA; 2.5 ?l of RNAguard™ RNase inhibitor (37 U/?l)j; 5 ?l of 
m7G(5')PPP(5')G RNA cap structure analoguek; 5 ?l of ribonucleotides ATP (adenosine 
5'-triphosphate), CTP (cytidine 5'-triphosphate), GTP (guanosine 5'-triphosphate), and 
UTP (uridine 5'-triphosphate; 10 mM each mix)l; 2.5 ?l of 100 mM dithiothreitol (DTT)m; 
2.5 ?l of SP6 RNA polymerasem; and 1 ? transcription bufferm was incubated at 37 °C for 
2 hr. The template plasmid DNA was then digested with RNase-free DNase I.n The RNA 
transcripts were purified using a commercial column,o eluted in 50 ?l of water, and 
quantified by spectrophotometrical analysis. The IVT ORF7 RNA was stored at -80 °C 
until used. The concentration of the IVT ORF7 RNA molecules per microliter was 
calculated according to the following formula: 
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No. of IVT ORF7 RNA molecules/µl = Avogadro number (6.022 × 1023) × IVT ORF7 RNA concentration (g/?l) 
      IVT ORF7 RNA molecular weight (g) 
The dilution of RNA transcripts (101-1010 molecules) was carried out in RNase- and 
DNase-free molecular biologic grade water containing 0.1 mg/ml acetylated BSAm and 
0.74 U/?l RNAguard™ RNase inhibitor.j 
Real-time TaqMan RT-PCR assays 
A one-tube real-time TaqMan RT-PCR assay was performed using the TaqMan® 
One-Step RT-PCR Master Mixp in a 7500 Fast Real-Time PCR System.q The primers and 
probes used in the 2 assays were identical to those previously for each respective assay 
(Table 2.1).373,379 Every sample was tested in duplicate in each assay. Briefly, 25 ?l of 
RT-PCR mixture for each reaction contained 12.5 ?l of 2 × Master Mix without UNG 
(uracil-N-glycosylase), 40 × MultiScribe and RNase Inhibitor Mix, 900 nM of forward 
and reverse primers (0.45 ?l), 250 nM probe (0.625 ?l), nuclease free water (5.35 ?l), and 
5 ?l of test sample RNA. The following thermocycling conditions were used under 
standard mode as per manufacturer’s recommendation: 30 min at 48 °C, 10 min at 95 °C, 
followed by 40 cycles at 95 °C for 15 sec and 60 °C for 1 min. Each RT-PCR run 
included a control without RNA (containing the reaction mix with 5 ?l of water [no 
template control]) and positive controls containing IVT ORF7 RNA. The analytical 
sensitivity of each real-time PCR assay was determined using IVT ORF7 RNA. 
Statistical analysis 
Statistical evaluation of the performance of semen and TCF-based real-time PCR 
assays for the detection of EAV nucleic acids was carried out to estimate and compare 
the sensitivity, specificity, accuracy, and reproducibility of the T1 and T2 real-time PCR 
assays in relation to VI. For the purpose of the analysis, T+ denotes a positive real-time 
PCR test result and I+ denotes a VI-positive specimen, with T- and I- denoting a negative 
real-time PCR test result and a VI-negative specimen, respectively. Accordingly, the 
sensitivity (Se) of either diagnostic test is the likelihood that an EAV carrier stallion tests 
positive, namely Se = Pr(T+|I+), and its specificity (Sp) is Sp = Pr(T-|I-). Accuracy is 
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defined as the likelihood of a correct test result; this is a composite measure of diagnostic 
performance based on both sensitivity and specificity. Test repeatability was 
characterized by the coefficients of variation when duplicates of serial decimal molecule 
dilutions (101-1010) of IVT ORF7 RNA were used in five independent assays. 
Sensitivity, specificity, and accuracy were calculated using Clopper-Pearson 95% 
exact binomial confidence intervals.389 Exact binomial methods were also used to test the 
hypothesis of equal sensitivity (i.e., that Se1 = Se2) versus the two-sided alternative for 
the semen and tissue culture fluid PCRs. Empirical coefficients of variation (CV) were 
calculated as the sample standard deviation divided by the sample mean. Statistical 
significance was set at ? = 0.05. The analysis was performed using the S-Plus 8.0r and 
Minitab 15s software packages. 
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Table 2.1. Primers and probes used in the T1 and T2 real-time reverse transcription 
polymerase chain reaction (RT-PCR) assays. 
Assay 
name 
Primer or probe Sequence 5' to 3' (nucleotide location
‡
) 
Length of 
fragment 
(bp) 
Reference 
no. 
T1 real-time 
RT-PCR 
Forward primer: 
EAV7.53F 
GGCGACAGCCTACAAGCTACA  
(12,365-12,385; ORF7) 
204 (12365-
12568) 
4 
Reverse primer: 
EAV7.256R 
CGGCATCTGCAGTGAGTGA  
(12,550-12,568; ORF7) 
Probe: 
EAV7.92P 
*TTGCGGACCCGCATCTGACCAA† 
(12,404-12,425; ORF7) 
T2 real-time 
RT-PCR 
Forward primer: 
EAV10F 
GTACACCGCAGTTGGTAACA  
(12,284-12,303; ORF6) 
399 (12284-
12682) 
50 Reverse Primer: 
EAV12R 
ACTTCAACATGACGCCACAC (12,663-
12,682; 3’ NTR) 
Probe: EAV11P 
*TGGTTCACTCACTGCAGATGCCGG† 
(12,546-12,569; ORF7) 
* Reporter dye (FAM; 6-carboxyfluorescein) labeled nucleotide. 
† Quencher dye (TAMRA; 6-carboxy-tetramethyl-rhodamine) labeled nucleotide. 
‡ Numbered according to GenBank accession no. Y07862261. 
 
 
2.4.  RESULTS 
Analytical sensitivity of the two real-time RT-PCR assays 
In order to determine the analytical sensitivity of the 2 real-time PCR assays in 
detecting EAV nucleic acid, serial decimal molecule dilutions (101-1010) of IVT ORF7 
RNA containing EAV ORF7 with flanking regions of ORF6 and 3' UTR were tested in 
duplicate. The assays were repeated five times, each time with freshly diluted IVT ORF7 
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RNA. The IVT ORF7 RNA molecule numbers were calculated based on the molecular 
weight and concentration of the IVT RNA. Regression analysis confirmed linearity in 
both assays (T1: R2 = 0.9984; T2: R2 = 0.9979; Fig 2.1). The T1 real-time PCR was linear 
over the full molecule range tested (101-1010) with high reproducibility and a mean CV 
ranging from a low value of 0.32% to a high of 3.18%. While the T2 real-time PCR was 
also linear, the analytical sensitivity of this test was only 102 molecules of IVT RNA. The 
range of nine orders of magnitude (102-1010 molecules) detected by the T2 real-time PCR 
was reproducible with a mean CV from a low value of 1.39% to a high of 9.55%. The T1 
real-time PCR always had a lower cycle threshold (Ct) value than the T2 real-time PCR 
over all the IVT RNA dilutions tested. These data indicate that the T1 real-time PCR has 
a higher analytical sensitivity than the T2 real-time PCR. 
 
Fig 2.1. Comparison of analytical sensitivity between the two real-time reverse 
transcription polymerase chain reaction assays, T1 (y = –3.6594x + 39.341, R2 = 0.9984) 
and T2 (y = –3.9474x + 44.171, R2 = 0.9979), using in vitro transcribed ORF7 RNA. 
 
Evaluation of the two real-time RT-PCR assays for detection of EAV in TCF 
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Nucleic acids extracted from a total of 155 TCF samples were tested by these 2 
real-time PCR assays. Of the TCF samples positive for infectious EAV, 62 (62/62) and 
59 (59/62) were positive by the T1 real-time PCR and T2 real-time PCR, respectively 
(Table 2.2). There is no significant difference between the sensitivity of both assays when 
RNA from TCF containing EAV was evaluated (p = 0.248). Sensitivity of the T1 real-
time PCR for detecting EAV nucleic acid in TCF was 100.0% (95% confidence interval 
[CI]: 95.3-100.0%) whereas the sensitivity of the T2 real-time PCR was 95.2% (95% CI: 
86.5-99.0%; Table 2.3). There was no detectable fluorescence signal in the non-template 
controls containing molecular biologic grade water nor in the tubes that contained nucleic 
acid from other viral pathogens, confirming that both assays were highly specific (100%) 
for the detection of EAV nucleic acid. In terms of accuracy, the T1 real-time PCR 
correctly diagnosed 155 out of 155 samples, providing an accuracy of 100.0% (exact 95% 
CI: 98.1-100.0%). In the case of the T2 real-time PCR, it correctly diagnosed 152 out of 
155 samples, providing an accuracy of 98.1% (exact 95% CI: 94.4-99.6%). 
Table 2.2. Detection of equine arteritis virus (EAV) nucleic acid in semen and tissue 
culture fluid (TCF) using the T1 and T2 real-time reverse transcription polymerase chain 
reaction (RT-PCR) assays 
Sample type (number of 
samples analyzed) 
Virus isolation
*
 
T1 real-time RT-
PCR
4
 
T2 real-time RT-
PCR
379
 
Positive Negative Positive Negative Positive Negative
Semen samples (n = 300) 61 239 57 243 26 274 
Tissue culture fluid (n = 
155)† 
62 93 62 93 59 96 
* Virus isolation attempted in 2 rabbit kidney cell lines (RK-13; ATCC CCL37 and RK-
13 KY) and confirmed by one-way neutralization assay. 
† EAV positive and negative TCF. 
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Table 2.3. Sensitivity, specificity, and accuracy of two real-time reverse transcription 
polymerase chain reaction (RT-PCR) assays for detection of equine arteritis virus in 
tissue culture fluid as compared to virus isolation. 
 
T1 real-time RT-
PCR
4
 (%) 
T2 real-time RT-
PCR
379
 (%) 
Sensitivity 100.0 95.2 
95% CI* 95.3-100.0 86.5-99.0 
Specificity 100.0 100.0 
95% CI 96.8-100.0 96.8-100.0 
Accuracy 100.0 98.1 
95% CI 98.1-100.0 94.4-99.6 
* Confidence interval. 
 
Evaluation of the two real-time RT-PCR assays for the detection of EAV nucleic 
acid in semen samples 
Of the 300 equine semen samples tested, 61 (61/300) were positive for EAV by 
VI isolation in the RK-13 cell lines (Table 2.2). When nucleic acid extracted from these 
semen samples was tested, 57 (57/300) and 26 (26/300) were positive for the presence of 
EAV RNA using the T1 real-time PCR and the T2 real-time PCR, respectively. The T2 
real-time PCR assay had a significantly higher number of false negatives (35) as 
compared to the T1 real-time PCR assay (4). Of the four false-negative semen samples 
detected by the T1 real-time PCR, 3 had very low infectivity titers (1 ? 101 to 4.5 ? 101 
pfu/ml). However, 1 semen sample had a moderate infectivity titer (2.9 ? 103 pfu/ml). 
When these 2 real-time PCR assays were subjected to the exact binomial test of 
equal sensitivity, the sensitivity of the respective assays was significantly different (p < 
0.001). The sensitivity of the T1 real-time PCR in detecting EAV nucleic acid in semen 
was 93.4% (exact 95% CI: 84.1-98.2%), whereas the sensitivity of the T2 real-time PCR 
was much lower (42.6%; exact 95% CI: 30.0-55.9%; Table 2.4). There was no detectable 
fluorescence signal in non-template controls containing molecular biologic grade water 
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nor in the tubes containing RNA from the VI-negative semen samples, confirming that 
both assays were highly specific (100%) for the detection of EAV nucleic acid. Since the 
T1 real-time PCR correctly diagnosed 296 out of 300 samples, the accuracy of this assay 
was 98.7% (exact 95% CI: 96.6-99.6%), compared to the T2 real-time PCR, which 
correctly diagnosed 265 out of 300 samples for an accuracy of 88.3% (exact 95% CI: 
84.1-91.7%). 
 
Table 2.4. Sensitivity, specificity, and accuracy of two real-time reverse transcription 
polymerase chain reaction (RT-PCR) assays for detection of equine arteritis virus in 
semen as compared to virus isolation. 
 
T1 real-time RT-
PCR
4 (%) 
T2 real-time RT-
PCR
379 (%) 
Sensitivity 93.4 42.6 
95% CI* 84.1-98.2 30.0-55.9 
Specificity 100.0 100.0 
95% CI 98.8-100.0 98.8-100.0 
Accuracy 98.7 88.3 
95% CI 96.6-99.6 84.1-91.7 
* Confidence interval. 
 
2.5.  DISCUSSION 
The one-tube real-time PCR assay for EAV provides a simple, rapid, and reliable 
method for the detection and identification of viral nucleic acid in equine TCF and semen. 
The real-time PCR has the following important advantages over the standard two-step 
RT-PCR: 1) eliminating the possibility of cross contamination between samples with 
previously amplified products since the sample tube is never opened; and 2) reducing the 
chance of false-positive reactions because the real-time PCR product is detected with a 
sequence specific probe. The original reports describing the respective real-time PCR 
assays to detect EAV nucleic acid suffered from the limitation that each study was based 
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on testing only a small number of samples (21 TCF and 20 semen samples in the T1 
study;373 28 TCF and 33 semen samples in the T2 study379). Clearly, before 
recommending either real-time PCR assay as an alternative to VI for the detection of 
EAV in TCF and semen, each assay needed to be more comprehensively validated using 
a significantly larger number of specimens. 
In the present study, the analytical sensitivity of the T1 real-time PCR and T2 
real-time PCR assays were first evaluated using IVT ORF7 RNA. Both T1 real-time PCR 
and T2 real-time PCR assays were shown to have a very high analytical sensitivity for 
IVT ORF7 RNA, detecting 10 and 100 RNA molecules, respectively. The T1 real-time 
PCR was at least ten times more sensitive than the T2 real-time PCR and consistently had 
a lower Ct value with different IVT RNA concentrations. The difference in analytical 
sensitivity between these 2 assays is likely attributable to the size of the amplicons they 
generated. The T1 real-time PCR amplicon length was much shorter than the T2 real-time 
PCR amplicon (204 bp vs. 399 bp) which suggested that it was amplified more efficiently 
than the longer real-time PCR product. Furthermore, it has been reported that shorter 
PCR products are more responsive to reaction conditions and allow primers and probe to 
bind to the target molecule more efficiently.390 
The primary goal of this study was to directly compare the diagnostic sensitivity 
and specificity of 2 published real-time PCR assays for the detection of EAV nucleic acid 
based on testing an extensive number of TCF and semen samples. With the exception of 
the primers and probe, all of the other test conditions were identical for both assays, 
which were performed in parallel at the same time. Under the conditions of this study, the 
T1 real-time PCR has a higher diagnostic sensitivity than the T2 real-time PCR in 
detecting EAV nucleic acid in semen (93.4% vs. 42.6%) and to a lesser degree in TCF 
(100.0% vs. 95.2%) using the TaqMan One-Step RT-PCR Master Mix Reagents kit.p 
Several factors could have adversely affected the diagnostic sensitivity of the T2 
real-time PCR assay, including the length of the real-time PCR product previously 
mentioned, nucleotide mismatch in the primer and probe binding regions, and the use of 
proprietary reagents and cycle parameters that are optimized for use with the ABI 7500 
Fast Real-Time PCR system.q The authors aligned 54 EAV sequences available in 
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GenBank (nt # 12069 to 12645 [ORF6-ORF7]; data not shown) to determine the degree 
of conservation in the regions to which the primers and probe are directed in the 2 assays. 
The forward primer-binding region (nt # 12365-12385) of the T1 real-time PCR was 
highly conserved (no mismatches) among the aligned EAV strains. However, both 
reverse primer- (nt # 12550-12568) and probe- (nt # 12404-12425) binding regions had 
one nucleotide mismatch. The reverse primer-binding region (nt # 12663-12682) of the 
T2 real-time PCR was highly conserved (only 17 aligned sequences cover the 3' NTR). In 
contrast, the forward primer- (nt # 12284-12303) and probe- (nt # 12546-12569) binding 
regions had three and five nucleotide mismatches, respectively. This clearly suggests that 
with respect to field strains of EAV, the forward primer- and/or probe-binding regions 
targeted by the T2 real-time PCR is less conserved than the regions targeted by the T1 
real-time PCR. It has been shown that a single nucleotide mismatch in the primer- or 
probe-binding site may have minimal or zero effect on PCR amplification or 
detection.391-392 In contrast, three or four nucleotide mismatches at certain critical 
locations within the primer- or probe-binding region can have a considerable effect 
including complete failure of detection.391-392 In light of this, the mismatches of the 
forward primer and probe within the T2 real-time PCR assay may have significantly 
reduced the efficiency of the PCR reaction, especially in the case of specimens containing 
low quantities of EAV nucleic acid. In order to compare the 2 assays in a standard and 
normalized manner, a commercial kit and manufacture’s recommended real-time RT-
PCR cycle parameters were used in this study. Therefore, the reagents and real-time RT-
PCR cycle conditions used in this study were not identical to the original T2 assay. These 
modifications may also have contributed to the reduced sensitivity of the T2 assay. 
There was good overall agreement between the T1 real-time PCR and the VI 
assay, which is the current gold standard for the detection of EAV in semen.371 However, 
under the conditions of this study, the T1 real-time PCR was less sensitive (93.4%) than 
the VI assay for detection of EAV nucleic acid in semen. The sensitivity of the real-time 
PCR assay versus VI may be adversely affected by various factors including use of the 
one-step RT-PCR method, reaction conditions (e.g., Mg2+ concentration, annealing 
temperature), amount of virus in the original sample, RT-PCR inhibitory substances in 
certain samples, mutations in the primer- and probe-binding regions of the template (see 
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above), inefficient RNA extraction from semen samples, and the potential for RNA 
degradation before testing. The T1 real-time PCR assay was designed to balance both 
sensitivity and ease of use so that the procedure could be performed rapidly and on a 
large scale. A single-step real-time PCR was performed with a commercial kit and RT-
PCR conditions pre-optimized by the manufacturer, notwithstanding the fact that the one-
step method is reported to be less sensitive than a two-step RT-PCR procedure.393 The T1 
real-time PCR allows detection of EAV in clinical samples or TCF containing at least 50 
viral RNA molecules per ml when 140 ?l specimen is used for RNA extraction.373 The 
titer of EAV in semen from carrier stallions can vary from 1 × 101 pfu/ml to >105 pfu/ml. 
Over 97% of the semen samples submitted to the OIE EAV Reference Laboratory 
contain at least 1.5 × 102 pfu/ml and the remaining samples contain <1.5 × 102 pfu/ml. 
Three of the four false-negative semen samples in the T1 real-time PCR had very low 
infectivity titers ranging from 1 × 101 pfu/ml to 4.5 × 101 pfu/ml. Interestingly, all these 
semen samples were from stallions in the process of spontaneously clearing the carrier 
state. Notwithstanding their very low infectivity content, it was possible to isolate EAV 
in RK-13 cells from all three semen samples. The fourth false-negative semen sample 
was of poor quality in that a large amount of smegma-like material was present which 
may contain some unknown real-time PCR inhibitors. This clearly indicates that the T1 
real-time PCR as described is less sensitive than VI attempted in RK-13 cells. In view of 
this finding, any semen sample negative in the T1 real-time PCR assay that is from an 
EAV-seropositive stallion should also be screened for virus in RK-13 cells. 
It should be noted, however, that genomic variation among field isolates of EAV 
may reduce the accuracy of the real-time PCR, even when the primers and probe are 
based on the most conserved region of EAV genome (ORF7). Therefore, the presence of 
EAV in VI-positive but real-time PCR-negative TCF samples should be confirmed in a 
one-way neutralization assay using an EAV-positive antiserum or by immunofluorescent 
assay using monoclonal antibodies to GP5 of EAV. If negative for EAV, such TCF 
samples should be tested for other equine viral pathogens. 
In summary, 2 previously described real-time PCR assays were compared to each 
other, as well as to attempted VI in cell culture for the detection of EAV in TCF samples 
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and semen. The T1 real-time PCR had a higher sensitivity than the T2 real-time PCR in 
detecting EAV nucleic acid in TCF and semen samples. Neither real-time PCR was 
superior to the OIE-prescribed VI test (gold standard) for the detection of EAV in semen. 
In light of these findings, semen from an EAV-seropositive stallion that is negative for 
viral nucleic acid by real-time PCR should also be tested by VI. The findings of this 
study illustrate the importance of comparative evaluation and validation of real-time PCR 
assays prior to their recommended use in a diagnostic laboratory for the detection and 
identification of infectious agents. 
 
Sources and manufactures 
a. EAV modified live vaccine (Arvac®), Fort Dodge Animal Health, Fort Dodge, IA. 
b. Equine herpesvirus-1, -2, -3, and -4, equine influenza virus type A1 and low passage 
RK-13 cell line, American Type Culture Collection, Manassas, VA. 
c. Equine rhinitis virus A and B, equine adenovirus 1 and equine influenza virus type A2, 
National Veterinary Services Laboratory, Ames, Iowa. 
d. Eagle’s minimum essential medium, penicillin and streptomycin, and amphotericin B, 
Mediatech Inc., Herndon, VA. 
e. Ferritin-supplemented bovine calf serum, Hyclone Laboratories. Inc., Logan, UT. 
f. Carboxymethyl cellulose, Sigma-Aldrich, St Louis, MO. 
g. QIAamp® Viral RNA isolation kit, Qiagen, Inc., Santa Clara, CA. 
h. Qiagen PCR cloning kit, Qiagen, Inc., Santa Clara, CA. 
i. QIAamp® Miniprep kit, Qiagen, Inc., Santa Clara, CA. 
j. RNA guard, Amersham Bioscience, Pittsburgh, PA. 
k. m7G(5')PPP(5')G RNA cap structure analogue, New England BioLabs, Beverly, MA. 
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l. 10 mM rATP, rCTP, rGTP, and rUTP, Amersham Bioscience, Pittsburgh, PA. 
m. 100mM DTT, SP6 RNA polymerase, 1? transcription buffer and acetylated BSA, 
Promega Corp., Madison, WI. 
n. RNase-free DNase I, Ambion, Austin, TX. 
o. QIAamp? RNeasy Mini kit, Qiagen Inc., Santa Clara, CA. 
p. TaqMan® One-Step RT-PCR Master Mix, Applied Biosystems, Foster City, CA. 
q. 7500 Fast Real-Time PCR System, Applied Biosystems, Foster City, CA. 
r. S-Plus 8.0, Insightful Corp., Seattle, WA. 
s. Minitab 15, Minitab, Inc., State College, PA. 
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CHAPTER THREE 
 
Development and evaluation of one-step TaqMan
®
 real-time reverse transcription-
PCR assays targeting nucleoprotein, matrix, and hemagglutinin genes of equine 
influenza virus 
J Clin Microbiol. 2009 Dec;47(12):3907-13.  
Reprinted with permission 
 
3.1.  SUMMARY 
 The objective of this study was to develop and evaluate new TaqMan real-time 
reverse transcription-PCR (rRT-PCR) assays by the use of the minor groove binding 
probe to detect a wide range of equine influenza virus(EIV) strains comprising both 
subtypes of the virus (H3N8 and H7N7). A total of eight rRT-PCR assays were 
developed, targeting the nucleoprotein (NP), matrix (M), and hemagglutinin (HA) genes 
of the two EIV subtypes. None of the eight assays cross-reacted with any of the other 
known equine respiratory viruses. Three rRT-PCR assays (EqFlu NP, M, and HA3) 
which can detect strains of the H3N8 subtype were evaluated using nasal swabs received 
for routine diagnosis and swabs collected from experimentally inoculated horses. All 
three rRT-PCR assays have greater specificity and sensitivity than virus isolation by egg 
inoculation (93%, 89%, and 87% sensitivity for EqFlu NP, EqFlu M, and EqFlu HA3 
assays, respectively). These assays had analytical sensitivities of >10 EIV RNA 
molecules. Comparison of the sensitivities of rRT-PCR assays targeting the NP and M 
genes of both subtypes with egg inoculation and the Directigen Flu A test clearly shows 
that molecular assays provide the highest sensitivity. The EqFlu HA7 assay targeting the 
H7 HA gene is highly specific for the H7N7 subtype of EIV. It should enable highly 
reliable surveillance for the H7N7 subtype, which is thought to be extinct or possibly still 
circulating at a very low level in nature. The assays that we developed provide a fast and 
reliable means of EIV diagnosis and subtype identification of EIV subtypes. 
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3.2.  INTRODUCTION 
Equine influenza (EI) is an acute, highly contagious viral respiratory disease of 
equids (horses, donkeys, mules and zebras) caused by infection with type A influenza 
virus.394 Equine influenza virus (EIV) possesses a segmented (8 segments), single-
stranded RNA genome of negative sense. The eight gene segments encode at least ten 
polypeptides: two envelope glycoproteins (hemagglutinin [HA] and neuraminidase [NA]), 
two matrix proteins (M1 and M2), two nonstructural proteins (NS1 and NS2/nuclear 
export protein), three proteins that make up the viral RNA polymerase (PB1, PB2 and PA) 
and the nucleoprotein (NP). Some strains of EIV also express a recently discovered PB1-
F2 mitochondrial protein.10,12 The first strain of EIV isolated in 1956 was of H7N7 
configuration and designated influenza virus A/equine/Prague/56.13-14 The last confirmed 
outbreak caused by an H7N7 subtype in horses was recorded in 1979.13,16 A second EIV 
subtype, H3N8 was first isolated in 1963 and designated influenza virus 
A/equine/Miami/63.15-16 This subtype has been associated with all confirmed outbreaks 
of equine influenza since 1980. Extensive antigenic drift has been detected in this virus 
over the years 17,22,395-399. This led to categorization of H3N8 EIV isolates from around 
the world into two lineages: American and Eurasian lineages.21-22 Currently, equine 
H3N8 influenza virus continues to be the most important equine respiratory pathogen of 
horses in many countries around the world. Equine influenza is considered endemic in the 
USA, UK and many other European countries.400  New Zealand and Iceland are the only 
countries that have remained continuously free of equine influenza. In 2005, inter-species 
transmission of H3N8 EIV from horse to dog was reported for the first time.24 
Influenza H3N8 virus spreads rapidly in susceptible horses and can result in very 
high morbidity within 24-48 hours after exposure to the virus.  Outbreaks of clinically 
mild forms of influenza or subclinical infections have been reported among vaccinated 
horses that are incompletely protected.  Furthermore, many of the clinical signs of EI 
resemble those caused by other equine viral respiratory pathogens such as equine 
herpesvirus-1 and -4 (EHV-1 and EHV-4), equine arteritis virus (EAV), equine rhinitis 
virus A and B, and equine adenoviruses.6-7  In light of its clinical similarity to other 
equine respiratory diseases, a provisional diagnosis of equine influenza must be 
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confirmed by laboratory testing. The need to achieve a rapid diagnosis and to implement 
effective quarantine and movement restrictions are critical in controlling the spread of EI. 
Traditionally, the gold standard laboratory test for the diagnosis of EI was 
attempted virus isolation (VI) from nasal swabs/washings in embryonated hens’ eggs.401  
Following isolation, the virus was subtyped by means of the hemagglutination-inhibition 
test using sera specific for the H3N8 or H7N7 subtypes.  These methods are time-
consuming and cumbersome.  In the past decade, antigen detection immunoassays such 
as the Directigen Flu A® test kit (Becton-Dickinson, Sparks, MD) and nucleic acid 
amplification based assays (standard reverse transcription PCR [RT-PCR] or real-time 
RT-PCR [rRT-PCR]) were developed and evaluated by various groups.204,402-409 The 
antigen detection immunoassay kits are designed to detect the NP of both influenza A and 
B viruses.16,402  Of the commercially available antigen detection immunoassays, the 
Directigen Flu A® test has been used for some considerable time to detect EIV in nasal 
swabs by certain laboratories.402,407  While this assay has been found to be most useful as 
an initial screening test to confirm a diagnosis of EI during an outbreak, its limited 
sensitivity does not make it an ideal method for the diagnosis of EIV infection on an 
individual animal basis.408  There have been several reports of the use of RT-PCR assays 
for the detection of influenza virus in clinical specimens,403,406,409-410 however, such 
assays were not widely used for the routine diagnosis of this disease. This changed, 
however, following the introduction of EI into Australia in 2007, when a rRT-PCR 
developed to detect the avian influenza virus matrix gene, was used as the molecular 
diagnostic method of choice for EI.409,411  That country now requires RT-PCR testing for 
EIV as part of both the pre-entry and post-entry system of quarantine and testing of 
horses from countries where EIV is endemic.412 The objective of the current study was to 
develop several TaqMan® rRT-PCR assays capable of detecting a wide range of EIV 
strains comprising both subtypes of EIV without the inherent problems associated with 
the current laboratory diagnosis of EI. The approach taken was to develop new rRT-PCR 
assays using a TaqMan® minor groove binding (MGB™) probe targeting the NP, M, H3 
and H7 HA genes of the virus. MGB™ rRT-PCR assays targeting the NP and M genes of 
EIV have not been previously reported. The assays were developed using the subtype 
prototype strains of EIV and then evaluated using archived strains of EIV and clinical 
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specimens. The overall goal was to identify which of these assays would be of greatest 
value for confirmation of a diagnosis of this infection.  
3.3.  MATERIALS AND METHODS 
Viruses 
EIV strains A/equine/Prague/56, A/equine/Alaska/91, A/equine/Kentucky/81 and 
A/equine/Miami/63 were obtained from the National Veterinary Service Laboratories 
(NVSL), Ames, IA (Table 3.1). Six EIV isolates A/equine/New York/73, 
A/equine/Kentucky/02, A/equine/Ohio/03, A/equine/Newmarket/2/93, 
A/equine/Aboyne/05 and A/equine/Richmond/07 were obtained from the OIE (World 
Organization for Animal Health) Reference Laboratory for EI at the Gluck Equine 
Research Center, University of Kentucky. In addition, 13 previously confirmed EIV 
isolates from the Livestock Disease Diagnostic Center, University of Kentucky and the 
Animal Health Diagnostic Center, New York State College of Veterinary Medicine, 
Cornell University were also included in the study.  In order to determine the specificity 
of the rRT-PCR assays, other equine viral pathogens were also included in the study: the 
reference Bucyrus strain of EAV, equine herpesviruses 1 to 5 (EHV-1, EHV-2, EHV-3, 
EHV-4, EHV-5), equine rhinitis viruses A and B, equine adenovirus 1 and 2, and Salem 
virus. 
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Table 3.1. List of Influenza A virus strains and other equine viral pathogens 
tested by rRT-PCR assays in order to determine the specificity of each assay. 
Virus name Origin Catalog number 
Equine Influenza H3N8 Subtype   
A/equine/Alaska/91 NVSL 020IDV9101 
A/equine/Kentucky/81 NVSL 040IDV0001 
A/equine/Miami/63 NVSL 060IDV0501 
A/equine/New York/73 GERCb N/Ag 
A/equine/Kentucky/02 GERC N/A 
A/equine/Ohio/03 GERC N/A 
A/equine/Newmarket/2/93 GERC N/A 
A/equine/Aboyne/05 GERC N/A 
A/equine/Richmond/07 GERC N/A 
A/equine/Ohio/05 AHDCc N/A 
A/equine/Texas/05 AHDC N/A 
A/equine/Montana/07 AHDC N/A 
A/equine/Virginia/05 AHDC N/A 
Equine Influenza H7N7 Subtype   
A/equine/Prague/56 NVSLa 021IDV9201 
A/equine/New York/07 AHDC N/A 
#110600 AHDC N/A 
#239936-99 AHDC N/A 
#13187-99 LDDCd N/A 
#36770-02 LDDC N/A 
#371106-02 LDDC N/A 
#38144-02 LDDC N/A 
#38360-02 LDDC N/A 
#38362-02 LDDC N/A 
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Table 3.1-continued   
Equine arteritis virus Bucyrus strain ATCC VR-796 
Equine herpesvirus 1 ATCC VR-700 
Equine herpesvirus 2 GERC N/A 
Equine herpesvirus 3 ATCC VR-352 
Equine herpesvirus 4 ATCC VR-2230 
Equine herpesvirus 5 UCDf N/A 
Equine rhinitis virus A NVSL 0600EDV8501 
Equine rhinitis virus B NVSL 0610EDV85010 
Equine adenovirus 1 NVSL 001EDV8401 
Equine adenovirus 2 LDDC N/A 
Salem virus AHDC N/A 
a National Veterinary Service Laboratories, Ames, IA 
b OIE Reference Laboratory, Maxwell Gluck Equine Research Center, University of Kentucky, KY 
c Animal Health Diagnostic Center, Cornell University , NY 
d Livestock Disease Diagnostic Center, University of Kentucky, KY 
e American Type Culture Collection , Manassas, VA 
f University of California, Davis, CA 
g Not applicable 
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Clinical samples 
A total of 211 archived nasal swabs from horses experimentally inoculated with 
the EIV A/equine/Kentucky/02 strain and 149 archived nasal swabs (field samples) 
submitted to the OIE Reference laboratory for routine EI diagnostic testing were included 
in the study. The 149 field samples included 48 nasal swab samples collected from horses 
in pre-export quarantine and the remaining 101 samples were collected from horses with 
evidence of respiratory disease where EI was suspected. Field samples were submitted as 
swabs and transported at 4 °C to the OIE Reference Laboratory for EI at the Gluck 
Equine Research Center.  Each nasal swab from the field was resuspended in 2.5 ml of 
phosphate buffered saline (PBS, pH=7.5) and stored at 4 °C.  The 211 archived nasal 
samples were collected from 25 horses that were experimentally challenged with the 
A/equine/Kentucky/02 strain of EIV. The samples were collected from day 1 to 8 post 
exposure. The remaining 11 samples were collected from 11 horses 3 days prior to 
experimental exposure to the virus.  The nasal swabs from experimentally challenged 
horses were placed in 5 ml of transport medium (PBS containing 10% glycerol, 1mg/ml 
gentamicin together with 8 IU/ml of penicillin, 8 µg/ml of streptomycin and 0.02 IU/ml 
of amphotericin B, [Invitrogen, Carlsbad, CA]) and stored at 4 °C. 
 
Virus isolation  
 All the samples submitted for attempted virus isolation (VI) were processed 
within 24 hr of collection at the OIE Reference Laboratory for EI at the Gluck Equine 
Research Center.  The 149 nasal swabs collected in the field between 2007 and 2009 and 
the 211 nasal swabs from an experimental horse challenge study were inoculated into the 
allantoic cavity of embryonated hens’ eggs and harvested as described previously.401   
 
Viral nucleic acid isolation  
Viral nucleic acid was isolated from archived nasal swabs (stored at -80 °C), 
allantoic fluid (AF) of EIV isolates or tissue culture fluid (TCF) containing other equine 
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respiratory viruses using a commercial kit (Macherey-Nagel NucleoSpin 8 Virus Kit, 
Bethlehem, PA) and automatic nucleic acid extraction machine XTR-1820 (Qiagen Inc., 
Santa Clara, CA). The rRT-PCR reactions were set up with a CAS-1200 machine 
(Qiagen Inc., Santa Clara, CA).  Briefly, 140 ?l of each sample was used for nucleic acid 
extraction according to the manufacturer’s instructions.  The viral nucleic acid was eluted 
in 60 ?l of nuclease-free water and stored at -80 °C.   
 
Primers and probes 
The primers and probes used in this study were designed using Primer Express® 
software v3.0 (Applied Biosystems, Forest City, CA). Three primer and TaqMan® 
MGB™ probe sets (EqFlu NP, EqFlu M and EqFlu HA3) targeting conserved regions of 
the NP, M and H3 HA genes were designed after aligning 17, 21 and 79 sequences of 
H3N8 subtype of EIV respectively from GenBank (Table 3.2). The EqFlu HA3-Mia was 
designed to target the H3 HA gene particularly of the A/equine/Miami/63 strain. Three 
primer and probe sets (EqFlu NP-Pra, EqFlu M-Pra and EqFlu HA7-Pra) were designed 
solely based on the NP, M and H7 HA genes of the A/equine/Prague/56 strain, 
respectively. In addition, the EqFlu HA7 primer and probe set was designed to target a 
highly conserved region after aligning 12 H7 HA sequences available in GenBank.  
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Table 3.2. Primers and probes used in the rRT-PCR assays 
rRT-PCR 
assay name 
Equine 
influenza 
virus 
subtype 
Primer or probea Sequence 5' to 3' and nucleotide location  (nt) 
GenBank 
accession 
number 
EqFlu NP 
H3N8 
EqFlu NP F GAAGGGCGGCTGATTCAGA (157-175) 
DQ124184 EqFlu NP R TTCGTCGAATGCCGAAAGTAC (199-219) 
EqFlu NP Pr bCAGCATAACAATAGAAAGGAc (177-196) 
EqFlu M 
EqFlu M F ACCGAGGTCGAAACGTACGT (38-57) 
DQ124188 EqFlu M R CGCGATCTCGGCTTTGA (84-100) 
EqFlu M Pr bCTCTCTATCGTACCATCAGGc (59-78) 
EqFlu HA3 
EqFlu HA3 F TCACATGGACAGGTGTCACTCA(448-469) 
L39914 EqFlu HA3 R GGCTGATCCCCTTTTGCA (485-506) 
EqFlu HA3 Pr bAACGGAAGAAGTGGAGCc (471-487) 
EqFlu HA3-
Mia 
EqFlu HA3-Mia F GCAGTGCTTTCAGCAATTGC (346-365) 
M29257 EqFlu HA3-Mia R AGAGACCGGAGCGATGCA (389-406) 
EqFlu HA3-Mia Pr dCCATATGACGTCCCTGACTc (369-387) 
EqFlu NP-Pra 
H7N7 
EqFlu NP-Pra F GGCGTCTCAAGGCACCAA (48-65) 
M63748 EqFlu NP-Pra R TCTGGCGTTCTCCACCAGTT (87-106) 
EqFlu NP-Pra Pr bCGACCTTATGAACAAATGc (67-84) 
EqFlu M-Pra 
EqFlu M-Pra F CGCGCAGAGACTTGAGAATG (97-116) 
CY005801 EqFlu M-Pra R CATTCCATGAGAGCCTCAAGATCT(136-159) 
EqFlu M-Pra Pr bTTTGCAGGGAAAAATAc (119-134) 
EqFlu HA7-Pra 
EqFlu HA7-Pra F CAATGGAGAGACTAGCGCATGT (441-462) 
X62552 EqFlu HA7-Pra R AGAAGCCATTTCATCTCTGCATAA (483-506) 
EqFlu HA7-Pra Pr eAAGGTCAAGATCTTCCc (465-480) 
EqFlu HA7 
EqFlu HA7 F TCCTCTGTGTACGTGCAGATAAAATC (59-84) 
X62556 EqFlu HA7 R GGGTGTCTACTTTGGTTCCATTAGA (106-130) 
EqFlu HA7 Pr bCCTAGGACGTCATGCTGc (87-103) 
aF=Forward primer, R=Reverse primer and Pr=Probe 
bReporter dye (FAM; 6-carboxyfluorescein) labeled nucleotide 
cNonfluorescent quencher dye (MGB™; minor groove binding) labeled nucleotide 
dReporter dye (VIC) labeled nucleotide
eReporter dye (NED) labeled nucleotide
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One-step real-time RT-PCR  
 A one-tube TaqMan? rRT-PCR assay was performed using the TaqMan® one-step 
RT-PCR Master mix in a 7500 Fast Real-Time PCR system (Applied Biosystems, Foster 
City, CA) as described previously.201  Briefly, 25 ?l of RT-PCR mixture for each reaction 
contained 12.5 ?l of 2 × Master Mix without UNG (uracil-N-glycosylase), 40 × 
MultiScribe and RNase Inhibitor Mix (0.625 ?l), 50 µM of forward and reverse primers 
(0.45 ?l [900 nM]), 10 µM probe (0.625 ?l [250 nM]), nuclease free water (5.35 ?l), and 
5 ?l of test sample RNA. The following thermocycling conditions were used under 
standard mode as per manufacturer’s recommendation: 30 min at 48 °C, 10 min at 95 °C, 
followed by 40 cycles at 95 °C for 15 sec and 60 °C for 1 min.  Each RT-PCR run 
included a control without RNA (containing the reaction mix with 5 ?l of water [no 
template control]) and positive controls containing in vitro transcribed (IVT) RNA.   
 
In vitro transcribed RNA synthesis and determination of analytical sensitivity of 
rRT-PCR assays 
The viral nucleic acid extracted from the H3N8 strains A/equine/Miami/63 and 
A/equine/Kentucky/02 was used as the template for amplification of the NP, M and H3 
HA genes for IVT RNA generation. Briefly, these genes were RT-PCR amplified using 
forward and reverse primers flanking the target gene sequence in rRT-PCR assays (Table 
3.3).  The RT-PCR products were gel-purified and cloned into the pDrive cloning vector 
according to the manufacturer’s instructions (Qiagen PCR cloning kit, Qiagen Inc., Santa 
Clara, CA). The plasmids were purified using a commercial kit (QIAamp® Miniprep kit, 
Qiagen Inc., Santa Clara, CA). The authenticity of each RT-PCR product was confirmed 
by sequencing both strands of DNA. Following sequencing, the recombinant plasmids 
with the NP, M and H3 HA genes from two different EIV H3N8 strains 
(A/equine/Miami/63 and A/equine/Kentucky/02) were used to generate IVT RNA. 
Runoff RNA transcripts were generated from Bam HI-linearized recombinant plasmids 
(Sp6 orientation) or Xho I-linearized recombinant plasmids (T7 orientation) according to 
??  
a previously described protocol.384  The concentration of the IVT RNA molecules per 
microliter was calculated according to the following formula as described before 201:  
Number of IVT RNA molecules / µl = 
Avogadro number (6.022x1023) × IVT RNA concentration (g/?l)  
                  IVT RNA molecular weight (g) 
 
The analytical sensitivity of the EqFlu NP, EqFlu M, EqFlu HA3 and EqFlu HA3-
Mia rRT-PCR assays was determined using the specific IVT RNA generated from the 
recombinant plasmids.  
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Determination of detection limits of rRT-PCR, Directigen
 
Flu A
®
 test and egg 
inoculation 
Using serial decimal dilutions (10-1 to 10-10) of the H7N7 (A/equine/Prague/56 
[4.65 × 105 EID50/ml]) and H3N8 (A/equine/Kentucky/02 [10
7 EID50/ml]) subtype strains, 
the detection limits of the rRT-PCR assays, Directigen Flu A® test (Becton-Dickinson, 
Sparks, MD) and egg inoculation were evaluated.  To avoid inter-assay variation, the 
same aliquot of each dilution was used in all three assays. Briefly, 5 µl of RNA isolated 
from 140 µl of each decimal dilution were used in rRT-PCR assays as described above. 
125 µl of each specimen was tested in the Directigen Flu A® test according to the 
manufacturer’s recommendations. For egg inoculation, an inoculum of 100 µl of each 
specimen was used. A total of 4 eggs were inoculated with each sample.401  
 
RT-PCR amplification and sequencing of NP, M genes 
The full-length NP gene sequence (nucleotide numbers [nt # 1-1565]) and partial 
M gene sequence (nt # 1-830) of the A/equine/New York/73 strain were RT-PCR 
amplified using a standard laboratory protocol.  Briefly, viral nucleic acid was isolated 
from AF using a Qiagen viral RNA extraction kit (Qiagen Inc., Santa Clara, CA) 
according to the manufacturer’s instructions.  Viral RNA was reverse transcribed with 
UNI-12 primer (Table 3.3) using the Accuscript™ high fidelity RT-PCR system 
(Stratagene, La Jolla, CA).413 Each cDNA was then amplified by PCR using Accuprime 
Pfx DNA polymerase (Invitrogen, Carlsbad, CA) with NP and M specific forward and 
reverse primers (Table 3.3). Both PCR products were gel purified and the full-length NP 
(1565 bp) and partial M (1027 bp) genes of A/equine/New York/73 strain were 
determined by sequencing both strands of DNA using gene specific primers (Table 3.3).  
The NP sequence of the A/equine/New York/73 was compared to the published 
sequences of A/equine/Miami/63 and A/equine/Prague/56 (Genbank accession numbers 
M22575 and M63748, respectively). Similarly, the partial M sequence of A/equine/New 
York/73 was compared to the same prototype strains (Genbank accession? numbers 
AF001674 and CY005801, respectively). 
??
 
Statistical analysis 
 Statistical evaluation of the performance of the three EIV primer and probe sets 
(EqFlu NP, EqFlu M and EqFlu HA3) for the detection of EIV nucleic acids was carried 
out to determine the respective sensitivity and specificity of each assay, and to compare 
these values with that of VI by egg inoculation. Sensitivities for the three H3N8 subtype 
specific rRT-PCR assays and VI were estimated by Clopper-Pearson exact binomial 
methods using experimental samples, with statistical comparisons made employing exact 
binomial paired tests.389 
The analysis of data from testing field specimens was conducted using a Bayesian 
model developed by Branscum et al,414 that enables estimation of the sensitivity and 
specificity of a test when true infection status is unknown.  Separate models were used 
for comparing VI with each rRT-PCR assay under the assumption of conditional 
independence of tests.  Independent beta prior distributions for the four sensitivities were 
constructed using information derived from the horse challenge study.  Specifically, 
average sensitivities on days 2 to 8 were used as prior modes for the sensitivity on each 
of the three rRT-PCR assays, with the smallest values among the lower endpoints of days 
2 to 8 used as prior 5th percentiles.  The modes and lower percentiles were used to 
identify an appropriate beta prior distribution.  For the VI test, the prior 95th percentile for 
sensitivity was set at 0.93, with a mode of 0.51.  Based on testing for possible cross-
reaction with other viruses, the priors for the specificities of each of the 3 rRT-PCRs had 
a mode of 0.95 and a 5th percentile of 0.80.  The specificity of VI was set equal to 1.  An 
empirical Bayes approach was used to place a prior on the prevalence that had a mode of 
0.32 and a 99th percentile of 0.45.  Gibbs sampling was used to simulate from posterior 
distributions.  Five chains were run with separated starting values (there was no 
indication of lack of convergence), a burn-in of 10,000 iterates was used, and inferences 
were based on 100,000 iterates. Data analysis was implemented in R 2.7 and WinBUGS 
1.4.3. 415-416 
 
 
??
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3.4. RESULTS 
Selection of rRT-PCR assays targeting NP, M and HA genes of H3N8 and H7N7 
subtypes of equine influenza 
A total of eight rRT-PCR assays were developed to target the NP, M, and HA 
genes of H7N7 and H3N8 EIV subtypes (Table 3.2). The assays were evaluated using 
prototype strains of each EIV subtype as well as recent virus isolates representing both 
American and Eurasian lineages (Table 3.4). The EqFlu NP, EqFlu M, EqFlu HA3 and 
EqFlu HA3-Mia assays were designed to detect EIV H3N8 subtype. The EqFlu NP assay 
not only detected all tested H3N8 strains but also one H7N7 strain (A/equine/New 
York/73). The EqFlu M assay successfully distinguished all H3N8 strains and did not 
cross-react with either of the two H7N7 strains tested. The EqFlu HA3 assay was able to 
detect all H3N8 subtype strains except for the prototype virus (A/equine/Miami/63). On 
the other hand, the EqFlu HA3-Mia assay which was designed solely based on the 
A/equine/Miami/63 sequence could only detect the prototype virus (Table 3.4). Similarly, 
the other four (EqFlu NP-Pra, EqFlu M-Pra, EqFlu HA7-Pra and EqFlu HA7) assays 
were designed to detect the EIV H7N7 subtype. Both H7N7 subtype viruses tested gave 
positive results with EqFlu M-Pra, EqFlu HA7-Pra and EqFlu HA7 assays (Table 3.4). 
However, the EqFlu NP-Pra assay could only detect the prototype strain 
(A/equine/Prague/56) but not the A/equine/New York/73 strain. None of these assays 
specific for the H7N7 subtype cross-reacted with any viruses of the H3N8 subtype. All 
eight rRT-PCR assays were highly specific in that none of them detected any of the other 
common equine respiratory viruses tested.  
In summary, both EqFlu NP and EqFlu M primers and probe sets were able to 
detect all eight H3N8 strains representing both American and Eurasian lineages that were 
included in this study.  With the exception of the first A/equine/Miami/63 isolate, the 
EqFlu HA3 primers and probe set detected most recent H3N8 isolates. Therefore, three 
out of four rRT-PCR assays specific for H3N8 subtype, EqFlu NP, EqFlu M and EqFlu 
HA3 were selected for further evaluation with clinical specimens.  
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Analytical sensitivity of the rRT-PCR assays targeting NP, M and H3 HA genes of 
H3N8 subtype  
  In order to determine the analytical sensitivity of the rRT-PCR assays targeting 
the NP, M and H3 HA genes of EIV nucleic acid, serial decimal molecule dilutions (100-
1010) of IVT RNA containing these genes derived from A/equine/Miami/63 and 
A/equine/Kentucky/02 strains of EIV were tested with the EqFlu NP, EqFlu M, EqFlu 
HA3 and EqFlu HA3-Mia rRT-PCR assays. The assays were independently repeated 
three times. The IVT NP, M or H3 HA RNA from each strain was calculated based on 
the molecular weight and concentration of the IVT RNA. Regression analysis confirmed 
linearity in all six assays (EqFlu NP rRT-PCR: R2=0.9968 for A/equine/Miami/63 and 
R
2=0.9976 for A/equine/Kentucky/02; EqFlu M rRT-PCR: R2=0.996 for 
A/equine/Miami/63 and R2=0.995 for A/equine/Kentucky/02; EqFlu HA3 rRT-PCR: 
R
2=0.9987 for A/equine/Kentucky/02; EqFlu HA3-Mia rRT-PCR: R2=0.9994 for 
A/equine/Miami/63). The EqFlu NP rRT-PCR detected a minimum of 10 RNA molecules 
from both A/equine/Kentucky/02 and A/equine/Miami/63 strains, and the cycle threshold 
(Ct) value for A/equine/Kentucky/02 was at least 4 cycles lower than for 
A/equine/Miami/63 over all the IVT RNA dilutions tested (Fig 3.1). The ranges of 
magnitude using the EqFlu M rRT-PCR for the A/equine/Miami/63 and 
A/equine/Kentucky/02 strains were 1 and 10 molecules, respectively (Fig 3.2). Both 
EqFlu HA3 and EqFlu HA3-Mia rRT-PCR assays detected a minimum of 10 RNA 
molecules (Fig 3.3). These data clearly indicate that each of these assays could detect as 
low as 10 RNA molecules.   
 
 
 
 
 
??  
 
Fig 3.1. Comparison of analytical sensitivity between IVT RNA of different EIA strains 
using EqFlu NP rRT-PCR ([Miami/63: y=-3.6006x+44.482, R2=0.9968] and 
[Kentucky/02: y=-3.5186x + 37.625, R2=0.9976]). +2 standard errors were also shown on 
the figure. 
 
Fig 3.2. Comparison of analytical sensitivity between IVT RNA of different EIA strains 
using EqFlu M rRT-PCR. ([Miami/63: y=-3.4157x+ 40.141, R2=0.996] and [Kentucky/02: 
y=-3.4516x +40.988, R2=0.995]). +2 standard errors were also shown on the figure. 
??  
 
Fig 3.3. Comparison of analytical sensitivity between IVT RNA of different EIV strains 
using EqFlu HA3 rRT-PCR and EqFlu HA3-Mia rRT-PCR ([Miami/63: y = -3.3349x + 
41.306, R2=0.9994 with EqFlu HA3-Mia rRT-PCR] and [Kentucky/02: y = -3.5606x + 
38.098, R2=0.9987 with EqFlu HA3 rRT-PCR]). +2 standard errors were also shown on 
the figure. 
 
Comparison of sensitivity of rRT-PCR assays targeting NP and M genes, Directigen
 
Flu A
®
 test and egg inoculation 
  Using serial decimal dilutions of A/equine/Kentucky/02 (H3N8 subtype) and 
A/equine/Prague/56 (H7N7 subtype), the detection limits of the EqFlu NP, EqFlu M, 
EqFlu NP-Pra and EqFlu M-Pra rRT-PCR assays were compared to the Directigen Flu 
A® test and egg inoculation (Table 3.5).  The highest dilutions that the Directigen Flu A® 
test and egg inoculation could detect were the 10-2 and 10-6 virus dilutions, respectively. 
In contrast, the N and MP specific rRT-PCR assays targeting both subtypes of the virus 
were at least more than 104 times more sensitive than the Directigen Flu A® test. 
Similarly, the assays had at least one log higher sensitivity than egg inoculation.  
??  

a Serial decimal dilutions of EIV strains were tested in the comparison study by egg inoculation, Directigen 
Flu A® test and rRT-PCR assays. Numbers shown on the table represent the serial decimal dilution factors.  
 bNot applicable 
 
Evaluation of H3N8 subtype specific rRT-PCR assays for the detection of EIV in 
clinical specimens  
  Three rRT-PCR assays (EqFlu NP, EqFlu M and EqFlu HA3 assays) targeting the 
NP, M and H3 HA genes were further evaluated using a range of clinical specimens.  Of 
the 211 archived nasal swab samples collected from horses that were challenged with the 
A/equine/Kentucky/02 strain, 164, 166 and 153 tested positive using the rRT-PCR assays 
targeting NP, M and HA genes, respectively (Table 3.6). Of the 149 archived nasal swabs 
from field cases of respiratory disease, 41, 25 and 27 tested positive with the NP, M and 
HA assays, respectively. Of the 149 samples, 48 nasal swabs were from horses that were 
scheduled for international shipment and all these samples tested negative for EIV 
nucleic acid using each of these three rRT-PCR assays.  
 
 
 
 
Table 3.5. Comparison of subtype specific rRT-PCR assays targeting NP and M genes with 
egg inoculation and Directigen Flu A® testa 
     rRT-PCR assays 
EIV prototype strains Subtype 
Virus titer 
(EID50/ml) 
Directigen 
Flu A® test 
Egg 
inoculation 
EqFlu NP EqFlu M 
EqFlu NP-
Pra 
EqFlu M-
Pra 
A/equine/Kentucky/0
2 
H3N8 107 10-2 10-6 10-7 10-7 NAb NA 
         
A/equine/Prague/56 H7N7 4.65 × 105 10-2 10-5 NA NA 10-6 10-7 
 
??  
   
  In the case of the experimental horse challenge study, estimated sensitivities of 
each rRT-PCR assay and p-values for a possible difference in sensitivity with VI by egg 
inoculation on days 1 to 8 post infection were calculated based on the assumption that 
every swab tested was truly positive for EIV (Table 3.7).  The results indicate that the 
rRT-PCRs targeting the NP and M genes were significantly more sensitive than VI by 
egg inoculation on day 1 post-infection; also, these two assays had higher sensitivities 
between days 3 to 5.  At later time points in the horse inoculation experiment (day 6 to 8), 
all three rRT-PCRs were significantly more sensitive than VI (P?0.02). The data 
demonstrate that the rRT-PCR assays had comparable or greater sensitivity in detecting 
nucleic acid than VI by egg inoculation at each time point from day 1 to 8 post infection 
(Table 3.7). 
  The estimated sensitivity and specificity of each rRT-PCR assay and the 
difference in sensitivity between rRT-PCR and VI by egg inoculation were calculated 
using a Bayesian analysis of the 149 field samples (Table 3.8). Seven horses that tested 
VI + were classified as EIV +. A total of 48 horses that tested negative on all three rRT-
PCRs and were VI - were classified as EIV -.  The unknown EIV status of the remaining 
94 horses was imputed in the Bayesian analysis. All three rRT-PCR assays had higher 
 
Table 3.6: Virus isolation and rRT-PCR results of archived EIV prototypes and clinical 
specimens 
Clinical specimen 
tested 
Virus isolation
 rRT-PCR assays 
 EqFlu NP  EqFlu M  EqFlu HA3 
 
Posit
ive 
Negativ
e 
 
Positi
ve 
Negat
ive 
 
Posit
ive 
Negati
ve 
 
Posit
ive 
Negat
ive 
211 nasal swabs 
from a horse 
challenge study 
 98 113  164 47  166 45  153 58 
149 field nasal 
swabs 
 7 142  41 108  25 124  27 122 
??  
sensitivity (with posterior probability of 1) than VI by egg inoculation. The PCR assay 
targeting the NP gene had the highest sensitivity (93%; 95% credible interval: 77%-99%) 
and had the largest increase in sensitivity over VI (58%; 95% credible interval: 37%-
76%). The other two rRT-PCR assays (EqFlu M and EqFlu HA3) had similar high 
sensitivities (89% and 87%) with smaller increases in sensitivity over VI (39% and 35%), 
respectively. All three assays had estimated specificities that were ? 96%. The higher 
sensitivity of the rRT-PCR assay targeting the NP gene of the H3N8 virus compared to 
the other two assays targeting the M and H3 HA genes is consistent with the sequence 
conservation seen in the NP gene among various EIV strains.   
 
Table 3.7. Estimated sensitivity of each rRT-PCR assay and P values (in parenthesis) for a 
statistical difference between rRT-PCR and VI by egg inoculation  
Days Post Infection VI EqFlu NP EqFlu M EqFlu HA3 
1 8% 32% (0.03) 36% (0.02) 20% (0.25) 
2 80% 88% (0.5) 88% (0.5) 84% (1.00) 
3 72% 92% (0.06) 92% (0.06) 92% (0.06) 
4 72% 92% (0.06) 92% (0.06) 88% (0.22) 
5 68% 88% (0.06) 88% (0.06) 88% (0.06) 
6 60% 100% (0.002) 96% (0.004) 88% (0.02) 
7 28% 88% (<0.001) 88% (<0.001) 84% (<0.001) 
8 4% 76% (<0.001) 84% (<0.001) 68% (<0.001) 
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Table 3.8. Estimates and comparison of test performance parameters of three rRT-PCR 
assays using field samples 
 EqFlu NP EqFlu M EqFlu HA3 
Estimated sensitivity 93% 89% 87% 
95% credible interval 77%-99% 68%-98% 63%-98% 
    
Estimated specificity 96% 97% 96% 
95% credible interval 88%-99% 90%-100% 89%-99% 
  
Difference between sensitivity of rRT-
PCR and Egg inoculation 
58% 39% 35% 
95% credible interval 37%-76% 15%-63% 7%-59% 
    
Posterior probability that sensitivity of 
rRT-PCR is > sensitivity of Egg 
inoculation 
1.00 1.00 0.99 
 
 
Cross-reaction of EqFlu NP rRT-PCR assay with A/equine/New York/73 (H7N7)  
  Because the A/equine/New York/73 strain (H7N7 subtype) was detected by the 
EqFlu NP assay that was originally designed to detect H3N8 strains but not by the EqFlu 
NP-Pra assay, the NP and partial M gene of this virus were sequenced (Genbank 
accession numbers FJ499496 and FJ666099, respectively).  The M gene of 
A/equine/New York/73 had 97.7% identity when compared to A/equine/Prague/56 strain 
as expected.  In contrast, the NP gene of that strain had more sequence identity with the 
H3N8 prototype A/equine/Miami/63 than with the H7N7 prototype A/equine/Prague/56 
strain (96.3% and 83.3%, respectively). These data clearly indicate that despite being a 
H7N7 virus, the NP gene of the A/equine/New York/73 strain is very similar to that of 
the H3N8 virus. The forward primer of the EqFlu NP assay had a 100% match with the 
A/equine/New York/73 NP gene, while there was only a single nucleotide mismatch in 
both reverse primer and probe binding regions. These two changes did not compromise 
the detection capability of the rRT-PCR assay. In contrast, the reverse primer and the 
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probe of the EqFlu NP-Pra assay had 2 and 3 nucleotides mismatches, respectively, when 
compared with the A/equine/New York/73 strain, which compromised the sensitivity of 
the assay. 
 
3.5. DISCUSSION 
  Eight new MGB™ probe based rRT-PCR assays targeting the NP, M, H3 and H7 
HA genes of two EIV subtypes were developed and evaluated in this study. Four of the 
primer sets targeted the NP, M and H3 HA genes of H3N8 subtype and the remaining 
four targeted the respective genes of H7N7 subtype. The assays were based on MGB™ 
probes which provide several advantages over other real-time PCR chemistries.  The 
MGB™ probes are shorter in length (12-18 bases) compared to conventional TaqMan® 
probes. Since such probes are less liable to sequence mismatches, this results in increased 
specificity of the rRT-PCR assays.417 The 3’ end nonfluorescent quencher dye 
dramatically reduces the background fluorescence of the reaction, hence less chance of 
false positive results.150 For the primer and probe design, the conserved regions of these 
four genes were determined by alignment of sequences of the H3N8 and H7N7 strains 
available in GenBank.  The EqFlu NP and EqFlu M assays were able to detect all the 
prototype H3N8 strains. The EqFlu HA3 assay did not give a positive reaction with the 
A/equine/Miami/63 (H3N8) which may be the result of antigenic drift. Sequence 
comparison with a recent isolate revealed that the H3 HA gene of A/equine/Miami/63 
only has 91% sequence homology with that of A/equine/Kentucky/02 (data not shown). 
There are 1 and 3 nucleotide mismatches in the reverse primer and probe region of the 
EqFlu HA3 assay, respectively, compared to the H3 HA sequence of A/equine/Miami/63 
virus; thus reducing the efficiency of the assay. Sequence analysis of A/equine/New 
York/73 (H7N7) clearly indicates that its NP gene was derived from the H3N8 subtype, 
providing confirmation of reassortment between H3N8 and H7N7 strains of EIV in the 
field since the 1970s as previously reported.418-420 Since the EqFlu HA7 assay appears to 
be highly specific for H7N7 EIV, it should enable highly reliable surveillance for the 
H7N7 subtype which is thought to be extinct or possibly still circulating at a very low 
level in nature.10,421-423 Regrettably, the EqFLu HA7 assay could not be adequately 
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evaluated because of the very limited number of isolates of this EIV subtype available for 
testing in this study.  None of these assays specific for both EIV subtypes gave a positive 
result with other common equine respiratory viral pathogens such as equine herpes 
viruses and equine rhinitis viruses, confirming 100% specificity for EIV.  In summary, 
the primer and probe sets designed and evaluated in this study allow identification of both 
equine influenza subtypes. It would appear they likely can also detect any reassortments 
of these two EIV subtypes that may currently be in circulation in nature. Furthermore, 
H3N8 subtype specific assays were able to detect both Eurasian and American lineage 
strains of EIV.  
  Three rRT-PCR assays (EqFlu NP, EqFlu M and EqFlu HA3 assays) targeting the 
NP, M and H3 HA genes of H3N8 EIV subtype were further evaluated by using two sets 
of clinical samples: nasal swabs from an experimental challenge study and nasal swabs 
(field samples) submitted to the OIE Reference laboratory for EI for routine diagnostic 
testing. Using nucleic acid extracted from the samples collected from a group of 
experimentally inoculated horses, both the EqFlu NP and EqFlu M assays were shown to 
have significantly higher respective sensitivities than egg inoculation during the time 
course of the study (day 1 to 8). Furthermore, with few exceptions, all three assays were 
able to detect EI nucleic acid from day 1 post-challenge before clinical signs of disease 
were observed.  The samples that were positive only by rRT-PCR and not by VI were 
confirmed truly EIV positive by a previously published standard RT-PCR assay (data not 
shown).404  The minimal analytical sensitivity of these assays can reach up to 10 IVT 
RNA molecules. As such, these assays provide valuable tools for distinguishing EI from 
clinically similar diseases on an individual animal basis. These newly developed rRT-
PCR assays performed exceedingly well not only in virus detection but also in 
distinguishing the different subtypes of EIV based on the various samples evaluated in 
this study. Such assays can provide a fast and reliable means of EIV diagnosis and are 
especially useful in screening samples during a suspected outbreak of EI.   
  Comparison of the sensitivity of the four rRT-PCR assays targeting the NP and M 
genes with egg inoculation and the Directigen Flu A® test clearly show that the molecular 
assays provide the highest sensitivity. Previous studies have compared relative 
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sensitivities of VI in embryonated eggs, antigen detection (Directigen Flu A® test) and 
nucleic acid amplification (nested RT-PCR targeting the NP gene and standard RT-PCR 
targeting the M gene) for detection of EIV.408  The authors have shown that RT-PCR 
assays using M primers and VI in embryonated eggs proved to be the most sensitive 
methods for virus detection.  The Directigen Flu A® test was the least sensitive method 
for detection of EIV.  In a similar study, Yamanaka et al 407 demonstrated that VI in 
embryonated eggs is more sensitive than five rapid antigen detection kits evaluated.  
Furthermore, analysis of nasal swabs from a limited number of experimentally inoculated 
horses also showed that VI by egg inoculation and the standard RT-PCR had comparable 
sensitivities in detecting EIV.408  Data from this study also demonstrated that the 
Directigen Flu A® test had the least sensitivity followed by VI in embryonated eggs. 
Furthermore, evaluation of clinical samples and serial dilutions of EIV prototype strains 
has confirmed that rRT-PCR assays have higher sensitivity than egg inoculation.  
 In conclusion, newly developed rRT-PCR assays targeting NP, M and HA genes 
were found to be highly sensitive and specific compared to the Directigen Flu A® test and 
VI in embryonated eggs. The assays provided a fast and reliable means of virus detection 
and disease surveillance, with it would appear, the additional advantage of being able to 
identify antigenic shift between the two subtypes of EIV. 
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CHAPTER FOUR 
 
Diagnostic application of H3N8-specific equine influenza real-time reverse 
transcription polymerase chain reaction assays for the detection of Canine influenza 
virus in clinical specimens 
J Vet Diagn Invest 22 (6):942-5 (2010) 
Reprinted with permission 
 
4.1.  SUMMARY 
The objective of the current study was to determine the capability of 3 recently 
described one-step TaqMan® real-time reverse transcription polymerase chain reaction 
(RT-PCR) assays targeting the nucleoprotein (NP), matrix (M), and hemagglutinin (HA) 
genes of H3N8 Equine influenza virus (EIV NP, EIV M, and EIV HA3 assays, 
respectively) to detect Canine influenza virus (CIV). The assays were initially evaluated 
with nucleic acid extracted from tissue culture fluid (TCF) containing the 
A/canine/FL/43/04 strain of Influenza A virus associated with the canine influenza 
outbreak in Florida in 2004. The EIV NP, EIV M, and EIV HA3 assays could detect CIV 
nucleic acid at threshold cycle (Ct) values of 16.31, 23.71, and 15.28, respectively. Three 
assays using TCF or allantoic fluid (AF) samples containing CIV (n = 13) and archived 
canine nasal swab samples (n = 20) originally submitted for laboratory diagnosis of CIV 
were further evaluated. All TCF and AF samples, together with 10 nasal swab samples 
that previously tested positive for virus by attempted isolation in embryonated hens’ eggs 
or Madin-Darby canine kidney cells, were positive in all 3 real-time RT-PCR assays. 
None of the 3 assays detected the H1N1 Swine influenza virus strain in current 
circulation. These findings demonstrate that previously described real-time RT-PCR 
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assays targeting NP, M, and H3 HA gene segments of H3N8 EIV are also valuable for 
the diagnosis of CIV infection in dogs. The assays could expedite the detection and 
identification of CIV. 
 
4.2.  MAIN TEXT 
Influenza A viruses infect a variety of mammalian and avian species, including 
pigs, horses, birds, certain wildlife species, as well as humans.11  Interspecies 
transmission of influenza A virus plays an important role in its ecology and 
epidemiology.424  A significant outbreak of canine influenza (CI) was reported in 
greyhound dogs in Florida in early 2004 which was shown to be due to cross species 
transmission of H3N8 equine influenza virus (EIV).24  Furthermore, there are reports of 
experimental transmission of H5N1 and natural transmission of H3N2 avian influenza 
viruses to dogs.425-431  More recently, it has been reported that a novel influenza A/H1N1 
virus, a reassortant of human, swine and avian influenza viruses, is capable of infecting 
dogs.432-434  Samples from two sick dogs tested positive for A/H1N1 influenza virus and 
both virus isolates were 99% identical with the strains isolated from humans.434  However, 
the significance of transmission of influenza A viruses to dogs from other mammal and 
avian species including humans has yet to be determined.   
Since the initial CI outbreak in Florida, evidence of virus activity has been 
reported in 30 states in the United States, reportedly affecting tens of thousands of 
dogs.24,435  Sequence analysis of the canine influenza virus (CIV) from the original 
outbreak (A/canine/FL/43/04) revealed that 8 gene segments of this virus shared ?96% 
nucleotide sequence homology with that of equine influenza virus (EIV) H3N8 subtype, 
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suggesting that CIV resulted from direct interspecies transmission of EIV to dogs without 
genetic reassortment.24,436  The sequence changes in the hemagglutinin gene (H3 HA) are 
indicative of adaptive evolution of the virus in its new host.  Phylogenetic analysis of 4 
greyhound isolates and 2 pet dog isolates revealed that these viruses were closely related 
to EIV strains recovered from horses since 2000, belonging to the Florida sublineage of 
the American lineage of equine influenza H3N8 virus.24,436 The isolation of four closely 
related EIV H3N8 subtype strains from dogs that died in different locations over a 2-year 
period of time, together with serological evidence of widespread infection among 
greyhounds in different states, strongly confirmed sustained circulation of CIV involving 
dog-to-dog transmission of the virus.24,436-437 
Most outbreaks of CI occur in rescued, kenneled, or boarded dogs.435  Clinical 
signs of the disease include low-grade fever, lethargy, anorexia, nasal discharge and 
prolonged cough.435-436 These signs can mimic those caused by other canine respiratory 
pathogens.  Accordingly, it is especially important to be able to distinguish CIV from 
other agents capable of causing canine respiratory disease.435  Detection of CIV at the 
early stage of infection is especially important for facilitating management and control of 
the disease.  Up to the present, there have been few publications describing specific 
diagnostic assays to detect CIV in clinical specimens.  Detection of CIV is frequently 
attempted by traditional virus isolation (VI) in embryonated hens’ eggs or in Madin-
Darby canine kidney (MDCK) cells.435  There have been some conflicting reports over 
the sensitivity of antigen-capture ELISA tests for the detection of CIV in dogs.435,438 
Presence of CIV nucleic acid in clinical specimens has been confirmed by traditional RT-
PCR and real-time RT-PCR (rRT-PCR) assays targeting the matrix (M) gene of avian 
??   

influenza virus or by an rRT-PCR assay specific for the H3 HA or the M gene of 
CIV.435,436,438  Recently, we developed and evaluated three rRT-PCR assays targeting the 
nucleoprotein (NP), M and H3 HA genes of H3N8 subtype of EIV (EqFlu NP, EqFlu M 
and EqFlu HA3 assays, respectively; Table 4.1).202  EqFlu NP, EqFlu M and EqFlu HA3 
primer and probe sets were 100% identical to the published NP, M and H3 HA sequences 
of CIV, respectively.  Therefore, the purpose of this study was to determine whether 
these three rRT-PCR assays were capable of detecting CIV nucleic acid in nasal swab 
specimens obtained from infected dogs. 
Table 4.1. Primers and probe sets used in this study 
rRT-PCR Assay 
Name 
Primer or Probe 
Name* 
Sequence 5' to 3' and Nucleotide Location 
GenBank Accession 
Number 
EqFlu NP 
EqFlu NP F GAAGGGCGGCTGATTCAGA  (157-175) 
DQ12418411 EqFlu NP R TTCGTCGAATGCCGAAAGTAC (199-219) 
EqFlu NP Pr †CAGCATAACAATAGAAAGGA‡  (177-196) 
EqFlu M 
EqFlu M F ACCGAGGTCGAAACGTACGT (38-57) 
DQ12418811 EqFlu M R CGCGATCTCGGCTTTGA (84-100) 
EqFlu M Pr †CTCTCTATCGTACCATCAGG‡ (59-78) 
EqFlu HA3 
EqFlu HA3 F TCACATGGACAGGTGTCACTCA (448-469) 
L3991411 EqFlu HA3 R GGCTGATCCCCTTTTGCA (485-506) 
EqFlu HA3 Pr †AACGGAAGAAGTGGAGC‡ (471-487) 
H1N1 
NH1 forward TGAGATATTCCCCAAGACAAGTTC (393-416) 
FJ9669603 NH1 reverse TTTGTAGAAGCTTTTTGCTCCAG (489-467) 
NH1 probe †TCATGACTCGAACAAAGGTGTAACGG§ (426-451) 
*F=Forward primer. R=Reverse primer. Pr=Probe
†
Reporter dye (FAM; 6-carboxyfluorescein) labeled nucleotide 
‡
Nonfluorescent quencher dye (MGB™; minor groove binding) labeled nucleotide 
§BHQ1 (black hole quencher 1) dye labeled nucleotide 
 
In this study we evaluated the capability of EqFlu NP, EqFlu M and EqFlu HA3 
assays to detect not only H3N8 CIV but also the novel H1N1 virus that has been in 
widespread circulation around the world and which has proven capacity to infect 
dogs.24,434 Tissue culture fluid (TCF) containing the A/canine/FL/43/04 isolate and 13 
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other archived CIV isolates from the Animal Health Diagnostic Center, Cornell 
University, Ithaca, NY and Livestock Disease Diagnostic Center, University of Kentucky, 
Lexington, KY were tested in the study. Also included were 20 archived nasal swabs 
from dogs with signs of respiratory illness, 10 of which had previously tested positive for 
CIV by virus isolation in embryonated hens’ eggs or MDCK cells according to standard 
laboratory protocols.  Nasal specimens were collected using cotton or Dacron swabs 
moistened with a few drops of normal saline or viral transport medium.  The presence of 
CIV in TCF and allantoic fluid (AF) had previously been confirmed by either sequencing 
the entire genome (n=11) or H3 HA gene (n=3).  Of the ten CIV positive nasal swab 
samples, three were previously diagnosed as positive by rRT-PCR targeting the M gene.  
These three samples were subsequently tested by an N1 NA specific RT-PCR, thus ruling 
out H1N1 influenza virus.  The remaining seven CIV positive nasal swab samples were 
part of a study in which H3N8 virus was continuously circulating in a particular animal 
shelter.  The H3 HA gene from three isolates (representative of the total of seven samples) 
had been sequenced to confirm that they were H3N8 CIV.  A total of 38 nasal swabs 
from pigs that were experimentally infected with the A/CA/04/2009 strain of H1N1 virus, 
as well as swabs from 12 control pigs were also included in the study.439  The presence of 
H1N1 virus in pig samples was previously confirmed by VI in embryonated hens’ eggs.  
All archived nasal swab specimens, TCF and AF samples were stored at -80 °C prior to 
nucleic acid extraction.  Viral nucleic acid was isolated from 50 µl of TCF, AF or nasal 
swab samples with a commercial viral RNA isolation kita by using a commercial 
magnetic particle processor.b Viral RNA was eluted in 50 µl of nuclease free water and 
stored at -80 °C until further use.  The primers and probes used in this study were 
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identical to those previously described for the EqFlu NP, EqFlu M and EqFlu HA3 rRT-
PCR assays (Table 4.1).202  The primers and probe set specific for the H1 HA gene of the 
novel H1N1 strain were previously described (Table 4.1).440 A 1-tube rRT-PCR assay 
was performed using a commercial kit and machinec,d under the exact same conditions as 
previously reported.202  Each sample was tested in duplicate in each assay.  
Initially, we determined the ability of all three primer sets to detect CIV using 
RNA extracted from TCF containing the A/canine/FL/43/04 strain.  EqFlu NP, EqFlu M 
and EqFlu HA3 assays detected CIV RNA with average Ct values of 16.31, 23.71 and 
15.28, respectively.  In contrast, all three assays failed to detect influenza virus nucleic 
acid extracted from the A/CA/04/2009 strain of H1N1 virus.  Subsequently, we evaluated 
these assays with RNA extracted from the 13 TCF and AF samples containing other CIV 
isolates. All samples tested positive, with mean Ct values ranging from 20.12 ± 1.87 
(mean ± standard deviation) with EqFlu NP, 26.25 ± 7.61 with EqFlu M and 22.25 ± 4.03 
with EqFlu HA3 assays.  Comparison of Ct values indicated that the EqFlu NP assay had 
the lowest Ct value compared to the EqFlu M and EqFlu HA3 assays (p=0.0095 and 
p=0.0447, respectively). In addition, 20 canine nasal swab samples were tested in the 
study.  Ten of these canine nasal swabs that were positive by VI were also positive in all 
three rRT-PCR assays, with mean Ct values ranging from 25.51 ± 3.06 with EqFlu NP, 
27.18 ± 2.63 with EqFlu M and 26.98 ± 3.61 with EqFlu HA3 assays. The remaining ten 
nasal swab samples that were negative by VI were also negative in all three rRT-PCR 
assays.  The EqFlu NP assay had the lowest Ct values with all twenty four samples (TCF, 
AF and nasal swab samples) compared to the EqFluM and EqFlu HA3 assays (p=0.0024 
and p=0.0078, respectively).   
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Results of the three rRT-PCR assays using nucleic acid extracted from nasal 
swabs from dogs highly correlated with the VI results (100% sensitivity and specificity; 
Table 4.2).  These assays provide a rapid and convenient means of detecting CIV nucleic 
acid in nasal swab samples and for confirming a diagnosis of CI.  The sensitivity of the 
assays has been previously established to be ? 10 RNA molecules.202  The primers and 
probe specific for the H1 HA gene of the novel H1N1 strain failed to recognize the 
A/canine/FL/43/04 strain or any other H3N8 positive samples included in this study. In 
contrast, the assay readily detected the H1N1 viral nucleic acid in the 38 nasal swabs 
collected from the H1N1 experimentally infected pigs (mean Ct value 24.78; 100% 
sensitivity).440  None of the 12 nasal swab samples collected from control pigs reacted 
with the H1 HA gene specific primers and probe (100% specificity).  The data clearly 
demonstrated that the three EqFlu rRT-PCR assays and the rRT-PCR assay specially 
designed to detect the novel H1N1 virus are highly specific for each influenza subtype 
and could be used successfully to diagnose cases of respiratory disease due to either of 
these viruses in dogs.   
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Table 4.2. Detection of CIV or swine influenza virus nucleic acid by rRT-PCR assays 
targeting nucleoprotein (NP), matrix (M) and hemagglutinin (HA) genes of H3N8 equine 
influenza virus 
 rRT-PCR Assay Names 
Specimens Tested EqFlu NP*  EqFlu M*  EqFlu HA3* 
 Ct value† Mean+SD  Ct value† Mean+SD  Ct value† Mean+SD 
TCF or AF Containing CIV Isolates (n=14) 
A/Ca/FL/43/04 16.31 
20.12±1.87 
 23.71 
26.25±7.61 
 15.28 
22.25±4.03 
A/Ca/FL/15592/04 MDCK P1 20.21  20.20  19.63 
A/Ca/FL/61156,2/07 MDCK P1 21.80  35.32  23.41 
A/Ca/KY/1198778/06 Egg P1 21.02  21.15  21.88 
A/Ca/CO/17864/06 Egg P2 21.93  22.05  22.96 
A/Ca/NJ/73709/09 Egg P1 19.76  37.31  30.32 
A/Ca/VA/93653/09 Egg P1 19.17  38.87  29.40 
A/Ca/PA/10909/07 egg P2 20.32  21.00  22.13 
A/Ca/NY/115809/05 Egg P2 20.09  20.39  20.58 
A/Ca/CO/8880/06 MDCK P1 16.40  16.86  17.24 
A/Ca/PA/10915/06 Egg P2 23.01  23.32  24.75 
A/Ca/NY/49601/06 MDCK P1 20.58  35.39  21.00 
A/Ca/CA/70645/06 Egg P2 20.42  20.55  21.13 
A/Ca/KY/49417-06 MDCK P1  20.59  31.49  21.74 
 
Canine Nasal Swabs Samples Positive by VI‡ (n=10)
1623-10-2-1 NY 29.59 
25.51±3.06 
 30.11 
27.18±2.63 
 30.34 
26.98±3.61 
3699-10 NY 20.19  23.88  21.35 
133-10 NY 29.00  31.69  30.35 
96978-09 PA 24.57  26.33  32.82 
61621-08 NY 25.78  27.45  26.89 
97293-08 NY 25.24  25.91  25.29 
95945-08 NY 24.40  26.50  25.04 
68912-08 NY 24.37  25.99  25.55 
51790-08 NY 29.39  29.96  29.14 
113945-08 NY 22.55  23.94  23.03 
 
Canine Nasal Swab Samples Negative by VI‡ (n=10)
1F 09 FL - 
- 
 - 
- 
 - 
- 
2F 09 FL -  -  - 
3F 09 FL -  -  - 
4F 09 FL -  -  - 
5F 09 FL -  -  - 
6F 09 FL -  -  - 
7F 09 FL -  -  - 
8F 09 FL -  -  - 
9F 09 FL -  -  - 
10F 09 FL -  -  - 
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Table 4.2.-continued 
Swine Nasal Swab Sample Positive by VI* for novel H1N1 virus (n=38) 
A/CA/04/2009 -   -   -  
         
Swine Nasal Swab Sample Negative by VI* for novel H1N1 virus (n=12) 
 -   -   -  
* The cut-off  point for Ct value is 40 cycles 
† p value were calculated based on Ct values of all 24 positive samples. p=0.0024 (EqFlu NP compared to 
EqFlu M) and p=0.0078 (EqFlu NP compared to EqFlu HA3) 
‡ 
Attempted virus isolation in MDCK cells or embryonated hens’ eggs 
 
In summary, the three rRT-PCR assays we developed were able to recognize both 
equine and canine H3N8 viruses in clinical specimens and could be used as a routine 
laboratory test for the diagnosis of influenza in both animal species.  The assays are 
highly specific and do not detect recently emerged H1N1 strain of influenza virus.  Since 
the EqFlu NP assay has the highest sensitivity, it is recommended for the routine 
diagnosis of CIV in dogs.  Furthermore, the EqFlu HA3 assay has the capability to 
distinguish canine influenza cases resulting from H3N8 subtype from H1N1 subtype 
infections which will not be detected by this assay.   
Sources and manufacturers 
a. MagMAX™-96 viral RNA isolation kit, Applied Biosystems, Foster City, CA. 
b. KingFisher® magnetic particle processor, Thermo Fisher Scientific, Waltham, MA. 
c. TaqMan® one-step RT-PCR master mix, Applied Biosystems, Foster City, CA. 
d. 7500 Fast real-time PCR system, Applied Biosystems, Foster City, CA. 
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CHAPTER FIVE 
 
Development of one-step TaqMan
® 
real-time reverse transcription-PCR and 
conventional reverse transcription PCR assays for the detection of equine rhinitis A 
and B viruses 
(submitted to BMC Veterinary Research) 
 
5.1.  SUMMARY 
Background: Equine rhinitis virus A and B (ERAV and ERBV) are common equine 
respiratory viruses belonging to the family Picornaviridae.  There is evidence that these 
two viral infections are prevalent in countries in which sero-survaillence studies have 
been undertaken.  Currently there is a lack of rapid and reliable diagnostic methods for 
virus detection and antibody determination.  The sensitivity of virus isolation varies 
between laboratories and is confounded by difficulties in isolating virus from the urine of 
carrier horses.  The objective of this study was to develop molecular diagnostic assays 
(real-time RT-PCR [rRT-PCR] and conventional RT-PCR [cRT-PCR] assays) capable of 
detecting and distinguishing ERAV from ERBV without the inherent problems associated 
with the current laboratory diagnosis of these infections.  
Results: Three rRT-PCR assays targeting the 5'-UTR of ERAV and ERBV were 
developed. One assay was specific for ERAV, whereas the remaining two assays were 
specific for ERBV. In addition, six cRT-PCR assays targeting the 5'-UTR and 3D 
polymerase regions of ERAV and ERBV were also developed.  Both rRT-PCR and cRT-
PCR assays were evaluated using RNA extracted from 21 archived tissue culture fluid 
samples which were previously determined to be positive for ERAV or ERBV with virus 
specific rabbit antiserum.  All rRT-PCR and cRT-PCR assays targeting ERAV could only 
detect ERAV isolates (n=11) and did not cross-react with any ERBV isolates (n=10).  
Similarly, the rRT-PCR and cRT-PCR assays targeting ERBV could only detect ERBV 
isolates and did not cross-react with ERAV isolates.  None of the rRT-PCR or cRT-PCR 
assays cross-reacted with any of the other common equine respiratory viruses.  With the 
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exception of one cRT-PCR assay, the detection limit among all these assays was 1 plaque 
forming unit per ml (pfu/ml).      
Conclusion: These new rRT-PCR and cRT-PCR assays provide useful diagnostic tools 
for the detection and differentiation of ERAV and ERBV.  While the results of this study 
are very promising, a much greater number of clinical specimens needs to be tested 
before each assay is fully validated for the detection of ERAV and/or ERBV in suspect 
cases of either viral infection.    
 
5.2.  INTRODUCTION 
The family Picornaviridae is a large family of viruses classified into several 
genera with extensive diversity in physical properties, antigenicity and mechanisms of 
pathogenesis.441  Although there are many different picornaviruses with various degrees 
of relatedness, all share several features in common. All picornaviruses have a single-
stranded positive-sense RNA genome whose 5'-end is covalently linked to a VPg (virion 
protein genome-linked) protein. The RNA genome contains a 5? untranslated region 
(UTR) with an internal ribosome entry site (IRES), a single open reading frame (ORF) 
encoding the viral capsid proteins and the viral replicase proteins, a 3? UTR and a 3? 
poly(A) tail.442  The ORF is divided into three regions: P2 encodes four structural 
proteins (VP1-VP4), P2 (2A-2C) and P3 (3A-3D) encode seven non-structural 
proteins.443  A key component of the replication machinery is the RNA-dependent RNA 
polymerase (RdRp), also referred to as 3D polymerase (3Dpol) in picornaviruses.  This 
protein is responsible for the synthesis of both plus- and minus- strand viral RNA.444  
Equine piconaviruses, formerly known as the equine rhinoviruses 1, 2 and 3 have been 
reclassified as equine rhinitis A virus (ERAV) and equine rhinitis B 1 and 2 viruses 
(ERBV1 and ERBV2, respectively). ERAV (formerly equine rhinovirus 1 [prototype 
ERAV.P393/76]) is a member of the genus Aphthovirus, in the family Picornaviridae, 
and was first isolated in the United Kingdom in 1962.32,445-446  The genome organization 
and structure of ERAV is very similar to other Picornaviruses (e.g. foot-and-mouth 
disease virus).  The second equine rhinitis virus, ERBV1 (formerly equine rhinovirus 2 
??   
[prototype P1436/71]) was first isolated in Switzerland and subsequent sequence 
determination resulted in it being classified in a new genus Erbovirus, also in the family 
Picornaviridae.446-447  The ERBV1 serotype comprises two distinct phylogenetic groups, 
one of which is phenotypically acid stable and the other is acid labile.448  Subsequently, a 
third equine rhinovirus virus (equine rhinovirus 3) was also isolated in Switzerland and 
following sequence analysis of its viral capsid proteins, it was shown to be a second 
serotype in the genus Erbovirus, and was designated as ERBV2 (prototype P313/75).448-
450  
Strains of ERAV, ERBV1 and ERBV2 have been identified with both subclinical 
and clinical upper respiratory tract infections in horses worldwide.28,33,451-452 Little is 
known about the pathogenesis of ERAV and ERBV, which could be attributable in part 
to the lack of suitable laboratory methods for the diagnosis of these infectious agents.  
Seroprevalence data reported by different investigators indicate that neutralizing 
antibodies to ERAV and ERBV can be found in 50% to 80% of horses worldwide and the 
seropositive percentage seems to be correlated with the age of the animals.9,28-31  Most 
ERAV, ERBV1 and ERBV2 isolates were recovered from horses with acute febrile 
respiratory disease with clinical signs of high fever for 1-3 days, serous to mucopurulent 
nasal discharge, anorexia, leg edema and enlarged lymph nodes of the head and neck that 
were sensitive on palpation.  A significant number of horses may carry and shed virus in 
their urine for a long time.  Subclinical infection and subsequent seroconversion have 
also been reported.32-33,453-454 
The clinical signs of equine influenza virus, equine herpesvirus-1 and -4, equine 
rhinitis A and B (ERAV, ERBV1, ERBV2), equine adenovirus 1 (EAdV1) and equine 
arteritis virus (EAV) infections are very similar and resemble a number of other 
infectious and non-infectious equine respiratory diseases.6-7 Accordingly, a provisional 
clinical diagnosis based solely on the respiratory signs must be confirmed by laboratory 
testing.  Furthermore, rapid and accurate identification of these viruses is critical to the 
control of the diseases they cause, particularly in light of the fact that each of them can 
cause very similar clinical signs in affected horses. Therefore, the development of rapid, 
highly sensitive and specific diagnostic assays is essential to the identification and 
??   
differentiation of ERAV and ERBV in infected horses during outbreaks of disease. In 
addition, such assays would facilitate epidemiological investigations.    
Traditionally, ERAV and ERBV have been detected by virus isolation in 
susceptible cells lines such as African green monkey kidney (Vero) or rabbit kidney-13 
(RK-13) cells. The source of these viruses can include nasal swabs, blood, feces and 
urine.33,455-456 Virus isolation can be challenging because strains of these viruses may 
grow poorly in cell culture and may not give rise to visible cytopathic effect.27,457  A 
modified culture medium supplemented with MgCl2 can enhance the growth of some 
ERBV strains, but it is unsuitable for diagnostic purposes due to lack of sensitivity.457  
Furthermore, successful virus isolation frequently requires multiple blind passages and 
subsequent confirmation by electron microscopy or immunofluorescence for testing in 
the case of non-cytopathic strains.  ERAV and ERBV can also be detected serologically 
by demonstration of a four-fold or greater rise in antibody titer between paired sera by 
serum neutralization33,447,458 or complement fixation.451,459  These traditional serologic 
techniques, although sensitive and specific, are time consuming and tedious. Several 
rapid molecular tests such as conventional RT-PCR (cRT-PCR) and real-time RT-PCR 
(rRT-PCR) have been developed for ERAV and ERBV.106,205-206,457  The primers used in 
these assays were located in the 3Dpol, 3'-UTR, 5'-UTR or VP1-2A regions of the viral 
genome.  In the present study, we developed a panel of three new rRT-PCR assays for 
ERAV and ERBV targeting the 5'-UTR region of each viral genome, respectively.  In 
addition, a panel of six cRT-PCR assays targeting the 5'-UTR and 3Dpol regions of ERAV 
or ERBV were also developed.   
 
5.3.  MATERIALS AND METHODS 
Viruses and cells 
Twenty-one TCF samples containing ERAV, ERBV1 and ERBV2 were included 
in this study.  These samples were previously isolated from nasal swabs and urine 
samples from horses and characterized by the late Dr. William H. McCollum at the 
Maxwell H. Gluck Equine Research Center, University of Kentucky.460  The prototype 
??   

strains of ERAV (NVSL-0600EDV8501) and ERBV (NVSL-0610EDV85010) from 
NVSL, Ames, IA were also included in the study.  Virus working stocks were produced 
by propagating the viruses in RK-13 cells (ATCC CCL37).  
To determine the specificity of the rRT-PCR and cCR-PCR assays, viral nucleic 
acid from each of the following equine viral pathogens was included in the study: equine 
arteritis virus (ATCC VR-796), equine herpesviruses 1-5 (EHV-1 [ATCC VR-700], 
EHV-2 [ATCC VR-701], EHV-3 [ATCC VR-352], EHV-4 [ATCC VR-2230], and EHV-
5386); equine adenovirus 1 (NVSL-001EDV8401) and 2; equine influenza virus (EIV) 
type A1 (equine/Prague/1/56 [H7N7]; NVSL-021IDV9201) and A2 (equine/Miami/63/ 
[H3N8]; NVSL-060IDV0501], equine/Kentucky/81 [H3N8; NVSL-040IDV0001], 
equine/Alaska//91 [H3N8; NVSL-020IDV9101]); and Salem virus, a novel 
paramyxovirus of horses.387  The EHV-5 and Salem virus were kindly provided by Dr. 
Stephen Bell at University of California, Davis, CA and Dr. Edward Dubovi, Cornell 
University, Ithaca, NY, respectively. 
The high passage RK-13 cell line (RK-13 KY; passage level 399–409) was 
maintained in Eagle minimum essential medium (EMEM) supplemented with 10% 
ferritin-supplemented bovine calf serum (Hyclone Laboratories, Inc., Logan, UT),  1% 
penicillin and streptomycin, and 0.1% amphotericin B (1,000 µg/ml). The overlay 
medium used for inoculated cultures was 0.75% carboxymethylcellulose (CMC) (Sigma-
Aldrich, St. Louis, MO) in supplemented EMEM. All of the other reagents were obtained 
from Mediatech, Inc., Herndon, VA. 
 
RNA extraction 
Viral RNA was prepared from virus-infected tissue culture fluid (TCF) using the 
MagMAX™-96 Viral RNA Isolation Kit (Life Technologies, Forest City, CA) according 
to the manufacturer’s instructions.  Briefly, TCF samples were microcentrifuged at 
13,800 ?g for 2 min, and 50 ?l of supernatant was removed and used for nucleic acid 
extraction. The viral nucleic acid was eluted in 50 ?l nuclease free and stored at -80 °C. 
??   
Primers and probes 
 The conserved and variable regions of each equine rhinitis virus serotype (ERAV 
and ERBV) have been determined by alignment of 12 sequences (8 ERAV [GenBank 
accession numbers: L43052, DQ272127, NC_003982, X96870, DQ272578, DQ272577, 
DQ268580 and DQ272128], 2 ERBV1 [GenBank accession numbers: NC_003983 and 
X96871] and 2 ERBV2 [GenBank accession numbers: AF361253 and NC_003077]) 
available in GenBank.  The rRT-PCR fluorescent TaqMan® MGBTM (minor groove 
binding) probes and forward and reverse primers for ERAV, ERBV1 and ERBV2 were 
designed to the conserved regions in 5'-UTR of each strain using Primer ExpressTM 
software (Life Technologies, Foster City, CA).  Similarly, the cRT-PCR forward and 
reverse primers from both serotypes were designed to target the 5'-UTR and 3Dpol regions 
of the genome using Vector NTI (Life Technologies, Foster City, CA).  The four primers 
from a nested RT-PCR assay developed by Black et al (2007) were included in the study 
as four one-step RT-PCR assays according to the primers location.457  The primers and 
probe from a rRT-PCR assay developed by Quinlivan et al (2010) was also included in 
this study using our rRT-PCR reagents.206  
 
One-step rRT-PCR assay   
The one-step TaqMan® rRT-PCR assay was performed using the TaqMan One-
Step RT-PCR Master Mix in a 7500 Fast Real-Time PCR System as previously 
described.201  Every sample was tested in duplicate in each assay.  Briefly, 25 ?l of RT-
PCR mixture for each reaction contained 12.5 ?l of 2 × Master Mix without UNG (uracil-
N-glycosylase), 0.625 ?l of 40 × MultiScribe and RNase Inhibitor Mix, 0.45 ?l of 50 µM 
of forward and reverse primers (final concentration 900 nM), 0.625 ?l of 10 µM probe 
(final concentration 250 nM), 5.35 ?l of nuclease free water, and 5 ?l of test sample RNA. 
The following thermocycling conditions were used under standard mode as per 
manufacturer’s recommendation: 30 min at 48 °C, 10 min at 95 °C, followed by 40 
cycles at 95 °C for 15 sec and 60 °C for 1 min. Each RT-PCR run included a control 
??   
without RNA (containing the reaction mix with 5 ?l of water [no template control]) and 
positive controls containing ERAV or ERBV RNA. 
 
cRT-PCR assay and sequencing analysis 
 The cRT-PCR was performed using a Qiagen OneStep RT-PCR kit (Qiagen, 
Santa Clara, CA) and 5 ?l of test sample RNA in a mastercycler gradient thermal cycler 
(Eppendorf, Westbury, NY) according to the manufacturer’s recommendation. Briefly, 
50 ?l of RT-PCR reaction contains 10 ?l of 5 × Qiagen OneStep RT-PCR buffer, 2 ?l of 
Qiagen OneStep RT-PCR enzyme mix, 2 ?l of 10 mM dNTP mix, 1 ?l of RNase 
Inhibitor, 1 ?l of each of the forward and reverse primers, 28 ?l of nuclease free water 
and 5 ?l of RNA template. The following thermal cycler conditions were used: 50 °C for 
30 min, 95 °C for 15 min, followed by 40 cycles of 30 sec 94 °C denaturation, 30 sec 
50 °C annealing, 1  min 72°C extension with a 10 min 72 °C final extension. 
 The authenticity of the cRT-PCR products amplified from ERAV or ERBV 
NVSL prototype strains were sent out for further sequencing using the primers which 
were used to amplify the products. The sequence data were analyzed using Aligner 
version 1.5.2 (CodonCode, Dedham, MA) software program.   
 
Determination of detection limits of rRT-PCR and cRT-PCR assays 
 Using serial decimal dilutions (10-1 to 10-10) of ERAV and ERBV prototype 
strains (NVSL-0600EDV8501 and NVSL-0610EDV85010, respectively), the detection 
limits of the rRT-PCR and cRT-PCR assays were evaluated.  To avoid inter-assay 
variability, equal aliquots of each dilution were used in all three assays.  Briefly, 5 µl of 
RNA extracted from 50 µl of each decimal dilution were used in rRT-PCR and cRT-PCR 
assays as described above.  RNA was run in duplicate in rRT-PCR assays, and both cRT-
PCR and rRT-PCR assays were repeated three times independently.  
 
??   
5.4.  RESULTS AND  DISCUSSION 
Development of rRT-PCR assays for the detection of ERAV and ERBV 
 Three ERAV and ERBV specific primer and probe sets were developed targeting 
the conserved 5'-UTR region of the viral genomes (Table 5.1).  One primer and probe set 
was specific for ERAV (named ERAV rRT-PCR assay) and the primers were 
degenerated to accommodate nucleotide variations found in the sequences that are 
available in GenBank. The other primer and probe set named ERBV1 rRT-PCR assay 
was specific for ERBV1 strain.  The third assay named ERBV2 rRT-PCR assay consists 
of the same reverse primer and probe sequences as in the ERBV1 assay with the 
exception of the forward primer is specific for ERBV2.  The 4-nucleotide difference in 
the forward primer between ERBV1 and ERBV2 assays was designed to increase the 
likelihood of detection of ERBV2 strains. Three rRT-PCR assays were initially tested 
with two prototype strains of ERAV and ERBV obtained from the National Veterinary 
Services Laboratories (NVSL), Ames, IA.  All the assays were optimized using RNA 
xtracted from the prototype strains of ERAV and ERBV with different primers and probe 
concentrations using TaqMan® one-step RT-PCR master mix in a checkerboard assay.  
The optimal primer and probe concentrations producing the highest sensitivity and 
specificity for detection of ERAV and ERBV were selected for the final assay as 
developed in the material and methods section.  The ERAV assay could only detect the 
ERAV prototype strain with a mean cycle threshold (Ct) of 21.79 + 0.30 (mean + 
standard deviation [STD]) ranging from 21.58 to 22.00 and there was no cross-reaction 
with ERBV prototype strain.  Both ERBV rRT-PCR assays only the detected ERBV 
prototype strain but not the ERAV strain with the mean Ct of 12.99 + 0.01 (ranging from 
12.98 to 13) for ERBV1 and 29.01 + 0.02 (ranging from 29.00 to 29.03) for ERBV2 
assays, respectively.  Subsequently, the specificity of these assays was tested using a 
range of other equine respiratory viruses including equine arteritis virus, equine influenza 
virus type A1 and A2, equine adenovirus 1 and 2, equine herpesvirus 1-5, and Salem 
virus.  The assays were shown to be 100% specific with no cross-reactivity with nucleic 
acid extracted from the above mentioned equine respiratory pathogens.   
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 The three assays were further evaluated for detection capability using 21 archived 
ERAV (n=11) or ERBV (n=10) isolates whose identity was previously confirmed in a 
one-way neutralization test using virus specific rabbit antisera.33  All three assays 
identified the ERV subtype accurately and no cross-reactions between subtypes were 
observed. The mean Ct values of ERAV, ERBV1 and ERBV2 rRT-PCR assays are 24.53 
+ 3.45 (ranging from 22 to 29), 29.50 + 3.58 (ranging from 24 to 34) and 29.14 + 5.22 
(ranging from 18 to 35), respectively.  Both ERBV1 and ERBV2 rRT-PCR assays could 
detect two previously well characterized ERBV1 isolates (NS Count Wayne and 58-13 
NVS) 448. Therefore, none of the ERBV1 or ERBV2 rRT-PCR assays were able to 
distinguish viral RNA between ERBV1 and ERBV2 subtypes tested in the study.  Overall, 
the two assays designed to distinguish ERBV1 and ERBV2 were able to detect the NVSL 
prototype strain of ERBV, indicating that the nucleotide mismatches in the forward 
primer were not sufficient to provide serotype specificity.  This was further confirmed by 
their inability to distinguish the archived isolates as ERBV1 or ERBV2.  
 Previously Quinlivan et al (2010) developed two TaqMan® rRT-PCR assays 
targeting the conserved region of the 5'-UTR of the ERV genomes (Table 5.2).206 These 
two assays were also tested with our prototype strains of ERV and 21 field isolates.  The 
assay targeting ERAV could detect the ERAV prototype strain and the 11 ERAV positive 
isolates without cross-reacting with any ERBV samples. The mean Ct values were 15.31 
+ 1.29 (ranging between 14 and 19), which were lower than the ERAV assay developed 
in this study (24.53 + 3.45), indicating the published ERAV assay is more sensitive in 
detecting the field isolates as compared to the ERAV rRT-PCR assay developed in our 
study.  In contrast, the assay targeting ERBV could not detect any of the ERBV isolates 
nor the prototype strain of ERBV.  However, the reagents used in this study were not 
identical to the original publication by Quinlivan et al (2010) which may also have 
contributed to the reduced sensitivity of the ERBV assay.  
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Development of cRT-PCR assays for the detection of ERAV and ERBV 
 To provide more diagnostic options, we developed an additional panel of six cRT-
PCR assays to target the 5'-UTR and 3Dpol regions of ERAV and ERBV (Table 5.3).  All 
primers were designed to distinguish ERAV and ERBV subtype and were initially tested 
with the prototype strains of ERAV and ERBV from NVSL.  All primer pairs could 
detect the prototype strains for which they were designed and the cRT-PCR products 
matched the predicted size (Fig 5.1).  The authenticity of the cRT-PCR products were 
confirmed by sequencing. Subsequently, the primers were tested with the archived ERV 
TCF specimens.  Similar to the rRT-PCR results, the ERAV 5'-UTR, ERAV Poly 1 and 
ERAV Poly 2 cRT-PCR assays could detect all the ERAV field isolates and did not 
cross-react with the ERBV isolates.  The ERBV Poly 1 and ERBV Poly 2 cRT-PCR 
assays were also highly specific for ERBV strains without any cross-reacting with ERAV 
isolates.  Sequence comparison analysis between the ERBV1 prototype P1436/71 
(GenBank accession number X96871) and ERBV2 prototype P313/75 (GenBank 
accession number AF361253) revealed that these two strains shared 92.5% sequence 
identity in the 3Dpol region which is consistent with the previous findings that the 3Dpol 
region of ERBV is highly conserved and therefore commonly used for primer design 
205,450.   The high sequence similarity between ERBV1 and ERBV2 in 3Dpol region is 
good for primer design to differentiate ERBV from ERAV but may also prevent the 
successful differentiation between ERBV1 and ERBV2 serotypes.  In contrast to the high 
sensitivity of ERBV cRT-PCR assays targeting 3Dpol regions, the ERBV 5'-UTR cRT-
PCR assay that was developed could only detect 2 out of the 10 ERBV positive isolates 
(Table 5.4).  All six assays were specific for ERV and did not react with other common 
equine respiratory viruses. Therefore, we concluded that the assays developed in our 
laboratory could be used to distinguish ERAV from ERBV but not between ERBV 
serotypes. 
 Previously Black et al (2007) developed four primers for a RT nested-PCR for 
ERBV.457  We took these four primers and mix and matched them depending on their 
positions to generate four standard RT-PCR assays (Table 5.3).  These four assays 
(ERBV OUTER 1, ERBV OUTER 2, ERBV INNER 1 and ERBV INNER 2) could 
distinguish all ERBV positive isolates from ERAV isolates in a single reaction. The 
??   
application of one-step RT-PCR has a greater advantage over the nested RT-PCR because 
it eliminates the possibility of cross-contamination between samples and reduces the 
turnaround time.  
 
 
?
Fig 5.1. Agarose gel electrophoresis of ERAV or ERBV prototype strains from NVSL 
amplified with ERAV or ERBV specific cRT-PCR primers.  The anticipated product 
sizes were shown.  
? ?
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Comparison of sensitivities of the rRT-PCR and cRT-PCR 
 Using serial decimal dilutions (10-1 to 10-10) of the TCF containing ERAV and 
ERBV prototype strains, the detection limits of all rRT-PCR and cRT-PCR assays were 
compared (Table 5.5, Fig 5.2).  Viral RNA from each of the serial dilutions was eluted in 
50 µl of nuclease free water and 5 µl tested in duplicate in the rRT-PCR and cRT-PCR 
assays. The plaque number in the highest dilution was used to calculate the number of 
infectious particles that can be detected by each assay.  The amplification efficiency of 
the three ERAV, ERBV1 and ERBV2 rRT-PCR assays was 97.0%, 94.8% and 94.2%, 
respectively, calculated according to a previously described method (Fig 5.2.).373  The 
ERAV rRT-PCR assay and ERAV 5'-UTR cRT-PCR assay could detect viral RNA up to 
10-6 dilution of the ERAV in TCF which is approximately 1 pfu/ml of infectious virus 
particles.  The other two ERAV cRT-PCR assays (ERAV Poly1 and ERAV Poly 2) were 
10-fold less sensitive (10-5 virus dilution, approximately 10 pfu/ml) as compared to the 
rRT-PCR and cRT-PCR assays targeting the 5'-UTR regions (Fig. 5.2).  The ERBV1 
rRT-PCR assay could detect ERBV viral RNA up to 10-7 dilution which equals 1.2 
pfu/ml infectious virus particles. The third rRT-PCR assay targeting ERBV2 was 3 logs 
less sensitive compared to the ERBV1 rRT-PCR assay and could detect more than 550 
pfu/ml infectious virus particles.  This suggests that the ERBV1 rRT-PCR assay is more 
suitable for the detection of ERBV in clinical samples.  All the ERBV cRT-PCR assays 
except ERBV 5'-UTR cRT-PCR assay could detect 10 to 30 pfu/ml infectious virus 
particles (10-5 to 10-6 dilutions). The ERBV 5'-UTR cRT-PCR assay was the least 
sensitive and could only detect virus in the 10-1 dilution of TCF (2.75 × 105 pfu/ml 
infectious virus particles).  
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Fig 5.2. Comparison of detection sensitivity of the three rRT-PCR assays using ERAV or 
ERBV prototype strains from NVSL (ERAV rRT-PCR assay [y = 3.4543x + 17.373, 
R
2=0.9949], ERBV1 rRT-PCR assay [y = 3.4682x + 11.719, R2=0.9997] and ERBV2 
rRT-PCR assay [y = 3.397x + 26.055, R2=0.9959]). 
 
 Overall, the rRT-PCR assays were more sensitive than the cRT-PCR assays. 
There is approximately a 10-fold difference in the limit between the rRT-PCR and cRT-
PCR assays in detecting ERAV strains. There was significant difference in the sensitivity 
of the rRT-PCR and cRT-PCR assays targeting the ERBV strains.  The ERBV 5'-UTR 
cRT-PCR assay is the least sensitive among all the developed assays. This might be 
explained by the fact that the reverse primer of the ERBV 5'-UTR cRT-PCR assay was 
located in the higher order internal ribosome entry site.446 This complex sequence region 
may prevent efficient binding of the reverse primer to target sequences.  However, no 
plausible explanation can be provided for the high sensitivity of the ERAV 5'-UTR cRT-
PCR assay which was targeting the similar region as compared to ERBV.   
??   
 Although ERAV and ERBV infections are considered a common disease in 
horses, limited data are available about the pathogenesis and disease prevalence, likely 
attributable at least in part to the absence of suitable diagnostic methods for these 
infections.27-31,33,451-452,461-462 Currently there are few rapid molecular tests for the 
detection of these viruses including a duplex rRT-PCR developed by Mori et al (2009) 205 
and single rRT-PCR assays for ERAV or ERBV developed by Quinlivan et al (2010).206  
The duplex rRT-PCR by Mori et al (2009) was developed to differentiate ERAV from 
ERBV, but in reality, none of the tested samples were ERAV positive.205 Therefore the 
detection capability for ERAV in this duplex rRT-PCR assay is questionable.  The single 
rRT-PCR assays developed by Quinlivan et al (2010) detected 30 ERAV and 5 ERBV 
positives in 300 nasal swab samples collected over a 7 year period.206  As we discussed 
above, the ERBV rRT-PCR assay developed in that study was unable to detect any 
ERBV isolates tested in this study under the current rRT-PCR conditions.  The assays 
developed in our study were tested with a limited number and well-characterized ERAV 
and ERBV samples.448,457  The authors admitted that prior to the application of the assays 
on a routine diagnostic basis, both would need to be more fully evaluated using a greater 
number of clinical specimens positive for both ERAV and ERBV.  
 
5.5.  CONCLUSION 
 In the current study, we developed 1 rRT-PCR assay and 3 cRT-PCR assays for 
the detection of ERAV and 3 rRT-PCR assays and 3 cRT-PCR assays for ERBV. 
Twenty-one archived ERAV or ERBV field isolates were used to evaluate the detection 
capability of the assays.  Both the rRT-PCR and cRT-PCR assays designed for ERAV or 
ERBV could detect the serotype specific isolates without cross-reacting with other equine 
viral pathogens.  Comparison of the respective sensitivities of rRT-PCR assays and cRT-
PCR assays confirmed that the molecular rRT-PCR assays have the same or greater 
sensitivity in detecting ERV in decimal serial dilutions of tissue culture fluids.  Overall, 
the newly developed assays provide valuable tools for the detection of ERAV and ERBV.  
Copyright © Zhengchun Lu 2012 
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CHAPTER SIX 
 
Chimeric viruses containing the N-terminal ectodomains of GP5 and M proteins of 
porcine reproductive and respiratory syndrome virus do not change the cellular 
tropism of equine qrteritis virus 
 (submitted to Virology) 
 
6.1.  SUMMARY 
 Equine arteritis virus (EAV) and porcine reproductive and respiratory syndrome 
virus (PRRSV) are members of family Arteriviridae; they share many biological 
properties but differ significantly in cellular tropism.  Using an infectious cDNA clone of 
EAV, we engineered a panel of six chimeric viruses by exchanging the N-terminal 
ectodomains and/or full-lengths of the two major envelope proteins (GP5 and M) from 
PRRSV.  The recombinant viruses expressing the N-terminal ectodomain of PRRSV GP5 
alone or M alone or together (GP5ecto, Mecto and GP5&Mecto, respectively) in the 
EAV backbone were viable and genetically stable. Compared to the parental virus, these 
three chimeric viruses produced lower titers and smaller plaque sizes indicating that they 
have a compromised phenotype.  The three chimeric viruses could only infect EAV 
susceptible cell lines but not PRRSV susceptible cells.  Therefore, the two major 
envelope proteins may not be determining factors in the cellular tropism of EAV and 
other arteriviruses.  
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6.2.  INTRODUCTION 
? Members of the family Arteriviridae include equine arteritis virus (EAV), porcine 
reproductive and respiratory syndrome virus (PRRSV), lactate dehydrogenase-elevating 
virus (LDV) of mice and simian hemorrhagic fever virus (SHFV).255,463  Arteriviruses are 
small, enveloped animal viruses with an isometric core containing a positive sense RNA 
genome.320,464  EAV and PRRSV are the causative agents of equine viral arteritis (EVA) 
in horses and porcine reproductive and respiratory syndrome (PRRS) in pigs, 
respectively.212,465-466   The EAV and PRRSV genomes are polycistronic and contain at 
least 10 open reading frames [ORFs].260,263,467  The 5'-proximal three-quarters are 
occupied by two large ORFs (1a and 1b) that together encode all viral enzyme functions 
(collectively referred to as “replicase”) required for genome replication and subgenomic 
mRNA (sgmRNA) production.284,468  The ORFs 1a and 1b are translated to produce 
polyproteins 1a and 1ab (pp1a and pp1ab), with the latter being a C-terminally extended 
version of the former.256,264-265  Following autoproteolytic processing of the replicase 
pp1a and pp1ab, at least 12 (EAV) or 14 (PRRSV) cleavage products or ‘nonstructural 
proteins’ (nsps) are produced.265,284,320  The ORFs 2a, 2b, 3, 4, 5a, 5, 6, and 7 of EAV and 
PRRSV are partially overlapping and are located in the 3'-one-quarter of the genome, 
encoding seven envelope proteins (E, GP2, GP3, GP4, ORF5a protein, GP5 and 
membrane [M]) and a nucleocapsid protein (N).263,265,320,464,467 The glycosylated GP5 and 
the unglycosylated M protein (encoded by ORF5 and ORF6, respectively) are the major 
envelope proteins of EAV and PRRSV; they form a disulfide-linked heterodimer in the 
mature virus particles.266,469  The formation of GP5/M heterodimer is critical for the 
expression of neutralization epitopes of both viruses.272,470-472 The M protein is the most 
conserved envelope protein of arteriviruses.473  It consists of a short 19-amino acid N-
terminal domain exposed at the surface of the virion followed by three successive 
membrane-spanning domains and a C-terminal endodomain of 81-87 amino acids.474-476  
The GP5 protein has a similar membrane topology as compared to M protein except that 
it contains a cleavable N-terminal signal peptide and the ectodomain of EAV is 
approximately 68 amino acids (a.a.) longer than that of PRRSV.476-477  The GP5/M 
heterodimer is presumed to play important roles in attachment to the host cell receptor 
and in cell entry.464  In addition, the arterivirus envelope contains a heterotrimer of three 
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minor membrane glycoproteins (GP2 [encoded by ORF2b in EAV and ORF2a in 
PRRSV], GP3 [encoded by ORF3] and GP4 [encoded by ORF4]) and two unglycosylated 
envelope proteins (E [ORF2a in EAV and ORF2b in PRRSV]478-479 and ORF5a protein 
[ORF5a]).263,467  It has been shown that all three major structural proteins (N, GP5 and M) 
and four of the minor envelope proteins (E, GP2, GP3 and GP4) are essential for the 
production of infectious progeny virus.268,480  It has also been shown by reverse genetics 
that the elimination of ORF5a protein expression by knocking down the start and stop 
codon will cripple the EAV virus and lead to progeny virus with a small plaque 
phenotype and a significantly reduced virus titer in transfected cells.263  
 Arteriviruses are highly species specific and macrophages are the primary target 
cells of virus replication.235,481-485  However, EAV can replicate in a variety of primary 
cells including equine pulmonary artery endothelial,486 horse kidney, rabbit kidney and 
hamster kidney cells and a number of continuous cell lines including baby hamster 
kidney (BHK-21),281,487 rabbit kidney-13 (RK-13), African green monkey kidney 
(VERO),241,488 rhesus monkey kidney (LLC-MK2), MARC-145 and hamster lung 
(HmLu)488 cells.  In contrast, PRRSV can only replicate in a limited number of cell types.  
North American PRRSV (Type 2) strains replicate in primary porcine alveolar 
macrophages (PAM), and the African green monkey cell line, MA-104, or its derivative, 
MARC-145.489  Most, if not all, European PRRSV (Type 1) strains replicate best or 
exclusively in PAMs, but can be adapted to grow in MA-104 derived cell lines, including 
CL2621 and MARC-145.  Until recently, the viral envelope protein(s) involved in virus 
attachment and entry of EAV and PRRSV have not been fully characterized.294,490 In a 
previous study, Dobbe et al (2001) demonstrated that EAV expressing the ectodomain of 
GP5 of PRRSV IAF-Klop strain491 did not change the cellular tropism of the virus.  
Recently, in our laboratory, we have developed an infectious cDNA clone of the 
modified live virus (MLV) vaccine (ARVAC®) of EAV (prMLVB).492  This infectious 
cDNA clone was originally developed to design a marker vaccine for EAV and to 
increase the safety and efficacy of the current MLV vaccine, as well as a vector platform 
to express heterologous genes from other viruses.  In this study, we describe the use of 
this infectious cDNA clone to characterize the role of the major envelope proteins (GP5 
and M) for investigating the cellular tropism of EAV.  
??   
6.3.  MATERIALS AND METHODS 
Cells and viruses 
The cell lines used in the study included equine pulmonary artery endothelial cells 
(EECs, P12 to P22) 486, high passage rabbit kidney-13 cells (RK-13 KY, P399 to P409), 
baby hamster kidney cells (BHK-21 [ATCC CRL-12072], Manassas, VA), MARC-145 
cells and porcine macrophage cells 3D4/21 (ATCC CRL-2843, Manassas, VA).  The 
EECs were maintained in DMEM with high glucose supplemented with 10% fetal bovine 
serum (Hyclone, Logan, UT), penicillin, streptomycin, L-glutamine and non-essential 
amino acids (Life Technologies, Grand Island, NY).  RK-13 KY, BHK-21 and MARC-
145 were maintained at 37 °C in Eagle’s minimum essential medium with 10% ferritin-
supplemented bovine calf serum (Hyclone, Logan, UT) penicillin, streptomycin, 
amphotericin B, and sodium bicarbonate (Life Technologies, Grand Island, NY).  In 
addition, porcine alveolar macrophages (PAM) were isolated and stored at -80 ºC until 
used (kindly provided by Dr. Kay Faarberg, USDA-ARS, Ames, IA).  The PAM cells 
were maintained in Dulbecco’s MEM supplemented with 5% fetal bovine serum and 5% 
antibiotic/antimycotic (Life Technologies, Grand Island, NY).  The PRRSV IA1107 
strain was kindly provided by Fort Dodge Animal Health Laboratories (now Pfizer 
Animal Health Inc, Kalamazoo, MI).  This strain was isolated from the lung of a pig that 
died of PRRS and working virus stock was made by passaging once in MARC-145 cells.   
 
Construction of EAV/PRRSV chimeric infectious cDNA clones by swapping ORF5 
and 6 from PRRSV 
 The development and characterization of an infectious cDNA clone (prMLVB) of 
the modified live vaccine strain of EAV (ARVAC®) that was used as the backbone to 
develop the chimeric viruses has been previously described (GenBank accession number 
FJ798196).492  The generation of chimeric infectious cDNA clones was performed by a 
previously described method with some modifications.493 Briefly, three plasmid 
constructs were generated by separating the overlapping regions between ORFs 4/5 and 
5/6 of the prMLVB infectious cDNA clone of EAV (Fig 6.1).  The unique XbaI site at nt 
??   
position 14530-14535 was knocked out in the prMLVB clone to generate the shuttle 
vector prMLVB-XbaIko to facilitate the cloning strategy.  The ORFs 4/5 overlapping 
region (11144CAATGCTATCTATGATT11160) was first removed from the prMLVB-
XbaIko clone by site-directed mutagenesis and then the 
5'CAGTGCTATCTGTGAacttaagcaacatgctgtccatgaTT3? sequence was inserted into the 
corresponding region to obtain the prMLVB4/5 (GenBank accession number JQ844153) 
in which the ORF4 and ORF5 overlapping regions were separated. A unique restriction 
site AfIII (5?CTTAAG3?) was introduced into the region separating ORF4 and ORF5.  
Similarly, the ORFs 5/6 overlapping region 11899GTATGGGAGCCATAGAT11915 was 
removed from the prMLVB-XbaIko clone by insertion of the nucleotides 
5?GTGTGGGAGCCATAGagcggccgccaatgggagccatagAT3? into the corresponding 
region to obtain the clone prMLVB5/6 (GenBank accession number JQ844154). A 
unique restriction site NotI (5?GCGGCCGC3?) was introduced into the region separating 
ORF5 and ORF6 to facilitate the next cloning step.  Subsequently, using a similar 
approach, a third construct was developed in which both 4/5 and 5/6 ORFs were 
separated (prMLVB4/5/6, GenBank accession number JQ844155).  These three clones 
were used to generate various EAV/PRRSV chimeric viruses by swapping ORF5 and 
ORF6 (N-terminal ectodomains and as well as full-length) from PRRSV IA1107 strain.   
 The GP5 N-terminal ectodomain of PRRSV IA1107 strain (nt 11788-11979; 
numbered according to GenBank accession number U87392) was reverse transcribed 
with primer PVGP5ectoN followed by PCR amplification using primers PVGP5ectoP 
and PVGP5ectoN (Table 6.1) using a commercial one-step RT-PCR kit (Qiagen, 
Valencia, CA).  The PRRSV GP5 ectodomain was then cloned into the plasmid 
prMLVB4/5 using unique restriction sites AflII and EcoRI to obtain the recombinant 
plasmid prMLVB4/5GP5ecto (GenBank accession number JQ844156). The GP5 full-
length domain of PRRSV IA1107 (nt 13788-14390) was RT-PCR amplified with primer 
PV15364N followed by PCR amplification using primers PVGP5ectoP and PVGP5fullN 
and cloned into prMLVB4/5 with restriction sites NotI and XbaI to obtain the 
recombinant plasmid prMLVB4/5GP5full.  Similarly, the M full-length domain of 
PRRSV IA1107 (nt 14375-14899) was reverse transcribed with primer PV15364N and 
PCR amplified using primers PVMfullP and PVMfullN and cloned into prMLVB5/6 with 
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restriction sites NotI and XbaI to generate the chimera construct prMLVB5/6Mfull.  
Because of the short length of the M protein N-terminal ectodomain sequence, the N-
terminal ectodomain of PRRSV IA1107 M protein (nt 14375-14425) was directly 
inserted into the shuttle vector prMLVB-XbaIko4/5/6RemMecto, in which the M protein 
N-terminal ectodomain of EAV was removed via site-directed mutagenesis, using primer 
EAVinsPVMectoP and EAVinsIA1107MectoN to generate prMLVB4/5/6 Mecto 
(GenBank accession number JQ844157).  The specific nucleotide locations were 
identified according to the North American VR2332 strain of PRRSV sequence 
(GenBank accession number U87392).  The prMLVB4/5/6 Mecto and prMLVB4/5/6 
Mfull were further used as vectors to introduce the PRRSV GP5 N-terminal ectodomain 
and GP5 full-length sequences using the above described cloning strategies to generate 
prMLVB4/5/6 GP5&Mecto (GenBank accession number JQ844158) and prMLVB4/5/6 
GP5&Mfull plasmids. The nucleotide sequences of the primers used in this study are 
listed in the Table 6.1. The panel of chimeric constructs between the EAV and PRRSV 
major envelope protein coding genes is shown in Figure 6.1.  
 
Sequencing of the plasmid constructs 
 The region spanning from ORFs 4-7 of prMLVB4/5, prMLVB5/6, and 
prMLVB4/5/6 plasmids, as well as all five chimeric plasmids were PCR amplified and 
sequenced to confirm their authenticity.  Briefly, each of the plasmids was amplified 
using primers that were specific for the 5' end of the ORFs 4 and the 3' end of ORF7 
(10763P and 12568N primers [Table 6.1]; numbered according to the published sequence 
of the VB strain of EAV, GenBank accession number DQ846750) using the high-fidelity 
proofreading Pfu Turbo DNA polymerase (Agilent Technology, Santa Clara, CA) 
according to a previously described protocol.494  Both sense and antisense strands of the 
chimeric plasmids were sequenced using EAV specific primers 10763P, 11691N, 11557P 
and 12568N (Table 6.1) at MWG Operon, Huntsville, AL.  The sequence data were 
analyzed using Aligner version 1.5.2 (CodonCode, Dedham, MA) software program.  
Comparative nucleotide and amino acid sequence analysis of the 3'-end of all the plasmid 
were performed with Vector NTI (Life Technologies, Carlsbad, CA) software.   
? ?
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Fig 6.1. Schematic presentation of parental, recombinant and chimeric cDNA clones. 
Only the ORFs 4 to 7 and 3' nontranslated region is depicted. The restriction sites 
introduced to separate ORF4 and 5 (AflII), and ORF 5 and 6 (NotI), and ORF 4, 5, and 6 
(AflII and NotI) are depicted. The transcriptional regulatory sequences (TRS) that 
regulate leader-body junction during viral subgenomic RNA synthesis are indicated by 
triangles. The stop codon for each chimeric construct is identified with an asterisk (*).  
The N-terminal ectodomain or full-length of PRRSV GP5 protein is labeled in blue. The 
N-terminal ectodomain or full-length of PRRSV M protein is labeled in green. 
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In vitro transcription (IVT) and generation of recombinant chimeric viruses 
 Run-off viral RNA transcripts were generated as previously described from each 
recombinant/chimeric infectious clone after linearization with restriction enzyme XhoI.261  
Eighty micrograms of full-length IVT RNA generated from each recombinant and 
chimeric plasmid construct were transfected into BHK-21 cells by electroporation as 
previously described.261,388  Cells were incubated at room temperature for 10 min after 
electroporation and mixed with 12 ml of complete BHK-21 medium warmed to room 
temperature.  The cells were seeded into 10-cm-diameter tissue culture plates (Falcon) 
and incubated at 37 ºC for 48-72 hr until cytopathic effect (CPE) was evident.  The tissue 
culture fluid (TCF) supernatant collected after IVT RNA transfection was designated P0 
virus and used for further characterization.  The stability of each recombinant/chimeric 
virus was determined by 10 sequential passages in BHK-21 cells and sequencing the 
RNA extracted from passages 0, 5 and 10 (See below).  
RT-PCR amplification and sequencing of ORF5 of recombinant viruses 
The authenticity of each recombinant/chimeric virus stock was determined by RT-
PCR amplification and sequencing of the ORFs 5-6 region from RNA that was isolated 
from TCF from P0, P5 and P10 of each virus as previously described.384  Briefly, RNA 
was directly isolated from the TCF using QIAmp viral RNA isolation kit (Qiagen, 
Valencia, CA).  The purified RNA was treated with DNase I (Life Technologies, Grand 
Island, NY) for 30 min at 37 ºC to remove any contaminating plasmid DNA before RT-
PCR amplification.  The ORFs 5-6 region was RT-PCR amplified using EAV specific 
primers 10763P and 11691N (Table 6.1).  The PCR was also performed with a non-RT 
step to eliminate the possibility of amplifying any remaining plasmid DNA.  Sequence 
data were analyzed as described previously.   
 
Antibodies 
??   
 The monoclonal antibodies (MAbs) 3E2 and SDOW-17 (Rural Technology Inc., 
Brookings, SD) against N proteins of EAV and PRRSV, respectively, have been 
previously described.251,495  Swine polyclonal anti-PRRSV serum (PHGB 2008 ID#1467) 
was obtained from a PRRSV infected pig showing high PRRSV neutralizing activity.  
Commercial fluorescent labeled anti-swine (FITC conjugated anti-swine IgG [Santa Cruz 
Biotechnology, Santa Cruz, CA]) and anti-mouse (Texas red-conjugated goat anti-mouse 
IgG [Thermo Scientific, Rockford, IL]) were used in indirect immunofluorescence assays. 
 
Indirect immunofluorescence assay (IFA) 
 Various cell types (EEC, BHK-21, RK-13, PAM, 3D4/21, MARC-145) grown in 
Lab-Tek™ eight-well chamber slides (Nalge-Nunc, Rochester, NY) were either mock 
infected or infected with various recombinant chimeric viruses (P0) and incubated at 
37 °C for 36-48 hrs.  The slides were fixed with 3% paraformaldehyde in PBS (pH=7.4) 
and stained with EAV N protein specific MAb 3E2 followed by secondary Texas red-
conjugated goat anti-mouse IgG staining.  The MARC-145, PAM and 3D4/21 cells 
infected with PRRSV were stained with FITC conjugated MAb against PRRSV N protein 
(SDOW-17).251,495  Since PRRSV GP5 and M protein specific antibodies were not 
available, swine polyclonal anti-PRRSV serum was used detect the chimeric PRRSV 
proteins in infected cells.  EAV antibodies were incubated for 1 hr at room temperature 
prior to secondary antibody staining. PRRSV MAb against N protein (SDOW-17) or 
swine polyclonal anti-PRRSV serum was incubated for 1 hr at 37 ºC followed by 4 ºC 
overnight incubation to enhance the antibody signal.  
 
In vitro growth characteristics of EAV-PRRSV chimeric viruses   
 BHK-21 cells grown in six-well plates were inoculated with EAV-PRRSV 
chimeric viruses (P0) as well as parental rMLVB virus and its derivatives (rMLVB4/5, 
rMLVB5/6 and rMLVB4/5/6) at an MOI of 1 and incubated at 37 ºC for 1 hr. The 
inocula were removed and cells were washed with PBS (pH=7.4) three times to remove 
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unbound virus before being overlaid with 4 ml of EMEM.  At 0, 6, 12, 24, 48, 72 hr post-
infection, TCFs were collected and virus titers were determined by plaque assays in RK-
13 cells as previously described.279   
 
Plaque morphology 
 The plaque morphology of the recombinant viruses was determined by plaque 
assays in EECs.  Briefly, confluent monolayers of EECs in 6-well culture plates were 
infected with 10-fold serial dilutions of each recombinant/chimeric virus (rMLVB, 
rMLVB4/5 and rMLVB4/5/6, rMLVB4/5GP5ecto, rMLVB4/5/6Mecto and 
rMLVB4/5/6GP5&Mecto) virus in duplicate.  Following 1 hr incubation, 0.75% CMC 
(caboxymethylcellulose)-DMEM was added to each well and cells were incubated at 
37°C for 96 hr.276  Plaques were stained with 1% formalin-crystal violet solution 
containing 1% formaldehyde at 96 hr post-infection and titers were expressed as pfu/ml. 
 
6.4.  RESULTS AND DISCUSSION 
Generation of EAV/PRRSV chimeric viruses 
The infectious cDNA clone (prMLVB) of the MLV vaccine strain of EAV 
(ARVAC®) was used as the backbone to generate a panel of 6 recombinant chimeric 
viruses by replacing either the full-length or the N-terminal ectodomains of GP5 and M 
proteins of EAV with the IA-1107 strain of North American PRRSV (Fig 6.1, Table 6.1).  
Because of the overlapping gene arrangement in the 3' end of the EAV genome, it was 
necessary to separate ORF 5 from flanking ORFs 4 and 6 without disrupting the coding 
sequences of each of the three ORFs.  The ORFs 4 and 5, ORFs 5 and 6, and ORFs 4, 5 
and 6 were separated in the prMLVB plasmid to generate the plasmids prMLVB4/5, 
prMLVB5/6 and prMLVB4/5/6 (GenBank accession numbers JQ844153, JQ844154 and 
??   

JQ844155), respectively.  The authenticities of these plasmid constructs were first 
confirmed by sequencing ORFs 4-7 (data not shown).  The same amount of full-length in 
vitro transcribed (IVT) RNA generated from linearized prMLVB, as well as mutant 
prMLVB4/5, prMLVB5/6 and prMLVB4/5/6 cDNA clones were electroporated into 
BHK-21 cells for generation of recombinant viruses as previously described.261,384  The 
viability of each recombinant clone was determined by indirect immunofluorescence 
assay (IFA) using EAV N protein specific monoclonal antibody (MAb 3E2) to stain 
BHK-21 cells 24 hours post transfection with IVT RNA generated from each linearized 
plasmid construct (data not shown).  The cells transfected with each of the three 
recombinant transcripts produced 90-100% cytopathic effect (CPE) in transfected cells 
after 72-96 hours post transfection, and virus stocks were made from these tissue culture 
fluids (TCF; P0).  The authenticity of all three recombinant viruses was confirmed by 
sequencing ORFs 4-7 from RNA extracted from each TCF (P0).  All virus sequences 
were identical to the plasmid sequence from which they were derived.  The TCFs (P0) 
containing each recombinant virus were then used to infect BHK-21 cells at a multiplicity 
of infection (MOI) of 1 and progeny viruses were collected at different time points for 
titration. The growth characteristics and plaque morphology were compared in RK-13 
and EEC, respectively. All of the recombinant rMLVB4/5, rMLVB5/6 and rMLVB4/5/6 
viruses had the highest progeny virus titer at 48 hours post infection. They had 
approximately 2 log10 lower titer as compared to the parental rMLVB virus at this time 
point (Fig 6.2).  When compared to the parental virus, the recombinant viruses showed a 
48-60% reduction in plaque size in EECs. The parental rMLVB produced 5 mm diameter 
large sized plaques while the recombinant rMLVB4/5, rMLVB5/6 and rMLVB4/5/6 
??   
produced 2.4, 3 and 2.8 mm diameter medium sized plaques in EECs, respectively.  
However, there was no significant difference in growth characteristics among these three 
recombinant viruses.  All three recombinant viruses were stable for more than 10 serial 
passages in BHK-21 cells.  The separation of these ORFs did not alter the amino acid 
sequence of GP4, GP5 and M proteins of EAV but the ORFs 4/5 separation changed the 
N-terminal amino acid sequence of ORF5a protein (Fig 6.3).  In a recent study, we 
demonstrated that complete elimination of ORF5a protein experimentally could lead to 2-
3 log lower virus titer and tiny plaques.263  Interestingly, the addition of extra nucleotides 
to the ORF5a coding sequence did not cripple the recombinant viruses to the same extent 
as the ORF5a knockout virus263 indicating that this region of the EAV genome was 
tolerant for insertion of a small stretch of nucleotides (see below).  Collectively, these 
data demonstrated that separation of these ORFs did not seriously compromise the 
viruses.  Furthermore, the constructs were stable and could be used for further studies.   
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Fig 6.2. Replication characteristics of parental rMLVB, recombinant rMLVB4/5, 
rMLVB5/6 and rMLVB4/5/6 and chimeric rMLVB4/5 GP5ecto, rMLBV4/5/6 Mecto and 
rMLVB4/5/6 GP5&Mecto viruses in BHK-21 cells. Subconfluent monolayers of BHK-
21 cells were grown in 6-well plates, inoculated with each P0 virus (MOI of 1) and 
incubated at 37 ºC for 1 hr. After removal of the inoculum, the cells were rinsed three 
times with PBS and overlaid with 4 ml of EMEM. At indicated time points, supernatants 
were harvested and titrated by plaque assay in RK-13 cells.  
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Fig 6.3. Sequence alignments of amino acids of the ORF5a and GP5 proteins of parental 
EAV and chimeric viruses. The amino acid sequence changes due to ORF4 and 5 
separations are highlighted in blue. The remaining ORF5 from EAVrMLVB backbone in 
the GP5ecto chimera construct is marked in green. The ectodomains of PRRSV are 
labeled in red. The common region of ORF5a between PRRSV and GP5ecto chimera is 
labeled in purple.  
 
 The next step was to generate a panel of EAV-PRRSV chimeric plasmids by 
replacing the nucleotide (nt) sequence encoding the N-terminal ectodomain or full-length 
of GP5 and/or the M protein on an EAV backbone with corresponding sequences from 
North American PRRSV IA1107 strain using prMLVB4/5, prMLVB5/6 and 
prMLVB4/5/6 plasmids (Fig 6.1, Table 6.2).  We have exchanged the N-terminal 
ectodomain (a.a. 1-64) and full-length (a.a. 1-200) of PRRSV GP5 with ectodomain (a.a. 
1-114) of EAV GP5 to generate prMLVB4/5 GP5ecto and prMLVB4/5 GP5full 
constructs on a prMLVB4/5 backbone.  Similarly, the N-terminal ectodomain (a.a. 1-17) 
and full-length (a.a. 1-175) of PRRSV M were exchanged with the N-terminal 
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ectodomain (a.a. 1-16) of EAV M protein, respectively, to generate prMLVB4/5/6 Mecto 
and prMLVB5/6 Mfull constructs on the prMLVB4/5/6 and prMLVB5/6 backbones, 
respectively (Fig 6.1, Table 6.2).  The ORF5 and ORF6 regions of all chimeric plasmid 
constructs were RT-PCR amplified with two EAV specific primers (10763P and 12568N) 
and visualized by agarose gel electrophoresis (Fig 6.4).  Subsequently, the RT-PCR 
products were sequenced to confirm the authenticity of the chimeric plasmid constructs.  
All chimeric constructs maintained in-frame coding sequences in ORF5a, ORF5 and 
ORF6.  Full-length IVT RNA from linearized chimeric plasmids were transfected into 
BHK-21 cells as previously described 261,384.  A portion of transfected cells were seeded 
into chamber slides for IFA staining to check for the expression of EAV N protein 24 
hours post transfection.   With the exception of BHK-21 transfected with prMLVB4/5 
GP5full, prMLVB5/6 Mfull and prMLVB4/5/6 GP5&Mfull, cells transfected with 
prMLVB4/5 GP5ecto, prMLVB4/5/6 Mecto and prMVLB4/5/6 GP5&Mecto stained 
positive for EAV N protein (data not shown).  This observation was further confirmed by 
the development of 90-100% CPE 72-120 hours post transfection in BHK-21 cells that 
were transfected with IVT RNA from prMLVB4/5 GP5ecto, prMLVB4/5/6 Mecto and 
prMLVB4/5/6 GP5&Mecto. The experiments have been repeated two times 
independently. Collectively, these data suggested that only 3 of the 6 chimeric constructs 
could produce infectious progeny viruses.  Each of the three progeny viruses was 
harvested (P0) and subjected to further in vitro characterization.  Of the 6 chimeric 
constructs, only rMLVB4/5 GP5ecto, rMLVB4/5/6 Mecto and rMLVB4/5/6 GP5&Mecto 
could generate infectious progeny viruses following transfection of IVT RNA into BHK-
21 cells (GenBank accession numbers JQ844156, JQ844157 and JQ844158, respectively).  
??   
The IVT RNA generated from plasmids containing full-length GP5 or M replacement of 
PRRSV IA-1107 strain (prMLVB4/5 GP5full, prMLVB5/6 Mfull and prMLVB4/5/6 
GP5&Mfull) failed to generate infectious progeny viruses.  The genetic stabilities of each 
of the three replicating chimeric viruses were determined by 10 serial passages in BHK-
21 cells and subsequent RT-PCR amplification and sequencing of ORF5-6 from RNA 
extracted from P0, P5 and P10 TCF. The sequence data revealed no substitutions, 
insertions or deletions in this region of all three chimeric viruses following serial cell 
culture passage.  These results unequivocally demonstrated that these three chimeric 
viruses are highly stable following serial passage in cell culture.  The failure to generate 
chimeric viruses containing full-length PRRSV GP5, M or GP5/M proteins on the EAV 
backbone may due to the fact that being the smallest arterivirus in the family 
Arteriviridae, EAV has evolved to the point that it does not tolerate any large nucleotide 
inserts into the genome. However, it has been reported that EAV can tolerate small 
segments of nucleotides in the structural proteins genes.291,496   
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Fig 6.4. Agarose gel electrophoresis of RT-PCR amplified ORF5 and ORF6 products of 
EAV-PRRSV chimeric plasmids using EAV specific primers.  
 
Growth characteristic and plaque morphology of EAV/PRRSV chimeric viruses   
 The growth characteristics and plaque morphologies of rMLVB4/5 GP5ecto, 
rMLVB4/5/6 Mecto and rMLVB4/5/6 GP5&Mecto chimeric viruses were compared in 
RK-13 cells and EEC, respectively, as described before.  All three EAV-PRRSV 
chimeric viruses rMLVB4/5 GP5ecto, rMLVB4/5/6 Mecto and rMLVB4/5/6 
GP5&Mecto gave similar growth curves.  Replication titers were 3 log10 lower as 
compared to parental rMLVB virus and 1 log lower as compared to the recombinant 
cloned viruses (rMLVB 4/5 and rMLVB4/5/6); these were derived 48 hours post 
infection (Fig 6.2).  Furthermore, P5 and P10 TCF of all three chimeric viruses gave 
??   
similar growth curves as compared to P0 TCF (Table 6.3).  Plaque assays were performed 
in EECs for all three chimeric viruses and their plaque morphology was compared to 
parental rMLVB, recombinant rMLVB4/5, rMLVB5/6 and rMLVB4/5/6 viruses.  The 
three chimeric viruses (rMLVB4/5 GP5ecto, rMLVB4/5/6 Mecto and rMLVB4/5/6 
GP5&Mecto) produced small sized plaques (0.5 mm to 1 mm) as compared to the 
parental rMLVB virus (5 mm) and the three recombinant viruses from which the 
chimeric viruses were derived from (2.4 to 3 mm).  The lower titers and smaller plaque 
sizes of the chimeric viruses clearly indicated that although the viruses are genetically 
stable (Fig. 6.5), they have significantly compromised phenotypes and were disabled in 
replication and spreading when compared to parental rMLVB or the three recombinant 
viruses from which they are derived (ORF4/5, ORF5/6 and ORFs4/5/6).  Interestingly, 
when progeny viruses (P0) produced in BHK-21 cells were titrated in RK-13 cells for 
growth curve analysis, the reduction of titer of the chimeric viruses was not as significant 
as that observed in EECs, in which there was a reduction in plaque size (medium to 
pinpoint).   This observation suggested that infection and spreading depended on the cell 
in which the viruses are propagated.  Specifically, EAV field strains were found to 
produce different plaque sizes in EEC but not in RK-13.278  Taken together, the data 
clearly showed that the presence of PRRSV N-terminal ectodomains of GP5 and M 
altered the growth characteristics and cell to cell spread of the chimeric viruses.  
Furthermore, it has long been proposed that the GP5 and M proteins of arteriviruses play 
a major role in virus attachment.252,291,497  However, nonspecific interactions have been 
shown between PRRSV M protein and a heparin-like receptor on PAM cells.341    
 
??   

Table 6.3: Stability of EAV- PRRSV chimeric viruses following 10 serial passages in 
BHK-21 cells 
Virus passage 
Virus titer (pfu/ml) 
rMLVB4/5 GP5ecto rMLVB4/5/6 Mecto rMLVB4/5/6 GP5&Mecto 
P0* 3.5 x 106 8.2 x 105 2.6 x 106 
P1 1.1 x 106 3.8 x 105 3.6 x 106 
P2 1.2 x 106 3.4 x 105 1.5 x 106 
P3 1.3 x 106 5.1 x 105 2.1 x 106 
P4 8.3 x 105 2.6 x 105 2.4 x 106 
P5* 1.0 x 106 2.5 x 105 2.5 x 106 
P6 5.5 x 106 8.9 x 105 3.0 x 106 
P7 1.3 x 106 1.6 x 105 1.3 x 106 
P8 5.9 x 106 2.6 x 105 5.4 x 106 
P9 2.0 x 106 1.8 x 105 1.7 x 106 
P10* 9.7 x 106 7.3 x 105 2.3 x 106 
*P0, P5 and P10 viruses were sequenced and found genetically stable. 
?
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Fig 6.5. (A). Comparison of plaque morphology on equine endothelial cells (EEC) of 
parental rMLVB, recombinant rMLVB4/5, rMLVB5/6 and rMLVB4/5/6 and chimeric 
rMLVB4/5 GP5ecto, rMLVB4/5/6 Mecto and rMLVB4/5/6 GP5&Mecto viruses. (B). 
Illustration of plaque morphology of ORF5a knockout mutants (EAV515-?5a, VBS-?5a) 
as compared to the parental rMLVB, recombinant rMLVB4/5 and chimeric rMLVB4/5/ 
GP5ecto viruses. The insertion of 8-10 amino acids into the ORF5a protein of EAV did 
not cripple the virus to the same extent as the knockout mutants.  
 
rMLVB4/5/6 Mecto
rMLVB4/5 rMLVB4/5/6
Parental rMLVB
rMLVB4/5 GP5ecto rMLVB4/5/6 GP5&Mecto
rMLVB5/6
A
B
Mutant 
EAV515-?5a
Mutant 
VBS-?5a
rMLVB4/5Parental rMLVB rMLVB4/5 GP5ecto
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Cellular tropism of EAV/PRRSV chimeric viruses 
Although EAV and PRRSV infect cells from the monocyte/macrophage lineage in 
their natural host, they present different cellular tropisms in cell culture.256,482,485  EAV 
can infect a wide variety of cell lines while PRRSV can only infect PAM and African 
green monkey kidney (MA-104) cells and their derivative (MARC-145).256,481  The 
chimeric viruses derived by swapping the ectodomains of PRRSV GP5 and M proteins 
into an EAV backbone provide valuable tools to study cellular tropisms. Therefore, the 
three viable chimeric viruses were tested in different EAV-susceptible cell lines (EEC, 
RK-13, BHK-21, MARC-145), PRRSV-susceptible cell lines (PAM and MARC-145) 
and porcine alveolar macrophage cell line (3D4/21) to confirm the progeny virus cellular 
tropism and infectivity.  Virus replication in various cell lines was determined by IFA 
staining with MAb 3E2 (?-N of EAV) and polyclonal pig anti-PRRSV sera (Fig 6.6 and 
Table 3).  Interestingly, the three chimeric viruses (rMLVB4/5 GP5ecto, rMLVB4/5/6 
Mecto and rMLVB4/5/6 GP5&Mecto), along with the rMLVB parental virus, were able 
to infect EEC, MARC-145, BHK-21, and RK-13 cells as determined by IFA staining for 
the N protein of EAV (Fig 6.6).  Similarly, MARC-145 cells were infected with the wild 
type PRRSV, parental rMLVB and the three chimeric viruses (rMLVB4/5 GP5ecto, 
rMLVB4/5/6 Mecto and rMLVB4/5/6 GP5&Mecto) as determined by positive staining in 
IFA with pig anti-PRRSV polyclonal serum.  None of the viruses were able to infect 
3D4/21 cells.  This finding was consistent with previous observations that 3D4/21, a 
continuous porcine alveolar macrophage cell line, does not support replication of 
PRRSV.498  The exchange of GP5 and/or M protein N-terminal ectodomains from 
PRRSV (individual or double) could not alter the tropism of the chimeric viruses. 
??   
Similarly, a previous study has shown that exchanging the GP5 ectodomains from 
another PRRSV IAF-Klop strain did not change the EAV or PRRSV cell tropism.291  In 
that study, it was shown that chimeric viruses containing the N-terminal ectodomains of 
M envelope proteins of PRRSV and LDV on an EAV backbone are replication- and 
transcription-competent (as determined by the synthesis of both non-structural and 
structural proteins), but unable to produce infectious progeny virus.  Dobbe et al (2001) 
indicated that this was due to the failure of formation of the GP5/M heterodimer in the 
chimeric proteins.  In contrast, we demonstrated that the N-terminal ectodomain of the M 
protein of EAV can be replaced by the N-terminal ectodomain of PRRSV M protein 
without compromising the production of viable progeny virus using a different infectious 
cDNA clone of EAV and a more recent North American strain of PRRSV IA1107.  Our 
findings indicate that neither the GP5 nor M protein is involved in determining the 
cellular tropism of EAV. This supports the hypothesis that EAV and perhaps PRRSV 
major envelope proteins are not determinants of the cellular tropism of these two viruses.  
Interestingly, in a very recent study, PRRSV infectious cDNA clone was used as a vector 
to construct a chimera in which PRRSV ORFs 2a, 2b, 3 and 4 were replaced by the 
corresponding ORFs from EAV 294.  This PRRSV/EAV chimeric virus gained the broad 
cell tropism that is typical of EAV, and  clearly indicated that the minor envelope protein 
(GP2, GP3 and GP4) and E protein play a key role in determining the cellular tropism of 
arteriviruses and play a major role in virus attachment and entry.294  However, the major 
neutralization determinants of EAV and PRRSV are both localized in the N-terminal 
ectodomain of GP5 252,471,499-501 and we have shown previously that recombinant EAV 
(A45.C2) containing the GP5 ectodomain of PRRSV (IAF-Klop) is not neutralized by 
??  
 
any EAV specific MAbs or by the polyclonal equine antisera.253  Therefore, it will be 
interesting to determine the replication and immunogenic kinetics of these viable 
EAV/PRRSV chimeras in pigs.  
 
Fig 6.6. Determination of cellular tropism of EAV-PRRSV chimeric viruses using 
indirect immunofluorescence assay (IFA). Various cell lines used in this study are listed 
on the left side of the figure. The names of the P0 viruses used to infect cells are 
identified at the top center. The primary antibodies or anti-sera used in IFA are shown at 
the bottom of the figure. In Fig. 6A, PRRSV infected cells (first column) were stained 
with FITC-conjugated SDOW17 MAb which was used to stain PRRSV N protein (green). 
The remaining columns show the chimeric virus-infected cell lines stained with EAV 
PAM
?-sera (PRRSV)
3D4/21
rMLVB GP5ecto Mecto GP5&MectoPRRSV
Cells Viruses
BHK-21
RK-13 
EEC
?-N (EAV, 3E2 )?-N (PRRSV, SDOW17)
MARC-145
MARC-145
A
B
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MAb (3E2) against N protein followed by Texas-red conjugated secondary antibody 
staining (red). In Fig. 6B, MARC-145 cells infected with PRRSV or rMLVB or chimeric 
viruses were stained with pig polyclonal anti-PRRSV sera followed by FITC-conjugated 
secondary antibody staining.  
 
Effect of ORFs4/5 and ORFs5/6 separations on ORF5a protein, GP5 and M proteins 
 Recently, a novel small ORF5a protein (encoded by ORF5a) which overlaps with 
the 5' end of ORF5 has been identified.263,467  The effect of ORF4/5 separation on ORF5a 
protein and GP5 were determined by comparative amino acid sequence analysis (Fig. 6.3).  
The insertion of the 24 nucleotide sequence to separate ORFs4/5 in the prMLVB vector 
resulted in replacement of 4 amino acids (NAIY [a.a. 12-15]) with 12 amino acids 
(SAICELKOHAVH [a.a. 12-23]) which expanded the length of the EAV ORF5a protein 
by 8 amino acids.  The insertion of 24 nucleotides did not affect the transcriptional 
regulatory sequence (TRS) upstream of ORF5 of rMLVB4/5.  It also did not alter the 
coding sequences of GP5 and M proteins nor the TRS upstream of ORF6.  The growth 
curve and plaque morphology of rMLVB4/5 indicated that separation of ORF4/5/6 had 
some negative impact on the recombinant viruses.  However, these changes did not have 
a significant crippling effect on the recombinant virus.  Previously it was reported that a 
complete knock out of the ORF5a protein in two infectious cDNA clones pEAV515, a 
derivative of pEAV030261 and pEAVrVBS388, had a significant crippling effect on the 
progeny viruses, which produced lower titered virus and pinpoint plaques.263  In this 
current study, insertion of 8 random amino acids to the ORF5a protein of EAV ORF4/5 
recombinant virus did not cripple the virus to the same extent compared to the ORF5a 
knockout mutants (Fig 6.5B).   Following the replacement of EAV GP5 N-terminal 
ectodomain (a.a. 1-114) with PRRSV IA1107 GP5 N-terminal ectodomain (a.a 1-64), the 
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new EAV/PRRSV fusion ORF5a protein consists of 11 amino acids (MFFYDWYVGLN) 
from EAV ORF5a protein followed by 10 random amino acids (SAICELKQHV) 
encoded by the nucleotide sequence that was inserted for the separation of ORFs4/5 and 
the PRRSV ORF5a amino acid sequence (a.a. 22-62) corresponding to amino acids 6 to 
46 of the PRRSV ORF5a protein.  The recombinant EAV/PRRSV ORF5a fusion protein 
containing the PRRSV GP5 ectodomain was 16 amino acids longer (46 versus 62 a.a.) 
than the authentic protein and its first 11 amino acids were identical to EAV ORF5a 
protein.  Interestingly, the chimeric viruses with this ORF5a protein (rMLVB4/5 GP5ecto 
and rMLVB GP5&Mecto) were stable and replicated to titers of 9.5 × 105 pfu/ml.  Taken 
together, these data further confirmed the importance of the ORF5a protein in virus 
infection as well as the plasticity of this region to accommodate small stretches of 
additional nucleotides.  This observation is further supported by previous attempts to 
engineer an EAV vectored vaccine by fortuitously introducing a 24 nt insertion to disrupt 
the ORF4/5 overlap.493  Furthermore, the difference in length of the ORF5a protein 
among arteriviruses (EAV 59 codons, PRRSV-NA 46 or 56 codons, PRRSV-EU 43 
codons, LDV 47 codons and SHFV 64 codons) and spontaneous insertion of 12 nt into 
ORF5a during 70 serial passages of PRRSV-NA strain502 indicate the plasticity of this 
region of EAV and other arteriviruses.  
 In summary, in this study, we have generated three viable EAV/PRRSV chimeric 
viruses (rMLVB4/5GP5ecto, rMLVB4/5/6Mecto and rMLVB4/5/6GP5&Mecto). The 
chimeric viruses containing PRRSV M ectodomain are novel. We have used these three 
viruses to demonstrate unequivocally that the ectodomains of GP5 and M are not the 
major determinants of cellular tropism, further supporting the recent findings that the 
??   
minor envelope proteins GP2, GP3, GP4 and E are the critical proteins in mediating 
cellular tropism.294  
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CHAPTER SEVEN 
 
Conserved arginine residues in the E protein of equine arteritis virus may play a 
role in heparin binding 
  
7.1.  SUMMARY 
 Equine arteritis virus (EAV) is the causal agent of equine viral arteritis, a disease 
of members of the family Equidae. EAV has a relatively broad cell tropism and can infect 
a range of mammalian cells in vitro. In horses, EAV primarily replicates in macrophages 
and endothelial cells of small blood vessels. As yet, neither the cellular receptor(s) nor 
the mechanism(s) of virus attachment and entry have been determined for this virus. 
Previous studies have shown that heparin can inhibit EAV infection of RK13 cells. In this 
study, we investigated EAV attachment to equine endothelial cells (EECs). When heparin 
was mixed with EAV, it reduced virus infectivity in EEC up to 93%. Other 
glycosaminoglycans, similar to heparin, had no significant effect on EAV infectivity. 
Heparinase treatment of EECs resulted in a significant reduction in infection of EEC. 
When solubilized EAV virion proteins were subjected to heparin-affinity 
chromatography and SDS-PAGE analysis, it was found that the structural proteins E, 
GP2, GP5, M and N of EAV could bind heparin. We subsequently cloned and expressed 
each individual structural protein in mammalian cells and confirmed that all these 
proteins can interact with heparin. Comprehensive sequence analysis of 90 field strains of 
EAV revealed a conserved XBBXBX (X is a basic and B is a nonbasic amino acid) 
domain at the carboxyl terminus of the E protein which was previously predicted to be 
the heparin binding domain. Five basic arginine (R) residues are highly conserved within 
the region. To further characterize the role of this heparin binding domain, we used site-
directed mutatagenesis to generate a panel of arginine (R) ? glycine(G) mutations at the 
conserved C-terminal region in both the full-length EAV cDNA clone and in individual E 
protein expression vectors.  The mutant viruses rVBS R52G, rVBS R57G, rVBS 
R52,60G, rVBS R57,63G and rVBS R63,65G have similar growth patterns and plaque 
morphology compared to the parental control. In contrast, triple mutant rVBS 
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R52,60,65G virus grew significantly slower and produced tiny sized plaques. When these 
mutations were introduced in the E protein expression plasmid, mutant E R52G and E 
R57G did not affect the heparin binding capability while double mutant E R52,60G 
completely blocked the interaction between E protein and heparin. Other mutants could 
not be tested because the mutations involved the target locations of the E antibody. The 
results for double mutant R52,60G in which heparin interaction is blocked but virus 
infectivity was intact suggest that other attachment molecules may also exist. Collectively, 
our data suggest that while the conserved arginine residues at the C-terminus of the E 
protein are important for heparin binding of EAV, other as yet unknown attachment 
molecules might also be involved.  
 
7.2.  INTRODUCTION 
Equine arteritis virus (EAV) is a single-stranded, positive sense RNA virus in the 
family Arteriviridae, genus Arterivirus, order Nidovirales. It is the causative agent of 
equine viral arteritis (EVA) in horses and other equids species.212,255,257 Besides EAV, the 
family Arteriviridae contains three other viruses: porcine reproductive and respiratory 
syndrome virus (PRRSV), simian hemorrhagic fever virus (SHFV), and lactate 
dehydrogenase-elevating virus (LDV) of mice.256 The genome of EAV is approximately 
12.7 kilobases (kb) and includes 5’ and 3’ untranslated regions as well as ten known open 
reading frames (ORFs).256,263 The first two ORFs (1a and 1b) are approximately 9.5 kb 
and all located at the 5’ portion of the genome.  They encode for the replicase 
polyproteins (pp 1a and pp 1ab), with the latter requiring a -1 ribosomal frame-shift just 
before termination of the pp 1a translation.256,260,320 The pp 1a and pp 1ab are post-
translationally processed by three ORF 1a-encoded proteinases, (non-structural protein 
[nsp] 1, nsp 2 and nsp 4), yielding a number of processing intermediates and thirteen end-
products: nsp 1-12, including nsp 7? and nsp 7?.256,264,503-504 The remaining eight ORFs 
(ORFs 2a, 2b, 3, 4, 5a, 5-7) located at the 3’ end of the genome are approximately 2.7 kb 
and encode E, GP2, GP3, GP4, ORF5a, GP5, M envelope proteins, and the nucleocapsid 
protein (N), respectively.256,262-263  The EAV genomic RNA is encapsidated by the N 
protein into an isometric core which is surrounded by an envelope containing seven 
structural proteins.256 The glycosylated protein GP5 and nonglycosylated protein M are 
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the most abundant structural proteins in the envelope and occur in the virion as covalently 
linked heterodimers.266 The GP2, GP3 and GP4 are all minor glycoproteins and form a 
covalently linked heterotrimer in the virion.320,370 It has been suggested that the small 
envelope protein E interacts with GP2, GP3 and GP4 heterotrimer complex and draws the 
minor envelope glycoproteins into nascent particles.268  All seven structural proteins 
(excluding ORF5a) are essential for virus infectivity while inactivation of ORF5a 
expression by reverse genetics yielded a severely crippled EAV mutant which replicated 
to lower titer and produced tiny plaques.263,268 
 EAV has a relatively broad cell tropism and infects a range of animal and human 
cells in vitro.230,320  However, in vivo, it primarily infects equine macrophages and 
endothelial cells, but the virus can also replicate in other cell types such as epithelial cells, 
mesothelium, and smooth muscle cells of small blood vessels and myometrium.36,234-235 It 
has been shown that EAV enters baby hamster kidney (BHK) cells via clathrin-dependent 
endocytosis.283  However, details of the mechanism of virus attachment and entry in vivo 
are still not clear. Asagoe et al  (1997) have shown that heparin can inhibit EAV infection 
on BHK cells but the mechanism of the inhibitory activity by heparin was not 
elucidated.289  
 The small envelope E protein is a 67-amino-acid protein which consists of three 
domains: an N-terminal domain containing a potential myristoylation signal, a 
hydrophobic domain and a hydrophilic C-terminus containing a cluster of basic amino 
acids.262  The topology of the E protein within the viral membrane is not known. It is 
speculated that the hydrophobic domain might span the membrane once, leaving either 
the N or C terminus on the virion surface. Alternatively, the E protein may span the lipid 
bilayer twice with both termini exposed on the same side of the membrane. It is also 
possible that the E protein adopts a more complex multiple transmembrane 
configuration.262  The role of the E protein in EAV infection has not been well studied. 
Reverse genetics studies have shown that cells transfected with mutants lack the 
expression of E, GP2, GP3 or GP4 release virus-like particles (VLPs) consisting of viral 
RNA and the GP5, M and N proteins.268,505 Absence of the E protein completely blocked 
the incorporation of GP2, GP3 and GP4 proteins into viral particles.268 These finding 
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suggests that the E protein is essential for the production of infectious progeny but 
dispensable for virus assembly and release. The E protein may have an intermediate 
receptor binding and/or virus entry function with the GP2/GP3/GP4 complex.  A detailed 
amino acid function study revealed that although the N-terminal glycine site of the E 
protein is myristoylated, but myristoylation is not required for membrane association and 
particle budding.  
 Diverse cellular surface carbohydrates are major mediators of cell-to-cell 
interactions.506 The glycan synthesis of glycoproteins is associated with two main 
processes: N-glycosylation, which adds N-acetylglucosamine (GlcNAc) to the nitrogen 
atom of an asparagine residue, or O-glycosyaltion, which adds N-acetylgalactosamine 
(GalNAc) or xylose to the oxygen atom of a serine or a threonine residue.  The xylose 
addition leads to the synthesis of glycosaminoglycans (GAGs).  There are six different 
groups within GAGs depending on their structures: chondroitin sulphate, heparin 
sulphate (HS), dermatan sulphate, keratin sulphate, hyaluran, and heparin.507-509  HS is a 
copolymer of sulphated glucosamine and sulphated glucuronic or iduronic acid.510-511  
The structural diversity of HS is derived from the modification of individual disaccharide 
units within the oligosaccharide, which enables them to interact with a great variety of 
extracellular proteins, such as growth factors, cytokines, chemokines, matrix proteins and 
antimicrobial peptides and to get involved in many biological processes, such as 
morphogenesis, tissue repair, energy balance and host defence.510 HSs are commonly 
used as binding molecules for numerous viruses and other pathogens as they are 
ubiquitously present on the surface of animal cells and in the extracellular matrix, where 
the initial interactions of viruses and target cells occur. Herpes simplex virus, influenza A 
virus, Sendai virus, Japanese encephalitis virus, human cytomegalovirus, respiratory 
syncytial virus, dengue virus, adeno-associated virus, and many others, bind to HSs.327-
329,512-518  HSs contain a considerable number of negative charges under physiologic 
conditions and these may contribute to virus-cell interaction. However, this binding could 
be far more complex than just nonspecific ionic interactions.519  While heparin is the 
structural analog of HS, it undergoes more extensive sulfation and uronic acid 
eprimization.509 In addition to its anticoagulant function, heparin has also been used as a 
research reagent, in particular for affinity-purification of heparin-binding proteins.520 The 
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heparin-binding properties of many of these proteins represent their physiological 
interactions with HS, as the surface of most animal cells and extracellular matrices of a 
wide variety of tissues.  Heparin-binding domains of heparin-binding proteins have been 
shown to contain consensus sequence motifs, such as XBBXB and XBBBXXBX, where 
B is a basic amino acid and X is a neutral or hydrophobic amino acid.521 Besides the 
consensus sequence motifs, the spatial orientation of basic residues rather than sequence 
proximity is critical in determining heparin-binding affinity.522  
 The purpose of this study is to investigate the role of heparin in EAV infection of 
its natural target cell, the equine endothelial cell (EEC). We aligned the sequences 
available for E protein and identified the putative heparin-binding protein domain in this 
protein. A panel of conserved arginine to glycine mutations at the C-terminus of the E 
protein was generated using site-directed mutagenesis and reverse genetics. The effect of 
mutations on EAV infection and heparin binding was investigated.  
 
7.3.  MATERIALS AND METHODS 
Cells and viruses  
Equine pulmonary artery endothelial cells (EECs) were maintained and 
propagated in Dulbecco’s modified essential medium (DMEM, Mediatech, Herndon, VA) 
supplemented with sodium pyruvate, 10% fetal bovine serum (Hyclone Laboratories, Inc., 
Logan, UT), 100U/ml of penicillin/streptomycin and 200mM L-glutamine (Life 
Technologies, Grand Island, NY).486,523  RK-13 (ATCC, CCL-37) and mouse connective 
tissue (LM; ATCC CCL-1.2) cells used in the virus attachment study were cells were 
cultured and maintained in Eagle’s minimum essential medium (EMEM; [Mediatech, 
Herndon, VA]) supplemented with 10% fetal calf serum (FCS; Hyclone, Logan, UT), 
100U/ml penicillin, 100?g/ml streptomycin, 1?g/ml amphotericin B and 0.06% sodium 
bicarbonate at 37°C.  The experimentally derived highly virulent Bucyrus strain (VBS) of 
EAV (ATCC VR-796)524 was propagated in EEC to prepare high tittered working stock 
as previously described.486,523 Briefly, EECs infected with the VBS strain of EAV 
(thereafter named as EAV for simplicity) were frozen at -80ºC when 90-100% cytopathic 
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effect (CPE) was observed.  Cell lysates were clarified by centrifugation (500 ×g) at 4°C 
for 15 min, followed by ultracentrifugation (Beckman Coulter, Miami, FL) at 121,600 ×g 
through a 20% sucrose cushion in NET buffer (150 mM NaCl, 5 mM EDTA, and 50 mM 
Tris-HCl, pH 7.5) at 4 °C for 4 h to pellet the virus.  The partially purified VBS strain of 
EAV was resuspended in phosphate buffered saline (PBS; pH 7.4) and frozen at -80 °C.  
Virus stock was titrated by standard plaque assay in RK-13 cells (ATCC CCL-37; 
American Type Culture Collection, Manassas, VA) and infectivity titers were expressed 
as pfu/ml.525  The virus was used to characterize the effect of heparin on EAV infectivity 
on EECs.  
 
Antibodies 
 To detect the viral proteins that interacted with heparin in western blotting test, 
Previously described monoclonal antibodies (MAbs) against EAV nucleocapsid protein 
(N; MAb 3E2)234,254 and GP5 protein (MAb 6D10)475,526 were used in the study.  
Similarly, polyclonal rabbit antisera recognizing EAV GP2 (rabbit 4033),475 M (rabbit 
8887)251 and E (rabbit 2855 and 2586)262 were also included. The MAbs and antisera 
were used individually in the western blotting test.  
  
Treatment of viruses with heparin, other GAGs or heparinase I  
 To study the role of heparin and other GAGs on EAV infectivity, EAV was 
incubated with different concentrations (0, 0.01. 0.1, 0.5, 1, 1.5, 2, 2.5 3 and 6 mg/ml) of 
GAGs (heparin, heparan sulfate, chondroitin sulfate A and dermatan sulfate; Sigma-
Aldrich, St Louis, MO) at 37 °C for 1 hr to saturate putative heparin-binding viral 
proteins and thus prevent successful virus infection.  The VBS-GAG mixture was 
subsequently inoculated onto the confluent monolayers of EECs at a multiplicity of 
infection (MOI) of 2 and the inoculated cultures incubated at 37 °C for 1 hr.  The EEC 
culture were washed three times with Eagle’s minimal essential medium (MEM, Life 
Technology, Grand Island, NY) to remove any unbound virus and monolayer fixed at 12 
hpi with 4% paraformaldehyde for subsequent flow cytometric analysis.  In a separate 
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experiment, confluent EECs were treated with heparinase I for 1 hr at 37 ºC to remove 
the putative heparin-like molecules expressed on the surface of EECs.  EECs were then 
extensively washed with plain MEM to remove residual heparinase I followed by 
inoculation with EAV at a MOI of 2 for a further hour at 37 ºC.  Following incubation, 
EECs were again washed with MEM three times to remove unbound virus and fixed at 12 
hpi for flow cytometric analysis.   
 
Virus binding assay 
 The binding of EAV to EEC suspension was determined using a previously 
published protocol.341  Briefly, subconfluent monolayers of EEC were trypsinzed, washed 
and resuspended in ice-cold PBS supplemented with 2% FBS (PBS-F).  Cell suspensions 
were held on ice during the whole experiment.  An MOI of 15 of biotinylated VBS and 
different concentrations of heparin (0, 0.01, 0.1, 0.5, 1, 1.5, 2, 3, and 6 mg/ml) were 
mixed and added to the suspensions and inoculated for 1 hr at 4 ºC. Subsequently, the 
cells were incubated with 200 µl of a 1:100 dilution of streptavidin-FITC conjugate (GE 
healthcare, Pittsburgh, PA) in PBS-F buffer for an additional hr on a shaker at 4 ºC.  Cells 
were then washed with ice-cold PBS-F and resuspended in PBS-F for immediate flow 
cytometric analysis.    
 
Flow cytometric analysis 
 The intracellular immunofluorescence staining of EAV nsp1 was used to 
determine the infectivity of the VBS strain of EAV for EECs after GAG or heparinse I 
treatment. After the GAG and heaprinase I treatment, EECs were fixed with 4% 
paraformaldehyde for 30 min followed by incubation for 5 min in membrane 
permeabilization buffer (PBS containing 1% heat-inactivated normal goat serum, 0.1% 
sodium azide and 0.1% saponin, Sigma-Aldrich, St Louis, Mo). The permeablized EECs 
were incubated with EAV ?-nsp1 IgG (MAb 12E4) conjugated with Alexa Fluor® 488 
(Invitrogen, Carlsbad, CA) for 30 min. 106 EECs were obtained and analyzed with 
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FACScalibur and Cellquest software (Becton-Dickinson, San Jose, CA) to determine the 
percentage of EAV positively infected cells. 
The detection of biotinylated EAV surface proteins was used to determine 
whether there had been interaction between heparin and those proteins.  A 106 EECs were 
mixed with the biotinylated VBS strain of EAV were obtained and analyzed using 
FACScalibur and Cellquest software.  The median fluorescence intensity (MFI) was 
calculated according to the following formula: 100 × (MFI when heparin was added/MFI 
when no heparin was added). 
 
Cloning and expression of E, GP2 and N proteins of EAV 
 To individually express EAV viral proteins, the genes encoding E (ORF2a), GP2 
(ORF2b) and N (ORF7) proteins were cloned into the pVR21 plasmid vector downstream 
of a 26S promoter following a previously described protocol.272 The recombinant 
plasmids containing the E, GP2 and N genes of EAV were designated pVR21-E, pVR21-
GP2 and pVR21-N, respectively.  The authenticity of the cloned genes was confirmed by 
sequencing.  Two plasmids expressing major envelope proteins GP5 and M (pVR21-GP5 
and pVR21-M) was also included in this study.272  
Runoff RNA transcripts were generated from Not I-linearized recombinant 
plasmids including pVR21-GP2, pVR21-GP5, pVR21-M, pVR21-E and pVR21-N to 
generate in vitro transcript RNA (IVT RNA) according to a previously described 
protocol.384  Individual IVT RNA was transfected into EEC using a BTX electroporator 
(Harvard Apparatus, Holliston, MA   according to the manufacturer’s instructions.  The 
transfected EECs were solublized at 24 hpt to collect the expressed proteins and 
confirmed by western blot testing. Individual expressed structural protein was used to 
determine its binding capability to heparin sepharose beads. 
 
Binding of viral proteins to heparin sepharose 
The approach was modified from the protocol described by Delputte et al 
(2002).341 Firstly, partially purified EAV or individually expressed recombinant proteins 
of EAV (E, GP2, GP5, M and N) were solublized in solubilization buffer (20 mM 
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Tris.HCl [pH 7.6], 150 mM NaCl, 1% NP-40, 1mM EDTA) containing Halt protease 
inhibitor cocktail (Pierce, Rockford, IL) for 30 min at room temperature.  Then the 
solublized EAV viral proteins or recombinant proteins were incubated with heparin 
sepharose CL-6B (GE Healthcare, Piscataway, NJ) at room temperature for 1 hr with 
agitation and then washed with PBS containing 0.1% NP-40 (PBS-N) as recommended 
by the manufacturer. Bound viral proteins or recombinant proteins were eluted under 
different conditions including PBS-N containing 4 mg of heparin per ml (PBS-N-H) and 
a final concentration of 2 M NaCl as described previously.341 In a parallel experiment, the 
plain sepharose beads without heparin (Sigma-Aldrich, St Louis, MO) were used as a 
negative control.  The eluted proteins were mixed with lamella sample buffer containing 
100 nM DTT (Pierce, Rockford, IL) prior to running them on a 12% SDS-PAGE 
gel.499,526  The solublized VBS proteins were then transferred on to PVDF membranes 
and immunoblotted with EAV protein specific antibodies.  
  
SDS-PAGE and western blotting 
The solubilized VBS proteins or recombinant EAV viral proteins were mixed 
with 5X sample reducing buffer containing 100mM dithiothreitol (DTT; Pierce, Rockford, 
IL) and incubated for 10 min at room temperature.  Samples were resolved in a SDS-12% 
polyacrylamide gel (PAGE).   The gel was transferred to PVDF membranes (Bio-Rad, 
Hercules, CA) and blocked with TBS-T (10mM Tris-HCl [pH 7.6], 150mM NaCl, 0.05% 
Tween 20) with 5% skim milk powder.  Blots were incubated with primary antibody for 1 
h at room temperature followed by exposure to a 1:5000 dilution of biotinylated goat 
anti-mouse or anti-rabbit antibodies (Invitrogen, Carlsbad, CA) for 1 hr.  Subsequently, 
the blots were incubated with a 1:2000 dilution of streptavidin-horseradish peroxidase 
tertiary antibody (Invitrogen, Carlsbad, CA) and detected by means of an enhanced 
chemiluminescence reaction (ECL, Amersham, Piscataway, NJ).     
 
Comparative amino acid sequence analysis and membrane topology prediction of E 
protein 
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The EAV ORF2a nucleotide sequences which are available in the GenBank (n=90) 
were downloaded and translated into amino acid sequences using the Vector NTI 
Advance™ 11 software (Invitrogen, Carlsbad, CA).  Multiple amino acid sequence 
alignments were performed using CLUSTAL_X v1.83 to identify the conserved regions 
of E proteins.527  Prediction of membrane topology for E protein was performed using 
five most commonly used topology prediction methods available on the Internet: 
PSIPRED (http://www.psipred.net/psiform.html),528-529 TMHMM 
(http://www.cbs.dtu.dk/services/TMHMM/),530 TMPred 
(http://www.ch.embnet.org/software/TMPRED_form.html), TOPPRED 
(http://mobyle.pasteur.fr/cgi-bin/portal.py?#forms::toppred)531 SOSUI 
(http://bp.nuap.nagoya-u.ac.jp/sosui/sosui_submit.html) . All user-adjustable parameters 
were left at their default values. 
 
Site-directed mutagenesis to generate recombinant E protein mutants 
The full-length infectious cDNA clone pEAVrVBS388 was used to generate a 
panel of arginine to glycine mutations at the heparin-binding domain in the C-terminus of 
EAV ORF2a region using QuikChange Multi Site-directed Mutagenesis Kit (Stratagene, 
Santa Clara, CA) described previously.532  The mutations engineered are listed in Table 1. 
Arginine residues at position 52, 57, 60, 63, 65 were mutated to glysine to make single 
(R52G and R57G), double (R52,60G, R57,63G and R63,65G) or triple (R52,60,65G) 
mutations. BHK-21 cells were transfected with IVT RNAs by following previously 
described protocols384 to generate the recombinant viruses rVBS R52G, rVBS R57G,  
rVBS R52,60G, rVBS R57,63G, rVBS R63,65G and rVBS R52,60,65G.  A small portion 
of tranfected cells were seeded onto coverslips and incubated for 18 hr post transfection 
before being stained with EAV specific MAb (3E2) against N protein to confirm the 
replication of recombinant virus by IFA. The tissue culture fluid (TCF) supernatant 
collected after IVT RNA transfection was designated P0 virus and used for further 
characterization.  Similarly, the pVR21-E plasmid was used to generate the same panel of 
arginine to lysine mutations as described above. The expressed mutant proteins (R52G, 
R57G, R52,60G, R57,63G, R63,65G and R52,60,65G) were named E R52G, E R57G, E 
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R52,60G, E R57,63G, E R63,65G and E R52,60,65G, respectively.  These mutant E 
proteins were used to determine the interaction with heparin in a heparin binding assay.  
 
Immunofluorescence assays  
For the indirect immunoflurorescence assay (IFA),  EECs  transfected from IVT 
RNA generated from the full-length infectious pEAVrVBS clone or various E mutants 
were seeded on coverslips and fixed at 18 hpt in 4% paraformaldehyde in phosphate-
buffered saline (PBS; pH7.4) for 30 min at RT followed by washing three times in PBS 
(pH 7.4) containing 10mM glycine (glycine/PBS).  After permeabilization with 0.2% 
Triton X-100 in PBS (pH 7.4) for 10 min, coverslips were incubated with EAV MAb 3E2 
specific for the N protein in PBS containing 5% fetal bovine serum (FBS).  After three 
10mM glycine/PBS washes, coverslips were incubated with FITC-conjugated goat anti-
mouse (Southern Biotech, Birmingham, AL) for 1 h at RT.  Cover-slips were washed and 
mounted in 4’, 6’-diamidino-2-phenylindole (DAPI) containing aqueous mounting 
medium (Vector Laboratories, Burlingame, CA) and examined under an inverted 
fluorescence microscope.   
 
Growth characteristics and plaque morphology of mutant E viruses  
 Subconfluent monolayers of BHK-21 grown in six-well plates were inoculated 
with parental EAV rVBS or mutant E viruses at MOI of 1 and held at 37 ºC for 1 hr. The 
inocula were removed and the cells were washed three times with PBS to remove 
unbound virus before being overlaid with 4 ml of EMEM. At 6, 12, 18, 24 hpi, 
supernatants were collected and virus titers were determined by plaque assay in RK-13 
cells.279 For the plaque morphology study, EECs were used for virus infection and 
overlaid with DMEM containing 0.75% carboxymethyl cellulose and incubated for 4 
days.263 
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7.4.  RESULTS 
Effect of heparin and heparinase I on EAV infectivity 
 EAV was firstly incubated with various concentrations of heparin prior infection 
of EEC to see whether heparin could reduce the infectivity of EAV. Cells were fixed at 
12 hpi which only allows one cycle of viral replication. The number of EAV infected 
cells was determined by intracellular immunofluorescent staining of EAV nsp1 protein 
and flow cytometric analysis. A dose-dependent reduction of EAV infection was 
observed, with a maximal 93% and 91% reduction in a heparin concentration of 3 and 6 
mg/ml, respectively (Fig 7.1.).  To confirm that the inhibition effect was due to the 
interaction between heparin and virus and not between heparin and the cells, in a separate 
experiment, EEC was incubated with heparin prior EAV infection.  As shown in Figure 1, 
pretreatment of EEC with heparin had no significant effect on EAV infection.  To 
investigate if heparan sulfate proteoglycans, present on the cell surface, are involved in 
EAV infection, EEC was treated with different concentrations of heparinase I prior to 
EAV infection.  There was a significant reduction after heparinase I treatment of the EEC, 
with a maximum of 65% at 80 U/ml (Fig 7.2.) 
 
Fig 7.1. Effect of heparin on EAV infection of EEC. EAV (?) was incubated with various 
concentrations of heparin and the heparin and EAV mixture was inoculated into EECs 
and incubated at 37 °C for 1 hr. Subsequently, the cell monolayer was washed to remove 
unbound virus and finally stained with MAb 12A4 specific for nsp1 protein with flow 
cytometry at 12 hpi. In another experiment, EEC monolayer (?) was incubated with 
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heparin for 1 hr followed by extensive washing steps. Subsequently, EAV was inoculated 
into EEC monolayer for 1 hr followed by extensive washing.  EECs were stained with 
MAb 12A4 for nsp1 with flow cytometry.  The data represents the means+ standard 
errors (error bars) of triplicate experiments.  
 
 
Fig 7.2. Effect of heparinase I treatment of EEC on EAV infection. EEC was pretreated 
with heparinase I for 1 hr, extensively washed and infected with EAV for another hour at 
37 ºC. EEC were fixed at 12 hpi and stained with MAb12A4 for nsp1 for flow cytometric 
analysis. The data represents the means+ standard errors (error bars) of triplicate 
experiments. 
 
Effect of other glycosaminoglycans on EAV infection to EEC 
 To investigate if the reduction of EAV infection was due to a specific interaction 
of the virus with heparin or due to a general interaction with negatively charged 
molecules, EAV was incubated with other GAG molecules including heparan sulfate, 
chondroitin sulfate A and dermatan sulfate before inoculation. At the highest 
concentration of 6 mg/ml, all three GAGs reached their maximal reduction of 91% + 1%, 
55% + 1% and 35% + 12% (means + standard error), respectively, as compared to 
untreated control.  Chondroitin sulfate A at 0.1, 0.5, 1 or 3 mg/ml could reduce the EAV 
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infection to 30% as of the control.  Other concentrations of GAGs did not have 
significant reduction effect on EAV infectivity (Fig 7.3.).   
 
Fig 7.3. Effect of other glycoaminoglycans on EAV infection to EEC.  Different 
concentration of heparan sulfate (?), chondroitin sulfate A (?), dermatan sulfate (?) 
were mixed with EAV for 1 hr at 37 ºC. Subsequently, the EAV-GAG mixture was 
inoculated to the EEC monolayer for 1 hr at 37 ºC. The EAV-GAG mixture was removed 
and EEC monolayer was stained with MAb12A4 against EAV N protein for flow 
cytometric analysis at 12 hpi. The data represents the means+ standard errors (error bars) 
of triplicate experiments. 
 
Binding of EAV to heparin sepharose and identification of EAV heparin binding 
proteins 
 To identify the viral proteins which can bind to heparin, solublized EAV viral 
proteins were incubated with heparin sepharose beads for 1 hr at 37 ºC. After extensive 
washing, the bound proteins were eluted with heparin in combination with high salt 
concentration.  The proteins bound to heparin were identified by western blotting using 
MAb or polyclonal sera specific for the major envelope proteins (GP5 and M), minor 
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envelope proteins (E and GP2) and nucleocaspid protein N.  The results showed that all 
these tested structural proteins were able to bind to heparin sepharose beads (Fig. 7.4b). 
The representative gel for GP2 (Fig. 7.4a) clearly showed that GP2 can be detected in the 
original EAV solublized protein prior to heparin binding and the first two washing steps. 
No residual GP2 protein was found in the 5th and 8th washings. In the subsequent elution 
step, GP2 protein was able to be eluted in all three elution steps suggesting the bound 
GP2 were successfully washed off from the beads. When control sepharose beads were 
used, none of the proteins were eluted either from solublized EAV proteins or expressed 
proteins.  
 To further confirm the viral protein interaction with heparin, in another 
experiment, individually expressed EAV viral proteins E, GP2, GP5, M and N were 
mixed with heparin sepharose beads.  Proteins were eluted and subsequently identified in 
a western blotting assay using protein specific antibodies.  Each individually expressed 
protein was able to bind with heparin sepharose beads same as solublized EAV proteins 
(Fig. 7.4c).  One of the most interesting finding was the binding of minor envelope E 
protein to heparin sepharose.  The E protein occurs in virion particles in small amounts 
and its function is not fully understood.  Therefore, we tried to investigate the mechanism 
of heparin and E protein interaction in detail.  
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Fig 7.4. Western blotting analysis of the binding of EAV proteins to heparin sepharose. 
EAV particles were solublized and run through heparin sepharose column. The column 
was washed with PBS containing 0.1% NP40 (PBS-N) for eight times. The heparin 
bound proteins were eluted using PBS-N containing 4 mg of heparin per ml (PBS-N-H) 
and a final concentration of 2 M NaCl. 4a: Representative gel of GP2 from solublized 
purified VBS viral proteins binding to heparin sepharose. 4b: All the EAV viral proteins 
that were tested in this study could bind to heparin sepharose beads. 4c: Representative 
gel of expressed GP2 protein could bind to heparin sepharose beads.?
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Identification of a conservative heparin-binding motif in E protein 
 The search for a heparin-binding motif in the EAV proteins was guided by the 
heparin binding motif XBBBXXBX, where B stands for a basic amino acid (arginine in 
this sequence) and X is a neutral or hydrophobic amino acid.  Sequence analysis showed 
that with the exception of E protein, GP2, GP5, M and N proteins did not have an 
obvious heparin binding pattern.  The amino acids RSLVARCSRGARYR at C-terminus 
of E protein contain a cluster of basic R (arginine) residues which is consistent with the 
heparin binding motif.  Comparative amino acid sequence analysis of E protein from 
ninety EAV strains showed that five arginine residues at amino acid positions 52, 57, 60, 
63 and 65 were highly conserved among all aligned EAV sequences.  Other arteriviruses 
such as PRRSV, LDV and SHFV have at least two arginine residues and a lysine residue, 
which is also a basic amino acid (Fig 7.5.).  
 The membrane topology of E protein was predicted and results were quite 
variable. SOSUI predicted that the E protein has two transmembrane helices with C-
terminus toward the exterior side of the virion. All the other programs predicted that the 
C-terminus is located in the cytoplasm.  Despite the variable prediction, we continued to 
investigate the role of conserved the arginines using site-directed mutagenesis.    
 
 
Fig 7.5. Alignment of the sequences of E protein of all arteriviruses. Representative field 
strains of EAV and PRRSV were shown in the alignment. The conserved basic arginines 
(R) are highlighted in red.  
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Growth characteristic and plaque morphology of E mutant viruses 
 A panel of mutant constructs both in full-length infectious cDNA pEAVrVBS 
clone and expression pVR21 vector was generated substituting the conserved basic 
arginines with the neutral, nonpolar glycine.  The selection of glycine for mutagenesis 
was solely to maintain the in-frame coding of other overlapping ORFs.  Single mutant 
(R52G and R57G), double mutant (R52,60G; R57,63G and R63,65G) and triple mutant 
(R52,60,65G)  were introduced to both pEAVrVBS (Table 7.1) and pVR21 constructs 
(Table 7.2). 
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Table 7.1. Overview of the genotype and phenotype of EAV E protein mutants virus used in 
this studya 
  pEAVrVBS         
Construct 
Name 
 
Parental 
Codon 
Mutant 
Codon 
 
Mutation 
 
IFAb 
 Infectious 
Progeny 
(pfu/ml)c 
 
Summary of 
Phenotyped 
pEAVrVBS  NAe NA  None (parental)  +  + (1 × 105)  Wild type 
R52G  CGC GGC  Arg-52?Gly  +  + (7.5 × 104)  Wild type 
R57G  CGG GGG  Arg-57?Gly  +  + (8.5 × 104)  Wild type 
R52,60G 
 CGC 
CGA 
GGC 
GGA 
 Arg-52?Gly 
Arg-60?Gly 
 
+ 
 
+ (5.25 × 104) 
 
Wild type 
R57,63G 
 CGG 
CGT 
GGG 
GGT 
 Arg-57?Gly 
Arg-63?Gly 
 
+ 
 
+ (7.5 × 104) 
 
Wild type 
R63,65G 
 CGT 
AGA 
GGT 
GGA 
 Arg-63?Gly 
Arg-65?Gly 
 
+ 
 
+ (3.0 × 104) 
 
Wild type 
R52,60,65G 
 CGC 
CGA 
CGT 
GGC 
GGA 
GGT 
 Arg-52?Gly 
Arg-60?Gly 
Arg-63?Gly 
 
+ 
 
+ (8.0 × 102) 
 
Severely Crippled 
(pinpoint sized 
plaques) 
a Data from two independent transfection experiments are summarized. +, positive  
b Transfected cells were stained with EAV MAb (3E2) against N protein after one cycle of replication at 18 
hr posttransfection. IFA, immunofluorescence assay.  
cResults indicate the detection of infectious progeny using plaque assays in the medium from transfected 
cells harvested at 72-96 hr posttransfection when 90-100% CPE were developed, approximate virus titers 
are shown between brackets. 
d Phenotypes are based on growth characterization and plaque morphology.  
e Not applicable. 
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Table 7.2. Overveiw of the genotype and heparin binding capacity of EAV E mutant 
proteins used in this study 
  pVR21        
Construct 
Name 
 Parental 
Codon 
Mutant 
Codon 
 
Mutation 
 
IFAa 
 Heparin binding 
capability 
 
pVR21-E  NAb NA  None (parental)  +  +  
R52G  CGC GGC  Arg-52?Gly  +  +  
R57G  CGG GGG  Arg-57?Gly  +  +  
R52,60G 
 CGC 
CGA 
GGC 
GGA 
 Arg-52?Gly 
Arg-60?Gly 
 
+ 
 
- 
 
R57,63G 
 CGG 
CGT 
GGG 
GGT 
 Arg-57?Gly 
Arg-63?Gly 
 
NA 
 
NA 
 
R63,65G 
 CGT 
AGA 
GGT 
GGA 
 Arg-63?Gly 
Arg-65?Gly 
 
NA 
 
NA 
 
R52,60,65G 
 CGC 
CGA 
CGT 
GGC 
GGA 
GGT 
 Arg-52?Gly 
Arg-60?Gly 
Arg-63?Gly 
 
NA 
 
NA 
 
a Transfected cells were stained with antisera against E protein at 18 hr post transfection. 
The IFA and heparin binding assay were unavailable to the R57,63G; R63,65G; 
R52,60,65G mutants because the mutation overlap with the antibody reconition site. IFA, 
immunofluorescence assay. + positive 
b Not applicable 
 
 The same amount of full-length IVT RNA generated from linearized pEAVrVBS, 
as well as clones containing E mutants were electroporated into EEC for generation of 
recombinant mutant viruses. The viability of each mutant clone was determined by 
indirect immunofluorescence assay (IFA) using EAV monoclonal antibody (MAb 3E2) 
specific for N protein at 18 hr post transfection (Fig 7.6.).  The cells transfected with each 
of the parental and mutant transcripts produced 90-100% cytopathic effect (CPE) in 
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transfected cells after 72-96 hours post transfection, and virus stocks were made from 
these tissue culture fluids (TCF; P0).   
 
Fig 7.6. Immunofluorecence staining of nucleocapsid (N) protein of EECs transfected 
with parental EAV (pEAVrVBS) and E mutants IVT RNA at 24 hr posttransfection. 
 
The authenticity of all mutant viruses was confirmed by sequencing ORF2a from RNA 
extracted from each P0 TCF. All virus sequences were identical to the plasmid sequence 
from which they were derived.  The titers of the single or double arginine mutant P0 
viruses were similar to the parental rVBS virus (104-105 pfu/ml) but the titer for the triple 
mutant virus (rVBS R52, 60, 65G) was significantly reduced (102 pfu/ml) (Table 7.1).  
The TCFs (P0) containing each mutant virus were then used to infect BHK-21 cells at a 
multiplicity of infection (MOI) of 1 and progeny viruses were collected at different time 
points for titration. The growth characteristics and plaque morphology were compared in 
RK-13 and EEC, respectively.  All the mutant viruses had the highest virus titer at 24 hr 
post infection.  With the exception of rVBS R52,60,65G virus which had approximately 2 
log10 lower titer at this time point, all the other mutant viruses had similar titer as 
??   
compared to the parental rVBS virus (Fig 7.7.). When compared to the parental virus, all 
the mutant viruses except rVBS R52,60,65G virus showed similar medium sized plaques 
in EEC (2.5 mm to 3 mm) (Fig 7.8.).  The triple mutant rVBS R52,60,65G produced a 
pinpoint sized plaques (0.5 mm).   
 
 
Fig 7.7. Growth curve of E mutant viruses and parental rVBS virus. BHK21 cells were 
infected with an MOI of 1 of P0 transfected virus and tissue culture fluid containing 
progeny viruses were harvested at indicated time points. Virus titers were determined by 
plaque assays in RK-13 cells. 
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Fig 7.8. Comparison of plaque morphology on EECs of parental rVBS and E mutant 
viruses. All the mutants except triple mutation rVBS R52,60,65G produce similar plaque 
size as compared to the parental virus. The rVBS R52,60,65G triple mutant virus is 
severely crippled with pinpoint sized plaques.   
 
Arginine mutations abolish interaction with heparin  
 The effect of arginine residues on heparin binding were investigated using the 
expressed E mutant proteins. Each mutant pVR21-E construct was transfected into EEC 
and expressed proteins were collected for heparin binding assay. Wild type E protein was 
included as positive control. Heparin sepharose beads were mixed with expressed E 
protein prior to extensive washing and final elution. Washing fractions and eluted 
proteins were collected and tested in western blot using rabbit sera against E protein. 
Both wild type E protein and single mutant R52G protein and R57G protein were able to 
bind heparin (Table 7.2 and Fig 7.9.). Double mutant R52, 60G protein lost its heparin 
binding capability as no E protein was detected in the elution fractions. We were unable 
to detect the interaction between the double R63, 65G protein and triple R52,60,65G 
protein with heparin because these mutants disrupt the antisera recognition sites and 
failed to detect these two mutants in western blot.   
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Fig 7.9. Western blotting analysis of the binding of EAV E protein to heparin sepharose. 
Wild type or mutant (R57G and R52,60G) E protein expressed from pVR21-E vector was 
solublized with Tris buffer containing 1% NP-40. Solublized proteins were mixed with 
heparin sepharose beads, and washed 8 times with washing buffer (PBS containing NP-
40). Bound fractions were eluted with PBS containing 4 mg/ml heparin and 2M NaCl 
(PBS-H-NaCl). The original expressed E protein prior to heparin sepharose bead binding, 
various wash fractions and three elution fractions were detected with rabbit sera against E 
protein under reducing condition.   
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7.5.  DISCUSSION 
 In this study, we characterized the role of heparin on EAV infection of EEC in 
detail.  Heparin could significantly reduce the infectivity of EAV in a dose-dependent 
manner by interacting with the virus.  The results are consistent with the previous finding 
that heparin can inhibit EAV infection in RK-13 cells.289  The viral proteins interacting 
with heparin are major envelope proteins GP5 and M, minor envelope proteins E and 
GP2 and nucleocapsid N protein.  The conserved arginines on the linear heparin-binding 
motif found in the C-terminus of E protein play important roles on the interaction 
between heparin and E protein.  The double mutant R52,60G of E protein completely 
blocked the virus-heparin interaction however this mutant could still produce infectious 
progeny virus with a similar titer and plaque morphology as compared to parental rVBS 
virus.  There are several possible explanations: 1) Although sequence analysis did not 
reveal an obvious heparin-binding motif in major envelope proteins GP5 and M, it could 
not exclude the possibility that these major proteins could still interact with heparin in 
some way.  In fact, through an analysis of the available experimentally determined 
heparin-protein complexes, it became obvious that the spatial orientation of basic 
residues rather than sequence proximity is an important factor in determining heparin-
binding affinity.522 In such case, even the interaction between E and heparin is blocked, 
the major envelope proteins GP5 and M are still able to interact with heparin to facilitate 
virus infection.  2) There might be other attachment molecules besides heparin involved 
in EAV infection.  We have shown that the EAV infection on EEC could be reduced by 
heparin, however, no complete block of infection was observed.  Collectively, our data 
showed that heparin-like molecule on the EEC surface may function as an attachment 
factor to concentrate virions on the cell surface, hence allowing a more efficient infection 
but the presence of additional attachment factors may also be possible.  A very recent 
publication by Tian et al described the use of a PRRSV infectious cDNA clone as a 
vector to construct a chimera in which PRRSV ORFs 2a, 2b, 3 and 4 were replaced by 
the corresponding ORFs from EAV.294 This PRRSV/EAV chimeric virus gained a broad 
cell tropism that is typical of EAV, and clearly indicated that the minor envelope protein 
(GP2, GP3 and GP4) and E protein play a key role in determining the cellular tropism of 
arteriviruses and play a major role in virus attachment and entry. 294   
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 PRRSV is a close family member of EAV with its attachment and entry steps 
well-studied.  It is speculated that the PRRSV virion initially attaches to heparan sulfate 
GAGs present on the macrophage surface followed by a more stable binding between the 
sialoadhesin receptor and M/GP5 glycoprotein complexes in the viral envelope. Upon 
attachment of sialoadhesin, the virus receptor complex is internalized via clathrin-
mediated endocytosis.489  Scavenger receptor CD163 is essential for genome release and 
may exert its function through interaction with GP2 and GP4.345-346,533-534 Our results are 
consistent with the findings in PRRSV that the M and N protein could bind to the 
heparin-like receptor on porcine alveolar macrophage cells.341  It is possible that EAV use 
a similar attachment and entry pathway as compared to PRRSV. However, it is important 
to keep in mind that compared to PRRSV, EAV has a much broader cellular tropism. 
EAV might also use different cellular proteins and entry pathways depending on the cell 
type. A well-studied example is herpes simplex virus (HSV), which can infect a variety 
of host cells, including lymphocytes, epithelial cells, fibroblast and neurons.535  The 
pathways of HSV entry vary and depend on the host cell being targeted.535    
  There are several topology predictions of E protein according to its hydropathy 
profile although the exact membrane interaction feature is unknown yet. If the protein 
spans the membrane only once, it is predicted that the E protein is compatible with a type 
III protein orientation with the N terminus protruding outside of the cell and C terminus 
inside the cytoplasm (NexoCcyt).
262 It is also possible that the E protein spans the lipid 
bilayer twice, with both termini located at the cytoplasmic face of the membrane.262 A 
more complicated viral membrane topology has been identified in Sindbis virus and 
hepatitis B virus where the E2 glycoprotein of Sindbis virus can have transient 
translocation of the cytoplasmic domain into cellular membranes and the large envelope 
protein of HBV can have dual topology.536-538 Results in our study clearly showed that 
the double arginine mutant (R52,60G) blocked the interaction of heparin binding 
indicating that the C-terminus of E protein is likely exposed at the exterior site of the 
virus.  
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CHAPTER EIGHT 
 
SUMMARY OF DISSERTATION 
 
 Accurate and rapid identification of viral infectious pathogens is not only of 
interest to equine practitioners but also to research scientists. The ready availability of a 
confirmed diagnosis of a specific pathogen enables the veterinarian to take an early 
decision on patient care and management, address appropriate treatment strategies, and 
allow timely notification and discussion of management issues relevaent to prevention of 
disease spread.  This is particularly important after the discovery in 2004 that a strain of 
equine H3N8 influenza virus had crossed the species barrier and caused an extensive 
epidemic of respiratory disease in dogs.  In 2007, a second canine influenza that was 
confirmed in Korea and on that occasion, the causative agent was H3N2 avian influenza 
virus of avian origin. Although there is no evidence that equine respiratory viruses are 
zoonotic, the close association between humans and dogs, and to a lesser extent horses, 
emphasize the need for better surveillance and control strategies for emerged diseases in 
companion animals.  The first part of this dissertation focused on development and 
evaluation of rRT-PCR assays for the detection of common equine respiratory viruses 
including equine arteritis virus, equine influenza virus, equine rhinitis virus A and B. The 
application of equine influenza virus rRT-PCR to the diagnosis of canine influenza virus 
was also discussed. These molecular diagnostic assays were compared with conventional 
diagnostic tests and the advantage and disadvantage of each molecular method were 
discussed.  Each assay was evaluated using a large amount of clinical specimens.  Taken 
overall the assays that were developed were found to be highly sensitive and specific for 
the respective target viruses. Each had a very short turnaround time.  They provide fast 
and realible techniques for diagnosticians to use as diagnostic as well as confirmation 
tests.  Based on currently available rRT-PCR assays, we could develop a multi-plex rRT-
PCR for all these common equine respiratory viruses in the future.  This should provide a 
much simipler and rapid means of diagnosing multiple viral pathogens in a single 
reaction.  However, optimization of a multi-plex rRT-PCR is critical to establish the 
sensitivity and specificity of the assay before it can be used in a diagnostic setting. 
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 The second part of this dissertation is focused on the role of viral envelope 
proteins of EAV that might be involved in cellular tropism determination and host cell 
interaction.  At this proint, neither a virus attachment molecule nor a specific cell receptor 
has yet been identified for EAV.  It has been assumed that the major envelope proteins 
GP5 and M may determine the cellular tropism of EAV based on the fact that these two 
proteins carry neutralization antibody epitopes.  Using an infectious cDNA clone of the 
modified live virus (MLV) vaccine (ARVAC®) of EAV (prMLVB), we generated a panel 
of 6 recombinant chimeric viruses by replacing either the full-length or the N-terminal 
ectodomains of GP5 and M proteins of EAV with the IA-1107 North American strain of 
PRRSV, a member of the genus Arterivirius which has very narrow cellular tropism. The 
recombinant viruses expressing the N-terminal ectodomain of PRRSV GP5 alone or M 
alone or both (GP5ecto, Mecto, and GP5&Mecto, respectively) in the EAV backbone 
were viable and genetically stable. Compared to the parental virus, these three chimeric 
viruses produced lower titers and smaller plaque sizes indicating that they have a 
compromised phenotype.  The three chimeric viruses could only infect EAV susceptible 
cell lines but not PRRSV susceptible cells.  Therefore, the two major envelope proteins 
may not be determining factors in the cellular tropism of EAV.  However, in light of the 
lack of an effective PRRSV vaccine, these chimeric viruese might be good candidates to 
inoculate pigs and check their immunogenic kinetics. The marker prMLVB vaccine could 
be easily differentiated serologically between naturally infected animals and vaccinated 
animals. Although GP5 and M were not involved in cellular tropism determination, they 
were important in interaction with a heparin-like molecule on the surface of EECs, 
playing a siginificant role in EAV infection of equine endothelial cells.  Using heparin-
affinity chromatography and SDS-PAGE analysis, five structural proteins of EAV, E, 
GP2, GP5, M and N were identified as heparin-binding proteins. A specific heparin-
binding domain on E protein was found on the C-terminus of the protein.  Using site-
directed mutagenesis, five basic arginine residues were mutated to glycine and the growth 
characteristic of the mutant viruses and heparin binding capacity were investigated.  A 
double mutant R52,60G completely blocked the interaction with heparin but still 
replicated similar to the wild type virus control, indicating that another attachment 
molecule may exsit.  The triple mutant R52,60, 65G had very tiny plaque morphology on 
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EECs suggesting that the spread of the mutant virus had been affected.  These studies are 
valuable data in providing a better understanding the initial attachment step of EAV to its 
natural host cell, which is critical in appreciating the pathogenesis of the virus.   
 Collectively, the development of diagnostic methods for specific equine viral 
respiratory pathognes and investigation of the role of selected proteins of EAV on viral 
attachment to the cell are important in disease control and prevention.  This dissertation 
will benefit both equine practitioner and research scientist involving in the field of equine 
infectious disease.   
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APPENDIX 1 
 
List of Abreviations 
 
aa  Amino acid 
ACE2  Angiotensin-converting enzyme 2 
APN  Aminopeptidase N   
Arg  Arginine 
Asp  Aspartate 
BHK-21  Baby hamster kidney-21 
bp  base pair 
cDNA  Complementary deoxyribonucleic acid 
CEACAM carcinoembryonic antigen-related cell adhesion molecule 
CI  Canine influenza 
CIV  Canine influenza virus 
CMC  Caboxylmethyl cellulose  
CoV  Coronavirus  
CPE  Cytopathic effect  
Ct  Cycle threshold 
Cys  Cysteine 
DMV  Double membrane vesicle 
DNA  Deoxyribonucleic acid 
Dpi  Days post infection   
Ds  Double stranded 
E  Envelope protein 
EAV  Equine arteritis virus  
EAdV  Equine adenovirus 
EDTA  Ethylenediaminetetraacetic acid 
EEC  Equine endothelial cells 
EHV  Equine herpes virus  
eGFP  Enhanced green fluorescence protein 
EI  Equine influenza 
EIV  Equine influenza virus 
ELISA  Enzyme-linked immunosorbent assay 
EM  Electron microscope 
EMPF  Equine multinodular pulmonary fibrosis 
EPAEC  Equine pulmonary artery endothelial cells 
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ERAV  Equine rhinitis virus A 
ERBV   Equine rhinitis virus B 
ER  Endoplasmic reticulum 
ERGIC  ER-Golgi intermediate complex 
ERV   Equine rhitnis virus 
EtBr  Ethidium bromide 
EToV  Equine Torovirus 
EU  European 
EVA  Equine viral arteritis 
FIPV  Feline infectious peritonitis virus 
FRET  Fluorescence resonance energy transfer 
GAD  Glutamate decarboxylase 
GAG  Glycosaminoglycan 
GFP  Green fluorescent protein 
Gly  Glycine 
GP  Glycoprotein 
HA  Hemagglutinin 
HEL  Helicase 
Hela  human cervix cells 
HEK  Human embryonic kidney 
His  Histadine 
HIV  Human immunodeficiency virus 
HK  Horse kidney 
HMPV  Human metapneumovirus 
IEM  Immune electron microscope 
IF  Immunoflourescence 
IVT  In vitro transcription 
kDa  kilodalton 
LDV  Lactase dehydrogenase-elevating virus 
L-M  Mouse connective tissue 
LNA  Locked nucleic acid 
LSECtin  Lymph node sinusoidal endothelial cell C-type lectin 
M  Membrane protein 
MAb  Monoclonal antibody 
MDBK  Madin-Darby bovine kidney 
MGB  Minor-groove binding 
MHV  Murine hepatitis virus 
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MLV  Modified live virus 
MOI  Multiplicity of infection 
mRNA  Messenger RNA 
MW  Molecular weight 
N  Nucleocapsid protein 
NA   Neurominidase 
NC  Nucleocapsid 
NP  Nucleoprotein 
Nsp  Nonstructural protein 
NTR  Nontranslated region 
OIE  World Organisation for Animal Health 
ORF  Open reading frame 
PAM  Porcine alveolar macrophage 
PCP  Papain-like cysteine protease 
PCR  Polymerase chain reaction 
PFU  Plaque forming unit 
pp  Polyprotein  
PRRS  Porcine reproductive respiratory syndrome 
PRRSV  Porcine reproductive respiratory syndrome virus 
qrRT-PCR quantitative real-time reverse-transcription PCR 
PSCID  Primary severe combined immunodeficiency disease 
RdRp  RNA-dependent RNA polymerase 
RFS  Ribosomal frameshift 
RK  Rabbit kidney 
RK-13  Rabbit kidney-13 
rMLV  recombinant MLV 
RNA  Ribonucleic acid 
RT-PCR  Reverse transcription-polymerase chain reaction 
rRT-PCR Real time reverse transcription-polymerase chain reaction 
rVBS  recombinant VB strain 
SARS  Severe acute respiratory syndrome 
SARS-CoV Severe acute respiratory syndrome coronavirus 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Ser  Serine 
sg mRNA Subgenomic mRNA 
SHFV  Simian hemorrhagic fever virus 
SNP  Single nucleotide polymorphism  
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SP  Serine protease  
ss  Single stranded 
TCF  Tissue culture fluid  
TCID50  50% tissue culture infective dose 
TGEV  Transmissible gastroenteritis virus 
Thr  Threonine  
Tm  Melting temperature 
TRS  Transcription regulation sequence 
UTR  Untranslated region 
VB  Virulent Bucyrus 
VBS  Virulent Bucyrus strain  
Vero  African green monkey kidney 
VI  Virus isolation 
VN  Virus neutralization 
VNT  Virus neutralization test 
VP  Viral protein 
VRP  Venezuelan equine encephalitis virus replicon particle  
ZBD  Zinc-binding domain  
ZF  Zinc finger 
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APPENDIX 2 
 
Experimental Methods 
 
REAL TIME RT-PCR TECHNIQUES 
 
PRIMER AND PROBE DILUTION 
Orders from Applied Biosystems (Now Lifetechnologies)  
Primers: 
1. Quickly spin down the primer tube to make sure that powder is on the botttom. 
2. In PCR work station, add sterile nuclease-free water (store at -4C fridge in Room 440) to dissolve the 
powder. 
3. Put the tube into the shaker for half an hour to completely dissolve primer. Aliquote primer into 40?l/epp 
and freeze at -20C 
 
Primer ID 
Taqman 
Primer mass 
(pmols) 
?mol 
Working stock 
solution 50 ?molar 
(?M) in liters (L) 
Working stock solution 
50 ?M in ml 
Resuspend the 
primer in nuclease-
free water (?l) to 
get 50?M working 
stock 
Example 119000 0.119 0.00238 2.38 2380 
EAV 10F 10000 0.01 0.0002 0.2 200 
EqFlu NP F 80000 0.08 0.0016 1.6 1600 
 
Probes: 
1. After thawing, quickly spin down the probe tube to remove drops from the inside of the lid. 
2. Add stock probe into 1X TE buffer (store at -4C fridge in Room 440) in PCR hood room 446 Vortex 
completely.  
3. Spin down. Aliquote 60?l/epp and freeze -20C Rm 440 
4. Try to limit the time exposure to the light. 
5. NOTE: 1× TE buffer: 1mM Tris, 0.1mM EDTA, pH 8.0) 
 
probe ID 
Original  
Stock Pmol 
Original stock 
volumn (uL) 
Concentration 
Working 
stock of 10 
?M 
Add ?l of stock 
solution into 1X TE 
(1mM Tris, 0.1mM 
EDTA, pH8.0) to get 
10?M working stock 
Example 6000 60 100 µM 1:10 540 ?l 
EAV 7.92P 20000 200 100 ?M 1:10 1800 ?l 
ERAV 6000 60 100 µM 1:10 540 ?l 
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Orders from Bioresearch Technologies 
Primers and probes for swine influenza virus H1N1 subtype were obtained from Bioreseaerch Technologies.  
Primers 
1. See the lable on the tube, for example, if the tube has 15 nmol, 15*10=150. So add 150 ul of H2O 
to get 100 uM. 
2. To be consistent with ABI 50 uM working stock, in such case (15 nmol primer), we need to 
disolve in 300 ul of H2O. 
Primer ID nmol (from lables) 
Add ul of H2O to 
get 100 µM 
To be consistent 
with ABI 
condition, add ul 
of H2O to get 50 
µM 
NH1 forward 39.23 392.3 784.6 
NH1 reverse 39.83 398.3 796.6 
Aliquote 400 ul each for primers 
 
Probes 
1. Probes will be provided as 10 nmol pure powder. (This number is fixed for all the probes received, 
unlike primers) 
2. Dissolve in 100 µl H2O or TE (preferred) to get 100 µM probe. To be consistent with ABI 10 µM 
working stock, the probes are actually dissolve in 1000 µl TE buffer. 
3. NOTE: The TE buffer in Bioresearch Technolgies is 10 mM Tris.HCl/1mM EDTA, pH 8.0, which 
is different from the TE buffer used in ABI probe dilution 
10 mM Tris/1mM EDTA buffer dilution 
Stock need 
dilution 
factors 
solution 
 
1 M Tris pH 8.0 10 mM Tris x100 10 ul 
0.5 M EDTA pH 8.0 1 mM EDTA x 500 2 ul in 988 ul H2O  
 
 
Probe ID 
nmol (fixed 
amount, 
powder) 
Add ul of TE buffer (10 mM Tris.HCl/1mM EDTA, pH 
8.0, from company flyer came with the order) to get 10 
uM working stock 
NH1 probe 10 1000 
Aliquote 100 ul each for probes 
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Orders from Operon  
1. Primers and probes diluted in water as indicated in the product sheets. Here is one example.  
2. To further make 50 µM working stock primers and 10 µM working stock probes, the primes and 
probes were further diluted 1:2 or 1:10 for primer and probes, respectively. The 50 µM primer and 
10 µM probe concentrations are the same of ABI concentration.  
 
 
EMD REAL-TIME PCR REAGENT KIT ASSEMBLY 
1. Equine influenza virus, equine rhinitis virus and swine influenza virus H1N1 use the Taqman One-
step RT-PCR reagents (Life Techonologies, 4309169). This kit contains two components: 2 × 
master mix (5 ml) and 40 × multiscribe reverse transcriptase and RNase inhibitor mix (250 µl). 
2. Equine arteritis virus use the QuantiFast™ Probe RT-PCR kit (Qiagen, 204554). This kit contains 
RT-PCR master mix, ROX dye. 
 
For equine influenza kit: 
Kit Name EMD FluDetectNP® 
Catalogue Number EMD-001 
Quantity 60 reactions  
Kit information  TaqMan® One-Step RT-PCR Master Mix Reagents Kit (ABI 4309169) (store at -
20C freezer in RM 440) 
The kit contains: 
2X master mix: 5 ml 
40X Multiscibe reverse transcriptase and Rnase Inhibitor mix: 250 ul 
?
Product Information  
Components #1 EqFlu RT-PCR Master Mix (1 vial)--Need to aliquot from the ABI kit (the 
tube containing 2x master mix) 
#2 EqFlu Inhibitor Mix (1 vial)-- Need to aliquot from the ABI kit (the tube 
containing 40 X multriscribe reverse transcriptase and RNase Inhibitor mix) 
#3 EqFlu Primers and Probe Mix (1 vial)-- Need to mix primer and probes (-20ºC 
freezer Rack 1 boxes “Eq influenza real-time PCR probe general” and “Eq 
influenza real-time PCR primer general”)  
Tube #   Seq 5' to 3' OD Vol.ul nmol ug MW Tm Scale 
Add x µl 
H2O for 100 
µm 
1 AHSNS1FW08 
GTTGACCTCGCTC
TGCTTGAC 16.8 dry 93.2 592.9 6364.2 64.5 50nmol 932 
2 AHSNS1REV08 
AATCGCTTCCTTC
GTTGTATGAC 18.8 dry 90.8 634.1 6980.6 61 50nmol 908 
3 AHSNS1Prb08 
[6~FAM]TCCCAGT
GGTTGATTCAAA
AGTTGC[BHQ1a~6
FAM] 3.1 dry 11.5 100.8 8764.1 62.9 50nmol 115 
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#4 Nuclease Free water (1 vial) 
#5 EqFlu Positive Control RNA (1 vial) )—in Room 423 (centrifuge room) -80C 
freezer, Box “EIV positive control RNA” 
Recommended Use Detection of equine influenza virus nucleic acid in nasal secretions 
Features and Benefits  
Declaration Kit components are assembled in the Molecular Virology Laboratory at the 
Gluck Equine Research Center  
?
Components Volume per 
reaction (µl) 
Volume for 70 
reactions (µl) 
#1 RT-PCR Master Mix  12.5 875 
#2 Inhibitor Mix 0.625 43.75 
#3 Primers and Probe Mix (total 
1.525 ul/rxn) 
NP F Primer 
0.45  
31.5 
 
NP R Primer 
0.45 
31.5 
NP Probe  
0.625 
43.75 
 
#4 Sterile Water 5.35 500 ul 
Mix 20  
 RNA 5  
Total Volume per reaction 25  
?
Probe setting: 
Reporter Dye: FAM 
Quencher Dye: None  
 
Thermal Cycler Conditions: (Applied Biosystems 7500 Fast Real-time PCR machine, use Standard 
Mode) 
Reverse Transcription 48°C for 30 minutes 
Predenaturation   95°C for 10 minutes 
40 Cycles 
Denaturation  95°C for 15 seconds 
   60°C for 1 minute  
?
?
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For swine influenza H1N1 kit: 
Kit Name EMD SwineFlu H1N1  
Catalogue Number EMD-003 
Quantity 60 reactions  
 
Product Information  
Components #1 RT-PCR Master Mix (1 vial, 750 µl) 
#2 Inhibitor Mix (1 vial, 37.5 µl) 
#3 Primers and Probe Mix (1 vial, 91.5 µl) 
#4 Nuclease Free water (1 vial, 500 µl) 
#5 Control RNA (1 vial, 20 µl, Ct ?20) 
Recommended Use Detection of swine influenza virus H1N1 (2009) virus 
Features and Benefits Rapid detection of swine influenza virus nucleic acid in clinical specimens 
Declaration Kit components are assembled in the Molecular Virology Laboratory at the 
Gluck Equine Research Center  
 
Shipping and Storage  
Information 
 
Storage With the exception of control RNA (component #5), save all other components at 
-20°C (do not use a frost free freezer).  Component # 5 should be stored at -80°C.  
Expiration Date One year from the date of shipment 
Shipping Shipped on dry ice 
 
Components Volume per 
reaction (µl) 
Volume for 60 
reactions (µl) 
#1 RT-PCR Master Mix  12.5 750 
#2 Inhibitor Mix 0.625 37.5 
#3 Primers and Probe Mix (total 
1.525 µl/reaction) 
NH1 Forward 
0.45 
27 
NH1 Reverse 
0.45 
27 
NH1 Probe 
0.625 
37.5 
#4 Sterile Water 5.35 321 
               Mix 20 1200 
 RNA 5  
          Total Volume per Reaction 25  
 
Probe setting: 
Reporter Dye: FAM 
Quencher Dye: None  
 
Thermal Cycler Conditions: (Applied Biosystems 7500 Fast Real-time PCR machine, use Standard 
Mode) 
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Reverse Transcription 48°C for 30 minutes 
Predenaturation   95°C for 10 minutes 
40 Cycles 
Denaturation  95°C for 15 seconds 
   60°C for 1 minute  
 
For equine arteritis virus kit: 
Kit Name EMD EAVDetectN® 
Catalogue Number EMD-002 
Quantity 60 reactions  
Kit information  QuantiFast™ Probe RT-PCR Kit (QIAGEN,204554) (store at -20C freezer in 
RM 440) 
 
Product Information  
Components #1 EAV RT-PCR Master Mix (1 vial)—Need to aliquot from the QIAGEN kit 
#2 Primers Probes and ROX Mix (1 vial)—Need to mix primer probes (-20C 
freezer at RM 440, Rack 1 boxes named as “EAV primer 50 uM real-time PCR” 
and “Real-time probe stock 10 uM” and ROX dye (from the QIAGEN kit) 
#3 Nuclease Free water (1 vial) 
#4 Control RNA (1 vial)—in Room 423 (centrifuge room) -80C freezer, Box 
“EAV positive control RNA” 
Recommended Use Detection of equine arteritis virus nucleic acid in semen and tissue culture fluid 
Declaration Kit components are assembled in the Molecular Virology Laboratory at the 
Gluck Equine Research Center  
 
Components Volume per 
reaction (µl) 
Volume for 62 
reactions (µl) 
#1 RT-PCR Master Mix  12.75 790.5 
#2 Primers Probe and ROX Mix 
(total 1.8 ul/rxn) 
7.53 F Primer 0.4 
x60 = 24 
24.8 
 
7.256 R Primer 
0.4*60=24 
24.8 
 
7.92 Probe  
0. 5*60=30 
31 
50x ROX Dye 
0.5*60=30 
31 
#3 Sterile Water 5.45 500 ul 
               Mix 20  
 RNA 5  
          Total Volume per Reaction 25  
 
Probe setting: 
Reporter Dye: FAM 
?? Ł  
Quencher Dye: TAMRA  
 
Thermal Cycler Conditions: (Applied Biosystems 7500 Fast Real-time PCR machine, use Standard 
Mode) 
Reverse Transcription 48°C for 30 minutes 
Predenaturation   95°C for 10 minutes 
40 Cycles 
Denaturation  95°C for 15 seconds 
   60°C for 1 minute  
 
For canine influenza virus mix: 
Reagent 
Working 
Stock 
Concen 
Volume per 
Reaction(?l) 
Final 
Concentration 
# n 
reactions 
2X Master  Mix without 
UNG 
2X 12.5 1X 12.5 x n 
40X MultiScribe and RNase 
Inhibitor Mix 
40X 0.625 
0.25U/?l    
0.4U/?l 0.625 x n 
EqFlu NP F 50 ?M 0.45 900nM 0.45 x n 
EqFlu NP R 50 ?M 0.45 900nM 0.45 x n 
EqFlu NP MGB Probe 10 ?M 0.625 250 nM 0.625 x n 
Sterile Water 5.35 5.35 x n 
MASTER PREMIX  20 20 x n 
RNA  5 
Total 25 
 
Probe setting: 
Reporter Dye: FAM 
Quencher Dye: None  
 
Thermal Cycler Conditions: (Applied Biosystems 7500 Fast Real-time PCR machine, use Standard 
Mode) 
Reverse Transcription 48°C for 30 minutes 
Predenaturation   95°C for 10 minutes 
40 Cycles 
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Denaturation  95°C for 15 seconds 
   60°C for 1 minute  
 
HOTSTART PCR TO AMPLIFY GENE FROM PLASMID FOR PCR CLONING 
 
Components Volume (ul) # of Reactions 
10x PCR Buffer (with 15 mM 
MgCl2) 5.0 5 25 
25 mM MgCl2 (to get final 
conc. 2.5 mM) 2.0 5 10 
dNTP Mix (10 mM of each 
dNTP) 1.0 5 5 
QIAGEN HotStart DNA 
Polymerase 0.3 5 1.25 
RNase free water 38.3 5 191.25 
Master Mix Volume (ul) 46.5 232.5 
Aliquot 46.5 ul into reaction 
tubes 
Master Mix Per Reaction (ul) 46.5 
Primer 1 0.5 
EAV 12069P (12069-
12088) 
upstream of 
ORF7 
Primer 2 0.5 
EAV 12750N (12729-
12750) 
downstream 
ORF7 
Template DNA (ul) 2.5 
Total Volume (ul) 50.0 
Tube # EHV Primer pair 
Volumn 
(ul) Size (bp) 
EAV    1 
DNA plasmid 
pEAV2421/211 1 1 681 
2 
(from JQ, store in -20C freezer 
Rm416) 2 1 681 
3 "Zhengchun cDNA box" 3 1 681 
4 4 1 681 
Thermal Cycler Conditions: 
Initial activation step 95C/15 min. 
3-step cycling (35 cycles) 
Denaturation 94C/30 sec. 
Annealing gradient T/30 sec. 
#1 43.1C  #2 45C #3 
48.4C #4 49.9C  
Extension 72C/1 min. 
Final extension 72C/ 10 min. 
 
The PCR product will be used for ligation in pDrive cloning vector to calculate IVT RNA molecule 
numbers.  
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pDRIVE VECTOR CLONING FOR IVT RNA MOLECULE CALCULATION (Qiagen PCR 
cloning kit, 231122) 
Important notes before starting 
• Use of PCR products generated with proofreading DNA polymerases (i.e., DNA polymerases with 3'-5' 
exonuclease activity) will dramatically lower ligation efficiency as these PCR products do not have an A 
overhang. 
• We recommend using a molar ratio of 5–10 times more PCR product DNA than pDrive Cloning Vector 
DNA for ligation (Table 2). However, less PCR product may also be sufficient. PCR products can be 
concentrated using MinElute™ Kits. 
• Purification of PCR products prior to ligation (e.g., using QIAquick® or MinElute PCR 
Purification or Gel Extraction Kits) is optional but recommended, as this will generally result in higher 
transformation efficiency. See “Purification of PCR products” (Appendix, page 23). 
• The 5'-terminal base of the PCR primers can affect addition of an A overhang to PCR products by non-
proofreading DNA polymerases. See “Effect of the 5'-terminal base of PCR products on cloning efficiency” 
(Appendix, page 21). 
• Background colonies may appear following transformation if the PCR template was plasmid DNA 
containing a resistance gene for the antibiotic used for colony selection (i.e., an ampicillin- or kanamycin-
resistance gene). In these cases the PCR product should be gel-purified prior to ligation to remove template 
plasmid DNA. Gel-purification can be avoided by using kanamycin for selection if the template plasmid 
contains the ampicillin-resistance gene, and vice versa. 
• If electrocompetent cells will be used instead of QIAGEN EZ Competent Cells for transformation, we 
strongly recommend inactivating the ligase prior to electroporation by incubating the ligation-reaction 
mixture for 10 min at 70°C (see protocol step 4). 
 
Table 2. Guide for the amount of PCR product to use in the ligation reaction 
                                             Amount of PCR product to use in the ligation reaction 
PCR product size                 5-times molar excess*        10-times molar excess* 
          100 bp                                     6.5 ng                                     13 ng 
          200 bp                                      13 ng                                     26 ng 
          500 bp                                    32.5 ng                                   65 ng 
          1000 bp                                    65 ng                                    130 ng 
          1500 bp                                    97.5 ng                                 195 ng 
          2000 bp                                    130 ng                                  260 ng 
          3000 bp                                    195 ng                                  390 ng 
* Calculated for 50 ng pDrive Cloning Vector using the following equation: 
ng PCR product required = 50 ng x PCR product size (bp) x molar ratio 
3851 bp 
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Procedure 
1. Thaw 2x Ligation Master Mix, pDrive Cloning Vector DNA, and distilled water (provided). Place 
on ice after thawing. 
It is important to mix the solutions completely before use to avoid localized concentrations of salts. Keep 
2x Ligation Master Mix on ice and immediately store at –20°C or –70°C after use. 
2. Prepare a ligation-reaction mixture according to the following scheme: 
Component                                             Volume/reaction 
pDrive Cloning Vector (50 ng/?l)                       1 ?l 
PCR product                                                        1–4 ?l* 
Distilled water                                                      variable 
Ligation Master Mix, 2x†                                      5 ?l 
Total volume                                                       10 ?l 
* Purified PCR product. If using non-purified PCR product, do not add more than 2 ?l PCR product. 
† We recommend adding the Ligation Master Mix last. 
3. Briefly mix the ligation-reaction mixture then incubate for 30 min at 4–16°C (e.g., in a refrigerator, 
water bath, or thermal cycling block). 
Mix gently, for example by pipetting the ligation-reaction mixture up and down a few times. 
Note: Increasing the ligation time to 2 h can result in a 2–3 fold increase of recombinants. 
This might be especially useful for PCR fragments longer than 2 kb. If the total number of recombinants is 
not essential, however, the ligation time can be as short as 15 min. 
4. Proceed with the transformation protocol (page 14) or store ligation-reaction mixture at –20°C 
until use. 
IMPORTANT: The transformation protocol on page 14 is for use with QIAGEN EZ Competent Cells. If 
electrocompetent cells will be used, we strongly recommend inactivating the ligase in the ligation-
reaction mixture prior to electroporation. 
Incubate the ligation-reaction mixture for 10 min at 70°C, then proceed with electroporation. Alternatively, 
the MinElute Reaction Cleanup Kit can be used to remove ligase from the ligation-reaction mixture. The 
ligase does not need to be inactivated when using QIAGEN EZ Competent Cells. 
 
QIAGEN PCR Cloningplus Kit Transformation Protocol 
Important notes before starting 
• This protocol is for use with QIAGEN EZ Competent Cells. It is not for use with 
electrocompetent cells. If electrocompetent cells will be used, we strongly recommend inactivating the 
ligase in the ligation-reaction mixture prior to electroporation. See step 4 of the ligation protocol (page 13) 
for details. 
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• Competent cells are extremely sensitive to temperature and mechanical stress. Do not allow QIAGEN 
EZ Competent Cells to thaw at any point prior to transformation. Keep thawed cells on ice. Avoid 
excessive and/or rough handling, especially pipetting. Mix cells by gentle flicking. 
• Thaw SOC medium and warm to room temperature. Store at –20°C or –70°C after use. 
• Prepare fresh LB agar plates containing either ampicillin (100 ?g/ml LB agar) or kanamycin (30 ?g/ml 
LB agar) as a selection marker. Include IPTG (50 ?M) and X-gal (80 ?g/ml) for blue/white screening of 
recombinant colonies. See Appendix (page 27) for recipes. 
Procedure 
1. Thaw the appropriate number of tubes of QIAGEN EZ Competent Cells on ice. Thaw SOC 
medium and warm to room temperature. 
IMPORTANT: Competent cells should only be thawed on ice. Do not allow unused 
QIAGEN EZ Competent Cells to thaw. Test whether cells are thawed by gently flicking the tube. Proceed 
immediately to the transformation step once the cells have thawed. 
2. Add 1–2 ?l ligation-reaction mixture per tube of QIAGEN EZ Competent Cells, mix gently, and 
incubate on ice for 5 min. 
Mix gently, for example by flicking the transformation mixture a few times. 
3. Heat the tube(s) in a 42°C water bath or heating block for 30 s without shaking. 
4. Incubate the tube(s) on ice for 2 min. 
5. Add 250 ?l room temperature SOC medium per tube and directly plate 100 ?l each 
transformation mixture onto LB agar plates containing ampicillin. 
Note: For kanamycin selection, incubate the cells at 37°C for 30 min with shaking prior to plating to allow 
recombinant outgrowth. 
The transformation mixture can be plated using a sterile bent glass rod or a specialized spreader. It is 
generally recommended to plate different amounts of each transformation mixture onto separate plates (e.g. 
100 ?l and 20 ?l) to ensure good separation of colonies for subsequent single-colony isolation. For more 
efficient plating of small volumes of transformation mixture (<50 ?l) we recommend pipetting 100 ?l LB 
medium onto the plate, and then pipetting the transformation mixture into the liquid LB. 
6. Incubate the plate at room temperature until the transformation mixture has absorbed into the 
agar. Invert the plate and incubate at 37°C overnight (e.g., 15–18 h). 
Note: For blue/white screening, we recommend a second incubation at 4°C (e.g. in a refrigerator) for a few 
hours. This “cold” incubation step enhances blue color development and thereby facilitates differentiation 
between blue colonies and white colonies. 
?
GENERATION RECOMBINANT VIRUS FROM IN VITRO TRANSCRIBED RNA 
 
A. PURIFICATION OF LINEARIZED PLASMID 
 
1. Linearization of plasmid EAV infectious cDNA clone. Digestion of each plasmid DNA with Xho I to 
linearize the plasmid DNA. 
                Plasmid DNA                                   35.0 ?l 
           Xho I   (40U/?l, Roche)                    1.0 ?l 
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              Buffer H (10x) (Roche)                    4.0 ?l 
             Total:                                                40.0 ?l 
Prepare 1 digestion reaction for each plasmid DNA. Incubate at 37?C for 2 hours. 
 
2. Run 1 ?l digested plasmid DNA on 1% agarose gel to make sure that the plasmid DNA is linearized. 
        Digested plasmid DNA         1.0 ?l 
        6x loading buffer                   2.0 ?l 
        nuclease free water                9.0 ?l 
        Total:                                    12.0 ?l---------loading amount per well 
Run 12 ?l 1 kb DNA ladder (Invitrogen) 
 
3. Add 2 ?l of 20 mg/ml Proteinase K (Ambion) and bring the volume to 200 ?l with nuclease free water 
and incubate at 37?C for 30 min. 
 
4. 2? phenol chloroform extract and precipitate the DNA with 100% ethanol. 
 -  add 200 ?l of phenol : chloroform : isoamyl alcohol (25:24:1) (Cat # P3803, Sigma) and mix until an 
emulsion is formed 
- centrifuge at 13,000 rpm for 4 min at room temperature 
- remove 180 ?l of the upper aqueous phase into a new tube 
- add 180 ?l of phenol : chloroform : isoamyl alcohol (25:24:1) and repeat the extraction 
- remove 160 ?l of the upper aqueous phase into a new tube 
- add 500 ?l of 100% ethanol and 16 ?l of 3M sodium acetate to the DNA sample 
- mix and centrifuge at 13,000 rpm for 10 min 
 
 
5. Wash with 140 ?l of 70% ethanol. Spin at 13,000 rpm for 4 min. Aspirate the 70% ethanol and dry on 
the bench for 4-5 min. 
 
6. Resuspend the pellet in 32 ?l of nuclease free water and run 1 ?l on gel. 
        Phenol chloroform extracted linearized plasmid DNA     1.0 ?l 
        6x loading buffer                                                               2.0 ?l 
        nuclease free water                                                            9.0 ?l 
        Total                                                                          12.0 ?l---------loading amount per well 
 
 
B.  IN VITRO TRANSCRIPTION 
1. Prepare in vitro transcription reactions as follows. For linear DNA, rNTPs, BSA, DTT, 5 x 
transcription buffers, and cap analog, thaw them out at room temperature. Mix well before use. Always 
leave RNA guard RNase inhibitor and T7 RNA polymerase on ice. Use XhoI-linearized and phenol-
chloroform purified plasmid DNA  
 
        Master mix for in vitro transcription 
Linear DNA   15.0 µl 
 rNTPs mix (10mM each)    5.0 µl 
 BSA (1mg/ml)     5.0 µl 
 100 mM DTT     2.5 µl 
 5X T7 Transcription buffer 10.0 µl  
 Cap analog (10mM)    5.0 µl 
RNA guard RNase Inhibitor    2.5 µl 
 T7 RNA polymerase                 2.5 µl 
 Nuclease free water     2.5 µl 
     50.0 µl 
 Incubate at 37ºC for 2 hours. 
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2. Wash electrophoresis unit (electrophoresis tank, gel cast and running trays, comb) thoroughly with 
detergent. Then rinse thoroughly with dH2O. Spray electrophoresis unit with RNaseZap, then rinse 
thoroughly with dH2O. Let it air dry. 
3. Prepare 1x TAE buffer.  Cast 0.8% agarose gel. 
4. After 1 h of in vitro transcription at 37ºC, run 2 µl of in vitro transcribed RNA on a 0.8% agarose gel.  
  TE Buffer (pH=7.2)  8.0 µl 
  10%SDS   1.0 µl 
  0.5M EDTA (pH=8.0)                    0.25 µl 
? ? RNA                 2.0 µl 
 
 - place mix at 70ºC for 2 minutes and then place on ice for 2 minutes   
 - add 2.25 µl of 6X gel loading buffer 
- load 13.5 µl mixtures to each well of the gel. Run the gel at 90V. 
 
5. Check the gel under UV light. 
6. Measure RNA concentration with spectrophotometry. 
7. Dilute 2 ?l in vitro transcribed RNA into 198 ?l nuclease-free water and measure A260. Use nuclease-
free water as blank control. 
 
IVT RNA MOLECULE CALCULATIONS 
? Template: IVT RNA pDriveClone/NY/73/NVSL M product  (5.1; 12-28-7, aliquot 1)  
438.4 ug/ml ? 430 ng/ul (12-28-7)  
Size: 4359 bp    
Eq pDrive-Flu/NY/73/NVSL M RNA molecular weight = 1402612.8g = 1.4026x106g 
(1161A*329.2 + 1017C*305.2+ 1078G*345.2+ 1103U*306.2+159 (for 5’ triphosphate)) 
? Avogadro-number is 6.022x1023 
? Y (No of molecules per ul) = (Avogadro x concentration g/ul)/ molecular weight  
 = (6.022x1023 x 430 x10-9 g/ul)/ 1.4026x106g 
 = 1.846x 1011 molecules/ul ? 1.0 x 1011 molecules/ul  
Copy # (within the 5ul to 
RT-PCR) 
* 5 ?L 
Stock concentration of IVT RNA 
(molecules/?l) 
1010 5x1010 
109 5x109 
108 5x108 
107 5x107 
106 5x106 
105 5x105 
104 5x104 
103 5x103 
102 5x102 
101 5x101 
? Serial dilution: 
? Prepare dilution buffer [44ul H2O+5ul 1mg/ml acetylated BSA (promega) +1ul RNase guard 
(pharmacia)] to stabilize RNA: 
? 880ul H2O + 100ul 1mg/ml BSA + 20 ul RNase guard=1000 ul stabilization buffer 
(calculation based on IVT RNA and EAV one-step RT-PCR protocol)  
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1010 copies: 2 ul of IVT RNA pDriveClone/NY/73/NVSL M product stock 1.0 x 1011 molecules/ul into 98 
ul RNA STABILIZATIONBUFFER 
       final concentration is 1.0*100*2/100= 2x 109 molecules/ul  
       take 5ul out of 2x 109 molecules/ul into real time PCR well to get 1010 copies 
 109 copies: 10ul of 1010 copies stock+ 90 ul RNA STABILIZATIONBUFFER 
         final concentration is 10*2x 109/100= 2x 108 molecules/ul 
         take 5ul out of 2x 108 molecules/ul into real time PCR well to get 109 copies 
 108 copies: 10ul of 109 copies stock+ 90 ul RNA STABILIZATIONBUFFER 
         final concentration is 10*2x 108/100= 2x 107 molecules/ul 
         take 5ul out of 2x 107 molecules/ul into real time PCR well to get 108 copies 
 107 copies: 10ul of 108 copies stock+ 90 ul RNA STABILIZATIONBUFFER 
         final concentration is 10*2x 107/100= 2x 106 molecules/ul 
         take 5ul out of 2x 106 molecules/ul into real time PCR well to get 107 copies 
106 copies: 10ul of 107 copies stock+ 90 ul RNA STABILIZATIONBUFFER 
         final concentration is 10*2x 106/100= 2x 105 molecules/ul 
         take 5ul out of 2x 105 molecules/ul into real time PCR well to get 106 copies 
 105 copies: 10ul of 106 copies stock+ 90 ul RNA STABILIZATIONBUFFER 
         final concentration is 10*2x 105/100= 2x 104 molecules/ul 
         take 5ul out of 2x 104 molecules/ul into real time PCR well to get 105 copies 
104 copies: 10ul of 105 copies stock+ 90 ul RNA STABILIZATIONBUFFER 
         final concentration is 10*2x 104/100= 2x 103 molecules/ul 
         take 5ul out of 2x 103 molecules/ul into real time PCR well to get 104 copies 
103 copies: 10ul of 104 copies stock+ 90 ul RNA STABILIZATIONBUFFER 
         final concentration is 10*2x 103/100= 2x 102 molecules/ul 
         take 5ul out of 2x 102 molecules/ul into real time PCR well to get 103 copies 
102 copies: 10ul of 103 copies stock+ 90 ul RNA STABILIZATIONBUFFER 
         final concentration is 10*2x 102/100= 2x 101 molecules/ul 
         take 5ul out of 2x 101 molecules/ul into real time PCR well to get 102 copies 
101 copies: 10ul of 102 copies stock+ 90 ul RNA STABILIZATIONBUFFER 
         final concentration is 10*2x 101/100= 2x 100 molecules/ul 
         take 5ul out of 2x 100 molecules/ul into real time PCR well to get 101 copies 
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TRANSFECTION OF BHK21 CELLS WITH ELECTROPORATION 
 
Preparation of cells 
 
1. Make sure to use cells that are not confluent. Typically a flask of BHK21 cells were split 1:4 two days 
before planning to do the electroporation. One T-150 cm2 flask of BHK21 cells will be used for 2 
electroporations.  
2. Aspirate the medium from T-150 flasks of subconfluent BHK21 (P67) cells. Wash cells twice with 
PBS. Add 4 ml ATV to each T-150 flask. Shake for 30 sec. Let it sit at room temperature for 1 min. 
Then remove the ATV and put the flasks at 37ºC for a few minutes. 
3. After cells slough off, add 10 ml EMEM to each T-150 flask. 
4. Use a pipet with a wide bore to transfer cells to 50 ml conical centrifuge tube. Place immediately on 
ice.  
5. Spin cells at 4ºC, 600 rpm for 5min. Place cells back on ice. 
6. Remove medium and add 25 ml sterile ice cold PBS. Resuspend cell pellet by gentle shaking of tube. 
If you need to use a pipet to resuspend cells, use a wide bore pipet and pipet gently. 
7. Spin cells at 4ºC, 600 rpm for 5min. Place cells back on ice. 
8. Remove media and wash cells by the addition of 25 ml sterile ice cold PBS. At this time take a small 
sample of cells for counting with a hemocytometer. 
9. Spin cells at 4ºC, 600 rpm for 5min. Place cells back on ice. 
10. Remove PBS with a pipet and resuspend cell pellet in ice cold PBS to a final concentration of 1 x 107 
cells/ml.  
 
Electroporation of cells 
 
1. Place 25 ?l of freshly thawed in vitro transcribed into each microcentrifuge tube. Set up one tube 
without RNA as negative control. 
2. Add 500 ?l of BHK21 cells (5 × 106 cells) into microcentrifuge tube containing in vitro transcribed 
RNA and mix gently. 
3. Transfer RNA-cells mixture into each electroporation cuvette (0.4 cm electrode gap). Place the cuvette 
into the cuvette holder and pulse cells twice. The following settings are used: 850 volts, capacitance set 
at 25 ?F, and the pulse controller set at infinite ohms. When doing pulses, push the two buttons 
together until you hear the beep, then immediately push them again until you hear the second beep. 
4. After electroporation is complete, set cells aside (room temperature) for a 10 min ‘recovery period’. 
5. Do the next sample. 
6. After the recovery period is complete, transfer the cells from the cuvette into 15 ml of room 
temperature growth medium (EMEM) in a T-75 flask. Aliquot 0.15 ml of cells to each well of 8-well 
chamber slides for immunofluorescence assay (2 wells-mock transfected and 2 wells transfected).  
7. Place cells at 37ºC CO2 incubator. Check the development of CPE. When CPE is complete (usually 72-
96 h post transfection), tissue culture fluids were harvested and centrifuged at 1900 rpm for 10 min at 
4ºC.  The tissue culture fluids were titrated in RK13 cells.  
 
ELECTROPORATION USING BTXPRESS ELECTROPORATOR AND ELECTROPORATION 
SOLUTION 
 
Method 
A. PREPARE THE CELLS 
Divide the cells 18-24 hours prior to electroporation as needed and culture overnight. 
 
B. PREPARE FOR ELECTROPORATION 
1. Warm all solutions to RT before use. 
2. Harvest cells for electroporation, and count cells to determine cells/ml. 
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3. Determine the total volume needed for all the electroporations. Multiply the number of 
electroporations needed by 0.1 ml (for 0.2 cm cuvettes) OR by 0.25 ml (for 0.4 cm cuvettes) and add 
10% more for pipetting errors. Total volume needed= ________ ml. 
4. Determine the volume of cells required for each electroporation according to the formula: 
 
5. Volume needed (ml) = (#cells needed/ml [5 x 106 cells/ml]/# counted cells/ml) × Total volume of 
BTXpress Solution from step C 
 
6. Enter the calculated volume needed = ______________ml 
7. Pipette the volume of cells determined in step d into a new tube and centrifuge at 1000 ×g for 5 
minutes. Aspirate the supernatant. 
8. Prepare a culture vessel with pre-warmed complete medium.  
9. Immediately transfer to 60mm petri dish (21 cm2 surface area) containing growth   
 medium. (Each well of 6 well-plate is 10 cm2)? I decide to put everything in 6 well plate with 4 
ml growth medium. Then take 500 ul into chamber slides for IFA. 
10. Resuspend the centrifuged cells from step e in ____ ml BTXpress Solution according to the volume 
determined in step c. 
 
C. Add ______ ?l IVT RNA (use 20 ?g/ml of cells= 5 ?g) to the cells. Mix gently. 
i) pEAV-GFP IVT RNA (total 49 ?l RNA) 
ii) mock infection 
 
b) Aliquot 100 ?l (0.25 cm cuvette) or 250 ul (0.4 cm cuvette) DNA/cell mix to each cuvette. 
c) Eletroporate at RT. Using a square wave system set the voltage and pulse length given for your 
cells as described in Table1.  If using an exponential decay set the capacitance to 950 ?F and 
resistance to “None”. Use the voltage given for your cells from Table 1&2 for complete protocol. 
Voltage=____260 V____ 
 
D. Electroporation settings: 
 
Choose Mode:   T 500 V/Capacitance & Resistance (LV)   
Capacitance:    C 950F   
Set Resistance:   R R1 (13ohm) 
Chamber Gap: BTX Disposable Cuvette P/N 640 (4mm gap) 
Set Charging Voltage:      S 260V  
Desired Field Strength:     E 650 V/cm 
Desired Pulse Length:       t Approximately 9 msec (Reality: 10 msec) 
 
a) Immediately mix the cells gently and transfer to the dish prepared in step B-f. 
b) Incubate in complete medium for 12-72 hours or as required. 
c) Harvest cells and perform assay as required. 
 
MAMMALIAN CELL TRANSFECTION USING LIPID-BASED TRANSFECTION REAGENT 
 
Materials 
1. Lipofectamine™ 2000 (Invitrogen, Cat# 11668-027) 
2. Fugene HD (Roche, Cat# E2311) 
Method 
1. Place sterile glass cover slips onto wells to be used for IFA staining. 
2. Trypsinize T-75 flask of Vero 76 (ATCC #CRL-1587) cells and count the cells (One confluent T-75 
contains approx. 1 × 107 Vero cells). 
3. One day before transfection, plate 2 × 105 cells/well in 500 µl of growth medium so that cells will be 
90-95% confluent at the time of transfection. 
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4. For each transfection sample, prepare complexes as follows: 
a. Dilute 0.8 µg of plasmid DNA in 50 µl of Opti-MEM I.  Mix gently. 
b. Mix Lipofectamine™ 2000 gently before use, then dilute 2.0 µl of Lipofectamine in 50 µl of Opti-
MEM I medium.  Incubate for 5 min at RT. 
c. After the 5 min incubation, combine the diluted DNA with diluted Lipofectamine™ 2000 (total 
volume = 100 µl).  Mix gently and incubate for 20 min at RT. 
5. Add the 100 µl of transfection mix to each well containing cells and medium.  Mix gently by rocking 
the plate back and forth. 
6. Incubate cells at 37°C in a CO2 incubator for 4 hr. 
After incubation for 4 hr with the transfection mix, replace the mix with 500 µl of growth media 
(containing FBS).   Incubate at 37°C for 18-48 hours prior to testing for transgene expression. 
 
SITE-DIRECTED MUTAGENESIS 
PRIMER DILUTION 
Primers are diluted in water to get 1 µg/µl working stock.  
1. Prepare sample reactions as indicated below: 
Vector: make 150 ng/ul stock. In Tube 1, use 150 ng in the reaction. In tube 2, JQ said just use 1ul (220 ng) 
should be fine. 
Primer: 100 ng/ul (more strict) 
 
 Tube 1 Tube 2 
Components 
pEAVrMLVB-NotI 
(TEMPLATE) 
pVR21-2A R52G 
pEAV2421 (full length 
VBS strain) R52G 
10× reaction buffer 5 ?l 5 ?l 5 ?l 
Plasmid template 
pEAVrMLVB-1 
14553 bp (150 ng/?l) 
1.0 ?l 
pVR21-2A 
10130 bp (97 ng/?l) 
1.5 ?l 
pEAV2421 (12-25-05 
from JQ) 
12704 bp (220 ng/ul) 
1.0  ?l 
Primer 1 
Primer EAVinsNotI11431P 
1.25 ?l (125 ng) 
Primer C7715g 
1.25 ?l (125 ng) 
Primer C7715g 
1.25 ?l (125 ng) 
Primer 2 
Primer EAVinsNotI11431N 
1.25 ?l (125 ng) 
Primer 
C7715g_antisense 
1.25 ?l (125 ng) 
Primer 
C7715g_antisense 
1.25 ?l (125 ng) 
dNTP mix 1 ?l 1 ?l 1 ?l 
QuikSolution 3 ?l 3 ?l 3 ?l 
dH2O 36.5 ?l 36 ?l 36.5 ?l 
PfuUltra HF DNA 
polymerase (2.5 U/?l) 1 ?l 1 ?l 1 ?l 
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2. Perform cycling. 
 
Segment Cycles Temperature Time (Tube 1) Time (Tube 2) 
1 1 95°C 1 minute 1 minute 
2 18 95°C 50 seconds 50 seconds 
60°C 50 seconds 50 seconds 
68°C 11 minute (1min/kb of 
plasmid length) 
13 minute (1min/kb 
of plasmid 
length) 
3 1 68°C 7 minute 7 minute 
 
3. Following temperature cycling, place the reaction on ice for 2 minutes to cool the reaction to ?37 °C. 
4. Add 1 ?l of the Dpn I restriction enzyme (10 U/?l) directly to each amplification reaction. 
5. Gently and thoroughly mix each reaction mixture by pipetting the solution up and down several times. 
Spin down the reaction mixtures in a microcentrifuge for 1 minute and immediately incubate each 
reaction at 37C for 1.5 hours to digest the parental (i.e. the nonmutated supercoiled dsDNA). 
6. Gently thaw the XL10-Gold ultracompetent cells on ice. For each control and sample reaction to be 
transformed, aliquot 45 ?l of the ultracompetent cells to a prechilled 14-ml BD Falcon polypropylene 
round-bottom tube. (In my case, not necessary to use control reaction) 
7. Add 2 ?l of the ?-ME mix provided with the kit to the 45 ?l of cells.  
8. Swirl the contents of the tube gently. Incubate the cells on ice for 10 minutes, swirling gently every 2 
minutes. 
9. Transfer 2 ?l of the Dpn I-treated pVR21-2A R52G reaction mixture to separate aliquots of the 
supercompetent cells. Swirl the transformation reactions gently to mix and incubate the reaction on ice 
for 30 minutes. 
10. Heat pulse the transformation reactions for 30 seconds at 42C water bath and then place the reactions 
on ice for 2 minutes. (The duration of the heat pulse is critical for obtaining the highest efficiencies. Do 
not exceed 42C). 
11. Add 0.5 ml of SOC medium preheated to 42C and incubate the transformation reactions at 37C for 1 
hour with shaking at 225-250 rpm. 
12. Plate 250 ?l of sample reaction on each of two agar plates containing ampicillin. 
13. Incubate the transformation plates at 37C for > 16 hours. 
 
CONVENTIONAL ONE-STEP RT-PCR ASSAYS 
This assay can be used to detect EIV, EAV, ERAV and ERBV. 
 
Eq Influenza virus QIAGEN OneStep RT-PCR  
Components Volume (ul) # of Reactions 
RNase free water 14.0 34 476 
5x QIAGEN OneStep RT-PCR Buffer 5.0 34 170 
dNTP Mix (10 mM of each dNTP) 1.0 34 34 
QIAGEN OneStep RT-PCR Ezyme Mix 1.0 34 34 
RNase Inhibitor (RNA Guard; Pharmacia) 0.5 34 17 
Master Mix Volume (ul) 21.5 731 
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Aliquot 43.0 ul into reaction tubes 
Master Mix Per Reaction (ul) 21.5 
Primer pair MIX (1 ul of each) 1.0 
Template RNA (ul) 2.5 
Total Volume (ul) 25.0 
 
Thermal Cycler Conditions: 
Reverse transcription  50C/30 min. 
Initial PCR activation 95C/15 min. 
3-step cycling (40 cycles) 
Denaturation 94C/30 sec. 
Annealing 50C/30 sec. 
Extension 72C/1 min. 
Final extension 72C/ 10 min. 
 
 
CONVENTIONAL PCR ASSAYS 
 
Herpes Virus DNA QIAGEN HotStar Taq PCR  (Adenovirus primers) 
Components Volume (ul) # of Reactions 
10x PCR Buffer (with 15 mM MgCl2) 5.0 5 25 
25 mM MgCl2 (to get final conc. 2.5 mM) 2.0 5 10 
dNTP Mix (10 mM of each dNTP) 1.0 5 5 
QIAGEN HotStart DNA Polymerase 0.3 5 1.25 
RNase free water 38.3 5 191.25 
Master Mix Volume (ul) 46.5 232.5 
Aliquot 46.5 ul into reaction tubes 
Master Mix Per Reaction (ul) 46.5 
Primer 1 0.5 
Primer 2 0.5 
Template DNA (ul) 2.5 
Total Volume (ul) 50.0 
Tube # Template Primer pair 
1 
Equine Adenovirus 1 
NVSL 
EAdV1 
990P+1286N 
2 (extract on 8-22-6 ZC) 
EAdV2 
3948P+4516N 
001 EDV 9401 EAD 
EEK EEC P1 
Thermal Cycler Conditions: 
Initial activation step 95C/15 min. 
3-step cycling (35 cycles) 
Denaturation 94C/30 sec. 
?? Ł  
Annealing 60C/30 sec. 
Extension 72C/1 min. 
Final extension 72C/ 10 min. 
 
 
 
TISSUE CULTURE MEDIA RECIPES 
 
EPAEC (EQUINE PULMONARY ARTERY ENDOTHELIAL CELLS): 
 DMEM (with high glucose [4.5 g/L], without L-glutamine; Cellgro 15-013-CM)  1L 
 Fetal bovine serum (FBS, 10%; Hyclone SH30396.03)    110mL 
 Penicillin and streptomycin (10,000 U/ml and ?g/ml; Gibco 15140-122)   11mL 
 0.1 mM Non-essential amino acids (10 mM [100X] Gibco 11140-050)   11mL 
 2 mM L-glutamine (200 mM [100X] Gibco 25030)    10 mL 
 
HEK293T (HUMAN EMBRYONIC KIDNEY 293T CELLS):  
 DMEM (with high glucose [4.5 g/L], without L-glutamine; Cellgro 15-013-CM)  500 mL 
 Fetal bovine serum (FBS, 10%; Hyclone SH30396.03)    50 mL 
 Penicillin and streptomycin (10,000 U/ml and ?g/ml; Gibco 15140-122)   5 mL  
 200 mM L-glutamine (200 mM [100X] Gibco 25030)    5 mL 
  
A594 (HUMAN ALVEOLAR BASAL EPITHELIAL CELLS: ATCC CAT. # CCL-185):  
 F-12 Kaighn’s modification (Hyclone SH30526.01)    500 mL 
 Fetal bovine serum (FBS, 10%; Hyclone SH30396.03)    50 mL 
 Penicillin and streptomycin (10,000 U/ml and ?g/ml; Gibco 15140-122)   5 mL  
 
PBMC (PERIPHERAL BLOOD MONONUCLEAR CELLS): 
 RPMI 1640 (without L-glutamine; Gibco 21870)    500 ml 
 Fetal bovine serum (FBS, 10%; Hyclone SH30396.03)    50 mL 
 Penicillin and streptomycin (10,000 U/ml and ?g/ml; Gibco 15140-122)   5 mL  
 200 mM L-glutamine (200 mM [100X] Gibco 25030)    5 mL 
       55 ?M 2-mercaptoethanol (55 mM [1000X]; Gibco 21985-023)    0.5 ml 
 
RABBIT KIDNEY 13 HIGH PASSAGE AND LOW PASSAGE (P207) FROM BILL MCCOLLUM, 
UKY: 
Laboratory Designated Name: RK-13 HP# (High passage), RK-13 LP# (Low passage) 
 
EMEM (With Earle’s salts and L-glutamine; GIBCO 11095-080 500 ml 
Cosmic calf serum 10% (Hyclone SH30087.03)        50 ml 
Penicillin and Streptomycin (GIBCO 15140-122)          5 ml 
 
RABBIT KIDNEY 13 (ATCC CATALOG NO. CCL-37): 
Laboratory Designated Name: CCL-37-RK13 
  
Minimum Essential Medium (EMEM; 
With Earle’s salts and L-glutamine; GIBCO 11095-080     500 ml 
Fetal Bovine Serum 10% (Hyclone SH30396.03)        50 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)             5 ml 
1.0 mM Sodium pyruvate (100 mM [100x] GIBCO 11360-070)         5 ml 
0.1 mM Nonessential amino acids (10 mM [100x] GIBCO 11140-050)       5 ml  
 
 
 
RABBIT KIDNEY 1 (ATCC CATALOG NO. CCL-106): 
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Laboratory Designated Name: LLC-RK1 
 
Medium 199 (GIBCO 11150-059)         500 ml 
Horse serum 10% (Hyclone SH30074.03)      50 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)             5 ml 
 
 VERO 76 (ATCC CATALOG NO. CRL-1587): 
Laboratory Designated Name: VERO 76 
 
DMEM (With high glucose [4.5g/L] and L-glutamine; GIBCO 11965-092)   500 ml 
Fetal Bovine Serum 10% (Hyclone SH30396.03)        50 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)             5 ml 
 
VERO C1008 (ATCC CATALOG NO. CRL-1586): 
Laboratory Designated Name: VERO C1008  
 
EMEM (With Earle’s salts and L-glutamine; GIBCO 11095-080    500 ml 
Fetal Bovine Serum 10% (Hyclone SH30396.03)        50 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)             5 ml 
1.0 mM Sodium pyruvate (100 mM [100x] GIBCO 11360-070)         5 ml 
0.1 mM Nonessential amino acids (10 mM [100x] GIBCO 11140-050)   5 ml  
 
BHK-21 (C-13; ATCC CATALOG NO. CCL-10): 
Laboratory Designated Name: BHK-21 
 
EMEM (With Earle’s salts and L-glutamine; GIBCO 11095-080    500 ml 
Fetal Bovine Serum 10% (Hyclone SH30396.03)        50 ml 
TPB (Tryptose phosphate broth)       50 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)             5 ml 
 
EQUINE DERM CELLS (NBL-6; ATCC CATALOG NO. CCL-57): 
Laboratory Designated Name: ED (Equine derm) 
 
Minimum Essential Medium (EMEM; 
With Earle’s salts and L-glutamine; GIBCO 11095-080     500 ml 
Fetal Bovine Serum 10% (Hyclone SH30396.03)        50 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)             5 ml 
1.0 mM Sodium pyruvate (100 mM [100x] GIBCO 11360-070)         5 ml 
0.1 mM Nonessential amino acids (10 mM [100x] GIBCO 11140-050)      5 ml  
 
MDBK (BOVINE KIDNEY CELLS; ATCC CATALOG NO. CCL-22) 
Laboratory Designated Name: MDBK 
 
EMEM (With Earle’s salts and L-glutamine; GIBCO 11095-080)    500 ml 
Horse Serum 10% (Hyclone SH30396.03)          50 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)             5 ml 
1.0 mM Sodium pyruvate (100 mM [100x] GIBCO 11360-070)         5 ml 
0.1 mM Nonessential amino acids (10 mM [100x] GIBCO 11140-050)   5 ml  
 
FETAL EQUINE KIDNEY PRIMARY CELLS (FEK-XX1) FROM BILL MCCOLLUM, UKY  
Laboratory Designated Name: FEK 
 
EMEM (With Earle’s salts and L-glutamine; GIBCO 11095-080)    500 ml 
Fetal Bovine Serum 10% (Hyclone SH30396.03)         50 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)           5 ml 
EQUINE PULMONARY ARTERY ENDOTHELIAL CELL MEDIUM (ECMM) 
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Laboratory Designated Name: EPAEC 
 
DMEM (With high glucose [4.5g/L], without L-glutamine; Cellgro 15-013-CM)   1 L 
Fetal Bovine Serum 10% (Hyclone SH30396.03)        110 ml 
Penicillin and Streptomycin  (GIBCO 15140-122)             11 ml 
L-glutamine (200 mM; GIBCO        10 ml  
0.1 mM Nonessential amino acids (10 mM [100x] GIBCO 11140-050)         11 ml  
 
 
CELL LINES GROWN WITH EMEM 10% FSCS IN INCUBATOR WITHOUT CO2 
 
BHK-21 (Baby Hamster Kidney 21: C-13; ATCC Cat. # CCL-10); RK-13 (Rabbit Kidney 13 Low passage 
[P194-P204] from Bill McCollum, KY); RK-13 (Rabbit Kidney 13 High passage [P399-P409] from Bill 
McCollum, KY); Vero 76 (African Green Monkey Kidney: ATCC Cat. # CRL-1587); MDBK (Bovine 
Kidney cells: ATCC Cat. # CCL-22); ED (Equine Dermal cells: NBL-6; ATCC Cat. # CCL-57) 
  
   
LARGE SCALE (10 L) CELL CULTURE MEDIA, EMEM 10% FSCS: 
 
Materials 
1. EMEM (NEAA, L-glutamine; Mediatech #50-011-PB; 10L/bt)  10L/bottle    
2. Ferritin supplemented calf serum (FSCS; Hyclone SH30072.03)  1000 mL 
3. Penicillin and streptomycin (10,000 U/ml and ?g/ml; Gibco 15140-122) 100 mL 
4. Fungizone (Sigma A-9528, one vial)        10 mL 
Fungizone     50 mg 
Sterile distilled water     50 ml 
Dissolve fungizone in dH2O and dispense in 10 ml aliquots.  Store at -20 °C.   
Unreconstituted vial should be stored at 4 °C. 
5. Sodium bicarbonate (NaHCO3; Sigma Cat. # S5761-500g)   6 g 
6. Glass fiber prefilter (Millipore Cat. # AP2012450) 
7. Durapore® membrane filters (045 ?m; Millipore Cat. # HVLP14250) 
8. 12 L bottle and stir bar 
   Method 
EMEM       96.1g  
NaHCO3         6.0 g 
Penicillin/Streptomycin     100 ml  
Fungizone (Amphotericin 1,000?g/ml)     10 ml  
Serum –ferritin supplemented calf serum (FSCS)     1000 ml 
dH2O (tissue culture grade water)      q.s. to 10,000 ml 
 
1. Add 8 L dH2O to 12 L bottle with stir bar. 
2. Place on stirrer/hotplate and turn stirrer to setting #3. 
3. Add EMEM bottle (rinse twice with water) and mix until dissolved, about 15 min. 
4. Add sodium bicarbonate (color should change from yellow to red), penicillin/streptomycin (p/s), 
fungizone (f), and serum (rinse each container twice with water).  
5. Final concentration of penicillin/streptomycin 100 U/ml and 100?g/ml and fungizone 1 ?g/ml. 
6. Add water to 10 L and mix 5 min.  
7. In cell culture room, filter through sterile Millipore filter unit using a prefilter.  Dispense 1 
L/sterile 1 L bottle.   
8. Perform sterility check.  Store at 4 °C.   
 
CARBOXYMETHYLCELLULOSE (CMC) OVERLAY MEDIA (1.3X EMEM 10% FSCS): 
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Materials 
1.  Carboxymethylcellulose, medium viscosity (Sigma C-4888)      6.0 g 
2.  Distilled water             140 ml 
 
Method 
1. Add water to a 1 L bottle, swirl while adding 0.75% carboxymethylcellulose (CMC) and then 
shake if necessary. 
2. Let stand overnight at room temperature (shake occasionally). 
3. Autoclave for 20 min at 121 °C (liquid setting). 
4. When cooled to approx. 40 °C, add 1.3X EMEM 10% FSCS to the 800 ml mark. 
 
1.3X EMEM 10% FSCS: 
 
EMEM       96.1g  
NaHCO3         6.0 g 
Penicillin/Streptomycin     100 ml  
Fungizone (Amphotericin 1,000?g/ml)     10 ml  
Serum –ferritin supplemented calf serum (FSCS)     1000 ml 
dH2O (tissue culture grade water)      q.s. to 7,800 ml 
 
Prepare same as for EMEM 10% FSCS except start with 6 L dH2O and q.s. to 7.8 L. 
 
5. Perform sterility check.  Store at 4 °C. 
6. Before using, add 0.8 ml gentamicin/bottle (working concentration – 50 ?g/ml). 
 
VIRUS TRANSPORT MEDIUM: 
Hanks's Balanced Salt Solution w/ Phenol Red 1X (Invitrogen; 14170112)   500 ml 
HEPES Buffer (final concentration 25 mM; Invitrogen; 15630080)    20 ml  
Bovine Serum Albumin V (final concetration 0.5%; Sigma: A9647)    2.5 g  
Antibitic-Antimycotic (100X, Peniillin, Steptomycin & Amphotericin B; Invitrogen; 15240112) 5 ml 
Gentamicin Sulfate (final concentration 250 mg/L) Cellgro; 30-005-CR   2.5 ml 
    
 
NET BUFFER (PH 7.5) FOR RESUSPENSION OF VIRUS PELLET: 
 
Materials 
   50 mM Tris hydrochloride (500 ml dH2O)  3.938 g  
   50 mM Tris base (500 ml dH2O)    3.029 g 
   5 mM EDTA     0.95 g 
   150 mM NaCl     4.383 g  
    
Method 
1. Add? Tris base to Tris-hydrochloride until the mixture reaches pH 7.5.  (Add about 100ml of 50mM 
Tris-Base to 500ml of 50mM Tris-HCl to get pH 7.5) 
2. Add 5 mM EDTA and 150 mM NaCl to above 50 mM Tris-HCl pH 7.5 
3. Filter and store at 4 °C. 
 
 
DULBECCO’S PHOSPHATE-BUFFERED SALINE (PBS): 
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PBS (Gibco 21600-069)        95.5 g (1 bottle) 
Sterile distilled water       q.s. to 10,000 ml 
 
1. Add 9 L dH2O to 12 L bottle with stir bar.  Place on stirrer/hotplate and turn stirrer to setting #3. 
2. Add PBS bottle (rinse twice with water) and mix for 10 min.  
3. Add 800 ml to each 1 L bottles.  Autoclave for 20 min at 121 °C (liquid setting). 
4. Cool to room temperature before tightening caps and labeling.  Perform sterility check.  Store at 
room temperature. 
 
 
TRYPSIN EDTA SOLUTION: 
  PBS (sterile 1X)        180 ml 
  Trypsin EDTA (no phenol red [10X]; Gibco 15400-054)   20 ml 
 
FREEZING MEDIA:   
Dimethylsulfoxide (DMSO; Sigma D-2650)       10% 
EMEM 10% FSCS          90% 
 
or 
 
Recovery™ Cell Culture freezing medium (Gibco; 12648-010) 
 
GUINEA PIG COMPLEMENT:  
100 ml/bottle, (Rockland Cat # C300-0100).  Thaw and dispense (on ice) into 1 or 2 ml volumes and store 
at -70 °C. 
 
MISCELLANEOUS: 
 
0.5% Trypsin EDTA (no phenol red [10X]; Gibco 15400-054) 
Phosphate buffered saline (PBS, pH 7.4, without calcium chloride/magnesium chloride; Gibco 10010) 
Dulbecco’s Phosphate buffered saline (PBS 10L/bottle, Gibco 10010) 
HEPES buffer solution (1M; Gibco 15630) 
 
 
 
ANTIBIOTICS FOR CELL CULTURE 
 
Gentamicin:  
Gentamicin sulfate, 50 mg/ml, 10 ml/vial (Mediatech 30-005-CR).  Store at 4 °C. 
 
Pen-Strep: 
Penicillin and streptomycin (10,000 U/ml and ?g/ml; Gibco 15140-122) 
 
Antibiotic-Antimycotic: 
Anti-Anti (100X; Gibco 15240) 
 
Fungizone: 
Amphotericin B Solubilized (Sigma A-9528) 
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BACTERIAL MEDIA RECIPES  
LIQUID MEDIA 
 
LB Medium (Luria-Bertani Medium; 500 ml): 
  Deionized water        500 ml 
  Bacto-tryptone            5 g 
  Bacto-yeast extract       2.5 g 
  NaCl             5 g 
1. Stir until the solutes have dissolved.  Adjust the pH to 7.0 with 5N NaOH.   
2. Sterilize by autoclaving for 20 minutes on liquid cycle. 
 
Psi Broth (500 ml): 
Bacto-tryptone   5.0 g 
Bacto-yeast extract  2.5 g 
NaCl    2.5 g 
4 mM MgSO4  
10 mM KCl  
dH2O    to 500 ml 
1. Autoclave liquid cycle 30 min. 
 
 
MEDIA CONTAINING AGAR 
 
LB Agar Plates: 
Deionized water          500 ml 
  Bacto-tryptone          5 g 
  Bacto-yeast extract       2.5 g 
  NaCl           5 g 
 
1. Prepare LB medium according to the above recipe. Just before autoclaving, add 7.5 g of Bacto 
agar.  Sterilized by autoclaving for 20 minutes on liquid cycle.   
2. When the medium is removed from the autoclave, swirl it gently to distribute the melted agar 
throughout the solution (need to be very careful, the media may boil over when swirled).  Allow 
the medium to cool to 45-500C before adding antibiotics*.   
3. To avoid air bubbles, mix the medium by swirling.  Pour 20-25 ml of medium in a petri dish (use 
the tissue culture hood and fluorescent light should be off).   
4. When medium has hardened completely, invert the plates and wrap in aluminum foil and store 
them at 4 °C until needed.  The plates should be removed from storage 1-2 hours before they are 
used and allow them to dry.   
*Antibiotics solutions  
  Antibiotic     Working concentration  
Ampicillin     50 ?g / ml 
Streptomycin     50 ?g / ml 
Tetracycline     50 ?g / ml 
Kanamycin      50 ?g / ml 
Carbenicillin     60 ?g / ml 
Chloramphenicol     170 ?g / ml 
 
Stock solutions should be stored at -200C.  Avoid repeated freeze thawing and exposure to light.  
Magnesium ions are antagonists of tetracycline.  Use media without magnesium salts for selection of 
bacteria resistant to tetracycline.   
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STORAGE MEDIA FOR BACTERIA 
 
Cultures Containing Glycerol: 
1. Aliquot 0.85 ml of bacterial culture in to a freezing vial and add 0.15 ml of sterile glycerol 
(sterilized by autoclaving for 20 minutes on liquid cycle).  Vortex the culture to disperse glycerol 
evenly.  Freeze the culture in ethanol-dry ice or liquid nitrogen, and then transfer the tube to -
70 °C. 
2. To recover the bacteria, scrape the frozen surface of the culture with a sterile inoculating needle, 
and then immediately streak the bacteria that adhere to the needle onto the surface of an LB agar 
plate containing the appropriate antibiotics.  Incubate the plate at 37 °C.  Return the frozen culture 
to storage at -70 °C. 
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COMMONLY USED SOLUTIONS AND BUFFERS FOR MOLECULAR BIOLOGY 
 
 
0.5 M EDTA (pH 8.0) 
 Deionized water     115 ml 
 EDTA (di-sodium)    27.918 g 
 5N NaOH     15,825 µl 
 Bring the volume to 150 mls with deionized water 
 
5.0 M Sodium chloride 
 29.22 g of NaCl in 100 mls of distilled water 
 
10% SDS 
 10 g in of SDS in 100 mls of deionized water 
 
3.0 M Sodium acetate (pH 5.2) 
  Dissolve 24.609 g of sodium acetate in 60 mls of deionized water.  Adjust the pH to 5.2 with 
glacial acetic acid (approximately 25.6 mls).  Bring the volume to 100 mls with deionized water. 
 
10 M Ammonium Acetate (50 ml) 
 Ammonium acetate     38.5 g 
 Deionized water to     50 ml  
 
1 M MgCl2 (100 ml): 
 MgCl2  6H20     20.3 g 
 Deionized water to    100 ml 
 
1 M Dithiothreitol (DTT; 10 ml) 
 DTT     1.55 g 
 10 mM Sodium acetate (pH 5.2) to   10 ml 
 Store at -200C 
 
1M Tris HCl (pH 8.0) 
 Tris HCl    Tris base   Molarity 
 4.44 g / l   2.65 g / l   0.05 M 
 88.8 g / l   53.0 g / l   1.0 M 
 8.88 g / 100 mls 5.30 g / 100 mls 1.0 M 
 17.76 g / 200 mls 10.6 g / 200 mls 1.0 M 
 
1M Tris HCl (per liter) 
 Tris Base              121.1g 
 Add deionized water to 800 ml 
  Desired pH     Volume of HCl 
       pH 7.4     70 ml 
       pH 7.6     60 ml 
       pH 8.0     42 ml 
 Add deionized water to 1 liter 
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TE BUFFER 
  
 pH 8.0 
  10 mM Tris HCl (pH 8.0) 
  1 mM EDTA (pH 8.0) 
 
 pH 7.6 
  10 mM Tris HCl (pH 7.6) 
  1 mM EDTA (pH 8.0) 
  
 pH 7.4 
  10 mM Tris HCl (pH 7.4) 
  1 mM EDTA (pH 8.0) 
 
TAE (Tris-acetate; 50X concentrated stock solution [per liter]) 
 Tris base      242 g 
 Glacial acetic acid    57.1 ml 0.5 
 0.5 M EDTA (pH 8.0)   100 ml 
 Deionized water     q.s. 
 
Working concentration 1X (dilute 10 ml in 490 ml of deionized water) 
 
 
Proteinase K 2X Buffer 
Reagent   Final concentration  To make 100 mls of buffer 
Tris HCl (pH 8.0)  0.2 M   20 ml of 1.0 M Tris HCl (pH 8.0) 
NaCl     0.3 M   6.0 ml of 5.0 M NaCl 
EDTA (pH 8.0)   25 mM   5.0 ml of 0.5 M EDTA (pH 8.0) 
SDS    2.0%   20 ml of 10% SDS 
Deionized water      49 ml 
 
 
Ethidium Bromide (EtBr; 10 mg/ml) 
1. Add 1 g of EtBr to 100 ml of deionized water.  
2. Stir on a magnetic stir for several hours to ensure that the dye has dissolved.   
3. Wrap the container in aluminum foil or transfer the solution to a dark bottle and store at room 
temperature.   
4. Final concentration to be used: 0.5 ?g/ml 
Method 
1. EtBr in agarose:  5.0 ?l of EtBr (10 ?g/?l) solution per 100 ml of agarose 
2. EtBr staining solution (1× TAE with 0.5 ?g/ml EtBr): 25 ?l of EtBr stock solution in 500 ml of 1× 
TAE buffer 
 
Gel Loading Buffer (6X) 
0.25% bromophenol blue (MW 691.9) 
30% glycerol  
Dissolved in 1X TAE solution 
 
To make 40 ml 6X loading buffer: 
 0.25% bromophenol blue (MW 691.9)  0.1 g 
 30% glycerol     12 ml  
 1X TAE solution    to 40 ml  
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Preparation of 25 bp DNA ladder (Invitrogen Cat. # 10597-011) 
100 bp DNA ladder (1 ?g/?l)    50?l 
6× loading buffer    100 ?l 
Nuclease free water    450 ?l 
 
Preparation of 100 bp DNA ladder (Invitrogen Cat. #) 
100 bp DNA ladder (1 ?g/?l)    50?l 
6× loading buffer    100 ?l 
Nuclease free water    450 ?l 
        
Preparation of 1 kb plus DNA ladder (Invitrogen Cat. # 15615-024) 
1 kb plus DNA ladder (1 ?g/?l)   50 ?l 
6× loading buffer    100 ?l 
Nuclease free water     450 ?l 
 
Preparation of low DNA mass ladder (Invitrogen Cat. # 10068-013) 
Low DNA mass ladder    100 ?l 
6× loading buffer    100 ?l 
Nuclease free water    400 ?l 
 
Preparation of PCR products 
PCR products      10 ?l 
6× loading buffer    2 ?l 
 
Preparation of PCR products to estimate concentration 
PCR products      2 ?l 
6× loading buffer    2 ?l 
Nuclease free water    8 ?l 
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 BUFFERS AND REAGENTS FOR WESTERN IMMUNOBLOTTING 
 
10X SDS-PAGE RUNNING BUFFER (4 LITERS) 
 Glycine     580 g 
 Tris base     120 g 
 SDS     40 g 
 Distilled water to     4 liters 
 
TRANSFER BUFFER FOR WESTERN IIMMUNOBLOTTING (FOR PROTEINS <80,000 M.W) 
   1 Liter  4 Liters 
 Tris base 25 mM  2.9 g  11.6 g 
 Glycine 190 mM 14.5 g  58.0 g 
 Methanol 20% 200 ml  800 ml 
 Make up to 1 liter or 4 liters with distilled water (800 or 3200 mls) 
 
WASHING BUFFER FOR WESTERN IMMUNOBLOTTING (TBS-T/ TRIS BUFFERED SALINE 
WITH 0.05% TWEEN 20; pH 7.6) 
   1 Liter  4 Liters 
 Tris base  2.42 g (20 mM)  9.68 g 
 NaCl 8.0 g (137 mM)  32.0 g 
 6N HCl 3.8 ml  10.4 ml 
 Tween 20 (0.05%) 500 ?l 2 ml 
       Deionized water to   1 liter   4 liters 
 
ANTIBODY DILUTION BUFFER (ADB) FOR WESTERN IMMUNOBLOTTING 
 Nonfat dry milk 10 g 
 Sodium azide (NaN3) 0.1 g 
 NaCl  9.0 g 
 Na
2
HPO
4  4.5 g 
 NaH
2
PO
4  0.5 g  
 PBS (1X)  1 L 
 
AVIDIN-HRP CONJUGATE DILUTION BUFFER IN PBS FOR WESTERN 
IMMUNOBLOTTING 
 PBS (1X) 500 ml 
 1% Nonfat dry milk  5g  
 0.05% Tween 20  250 ?l  
 
 
BLOCKING AGENT FOR WESTERN IMMUNOBLOTTING 
5% Nonfat dry milk in TBS-T (25 g for 500 ml) 
(Use nonfat dry milk for horse serum to reduce the high background.  Generally BSA can be used as a 
blocking agent for western immunoblotting). 
 
MOLECULAR WEIGHT MARKERS AND SAMPLE BUFFER 
BenchMark™ Pre-stained protein ladder (Invitrogen; Cat. #10748-010) 
MagicMark™ XP Western protein standard (20-220kDa; Invitrogen; Cat. #LC5602) 
Lane Marker Reducing sample buffer (5X) (Thermo Scientific Pierce; Cat. # 39000) 
Laemmli sample buffer (2X) (BioRad; Cat. # 161-0737) 
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SOLUTIONS AND REAGENTS 
1.5 M Tris HCl, pH 8.8 (BioRad; Cat. # 161-0798) 
0.5 M Tris HCl, pH 6.8 (BioRad; Cat. # 161-0799) 
SDS solution 10% w/v (BioRad; Cat. # 161-0416) 
TEMED (N, N, N’, N’-Tetra-methylethylenediamine) (BioRad; Cat. # 161-0801) 
Blocking grade blocker non-fat dry milk (BioRad; Cat. # 170-6404) 
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COMMONLY USED STAINS 
 
 Crystal violet stain (stock solution): 
  Crystal violet (Mallinckrodt 8839)     12g 
Methanol (Fisher A412-20)        600 ml 
 
Crystal violet stain (working solution): 
1 part of above stock solution 
9 parts 10% buffered formalin (Fisher 23-245-685) 
 
Coomassie Blue R protein stain  
   Brilliant blue R      0.41 g 
   Glacial acetic acid    50 ml 
   95% Ethanol     225 ml 
   Distilled water      225 ml 
 
0.2% Trypan Blue for cell counting 
   Trypan blue  0.2 g 
   PBS  100 ml 
  Sterile filter. 
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ANTIBODIES 
EAV SPECIFIC ANTIBODIES 
 
Specificity Clone Species Origin Specifity 
EAV GP5 6D10 Mouse (MAb) EAV GP5 
EAV GP5 FP55 Rabbit EAV GP5 
EAV M 8887 Rabbit EAV M 
EAV N 3E2 Mouse (MAb) EAV N 
GP2 4033 Rabbit EAV GP2 
GP3 3509 Rabbit EAV GP3 
GP4 7466 Rabbit EAV GP4 
EAV nsp1 12A4 Mouse (MAb) EAV nsp1 
EAV nsp2 L3 Rabbit EAV nsp2 
EAV nsp3 98E Rabbit EAV nsp3 
EAV nsp4 T1 Rabbit EAV nsp4 
Nsp7 and 8 D (M1) Rabbit EAV nsp7 and nsp8 
?-EAV antibody† 11412 Rabbit EAV 
 
CONJUGATED-EAV SPECIFIC ANTIBODIES 
 
Specificity Clone Species Origin Conjugated Form Specifity 
Rabbit 8887 PB IgG Rabbit polyclonal Rabbit Alexa Fluor 488 Prebleed  
EHV-1  Monoclonal Mouse (MAb) Alexa Fluor 488 EHV-1 
EAV anti-nsp1 12A4 Mouse (MAb) Alexa Fluor 488 EAV nsp1 
EAV anti-N 3E2 Mouse (MAb) Alexa Fluor 488 EAV N 
 
SECONDARY CONJUGATED ANTIBODIES 
 
Specificity Conjugate Form Company Catalog # 
Goat F(ab’)2 Anti-mouse IgG1 FITC SouthernBiotech 1072-02 
Goat F(ab’)2 Anti-mouse IgG1 R-PE SouthernBiotech 1072-09 
Goat Anti-mouse IgG (H+L chain 
specific) 
Texas Red® 
(TXRD) 
SouthernBiotech 1031-07 
Goat F(ab’)2  Anti-rat IgG (H+L chain 
specific) 
FITC SouthernBiotech 3052-02 
Goat Anti-horse IgG (H+L chain specific) FITC Jackson 
ImmunoResearch 
108-096-
003 
Goat Anit-guinea Pig IgG (H+L) FITC Vector 
Laboratories 
FI-7000 
Goat Anti-rabbit IgG (H+L) Texas Red® Vector 
Laboratories 
TI-1000 
Goat Anti-horse IgG (H+L) Biotin Vector 
Laboratories 
BA-8000 
Goat Anti-horse IgG (H+L) Peroxidase Jackson 
ImmunoResearch 
108-035-
003 
Donkey F(ab’)2  Anti-goat IgG (H+L 
chain specific) 
Allophycocyanin Jackson 
ImmunoResearch 
705-136-
147 
Goat Anti-mouse IgG Alexa Fluor 488 Invitrogen A31561 
Goat Anti-rabbit IgG (H+L) DyLight 549 KPL 072-04-15-
16 
Goat F(ab’)2  Anti-mouse IgG (H+L 
chain specific) 
PE-Cy5.5 Caltag 
(Invitrogen) 
M35018 
Goat F(ab’)2  Anti-mouse IgG (H+L 
chain specific) 
R-PE Caltag 
(Invitrogen) 
M35004-1 
Goat F(ab’)2  Anti-rabbit IgG (H+L chain R-PE Caltag L43001 
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specific) (Invitrogen) 
Goat F(ab’)2  IgG Unlabeled (UNLB) Southern Biotech 0110-01 
Goat F(ab’)2  Anti-mouse IgG (H+L 
chain specific) 
Alexa Fluor 488 Invitrogen A11017 
Goat F(ab’)2  Anti-mouse IgG (H+L 
chain specific) 
R-PE Invitrogen A10543 
Goat ?-rabbit IgG (H+L) Biotin-XX Invitrogen B2770 
Goat ?-mouse IgG (H+L) Biotin-XX Invitrogen B2763 
Goat ?-rabbit IgG (H+L) HRP Southern Biotech 4050-05 
Goat ?-mouse IgG (H+L) HRP Southern Biotech 1031-05 
 
TISSUE CULTURE TECHNIQUES 
 
PROPAGATION OF CONTINUOUS CELL LINES (RK-13, BHK-21 AND VERO CELLS) 
 
Materials 
1. Trypsin EDTA (keep in the water bath for few minutes, at 370C) 
2. Confluent T-75 flask of cells  
3. Appropriate cell culture medium  
 
Method  
1. Cells must be confluent (3-7 days old). 
2. Pour off media. 
3. Rinse cells 2-3 times with PBS (pH 7.4) 
4. Add 1 ml (25 cm2 flask), 2 ml (75 cm2 flask), 4 ml (150 cm2 flask) trypsin-EDTA, and rock gently 
for 30 seconds, then let the flask(s) sit at RT for 1 min 
5. Pour off trypsin-EDTA (optional) and incubate the flask(s) another 7-8 minutes at 37 °C. 
6. Add appropriate amount of media EMEM + 10% FSCS + p/s/f for 1:5 split. 
 
Once a week split cells: 1-150 cm2 flask with confluent RK-13 cells is made up to approx. 300-
335 ml EMEM 10% FSCS. 
 10 ml is added to 25 cm2 flask, 
 30 ml to 75 cm2 flask, 
 60 ml to 150 cm2 flask 
Note 
To get a confluent monolayer within 24-36 hours transfer 2 ml of cell suspension into a T-75 flask and add 
20 ml of complete medium to the flask (1:5 split). 
Generally one T-75 flask is sufficient to seed five 96 well plates for neutralization or microtitration assays.  
For specific cell lines: 
  One T-75 flask of BHK-21 cells (confluent) is sufficient for 5-10, 96 well plates.   
  One T-75 flask of Vero cells (confluent) is sufficient for 3-4, 96 well plates. 
  One T-75 flask of RK-13 cells (confluent) is sufficient for 3-4, 96 well plates. 
 
COUNTING OF CELLS  
 
Manual method 
1. Trypsinize the cells and add 10 ml of complete medium.   
2. Centrifuge and resuspend the cells in 10 ml of complete medium. 
3. Make a 1:10 dilution of cell suspension (100 ?l in 900 ?l of complete medium).  Take 0.5 ml of diluted 
cell suspension into a snap cap tube and add 0.5 ml of 0.2% Trypan blue (1:2 dilution).  Load the 
hemocytometer and count the cells in each of the four large squares.  Some cells will be touching the 
outside borders.  Count only those cells touching two of the outside borders (e.g., the upper and left).  
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Determine the average number of cells per 10-4 ml (cells / ml = average number of cells per large 
square × 104 / ml × dilution factor). 
 
Automated method using cell viability analyzer, ViCell XR (Beckman Coulter) 
 
Materials 
 
ViCell XR Quad reagent pak (Beckman Coulter Cat. # 383722) 
4 ml sample cup 120/bag (Beckman Coulter Cat. # 383721) 
 
1. Make 1 ml of 1:10 dilution of cell suspension (100 ?l in 900 ?l of complete medium) 
2. Place 1 ml in a 4 ml sample cup (Beckman Coulter Cat. # 723908) 
3. Place the sample cup in the machine (position 1-10) 
4. Log in sample: position, sample ID, cell type, dilution factor.  OK or next sample when done. 
5. Start queue 
6. “Camera image” provides cell image while counting and “Autosample queue” provides average of 
number of counted cells and viability 
 
 
FREEZING CELLS 
 
Materials  
1. Freezing medium 
2. Cells in log phase of growth 
3. Trypsin EDTA (keep in the water bath for few minutes, at 370C) 
4. Nalgene™ Cryo 1 °C freezing container (Nalgene Cat. # 5100-0001) 
 
Method 
1. Pour off the media. 
2. Add 3-4 ml of trypsin EDTA solution and rinse the cells (this is to remove the fetal bovine serum).  
3. Add 3-4 ml of fresh trypsin EDTA solution and leave it for 3-4 min. (preferably at 370C) and bang 
on the flask to detach the cells from the surface. 
4. Add 10-12 mls of complete medium (the medium contain 10% fetal bovine serum and this will 
inhibit trypsin) and pour into a 50 ml conical tube. 
5. Centrifuge at 1100 or 1300 rpm (200 ×g) in a table top centrifuge for 5 minutes at 250C. 
6. Aspirate the supernatant and resuspend the cell pellet in freezing medium at approx. 107 cells / ml.  
Freeze in 2 ml vials (1 ml per vial).  
7. Freeze cells first in Nalgene™ Cryo 1 °C freezing container with isopropanol at -80 °C for 1 day 
8. Transfer frozen cell vials to liquid nitrogen container 
 
RECOVERY OF FROZEN CELLS 
 
Material 
1. Frozen cells (-70 °C) in aliquots. 
2. Growth medium  
 
Method: 
1. Rapid thawing of the cells is necessary.  Thaw the cells in the water bath at 37 °C, by swirling the 
tube (do not submerge the lid to avoid contamination of the cells). 
2. Resuspend in 15 ml of growth medium and centrifuge at 1200 or 1300 rpm (200 ×g) in a table top 
centrifuge for 5 minutes at 25 °C. 
3. Aspirate the supernatant and resuspend the cells in 10 ml of growth medium.  Transfer the cell 
suspension into a T-75 flask and add 10 ml of medium.  Incubate at 37 °C for 2-3 days.   
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CLASSICAL VIROLOGY TECHNIQUES 
 
PROCESSING OF NASAL SWABS FOR VIRUS ISOLATION 
 
Materials 
10 ml syringes  
Autoclaved plastic forceps 
0.45 µm syringe filter (Corning Cat. # 431220 or Millipore, Millex™ Cat. # SLHA033SB) 
1.7 ml screw cap tubes (Sardstedt Cat. # 72.694.996 [color cap], #72.694.006 [clear cap]) 
15 ml conical tubes  
 
Methods 
1. Thoroughly swab the nasopharyngeal area with a sterile rayon swabs (1/2” x 1”) with plastic shafts 
(16”). 
2. After collection, the rayon tip of each swab is cut off into 7 ml of virus transport medium (Hank’s 
balanced salt solution with penicillin, streptomycin, gentamicin sulfate and amphotericin B; all from 
Life Technologies, Carlsbad, CA).   
3. Squeeze the swab to recover maximum amount of media and centrifuge at 300 ×g for 10 min to 
remove debris. 
4. Transfer individual nasal swabs in transport medium to the barrel of a 12 ml disposable syringe and 
express through 0.45 µm syringe filter (Millipore).   
5. Collect the filtrate into a 15 ml conical tube.  Bring up the sample volume to 7 ml with plain MEM to 
normalize samples (e.g. after filtration usually approx. 6 ml is recovered).  Leave approximately 2.0 ml 
for virus isolation and aliquot the remaining filtrate (approximately 1 ml × 2) into tubes.  Freeze at -
70 °C until tested. 
6. Aspirate off media from confluent RK-13 cells in 6-well plates and inoculate 500 ?l specimen/well in 
duplicate. 
7. Incubate plates at 37 °C in presence of 5% CO2 for 1-2 hours. 
8. Add 10ml CMC overlay to each flask and incubate at 37 °C in the presence of 5% CO2 for 5 days.   
9. Do second passage on day 4 using the same cells. Stain cells on day 5 with crystal violet.  Archive the 
TCF at -80 °C. 
 
SERUM PROCESSING 
 
Materials 
Vacutainer needles  
Vacutainer adapters (Termuno, Venoject II Cat. # P-1316R) 
15 ml BD Vacutainer tubes (Kendall Monoject [no additive] Cat. # 8881 301819) 
1.7 ml screw cap tubes (Sardstedt Cat. # 72.694.006) 
Transfer disposable pipets for serology (Samco scientific Cat. # 202-1S) 
Methods 
1. Collect blood into vacutainer tubes via jugular venipuncture (about 15 ml blood). 
2. Transport blood tubes to the lab.  Spray tubes with diluted Roccal-D (1:200).  Rinse tubes and dry 
with paper towel.  Let stand at room temperature for 4-5 hours or for 1 hour at 37 °C (water bath 
works faster). 
3. Sediment blood cells at 2000 rpm (300 ×g) for 10 min. 
4. Collect serum and aliquot into tubes (1.4 ml × 4).  Freeze at -20 °C until tested for virus or 
antibody. 
5. Proceed as in steps 5-8 above for virus isolation. 
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BUFFY COAT PROCESSING FOR VIRUS ISOLATION (WITHOUT GRADIENT 
PURIFICATION) 
 
Methods 
1. Draw blood by venipuncture into vacutainer tubes containing sodium citrate or EDTA and mix 
thoroughly. 
2. Allow blood to stand for 1-2 hours or sediment at 600-700 rpm (100 ×g) for 10 min.  Remove plasma 
layer and sediment at 2000 rpm for 10 min.  The few red blood cells in pellet cause no apparent 
concern. 
3. Aspirate off supernatant; resuspend pellet in 5 ml EMEM 10% FSCS and vortex thoroughly. (If 
desired, pellet can be washed with PBS before resuspending in EMEM media).  Freeze or inoculate. 
4. Proceed as in steps 5-8 above. 
 
PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) PROCESSING FOR VIRUS 
ISOLATION 
 
Materials 
15 ml BD vacutainer tubes w/ACD (Citrate-dextrose solution; Sigma C3821- 50ML) 
Ficoll-Paque Plus (GE Healthcare Cat#17-1440-03) 
15 ml conical tubes  
50 ml conical tubes  
1.7 ml screw cap tubes (Sardstedt Cat. # 72.694.006) 
 
Preparation of Vacutainer tubes with Acid Citrate Dextrose (ACD) 
Using a small gauge needle and a 10 ml syringe, add 1.5 ml ACD to each 15 ml vacutainer tube.  Mark 
tubes to identify that they contain ACD.  Store at 4 °C.  
 
Preparation of Ficoll-Paque Plus gradients in 15 ml conical bottom polypropylene tubes 
 
Place 4.0 ml Ficoll-Paque Plus in each tube (will need 15 ml tube per 20 ml vacutainer of collected 
blood).  Centrifuge briefly to pull all of Ficoll-Paque Plus to bottom of the tube.  Store at 4 °C but 
warm to room temperature before use.  
 
Methods 
1. Collect blood via venipuncture into tubes with ACD (about 13.5 ml blood and the final volume is 
about 15 ml per tube).  Invert several times to mix.  Keep on ice at farm. 
2. Transport blood tubes to the lab.  Spray tubes with dilute Roccal.  Rinse tubes and dry with paper 
towel.  Invert tubes several times to re-mix blood (prevents PBMC from settling on top of RBC 
too much).  Keep at room temperature. 
3. Wait approximately 20-30 min until RBC has settled again, leaving cloudy, yellow plasma layer 
on top of RBC layer. 
4. Layering plasma onto Ficoll-Paque Plus using transfer disposable pipet. 
5. Using serological pipet, carefully aspirate plasma of one Vacutainer tube, stopping aspiration as 
reach the RBC layer (a few RBCs are OK but try not to pull lost of RBCs into pipet).  Layer 
plasma onto Ficoll-Paque Plus in conical tube.  Plasma from one 20 ml vacutainer of blood should 
approximately fill the Ficoll-Paque Plus tube to 14-15 ml height in tube.  Cap tube when finished.  
Keep at room temperature.  Continue, using the same pipet, and harvest all plasma layers from the 
vacutainers collected from one horse.  
6. Centrifuge at 500 ×g (2800 rpm), 30 min, 25 °C. 
7. Harvesting PBMC from gradient: 
? Aspirate plasma layer above gradient down to cloudy band of PBMC.  Discard into 
sterile beaker.  With same pipet, aspirate PBMC at interface (approx. 2-3 ml/15 ml tube) 
and place into 50 ml polypropylene centrifuge tube.  Continue removing plasma, 
harvesting interfaces. Combine PBMC from 4 gradient (15 ml conical) tubes into a 50 ml 
tube for washing. 
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8. Cell washing steps: 
? Add sterile PBS (pH 7.4) to bring the volume to 40 ml.  Cap tube and mix cells by 
inverting tube 5 times (or tapping tube with the index finger). 
? Centrifuge for 15 min at 500 ×g (2800 rpm), 4 °C. 
? Aspirate the supernatant without disturbing the cell pellet. 
? Add sterile PBS to bring the volume to 40 ml and cap tube.  Mix cells by tapping the tube 
with the index finger or by vortexing. 
? Centrifuge for 10 min at 500 ×g (2800 rpm), 4 °C. 
? Aspirate the supernatant without disturbing the cell pellet. 
? Resuspend the pellet in 8.0 ml of 10% EMEM (this gives about 1.5 × 107 – 3.0 × 107 cells 
per ml).  Leave 2.0 ml of buffy coat cells in the conical tube for virus isolation and 
aliquot the remaining cells (approximately 1.2 ml × 5) into tubes.  
? Freeze the remaining cells at -80 °C. 
 
ISOLATION OF EAV FROM SEMEN 
 
1. Thaw 15 ml tube containing semen sample in warm tap water, then place on ice. 
2. Label 8 flasks (25cm2) [4 RK-14 (KY) “high pass” and 4 RK-13 (ATCC-CCL37) “low 
pass”]/semen, 2 × 10-1, 1 × 10-2, 1?×10-3 for high pass, 2 × 10-1, 1 × 10-2, 1? × 10-3 for low pass. 
3. Sonicate (output 20, #4.5 on dial) samples on ice 3 × 15 sec.; let set on ice for 15 sec. 1 min 
between sonications (dilute small volumes to 5 ml).  Clean sonicator probe with 95% EtOH 2X 
between each sample.  Spin 300 × g (1900 rpm) for 10 min to remove sperm and debris, save and 
use supernatant (SSP). 
4. Set up 3 tubes (10-1 to 10-3) for each sample, 4.5 ml EMEM 10% FSCS per tube. 
5. Aspirate off media from 25 cm2 (3-6 day old RK-13 monolayers).  Do not rinse! Make 10-1 (0.5 ml 
sample in 4.5 ml diluent), vortex; with new pipet add 0.5 ml of 10-1 to tube #2 (10-2) and 1 ml to 
each of 4 flasks marked 10-1.  Continue the same way with dilutions 10-2 and 10-3 (2 flasks each). 
6. Incubate all flasks at 37 °C in air incubator (incubator without CO2) with caps closed for 1 hour (2 
hours maximum). 
7. Add 10 ml of CMC overlay to each flask and incubate at 37 °C in air incubator (incubator without 
CO2) with caps closed. 
8. Check for CPE on day 4. 
If bacterial contamination occurs, redo after bacteriological examination and sensitivity testing to 
find out which antibiotics to used in the TC media.  Repeat test as above and also note 
contamination. Specimen may be filtered through a 0.45 ?m filter using a 5 or 10 cc syringe, if 
necessary. 
9. If negative, a second passage is performed on day 4. (See 2nd passage) 
10. If sample is toxic this material is passages as is (2nd passage). 
11. If positive, supernatant is usually harvested from a 10-2 flask showing viral activity (store at -
20 °C) and a reverse SN-test is performed against known positive and negative sera (See reverse 
SN-test). 
12. After 5 days harvest supernatant from flasks and stain flasks with crystal violet using 2 ml crystal 
violet in buffered formalin.  Stain 1-24 hours, remove stain, rinse flasks with tap water and read.   
13. All semen samples are placed in freezer zip lock storage bags and stored at -70 °C. 
14. Permanently store negative SSP at -20 °C and positive SSP at -70 °C. 
Second passage 
1. Aspirate media from 2 “high pass” and 2 “low pass” confluent 3-5 day old RK-13 cells in 25 cm2 
flasks for each negative semen sample. 
2. From 2 flasks of 10-1 passage #1 take up 0.5 ml from each with same pipet (1ml) and add 1 ml to 1 
new flask for each high and low pass.  Do the same for 10-2 passage #1, taking up 1 ml from each.  
Do 10-1 and 10-2 only.  Close caps and incubate at 37 °C for 1-2 hours (minimum 1 hour) in air 
incubator. 
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3. Add 10 ml of CMC overlay to all flasks, close caps, and incubate at 37 °C in air incubator 
(without CO2).  
4. Read after 3-4 days. 
5. After 4 days, harvest media and stain flasks (See passage #1). 
 
MAKING WORKING VIRUS STOCKS 
 
Materials 
1. EAV  
2. Five confluent monolayers of RK-13 cells in T-150 flasks 
3. EMEM 
4. RK-13 medium 
5. 50 ml conical centrifuge tubes 
6. Freezing vials  
 
Method 
1. Inoculate monolayers with EAV at an m.o.i. of 1.  Resuspend the virus in approximately 50 ml of 
serum free MEM and add 10 ml per T-150 flask. 
2. At the same time mock infect one T-75 flask of RK-13 cells. 
3. Adsorb for 1 hour at 37 °C.  . 
4. Add 40 ml of complete RK -13 medium / T-150 flask.  Incubate at 37 °C for 48 hours or until 95% 
- 100% CPE. 
5. Centrifuge at 5000 g (or 3000 rpm in the table top centrifuge) at 4 °C for 15 minutes. 
6. Make 1.8 ml and 0.5 ml aliquots of supernatant and store at -70 °C. 
7. Use one 0.5 ml frozen vial to titrate the virus. 
 
PREPARATION OF HIGH TITER VIRUS STOCKS 
 
Methods 
1. Seed cells into 3, triple-deck flasks and grow until confluency.  
2. Remove the medium and leave approx. 50 ml of complete medium containing 10% fetal bovine 
serum.  Add 500 µl-1 ml of virus per flask.  If the titer of the virus is known use an m.o.i of 1 
(higher m.o.i will may produce deletion mutant). 
3. Adsorb for 1 hour at room temperature on the orbital shaker. 
4. Add 20-40 ml of complete medium containing 10% fetal bovine serum and incubate at 37 °C for 3-
4 days.  Check for signs of infection 2 days after the start of infection.   
5. Pellet down the cellular debris (3000 rpm / 4 °C / 15 minutes) and aliquot into freezing vials and 
store at 4 °C (stable for up to 6 months) and / or -70 °C (for long term storage). Virus should be 
stored away from the fluorescent lights since the virus titer appears to decrease when exposed to 
fluorescent light for prolonged period of time.   
6. Determine the virus titer using the plaque assay procedure.   
 
CONCENTRATION OF EQUINE ARTERITIS VIRUS USING A 20% SUCROSE CUSHION  
 
Materials 
1. 20% sucrose in NET buffer 
2. SF-MEM 
3. RK-13 Medium 
4. NET buffer 
Method 
1. Five T-150 flasks with 3 days old confluent monolayers of RK-13 cells. 
2. Inoculate EAV PP3 P3 at an m.o.i. of 5.  Use approximately 2 vials (1 ml / vial) / T-150 flask.  10 vials 
of virus for five T-150 flasks. 
3. Dissolve the virus in SF-MEM. 
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1. 10 mls / T-150 × 5 = 50 mls 
2. Take 40 mls of SF-MEM and add 10 ml of virus  
3. Add 10 mls / T-150 flask 
4. At the same time mock infect one T-75 flask of RK-13 cells. 
5. Adsorb for 1 hour at 370C.  . 
6. Add 20 ml of complete RK -13 medium / T-150 flask.  Incubate at 370C for 48 hours or until 95% - 
100% CPE. 
7. Collect the supernatant and centrifuge at 5000 g (or 3000 rpm) / 4 °C / 15 minutes to remove cellular 
debris.   
8. Filter the supernatant through 4.5?m bottle-top filter (optional) and overlay on to approx. 3-5 ml of 20% 
sucrose cushion placed in ultracentrifuge clear tubes.  Place each tube into ultracentrifuge bucket and 
balance to equal weight.   
9. Pellet the virus by ultra-centrifugation [36,000 rpm (155,300 g) / 4 °C / 4 hours in AH 650 rotor]. 
Remove brake. 
10. Aspirate the supernatant and resuspend the virus pellet in 300-500 ?l PBS (pH 7.4).  Sonicate for 15/15 
sec on and off for three times  
11. Store at -80 °C.   
12. It is better to collect following samples for micro-titration assay to determine the efficiency of 
purification.   
 
MICROTITRATION ASSAY TO ESTIMATE EQUINE ARTERITIS VIRUS TITERS 
 
Materials: 
1. 96 Wells microtitration plates (Falcon? 3072) 
2. Sterile snap cap tubes (Fisher or Falcon? 2054) 
3. Multi channel pipette (8 or 12 channels) 
4. Antiserum or ascitic fluid (Monoclonal antibodies) 
5. Negative control serum or control ascitic fluid 
6. EMEM (BioWhittaker?) 
7. Complete RK-13 medium  
8. Confluent RK-13 cells (one T-75 flask is sufficient for 5 ninety six well plates) 
9. Equine arteritis virus stock to be titrated 
10. Crystal violet staining / fix solution 
 
Method: 
 
1. Each test virus is done in triplicate.  Label the 96 well plates with cell controls. 
2. Dilute the test virus from 10-1 to 10-8 in EMEM (ten fold serial dilution).  Use 200 µl of virus + 
1800 µl of EMEM.   
3. Add 50 µl of EMEM to all the wells except to control wells (column 10, 11 and 12) where 100 µl 
of EMEM should be added. 
4. Trypsinize a confluent T -75 flask of RK-13 cells and resuspend the pellet in 10 ml of RK-13 
medium.  Take 2 ml of the cell suspension and resuspend in 10 ml (1:5) of RK-13 medium (or 4 
ml in 20 ml would be better.  This gives enough volume to work). 
5. Add 50 µl of diluted virus to test wells in triplicate.  Start with the highest dilution (10-8) and go to 
the lowest dilution (10-1; therefore, can use the same pipet tip) 
6. Add 100µl of resuspended RK-13 cells to each well.  Incubate at 37 °C for four days. 
7. Feed the plates with 50 µl of growth media on day 2 and day 3 (if necessary) to maintain 
monolayers. 
8. When CPE occurs (usually 4 days), dump out the media in sink and stain with 1% crystal violet 
solution/fix for 20-30 minutes (it is easy to leave the plate(s) in a bucket containing 1% crystal 
violet/fix solution because the 1% crystal violet/fix solution can be reused.) and then wash gently 
with tap water to remove excess Crystal violet (three times).  Air dry plates and determine EAV 
titer by Reed and Munch method. 
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9. 50% end point values, by Read and Munch Method:  Under lined numbers indicate logarithmic 
characteristic of end point dilution.  Triplicates; 
3 - 2 - 0 - 0 = 0.25  3 - 1 - 2 - 0 = 0.5 
3 - 2 - 1 - 0 = 0.5   3 - 1 - 3 - 0 = 0.2 
3 - 2 - 2 - 0 = 0.0   3 - 0 - 0 - 0 = 0.5 
3 - 2 - 3 - 0 = 0.3   3 - 0 - 1 - 0 = 0.7 
3 - 1 - 0 - 0 = 0.75  3 - 0 - 2 - 0 = 0.8 
3 - 1 - 1 - 0 = 0.0   3 - 0 - 3 - 0 = 0.0 
10. Report virus titers as TCID50 per 50 µl.  
 
?
PLAQUE ASSAY 
 
Materials: 
 6 well plates 
 RK-13 cells  
 Carboxymethylcellulose (CMC) overlay media (1.3X EMEM 10% FSCS) 
 Virus for titration 
 
METHOD: 
1. Prepare RK-13 in 6-well plates. 
2. Make virus dilution (10-1 to 10-8) in complete 10% EMEM growth media. 
3. Aspirate the medium and add 200 ?l of diluted virus to each well in duplicate(Start from 10-8  and go to 
10-1).  Mix gently by rocking the plate. 
4. Incubate the plate at 37 °C for 1 hour to allow virus particles to adsorb into cells. 
5. Following 1 hour incubation period, overlay cells with 4 ml (per well) of CMC overlay media adding 
to the side of the plate.   
6. Allow plates to sit undisturbed on a leveled surface for 4 days until visible plaques develop. 
7. After 4 days, discard supernatant and stain with crystal violet staining solution. 
8. Count >10 to <100 plaques per well.  
9. PFU/ml = (# of plaques in each well [duplicate]/2) × (highest dilution that gives # of plaques) × 
(dilution factor) 
10.  e.g. [(25 + 30)/2] × 10-5 × 5 (200 ?l) = 137.5 × 10-5 = 1.37 × 10-7 pfu/ml 
 
 
 
?? Ł  
SEROLOGY 
 
VIRUS NEUTRALIZATION TEST (VNT) 
 
Methods 
1. Inactivate sera at 56 °C for 30 minutes 
2. Put 25?l of serum diluent (10% GP complement in EMEM 10% FSCS [keep on ice until used]) in all 
wells. 
3. Put 25?l of test serum to the first well of two rows (No row for checking toxicity*).  Dilute with 25 ?l 
multichannel pipettor. 
4. Add 25 ?l of virus (200 TCID50) diluted in EMEM 10% FSCS to all wells except controls (“See 
controls”). 
5. Incubate plates at 37 °C (5% CO2 incubator) for one hour. 
6. Add 125 ?l of trypsinized cells (prepared as directed below) to every well. 
7. Seal plates and incubate at 37 °C (5% CO2 incubator).  Read after 48, read and final at 72 hours. 
Controls: cell controls, known positive and negative sera, and virus titration controls. 
Cell controls: add 50 ?l serum diluent to 2 wells. 
Serum controls: add 25 ?l serum diluent to 1 well/each test serum, add 25 ?l test serum. 
Known positive serum and known negative serum are set up the same way as test sera. 
 
Virus titration: Add 25 ?l serum diluent into each of 4 wells for cell controls (Row #1). 
     Add 25 ?l of working virus dilution to each of 4 wells (Row #2). 
Add 25 ?l of 1:10 dilution of working virus in EMEM 10% FSCS to each of 4 wells 
(Row #3). 
Add 25 ?l of 1:100 dilution of working virus in EMEM 10% FSCS to each of 4 wells 
(Row #4). 
Add 25 ?l of 1:100 dilution of working virus in EMEM 10% FSCS to each of 4 wells 
(Row #5). 
     Add 125 ?l of trypsinized cells to all 20 wells. 
 
*If serum is toxic in serum control well (1:4 dilution), then repeat test with a row to check for toxicity. 
 
 
REVERSE SN-TEST FOR EAV VERIFICATION – confirmation test 
 
Materials 
1. Known positive serum, inactivated and diluted 1:4 in PBS (should come from field sample(s), not from 
vaccinated horses). 
2. Known negative serum inactivated and diluted 1:4 in PBS. 
3. Stock virus (Bucyrus) 
4. Unknown virus isolate 
Methods 
1. Add 0.3 ml of known negative serum to 4 tubes for each virus sample to be tested (including stock 
virus). 
2. Add 0.3 ml of known positive serum to 3 tubes for each virus sample to be tested (including stock 
virus). 
3. Make up 1:10 dilution of guinea pig complement in EMEM + 10% FSCS + antibiotics (10 ml for each 
sample). 
4. Make up 10-1 to 10-5 dilutions of all virus samples to be tested using 1.8 ml of media in #3 and 0.2 ml 
of virus (It may be necessary to dilute stock virus to 10-3 before starting these dilutions). 
5. To positive serum (3 tubes) add 0.3 ml of 10-1, 10-2 and 10-3 virus dilutions. 
6. To negative serum (4 tubes) add 0.3 ml of 10-2, 10-3, 10-4 and 10-5 virus dilutions. 
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7. Incubate serum-virus mixture for 1 hour at 37 °C. 
8. 14 flasks 25 cm2 [7 RK-13 (KY) “high pass”, 7 RK-13 (ATCC-CCL37) “low pass”] are used for each 
virus to be tested.  Aspirate off media from 3-5 day RK-13 flasks and add 0.25 ml of above serum-
virus mixture to 2 flasks/dilution. 
9. Incubate for 2 hours at 37 °C (closed caps, no CO2), rock flasks after 1hour. 
10. Add 10 ml of CMC overlay/flask.  Incubate for 4-5 days according to development of CPE, remove 
media, and stain with crystal violet plaque stain. 
 
 
TREATMENT OF SERUM WITH TOXICITY DUE TO (DUVAXYN) ANTIBODIES TO RK-13 
CELLS 
 
This procedure has been used successfully to eliminate (or reduce to readable at 1:4) toxicity from serum 
samples demonstrating the vaccine-induced “European” toxicity at 1:4 and greater in the EAV SNT.  These 
horses have been vaccinated with Duvaxyn EHV 1,4 (the EHV-1 component is made in RK-13 cells).  
Always treat a known negative and a known positive serum whenever this treatment is performed on toxic 
serum specimens.  Preferably, use serum that has not been previously inactivated.  Use sterile technique for 
the following steps: 
 
Methods 
1. Decant growth media from as flask of 7-10 day old RK-13 (KY) cells (P399-409).  Wash flask 3X 
with 10 ml Dulbecco’s PBS.  Add 1 ml trypsin EDTA/flask, rotate to spread over cell monolayer, then 
incubate approximately 6-8 min at 37 °C. 
2. When cells have detached, add 2 ml EMEM with 10% FSCS/flask.  Mix well with 5 ml pipet, then 
divide between three 1.5 ml microcentrifuge tubes. 
3. Spin tubes at 2,0000 rpm for 15 sec in microcentrifuge.  Use a Pasteur pipet to remove and discard all 
supernatant.  
4. Add 0.5 ml of toxic serum or control serum per tube; mix with pipet until cells are resuspended; label 
tube appropriately.  Incubate for 1 hour at 37 °C.  Flick tubes after 30 min to resuspend. 
5. Spin 2,500 rpm for 15 sec.  Use a Pasteur pipet to transfer each serum to a new, labeled 1.5 ml 
microcentrifuge tube. 
6. Inactivate at 56 °C for 30 min if serum has not been inactivated previously.  Proceed with EAV SNT 
test, running sera (toxic, negative, positive) as usual and in pre-seeded (planted 18-24 hours prior) 
plates. 
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MOLECULAR BIOLOGY/ RECOMBINANT DNA TECHNIQUES 
 
DESIGNING OF PRIMERS 
 
The approach for designing of specific and efficient primers remains somewhat empirical; there are no hard 
and fast rules.  With experience and by using a good primer designing program (e.g., MacDNASIS v3.5; 
Hitachi) the majority of the primers can be made to work.  Following are some guidelines to design specific 
and efficient primers. 
1. Where possible, select primers with an average G+C content of around 50%.  
2. Where possible, select primers with a random base distribution.  Try to avoid primers with stretches of 
polypurines, polypyrimidines, or other unusual sequences. 
3. Melting temperature (Tm) should be between 55-75 °C.   
4. Increasing the Tm, therefore, the annealing temperature enhances discrimination  against 
incorrectly annealed primers and reduces misextension of incorrect nucleotides at the 3’ end of the 
primers.  Therefore, increasing the annealing temperature will help to increase the specificity.  An 
applicable annealing temperature is 5 °C below the true Tm of the amplification primer.  The best 
annealing temperatures is in the range of 55-72 °C.  Quick way to calculate annealing temperature is: 
5. Annealing temp. (°C) = (# of A and T [A+T] ? 2  +  # of G and C [G+C] × 4) – 5 °C. 
6. Try to design both positive and negative primers with same Tm (1-2
0C difference will not matter). 
7. Make sure the primer ends (3’) with a G or C. 
8. Primer length should be between 19 and 30 bases (19 to 22 bases are preferred).   
9. If possible select a unique area of the genome to design the primer. 
10. Avoid sequences with significant secondary structure (computer programs are very useful for this). 
11. Check the primers against each other for complementarily.  Avoiding primers with 3’ overlaps will 
reduce the incidence of “primer-dimer” artifacts.   
12. If possible do a simple homology matching (compare the primers with the whole genome using a 
computer program) and see whether primer(s) have <50% homology in the area closer to be amplified 
(or to the desired area).  This will reduce the number of nonspecific products of same size.   
 
 
AGAROSE GEL ELECTROPHORESIS  
 
Materials 
1. Agarose (SEAKEM? LE agarose; FMC Bio Products).   
2. 50X TAE buffer (Tris Acetate EDTA, pH 8.0). 
3. Gel casting plate. 
4. Gel sealing tape 
5. Buffer tank.   
 
Method 
1. Make 1000 ml of 1X TAE, by measuring 20 ml of 50X stock into a 1000 ml graduated cylinder and q.s. 
to 1000 ml mark with deionized distilled water.  
2. Weigh 1.0 g of agarose (for 1% gel) and dissolve it in 100 ml of 1X TAE.  Melt agarose solution in 
microwave until completely dissolved.  Let stand at room temperature (or at 45 °C in a water bath) to 
remove air bubbles but not enough to solidify. 
3. Prepare gel-casting plate by taping the ends with gel sealing tape.  Place the sample comb in the proper 
position on the plate.  
4. Pour 100 ml of 1% agarose on to the gel casting plate slowly and allow it to solidify (volume of 
agarose needed depends on the size of the gel casting plate).  The gel should be between 0.3 and 0.5 
cm thick.  After gel has set, final gelling carried out at 4 °C for 30 minutes.  There should not be any 
air bubbles in the gel.   
5. Remove the tapes and keep the gel plate in the buffer tank.  Add 1X TAE buffer into the reservoirs 
until it covers the surface of gel at a depth of 3-4 mm. 
6. Slowly remove the sample comb and load the samples into the wells (Mix 1-20?l of RNA or DNA 
with 6X gel loading buffer; loading volume depends on the sample and make sure gel loading buffer 
get diluted to 1X with sample). 
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7. Voltage 70V for 2-3 hours (95V for 45-60 minutes) or until the first band has migrated at least 2.5 
inches away from the wells.  The voltage must never exceed 100V.  For low melt Agarose use low 
voltage (70V).  Always run the gel in constant voltage. 
8. Stain gel in ethidium bromide, letting it sit for 5-10 min.  Destain gel by placing in deionized distilled 
water for 5 min. 
9. Transfer the gel onto a UV light source. Usually a trans illuminator is used to facilitate this step.  Place 
a piece of plastic wrap between the gel and surface of the illuminator.  Use a face shield, gloves, and 
body shield to minimize the UV exposure.  Take a picture for records. 
10. Locate the DNA or RNA bands and excise by using a sharp scalpel blade (e.g. to obtain the desired 
band) 
Note:  Range of separation in gels containing different concentrations of agarose. 
  
 % of agarose (%[w/v])                 Efficient range of separation of linear DNA molecules (Kb) 
  0.3   5-60 
  0.6   1-20 
  0.7   0.8-10 
  0.9   0.5-7 
  1.2   0.4-6 
  1.5   0.2-3 
  2.0   0.1-2 
 
 
 
REAL TIME RT-PCR MEASURING EQUINE CYTOKINE GENE EXPRESSION  
PREPARATION OF COMPETENT BACTERIA CELLS - DH5? 
 
Materials 
1. Large, autoclave tray with ice for the ice/water bath. 
2. 40 sterile microcentrifuge tubes. 
3. Glycerol 
4. LB agar plates without ampicillin. 
5. Autoclave centrifuge bottles, microcentrifuge tubes. Dry cycle. 30 min. 
6. Chill these: centrifuge bottle, 15 ml conical tube, 0.1 M MgCl2 and CaCl2 solutions. 
Perform all procedures using sterile plasticware and solutions. 
Solutions 
1. 100 ml of 0.1 M MgCl2 prepared from 1 M MgCl2 stock. 
2. 100 ml of 0.1 M CaCl2 prepared from 1 M CaCl2 stock. 
3. Stock solutions can be sterilized by autoclaving and stored at room temperature. 0.1M solutions should 
be prepared fresh. 
4. LB (10g Bacto-tryptone, 5g yeast extract, 5g NaCl for 1000 ml LB) supplemented with 1 g/L glucose. 
Autoclave. 
Preparation of solutions 
1.   Glucose-supplemented LB medium (500 ml) 
Bacto-tryptone    5.0 g 
Bacto-yeast extract    2.5 g  
NaCl    2.5 g  
Glucose    0.5 g  
dH2O  to 500 ml 
Autoclave. Liquid cycle 30 min. Store at 4C. 
 
2.   Glycerol 100 ml 
Autoclave. Liquid cycle 30 min. Store at 4C. 
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3.   1 M MgCl2 stock (100 ml) 
MgCl2·6H2O  (FW 203.30)    20.33 g 
dH2O  to 100 ml 
Autoclave. Liquid cycle 30 min. Store at Room temperature. 
 
4.   1 M CaCl2 stock (100 ml) 
CaCl2·2H2O  (FW 47.02)     14.70 g 
dH2O           to 100 ml 
Autoclave. Liquid cycle 30 min. Store at Room temperature. 
 
5.   0.1 M MgCl2 working solution (100 ml) and 0.1 M CaCl2 working solution (100 ml) 
 
Method 
 
1.   Streak out bacteria (DH5? or other strain) on an LB agar plate (without antibiotics). Allow to grow 
overnight at 37 °C. 
2.   The next day, pick a single colony and grow in 2 ml of LB medium (without antibiotics), shaking 
(250 rpm) at 37 °C overnight. Best to do this in the late afternoon. 
3.   Take 0.5 ml of the prepared LB medium to use as a blank for the OD. Transfer overnight bacterial 
prep to a 2L flask containing 500 ml of glucose-supplemented LB medium. Incubate at 37 °C with 
vigorous shaking. During this time chill all solutions and centrifuge bottles on ice and turn on 
spectrophotometer, set wavelength at 550. After several hours (2.5-3 h), remove 0.5 ml of bacteria 
using a sterile pipet and check OD550 (use LB/glucose as blank). Continue to check the culture until 
the OD550 reaches 0.5 (bacteria double about every 20 min). As soon as the correct OD is achieved 
immediately transfer the culture flask from the shaker to an ice/water bath. Constantly swirl flask for 
5 min until the whole sample is uniformly chilled. Pour the bacteria into the chilled centrifuge bottle 
and spin at 4000 rpm, 4 °C for 20 min. 
4.   Decant supernatant and place bottle with bacteria pellet on ice. Resuspend in 10 ml of ice cold 0.1 M 
MgCl2 using sterile 10 ml pipet. Once resuspended, add the remaining 90 ml of chilled 0.1 M 
MgCl2. Sit on ice for 5 min and spin for 20 min at 4000 rpm 4 °C. 
5.   While spinning, transfer 8.6 ml of 0.1 M CaCl2 to a 15 ml conical tube. Add 1.4 ml glycerol. Mix 
well and let sit on ice. 
6.   Decant supernatant and place bottle on ice. Resuspend in 10 ml of ice cold 0.1 M CaCl2 using 
sterile 10 ml pipet. Once resuspended, add the remaining 81.4 ml of ice cold 0.1 M CaCl2. Sit on 
ice for 20 min and spin in the centrifuge for 20 min at 4000 rpm 4 °C. 
7.   Decant supernatant well and place bottle on ice. Resuspend bacteria in a chilled solution of 8.6 ml 
0.1 M CaCl2 /1.4 ml glycerol. Mix well and transfer 0.25 ml aliquots to microcentrifuge tubes that 
have been placed in dry ice or drop tubes into liquid nitrogen. Quick freeze and store bacteria at -
80 °C until use. Once thawed, the cells should not be frozen  
 
TRANSFORMATION OF DH5? 
 
Materials 
 
1. Water bath at 42 °C 
2. Warm SOC medium to RT 
3. Warm 3 LB plates w/ampicillin 
4. Thaw on ice 1 vial of competent cells (DH5?) for each transformation 
 
Methods 
1. Thaw on ice, one vial of competent cells per transformation. 
2. Add all ligated product to 100ul of competent cell and mix by stirring gently with the pipette. Do not 
mix by pipetting up and down. 
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3. Incubate on ice for 30 min 
4. Heat-shock the cells for 45 seconds at 42 °C without shaking 
5. Immediately transfer the tubes on ice 2min 
6. Add 900ul of RT SOC medium 
7. Cap the tube tightly and shake the tube horizontally at 37 °C for 1 h (240rpm) 
8. After incubation at 37C for 1h. Transfer the culture to microcentrifuge tube. Decant the supernatant 
leaving about 100ul of media. Resuspend the bacterial pellet. 
9. Spread 100ul from each transformation on a prewarmed LB agar plate (w/ampicillin) and incubate 
overnight at 37° 
 
 
 
BCA PROTEIN ASSAY (adapted for Nanodrop use)  
 
The BCA Assay requires a standard curve to be generated each time it is run 
 
Materials 
BCA protein assay (Pierce; Cat# 23225) 
 
Method 
1.  Prepare diluted albumin (BSA) standards. 
- Dilute the contents of one BSA ampule into several clean vials. Preferably use the same diluent as the 
sample(s). Each 1 ml ampule of 2.0 mg/ml BSA is sufficient to prepare a set of diluted standards. 
 
 Working range = 20-2,000 ug/ml 
Vial Volume of Diluent Volume and Source of BSA Final BSA concentration 
A 0 300ul of Stock 2,000 ug/ml * 
B 125ul 375ul of Stock 1,500 ug/ml * 
C 325ul 325ul of Stock 1,000 ug/ml * 
D 175ul 175ul of vial B dilution 750 ug/ml  
E 325ul 325ul of vial C dilution 500 ug/ml * 
F 325ul 325ul of vial E dilution 250 ug/ml 
G 325ul 325ul of vial F dilution 125 ug/ml * 
H 400ul 100ul of vial G dilution 25 ug/ml 
I 400ul 0 0ug/ml= Blank 
If nanodrop allows only 5 standard points use these concentrations (*) to make the standard curve 
 
2. Prepare the BCA Working Reagent (WR) 
- Use the following formula to determine the total volume of WR required: 
(# standards + # unknowns) × (# replicates) × (volume of WR per sample) = total volume WR required 
 
3. Prepare WR 
- Mix 50 parts of BCA reagent A with 1 part of BCA reagent B (50:1, Reagent A:B) 
 
4.  Regular assay (using a 20:1 reagent/sample volume ratio).  
- Pipet 4 ul of sample in 80 ul of BCA reagent into a 1.7 ml centrifuge tube and mix well. 
- Incubate tubes at 37 °C for 30 minutes (working range = 20- 2,000 ug/ml). It is better to use water bath. 
- Cool all tubes to RT. 
 
5.  Measure protein concentration using Nanodrop. 
- A blank must be measured before the standard curve may be generated. 
- Step 1: Measure the blank (BCA reagent – a “0” standard) 
- Step 2: Up to 5 standards can be measured 
- Step 3: Measure samples 
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ANTIBODY PURIFICATION FROM ASCITES 
 
Materials 
 
1. Zeba Desalt Spin Columns (2ml, Thermo Scientific #89889; 5ml #89891) 
2. Melon Gel IgG Spin Purification Kit (Thermo Scientific # 45206) 
3. Ascites Conditioning Reagent (Thermo Scientific #45219) 
4. Variable-speed centrifuge 
5. 15 ml conical tubes 
6. Buffer for exchange 
7. Serum samples 
8. Pipettes and tips 
 
Methods 
 
A. Ascites Conditioning 
1. Measure the volume of the sample and transfer to a centrifuge tube 
2. Place one half the sample volume of 1 X Gel Purification Buffer into a tube and add 40 ?l of the 
Ascites Conditioning Reagent for every 1 ml of original sample volume. Pulse vortex for 10 sec. 
3. While mixing the sample, slowly add the buffer containing the Ascites Conditioning Reagent. 
4. Rock or rotate sample for 10 min at RT. (Mixture appears opaque after conditioning) 
5. Centrifuge sample at 5,000 ×g for 10 min. Take the supernatant and discard the pellet.  
6. Desalt sample using Zeba Desalt Spin Columns pre-equilibrated with 1X Melon Gel Purification 
Buffer. (For best results, use a sample volume less than 10% of the total Zeba Column volume) Follow 
the manufacter’s instructions about “Procedure for Protein Desalting”. 
 
B. IgG Purification from Ascites 
1. Equilibrate the Melon Gel IgG Purification Support and Buffer to RT 
2. Swirl bottle containing the Purification Support (don’t vortex) to obtain an even suspension. Dispense 
500?l of slurry into a Spin Column placed in a microcentrifuge tube. Swirl the bottle of gel slurry 
before pipetting each sample to maintain the gel suspension. 
3. Centrifuge the uncapped column/tube for 1 min at 2,000-6,000 × g, then remove the spin column and 
discard flow-through. 
4. Add 10 ?l of 5X Regenerant per 1 ml of sample to the conditioned ascites and mix. Add 100 ?l of the 
mixture to the gel, cap column, and incubate for 5 min at RT with end-over-end mixing. 
5. Remove the bottom cap from the column, loosen top cap and re-insert spin column in the collection 
tube. 
6. Centrifuge for 1 min to collect the purified antibody in the microcentrifuge tube. Repeat steps 5-7 for 
the second batch. 
7. The antibody may be directly used or stored at -20 °C 
 
NOTE: Discard or regenerate the gel. For gel regeneration, perform the following steps: 
 
1. Add 1.5 times the gel-bed volume of Melon Gel 1X Regenerant, mix for 5 min with end-over-end 
mixing, centrifuge and discard flow-through. Repeat this process a total of three times. 
2. Wash gel with 10 times the gel-bed volume of water. 
3. For storage, wash column with 10 times the gel-bed volume of 1X Melon Gel Purification Buffer. 
For storage longer than 1 week, add a final concentration of 0.02% sodium azide to the buffer used 
to wash the column. 
  
IgG ANTIBODY PURIFICATION FROM SERUM 
Materials 
 
1. Zeba Desalt Spin Columns (2ml, Thermo Scientific #89889; 5ml #89891) 
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2. Melon Gel IgG Spin Purification Kit (Thermo Scientific # 45206) 
3. Variable-speed centrifuge 
4. 15 ml conical tubes 
5. Buffer for exchange 
6. Serum samples 
7. Pipettes and tips 
 
Methods 
A. Procedure for buffer exchange 
1. Twist off the column’s bottom closure and loosen cap. Place column in a collection tube. 
2. Centrifuge column at 1,000 × g for 2 min to remove storage solution. Place a mark on the side of the 
column where the compacted resin is slanted upward. Place column in centrifuge with the mark facing 
outward in all subsequent centrifugation step. 
3. Add 1ml of Melon Gel Purification Buffer to the column. Centrifuge at 1,000 × g for 2 min to remove 
buffer. 
4. Repeat step 3 two additional times, discarding buffer from the collection tube. 
5. Place column in a new collection tube, remove cap and slowly apply 200-700 ?l sample to the center 
of the compact resin bed. 
6. To ensure maximal protein recovery from low-volume samples, apply a stacker of ultrapure water or 
buffer to the resin bed after the sample has fully absorbed (40 ?l stacker for samples <350?l) 
7. Centrifuge at 1,000 × g for 2 min to collect the sample. Discard column after use. 
 
B. Spin-column procedure for antibody purification 
1. Equilibrate the Melon Gel IgG Purification Support and Purification Buffer to RT (~ 15 min) 
2. Swirl bottle containing the Purification Support (don’t vortex) to obtain an even suspension. Dispense 
500?l of slurry into a Spin Column placed in a microcentrifuge tube. Swirl the bottle of gel slurry 
before pipetting each sample to maintain the gel suspension. 
3. Centrifuge the uncapped column/tube for 1 min at 2,000-6,000 × g, then remove the spin column and 
discard flow-through. 
4. Add 300 ?l of Purification Buffer to the column, pulse centrifuge for 10 sec and discard flow-through. 
Repeat this wash once. Place the bottom cap on the column. 
5. Add 10-100 ?l of buffer exchanged serum to the column. Cap column and incubate for 5 min at RT 
with end-over-end mixing.  
6. Remove the bottom cap from the column, loosen top cap and re-insert spin column in the collection 
tube. 
7. Centrifuge for 1 min to collect the purified antibody in the microcentrifuge tube. Repeat steps 5-7 for 
the second batch. 
8. The antibody may be directly used or stored at -20 °C. 
 
NOTE: Discard the used gel support. If the gel must be used again, it can be regenerated by adding 500?l 
of 5M NaCl or 0.5N NaOH, mix for 5 min, centrifuge, and discard flow-through. Wash gel five times by 
adding 500?l Purification Buffer, centrifuge and discard flow-through. Add 500?l Purification Buffer and 
store at 4 °C. The gel may be regenerated three times without significant loss of selectivity. 
 
 
BIOTINYLATION OF EAV RECOMBINANT VIRUSES  
 
Materials 
1. Amersham ECL Protein Biotinylation Module (RPN2203) 
2. Orbital shaker 
3. PBS, pH 7.5 
4. PBS containing 1% BSA 
5. Distilled water 
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Methods 
 
1. Determine the concentration of protein to be biotinylated (see BCA method using nanodrop) 
2. Prepare a 40 mM working concentration of bicarbonate buffer (BB) by diluting 1:20 in distilled water. 
(prepare always fresh) 
3. Place the biotinylation reagent at RT and ensure the vial has equilibrated to RT prior to opening. 
4. Dilute the protein to 1mg/ml in the diluted bicarbonate buffer. The maximum volume suitable for 
loading on to the column is 2.5 ml (the minimum volume is 2.0 ml). Add 40ul of biotinylation reagent 
for each mg of protein. 
5. Incubate at RT for 1 h with constant agitation. 
6. Discard the buffer at the top of the Sephadex G25 column, and cut 1-2 mm off the tip seal. Equilibrate 
the column with 5 ml of PBS-1% BSA (pH 7.5) followed by 20 ml of PBS. Discard the column 
washings. Do not allow the column to run dry. 
7. Allow the buffer level in the top of the column to fall to the level of the plastic sinter at the top of the 
gel bed. 
8. Apply the protein sample (in 2.0-2.5 ml) to the column. Allow the sample volume to enter the column 
before eluting with PBS and collecting fractions. 
9. Elute the sample in 5 ml of PBS (use 2-3 mls of PBS to wash the tubes containing virus). Collect 1 ml 
fractions (total 5 fractions). Measure protein concentration of 1-5 fractions to determine the eluted 
protein containing fractions. 
10. Measure either protein concentration or UV absorbance at 280nm to verify the fraction number 
containing the eluted protein.  
11. Aliquot in 0.5ml/tube. Make one tube with 110 ?l of biotinylated EAV for titration. Store at -80C   
 
VIRUS BINDING ASSAY  
 
Keep everything at 4 °C during the whole experiment 
1. See EEC in 6 well plates and wait to grow 100% confluent. 
2. Place cells at 4 °C for 30 min to cool down. 
3. Wash cells with cold PBS-2%FBS (PBS-F) 3 times before adding biotinylated VBS into each well. 
4. Incubate the virus and cell mixtures at 4 °C on a shaker for 60 min. 
5. Remove the inocula and wash the unbound cells extensively (3X) with cold PBS-F 
6. Add the non-enzymatic cell dissociation solution (Sigma, #C-5914, 1X, 1 ml/25cm2 flask), 
400ul/well and mix on a shaker. 
7. Incubate at 4 °C until cells are dissociated form the plates. 
8. Add 1ml PBS-F to each well to the cells and pipet repeatedly to dissociate clumps. Transfer the 
cell suspension in 1.5ml eppendorf tube. Spin at 1000xg for 5 min (in real time PCR room, cool 
centrifuge at 4C prior to the experiment) and wash with 1ml PBS-F once to remove non-enzymatic 
buffer. 
9. Incubate the washed cell pellets with 200ul 1:100 diluted streptavidin-FITC conjugated 
(Amersham, #RPN 1232) in PBS F for 60 min at 4C on a shaker 
10. Wash cells once with ice cold PBS, and resuspend in 500 ul PBS F for immediate flow cytometric 
analysis.  
 
Modified protocol for PBMC (EEC for control) 
1. Prepare PBMC as for conventional flow cytometry staining. Process AD and NAD cells separately. 
Incubate on ice to keep it at 4C. Also resuspend EEC cells to use as control. Count the cells and 
place 106 cells into each well or tube. 
2. Wash cells twice with ice cold PBS-2% FBS (PBS-F) at 4C 
3. Incubate cells with anti-equine CD3 MAb (100ul) and biot-EAV (10ug protein, m.o.i. of 100? I 
am not sure how much difference is between these or which one will work better yet) in facs 
buffer (1% NGS; prepare newly and keep it sterile) for 45 min on ice. 
4. Wash once with PBS-F 
5. Incubate and anti-mouse IgG PE and streptavidin-FITC (total volume 100ul) for 45 min on ice 
6. Wash twice with ice cold PBS-F followed by one wash with ice-cold PBS 
7. Resuspend in 300ul of 2% paraformaldehyde. 
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INDIRECT IMMUNOFLUORESCENT ASSAY 
 
Materials: 
 
1. Chamber slides (Lab-Tek? [Chamber Slide™]; Nunc, Inc.) or coverslips for 24-well plate 
2. Cover slips (large). 
3. Confluent monolayer of cells (BHK21, RK13 etc.) 
4. Cell medium (10% BCS-EMEM) 
5. Fixative: 4% paraformaldehyde 
6. Wash buffer: 10mM glycine in PBS  
7. Permeabilization buffer: PBS w/ 0.2% Triton-X 100  
8. Primary antibody dilution: PBS w/ 5% FBS 
9. Secondary antibody dilution buffer: PBS w/ 5% FBS or 0.02% evans blue in PBS 
10. FITC-conjugated goat anti-mouse IgG F(ab’)2 (Caltag) 
11. Mounting medium (Vector, Vectashield H-1000)  
 
Method: 
 
1. Trypsinize cells (T-75 flask) and resuspend into 60 mls of growth media. Plate 0.3 ml per well on to 8-
well chamber slides (in this case, usually cells in chamber slides will be ready for infection in 24 
hours). Incubate at 37 ºC. OR T-25 flask of cells were resuspended into 12 ml of growth medium. 
Plate 300µl cells per well on to eight chamber slides. Incubate at 37°C 
2. Twenty four hours later or when cells are subconfluent aspirate media and infect with EAV at a m.o.i. 
of 5 (100 ?l of diluted VBS53 EAV).  Adsorb for 1 hour at 37 ºC.  Add 0.3 ml of fresh medium and 
incubate for 24 hours. 
3. Aspirate cell media. 
4. Wash one time with cold PBS (0.6 ml per well). 
5. Fix with 4% paraformaldehyde in PBS for at least 30 min at room temperature.  
6. Rinse 3X in PBS/10mM glycine. 0.5-0.6ml/well. Leave the cells in your last PBS-glycine wash and store 
them at 4 °C until labeling 
7. Permeablize with PBS containing 0.2% Triton-X 100, leave at RT 5-10min. 
8. Wash 3X with PBS/10mM glycine with slides on a shaker.  
9. Dilute mouse MAb 12A4 against EAV nsp1  
Make 1:250 dilutions for unconjugated 12A4 (3.5µg/ml) 
Make 1:100 dilutions for AF488 conjugated 12A4 (1mg/ml) 
10. Place 100?l drops of diluted Ab to each well. Incubate at RT for 1 hour. Leave slides on a shaker. 
11. Wash 3X with PBS/10mM glycine 3 times with slides on a shaker. 
12. Dilute secondary Ab [FITC-conjugated goat anti-mouse IgG F(ab’)2 (Cat # 31543, Pierce 
Biotechnology) and FITC-conjugated goat anti-rabbit IgG(H+L) F(ab’)2 (Cat # 31573, Pierce 
Biotechnology)] 
Make 1:100 dilutions 
13. Incubate in dark for 1h at RT with slides on a shaker. 
14. Wash 3X with PBS/10mM glycine with slides on a shaker. 
15. Remove gaskets. Peel off the plastic stickers. Add a drop of mounting medium with DAPI (Vector, 
Vectashield H-1500) on each well of the chamber slides. Then place a coverslip over the stained slide. 
Store at 4 °C in dark. 
 
FLOW PROTOCOL FOR SURFACE AND INTRACELLULAR LABELING of AD and NAD 
PBMCs 
 
Materials 
 
1. 4% paraformaldehyde fixation 
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2. FACS buffer (DPBS with 0.1% (w/v) sodium azide. Filter 0.2 ?m pore membrane. Store at 4 °C. 
Add 1% NGS when needed) 
3. Permeabilization buffer: DPBS, 1% heat-inactivated NGS, 0.1% (w/v) sodium azide, 0.1% 
saponin (w/v) and sterile filter (0.2 ?m pore membrane) 
4. Antibodies with appropriate dilution (All intracellular antibody dilutions will be performed in 
permeabilization buffer/ surface marker Abs are diluted in FACS buffer) 
5. Secondary antibodies 
6. Blocking solution (Flow buffer with 10% FBS) 
 
 
Methods 
 
Virus infection 
 
1. Plate cells in each 150 mm culture dish and infect with virus at m.o.i. of 5. Dilute the virus in 
minimum volume of plain media (7 ml of plain RPMI is enough to cover 150 mm dish) Note: 
Include control cells (e.g. equine endothelial cells T-75 has approx. 1.5 × 107 cells)  
2. Adsorb virus for 1 h and add 18 ml of 10% cRPMI media into each dish. Incubate for 12, 18, 36 h. 
3. Cell collection. 
4. Non-adherent cells: collect TCF. Wash twice with PBS (10 ml each time) and pull them together 
with TCF. 
Adherent cells: discard TCF and wash with PBS (10 ml each time) and discard the washed fluid. 
After washing, collect adherent cells using a scrapper and wash the dish with PBS and collect the 
PBS wash. 
5. Pellet cells and count them. 
 
Surface staining 
 
1. Dilute the surface markers in facs buffer. Dilute cell pellet in facs buffer and equally aliquot ~1.0 x106 
cells into each of V-bottomed 96 well plate. 
2. Label cells with 100ul of cell surface marker. Mix by pipetting and incubate for 30 minutes at 4 °C 
(ice-bucket).  
3. Wash once with 200ul facs buffer, centrifuge at 500 g for 5 minutes. 
4. Label cells with 100ul of 2° Ab (goat anti-mouse IgG-PE conjugated diluted 1:200 in facs buffer). 
Incubate for 30 minutes at 4 °C covered with aluminum foil 
5. Wash once with 200ul facs buffer, centrifuge at 500 g for 5 min. Flick off excess 
 
E. INTRACELLULAR EAV STAINING 
6. Fix the cells with 200µl 4% paraformaldehyde for 30 minutes at RT in dark. Centrifuge at 500 g for 5 
minutes.  
7. Wash once with 200ul facs buffer.  
8. Permeabilize membrane with permeabilization buffer (200 µl /tube) for 5 minutes. 
9. Centrifuge at 500 g for 5 minutes.  
10. Block Fc receptors with 10% FBS in FACS buffer for 30 minutes at RT in dark. 
11. Dilute the intracellular labeling antibody in permeabilization buffer. 
12. Label with fluorochrome- conjugated intracellular antibody for 30 minutes at RT in dark.  
13. Wash 1X with 200 ul FACS buffer. 
14. Resuspend in 200 ul of 0.5% paraformaldehyde/PBS and store at 4 °C for next day acquisition. 
 
 
SDS-PAGE and WESTERN BLOTTING 
A. SDS-PAGE 
Materials  
1. BIO-RAD minigel apparatus 
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2. Glass plates with 1.5 mm spacers (Bio-Rad Cat #1653312) 
3. Glass plates (short plates; Bio-Rad Cat#1653308) 
4. 1.5 mm combs, 10 lanes (Bio-Rad Cat #1653365) or 15 lanes (Bio-Rad Cat#1653366)  
5. Gaskets (Bio-Rad Cat #1653305) 
6. Casting frames (Bio-Rad Cat#1653304) 
7. 1.5 M Tris HCl pH 8.8, ml (Bio-Rad #161-0798) 
8. 0.5 M Tris HCl pH 6.8, ml (Bio-Rad #161-0799) 
9. Acrylamide/Bis, 30%/0.8% (Bio-Rad Cat #161-0158) 
10. 10% SDS, ?l (Bio-Rad Cat #161-0416) 
11. TEMED, ?l (Bio-Rad Cat #161-0801) 
12. 10% Ammonium persulfate (APS; Bio-Rad Cat #161-0700)  
13. Dissolve 1g of APS in 10ml of DW 
14. Prepare 1 ml aliquots and store at -20 °C 
15. Laemmli sample buffer (Bio-Rad Cat #161-0737) 
16. No-Weigh™ Dithiothreitol (DTT; Pierce Cat # 20291) 
17. BenchMark Pre-stained protein ladder (Invitrogen, Cat #10748-010) 
18. MagicMark XP (Invitrogen, Cat #LC5602) 
19. Molecular grade water 
 
<Gel Recipes: to make 2 mini-gels of 1.5mm thickness> 
 Resolving (lower) gel Stacking (upper) gel 
 10% 12% 4% 
30% AA 4.9 6 ml 0.675 ml 
1.5 M Tris HCl pH 8.8 3.75 3.75 ml - 
0.5 M Tris HCl pH 6.8 - - 1.25 ml 
dH2O 6 4.95 ml 3 ml 
10% SDS 150 ?l 150 ul 50 ?l 
10% AP 75 ?l 75 ?l 30 ?l 
TEMED 15 ?l 15 ?l 5.5 ?l 
 
Buffers (See below for buffer recipe) 
1. 1X TGS Running Buffer 
 
Methods 
1. Assemble the minigel apparatus:  Wash glass plates and spacers with distilled water and detergent.  
Air-dry in a rack.  The glass plates must be absolutely clean.  Just before assembly wipe the glass 
plates with 70% ethanol.   
2. Preparation of gel solutions using following table:  Make up 12% resolving gels for viral proteins.  
Make up 10% resolving gel if looking for heavy (50,000 kDa) and light (25,000 kDa) of purified 
immunoglobulins.  This will give best separation and resolution of heavy and light chains.  Make up 5% 
stacking gel at the same time.   
3. Prepare both gel solutions according to the recipe. Do not add TEMED until just before pouring the gel 
into the apparatus.  
4. Pour the gel solution between the glass plates. Leave enough space for the stacking gel (comb depth + 
1 cm approx). Overlay the gel with dH2O.  
5. Let the gel to polymerize (approx. 30 min), pour off the overlay and wash the top of gel several times 
with dH2O. Remove any remaining H2O with the edge of a paper towel.  
6. Add TEMED to the prepared stacking gel solution, mix and immediately pour over top of resolving gel.  
Add close to the top.  Place combs (before placing the combs should be washed with warm water and 
dried) in to the stacking gel (stop 3-5 mm above the inter phase of stacking and resolving gels).  Avoid 
air bubbles.  Allow 15 minutes for polymerization (during this time get the samples ready).  Remove 
combs.  Air bubbles should run in to replace combs.   
7. Make up one liter of 1X SDS-PAGE running buffer (4X = 232 g glycine, 48 g Tris base, 16 g SDS 
made up to 4 liters) and pour 500 ml into the buffer tank.  
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8. Remove the gels (molds with the plexiglass holders) from the casting stand and lock into the central 
unit with thumbs pushing from the bottom.  Small glass plate goes against the rubber gasket.  Bottom 
clicks into place on base pate of the central unit.  
9. Drop assemble unit into the buffer tank.  Add running buffer to center compartment until gels get 
submerged.  Do not allow inside buffer and buffer in the tank to communicate (not imperative).  Flush 
out each well with pipette before loading the samples.   
10. Preparation of Samples and Running the Gel:  Denature protein in sample buffer (with the appropriate 
concentrations of DTT Pierce #20291) for 1-3 minutes.  Can store the samples at -200C or -700C. Mix 
1 tube of DTT (500mM) with 250ul of sample buffer. Mix with sample 1:1 dilution (e.g. 15ul of DTT 
in sample buffer + 15ul of sample) 
11. Load 30-35 ?l (10 lane combs) or 15 ?l (15 lane combs) per lane.  Use long slender pipette tips.  Slip 
into space between two glass plates gently eject the sample into the well made by the comb.  Load 1X 
sample buffer into lane 1 and 10 (or 15; do not load samples into these lanes and this will avoid the 
smiling effect).  Load appropriate molecular weight markers to the second lane.   
12. Add running buffer to the buffer tank until the level of the top of the gels.  
13. Cover minigel unit (fits only one way) and fix red to red (positive), black to black (negative).  Proteins 
are negatively charged and they migrate to the anode at the bottom.  Run at 200 V, 30~40 min.  
14. Stop when the dye front reaches the bottom.  Turn off the power, pull off top and remove central gel 
unit and mark the left side of the glass plates with a “Sharpie” pen (this will indicate the lane one).  
Take apart the plates and cut the corner of the gel with a blade for identification (e.g. top left corner for 
gel).   
15. Gels are ready for transfer (for western immunoblotting), autoradiography (for immunoprecipitation), 
or staining with Coomassie or silver stains.  Proceed to appropriate protocol.  
 
B. Gel transfer to PVDF membrane 
 
Materials  
1. Immun-Blot® PVDF membrane (7×8.4 cm; Bio-Rad Cat #162-0174) 
2. Extra thick blot paper (cut to same size as blot membranes; Bio-Rad Cat#1703969) 
3. Methanol (Fisher Cat#A412-4) 
4. Clean forceps 
 
Buffers (See below for buffer recipe) 
1. Transfer buffer 
2. TBS-T 
 
Methods 
1. Soak 2 filter papers for each gel in transfer buffer. 
2. Pre-wet PVDF membrane in 100% methanol for 1-2 min and equilibrate the membrane in DW for 2 
min and let it in transfer buffer. 
3. Equilibrate the gel for 10 min in transfer buffer 
4. For transfer, place one filter paper, PVDF membrane, SDS-PAGE and on top the second filter paper. 
5. Assemble the transfer unit.  Run at 15V for 1hr.  
6. Rinse the transferred membrane in TBS-T buffer and proceed to western blotting step. 
 
C. Western Blotting 
Materials 
1. Skim milk (Bio-Rad Cat#170-6404) 
2. Antibody saver trays (Scienceware, small size) 
3. Primary antibody (e.g. anti-EAV nsp1 [12A4] purified IgG) 
4. Biotinylated goat anti-mouse IgG (Zymed Cat #81-6540) or biotinylated goat anti-rabbit IgG (Zymed 
Cat #81-6140) 
5. Streptavidin-HRP (Zymed Cat #43-8323) 
6. ECL™ Western blotting analysis system (GE Healthcare Cat #RPN2109) 
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7. Rad Tape (Midsci Cat #RAD-10) 
 
Buffers (See below for buffer recipe)  
1. TBS-T 
2. Antibody dilution buffer (ADB) 
3. 5% nonfat dry milk/PBS blocking buffer 
 
 
Methods 
1. Block the membrane in blocking buffer at 4 °C O/N on a shaker or 1-2 hr at RT. 
2. Wash the membrane with TBS-T once. 
3.  Incubate with primary antibody (most of MAb work at 1µg/ml) 1 hr at RT. 
4.  Wash 3 times with TBS-T (10 min/each) 
5.  Incubate with 1:5,000 diluted secondary antibody (Biotin-conjugated anti-Ms or anti-Rb) in ADB 1hr 
at RT. 
6.  Wash 3 times with TBS-T (10 min/each) 
7.  Incubate with 1:2,000 diluted Stv-HRP in Stv-HRP dilution buffer 1hr at RT. 
8.  Wash 3 times with TBS-T (10 min/each) 
9.  Mix 1:1 components of ECL to develop the membrane. 
 
 
COOMASSIE BLUE R PROTEIN STAINING FOR DETECTION OF PROTEIN IN SDS-PAGE 
GELS 
 
1. Place the gels on a glass dish and add 100 ml of Coomassie blue stain and leave on the rocker for 4 
hours or more (can stain over night) to allow staining.   
2. Remove the Coomassie blue stain (save can reuse) and add 200-250 ml of gel destaining buffer (40% 
methanol, 10% acetic acid in distilled water).  Leave on the rocker for 8 hours.  Keep a sponge or 
kimwipes in the glass dish to absorb stain.   
3. Dry the gels on cellophane/perspex frames.  Get two 12’’ x 10’’ cellophane sheets and wet with 
distilled water (wet one at a time).  Lay one wet cellophane sheet on the bottom frame (with center in 
place to support cellophane) and place the gels over that.  Overlay with second wet cellophane, avoid 
air bubbles, make good contact between gels and the cellophane sheets.  Place the top frame (no center 
needed).  Clamp edges together with bulldog clips while pulling cellophane tight.  Make small hole for 
drainage in bottom corner and leave upright.  Allow to dry 8-12 hours and remove the frames and store 
the gels.   
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